EPICORE Embase Updates

Total documents retrieved: 147

Results Generated From:
Embase <1980 to 2026 Week 10>
Embase Weekly Updates (updates since 2026-02-27) - (147 records)

<1>
Accession Number
2043358146
Title
Beyond White Light: Indocyanine-Green Fluorescence in Contemporary
Pediatric Surgery.
Source
Current Surgery Reports. 14(1) (no pagination), 2026. Article Number: 15.
Date of Publication: 01 Dec 2026.
Author
de Oliveira Junior W.E.; Rosa B.R.; Pereira H.M.; dos Santos L.S.; do
Nascimento A.L.B.; Bachette L.G.; Ortolan E.V.P.; Ribeiro R.C.
Institution
(de Oliveira Junior, Rosa, dos Santos, Ribeiro) Department of Pediatric
Surgery, Hospital de Cancer Infantojuvenil de Barretos, Av. Joao Baroni,
3025 - Dr. Paulo Prata, SP, Barretos, Brazil
(de Oliveira Junior, Rosa, dos Santos, Ribeiro) "Innovation in Healthcare"
Post-graduation Program, Fundacao Pio XII/Faculdade de Ciencias da Saude
"Dr Paulo Prata" (FACISB), SP, Barretos, Brazil
(Pereira) Pediatric Surgeon, Complexo Oncologico de Referencia do Estado
de Goias, GO, Goiania, Brazil
(Bachette) Department of Pediatric Anesthesia, Hospital de Cancer
Infantojuvenil de Barretos, SP, Barretos, Brazil
(do Nascimento) Medical Student, Barretos Medical School, Faculdade de
Ciencias da Saude "Dr Paulo Prata" (FACISB), SP, Barretos, Brazil
(Ortolan) Division of Surgery, Department of Pediatric Surgery, Botucatu
Medical School, State of Sao Paulo University, SP, Botucatu, Brazil
Publisher
Springer
Abstract
Purpose of Review: Near-infrared fluorescence imaging with
indocyanine-green (ICG) improves intra-operative visualization, yet its
adoption in pediatric surgery remains limited. This narrative review
summarizes current pharmacological knowledge, technical principles, and
clinical evidence to guide pediatric surgeons in the safe and effective
use of ICG across subspecialties. Recent Findings: Evidence from the last
decade indicates a steady expansion of fluorescence-guided techniques
beyond hepatobiliary procedures-where pre-operative ICG cholangiography
shortens operative time and reduces bile-duct injury-to urological,
oncological, thoracic, and colorectal operations. Weight-based doses of
0.25-0.5 mg/kg given 18-24 h before surgery improve biliary and tumor
contrast, while intratesticular or subcutaneous injections facilitate
lymphatic mapping. The "second-window" technique (1.0-5 mg/kg administered
24 h before resection) assists margin delineation in renal and hepatic
tumors. Across more than 700 pediatric cases in the literature,
fluorescence guidance has enhanced surgical outcomes without ICG-related
adverse events. Summary: ICG fluorescence is a versatile,
radiation-free adjunct that may increase precision and potentially improve
outcomes in complex pediatric operations. Nonetheless, heterogeneity in
age-specific dosing, limited pharmacokinetic data in neonates, and the
capital cost of near-infrared platforms continue to restrict widespread
use. Multicenter trials and cost-effectiveness analyses are important to
establish standardized protocols and confirm long-term benefit. As these
gaps narrow, fluorescence-guided surgery is likely to progress from an
experimental aid to a routine component of pediatric surgical
care. Copyright © The Author(s) 2026.

<2>
Accession Number
648778932
Title
EACTS Expert Consensus Statement on the Ross Procedure in Adult Patients.
Source
European journal of cardio-thoracic surgery : official journal of the
European Association for Cardio-thoracic Surgery. 68(2) (no pagination),
2026. Date of Publication: 05 Feb 2026.
Author
Vojacek J.; Gofus J.; Andreas M.; Bavaria J.E.; Berdajs D.; Casselman
F.P.A.; El-Hamamsy I.; Holubec T.; de Kerchove L.; Milojevic M.; Mulinari
L.; Ouzounian M.; Skillington P.; Takkenberg J.J.M.; Verbrugghe P.
Institution
(Vojacek, Gofus) Department of Cardiac Surgery, Charles University,
Faculty of Medicine and University Hospital in Hradec Kralove, Hradec
Kralove, Czechia
(Andreas) Division of Cardiac Surgery, Department of Surgery, Medical
University Graz, Graz, Austria
(Bavaria) Department of Surgery, Thomas Jefferson University,
Philadelphia, PA, United States
(Berdajs) Department of Cardiac Surgery, University Hospital of Basel,
Basel, Switzerland
(Casselman) Department of Cardiac Surgery, Heart Center Azorg, Aalst,
Belgium
(El-Hamamsy) Department of Cardiovascular Surgery, Mount Sinai Hospital
and Icahn School of Medicine at Mount Sinai, New York, NY, USA
(Holubec) Department of Cardiovascular Surgery, University Heart and
Vascular Centre, University Hospital Frankfurt and Goethe University
Frankfurt, Frankfurt/Main, Germany
(de Kerchove) Division of Cardiothoracic and Vascular Surgery, Pole de
Recherche Cardiovasculaire, Institut de Recherche Experimentale et
Clinique, Cliniques Universitaires Saint-LucUniversite Catholique de
Louvain, Brussels, Belgium
(Milojevic) Department of Cardiac Surgery and Cardiovascular Research,
Dedinje Cardiovascular Institute, Belgrade, Serbia
(Milojevic) Department of Cardiac Surgery, University Hospital Zurich,
University of Zurich, Zurich, Switzerland
(Mulinari) Pediatric and Congenital Cardiac Surgery, Department of
Surgery, Miller School of Medicine, University of Miami, Miami, FL, United
States
(Ouzounian) Peter Munk Cardiac Centre, Department of Surgery, University
of Toronto, University Health Network, ON, Canada
(Skillington) Department of Cardiothoracic Surgery, Royal Melbourne
Hospital, Epworth Hospital, Melbourne, VIC, Australia
(Takkenberg) Department of Cardio-Thoracic Surgery, Erasmus University
Medical Center, Rotterdam, Netherlands
(Verbrugghe) Department of Cardiac Surgery, UZ Leuven, Leuven, Belgium
Abstract
The Ross procedure, which involves replacing a diseased aortic valve with
the patient's own pulmonary valve (pulmonary autograft), has gained
renewed attention in adult patients due to mounting evidence of excellent
long-term outcomes. With increasing data demonstrating restoration of life
expectancy and improved valve-related outcomes, it is now considered a
viable first-line option for selected young and middle-aged adults with
non-repairable aortic valve disease. Nonetheless, its adoption remains
inconsistent across institutions, partly due to concerns about surgical
complexity, long-term durability, and the need for structured follow-up.
This expert consensus document, commissioned by the European Association
for Cardio-Thoracic Surgery, synthesizes the current evidence and offers
clinical statements for using the Ross procedure in adults. Developed
through a systematic review and informed by the collective experience of a
multidisciplinary panel of internationally recognized experts, the
document addresses key topics including patient selection, technical
refinements, and perioperative management. Emphasis is also placed on the
need for procedural standardization, high-volume surgical expertise, and
longitudinal imaging-based follow-up. Moreover, comparative outcome data
and subgroup considerations are critically appraised, and areas for future
investigation are outlined. This clinical practice document is intended to
assist clinicians and Heart Teams in making informed treatment decisions,
support harmonized implementation across centres, provide technical
considerations to optimize procedural success, and substantially improve
outcomes for patients considered for this complex but promising
procedure. Copyright © European Association for Cardio-Thoracic
Surgery 2025. Published by Oxford University Press on behalf of the
European Association for Cardio-Thoracic Surgery. All rights reserved. For
commercial re-use, please contact reprints@oup.com for reprints and
translation rights for reprints. All other permissions can be obtained
through our RightsLink service via the Permissions link on the article pa

<3>
Accession Number
2028162240
Title
A Controlled Trial Comparing One-Year Hemodynamics of Two Bovine
Pericardial Valves.
Source
Thoracic and Cardiovascular Surgeon. 73(2) (pp 132-140), 2023. Date of
Publication: 06 Mar 2025.
Author
Sohn S.H.; Kang Y.; Choi J.W.; Lee J.H.; Kim J.S.; Lim C.; Hwang H.Y.
Institution
(Sohn, Kang, Kim, Choi, Hwang) Department of Thoracic and Cardiovascular
Surgery, Seoul National University Hospital, Seoul National University,
College of Medicine, Seoul, South Korea
(Lee, Kim, Lim) Department of Thoracic and Cardiovascular Surgery, Seoul
National University Bundang Hospital, Seoul National University, College
of Medicine, Seongnam, South Korea
Publisher
Georg Thieme Verlag
Abstract
Background This randomized controlled trial was designed to compare 1-year
hemodynamic performances and clinical outcomes after aortic valve
replacement (AVR) using a recently introduced (the AVALUS group) and
worldwide used (the CEPME group) bovine pericardial bioprostheses. Methods
Patients were screened to enroll 70 patients in each group based on a
noninferiority design. The primary endpoint of the trial was the mean
pressure gradient across the aortic valve (AVMPG) at 1 year after surgery.
One-year echocardiographic data were obtained from 92.1% (129 of 140
patients) of the study patients. Results There were no differences in
baseline characteristics, including sex and body surface area (1.64 +/-
0.18 vs. 1.65 +/- 0.15 m 2) between the groups. The AVMPG on 1-year
echocardiography was 14.0 +/- 4.3 and 13.9 +/- 5.1 mmHg in the AVALUS and
CEPME groups, respectively (the p-value for noninferiority was 0.0004). In
the subgroup analyses for the respective size of the prostheses, AVMPG of
the 19-mm prostheses was significantly lower in the AVALUS group than in
the CEPME group (14.0 +/- 4.3 vs. 20.0 +/- 4.7 mmHg, p = 0.012), whereas
those of the other sizes were not significantly different between the two
groups. There were no significant differences in the effective orifice
area (1.49 +/- 0.40 vs. 1.53 +/- 0.38 cm 2, p = 0.500) or effective
orifice area index (0.91 +/- 0.22 vs 0.93 +/- 0.23 cm 2 /m 2, p = 0.570)
in all the patients, or in the subgroup analysis for the 19-mm prosthesis.
There were no differences in the 1-year clinical outcomes between the two
groups. Conclusion The 1-year hemodynamic and clinical outcomes of the
AVALUS group were noninferior to those of the CEPME group
(NCT03796442). Copyright © 2023. Thieme. All rights reserved.

<4>
Accession Number
2034207378
Title
Opioid-Sparing Effects of Erector Spinae Plane Block in Off-Pump Coronary
Artery Bypass Grafting with Median Sternotomy: A Randomized Controlled
Trial.
Source
Cardiovascular Drugs and Therapy. 40(1) (pp 241-249), 2026. Date of
Publication: 01 Feb 2026.
Author
Zhang Y.; Liu J.; Lv K.; Wang F.; Shi Y.; You P.; Wang W.
Institution
(Zhang, Lv, Wang, You, Wang) Department of Anesthesiology, Jining No. 1
People's Hospital, Shandong, Jining, China
(Liu) Department of Emergency Surgery, Jining No. 1 People's Hospital,
Shandong, Jining, China
(Shi) Department of Cardiac and Vascular Surgery, Jining No. 1 People's
Hospital, Shandong, Jining, China
Publisher
Springer
Abstract
Purpose: This study assessed the efficacy of preoperative erector spinae
plane block (ESPB) in reducing intraoperative opioid use and enhancing
recovery in off-pump coronary artery bypass grafting (OPCABG) patients,
who typically require high-dose opioids with associated postoperative
risks. Method(s): A prospective, double-blind randomized controlled
trial was conducted on 37 patients. Patients were randomized to receive
either bilateral ESPB with 0.375% ropivacaine or a sham block with normal
saline. Primary outcomes included intraoperative sufentanil consumption,
while secondary outcomes encompassed hemodynamic stability, postoperative
pain scores, mechanical ventilation (MV) duration, and hospital stay.
 Result(s): The ESPB group demonstrated a significant reduction in
intraoperative sufentanil consumption compared to the sham group (150.3
+/- 36.1 microg vs. 194.4 +/- 38.3 microg, p = 0.001). Postoperatively,
ESPB patients exhibited lower pain scores at rest and during coughing
within the first 6 h post-extubation (p < 0.001) and required less rescue
analgesia (5.3% vs. 50.0%, p = 0.003). Additionally, ESPB shortened MV
duration (5.43 +/- 1.65 h vs. 6.88 +/- 1.68 h, p = 0.013). No significant
differences were observed in cardiac care unit or hospital stay lengths.
 Conclusion(s): Preoperative ESPB effectively reduces intraoperative
opioid requirements and provides sustained analgesia in the early
postoperative period, facilitating earlier extubation. These findings
support ESPB as a valuable component of multimodal analgesia in OPCABG,
though further large-scale studies are needed to validate these results
and optimize its application. Clinical Trial Registration: The trial was
registered with the China Clinical Trials Center
(http://www.chictr.org.cn, ChiCTR2200066902) on December 21,
2022. Copyright © The Author(s), under exclusive licence to
Springer Science+Business Media, LLC, part of Springer Nature 2025.

<5>
Accession Number
2043824205
Title
Direct Anastomosis Versus Conduit Repair for Right Ventricular Outflow
Tract Reconstruction in Common Arterial Trunk: A Meta-Analysis of
Reconstructed Time-to-Event Data.
Source
Interdisciplinary Cardiovascular and Thoracic Surgery. 41(2) (no
pagination), 2026. Article Number: ivag029. Date of Publication: 01 Jan
2026.
Author
Almehandi A.; Diniz L.; Marrazzo E.B.; Veiga A.L.; Alotaibi L.; Ali Y.;
Al-Naseem A.O.; Al Kindi H.; Kerst G.; Caldonazo T.
Institution
(Almehandi) Department of Cardiovascular Science, University College
London, London, United Kingdom
(Diniz) Department of Medical Sciences, Federal Fluminense University, Rio
de Janeiro, Brazil
(Marrazzo) Pontifical Catholic University of Minas Gerais, Pocos de
Caldas, Brazil
(Veiga) Universidad de Buenos Aires, Buenos Aires, Argentina
(Alotaibi) Department of Surgery, Jaber Al-Ahmad Hospital, Kuwait City,
Kuwait
(Ali) Faculty of Life Sciences and Medicine, King's College London,
London, United Kingdom
(Al-Naseem) Department of Orthopaedic Surgery, McGill University,
Montreal, Canada
(Al Kindi) Department of Cardiothoracic Surgery, Sultan Qaboos University
Hospital, 123, Oman
(Kerst) Clinic for Pediatric Cardiology and Congenital Heart Disease,
Klinikum Stuttgart, Stuttgart, Germany
(Caldonazo) Department of Cardiothoracic Surgery, Jena University
Hospital, Friedrich Schiller University of Jena, Jena, Germany
Publisher
Oxford University Press
Abstract
Objectives Repair of common arterial trunk (CAT) involves establishing the
right ventricular outflow tract (RVOT) using either a conduit or a direct
right ventricle-pulmonary artery (RVPA) anastomosis (DA). Conduits offer a
valved pathway but are limited by durability and availability. The
comparative outcomes of these 2 techniques remain uncertain. This work
assessed whether DA improves survival, reduces complications and
reintervention outcomes compared to conduit repair. Methods PubMed, Web of
Science, EMBASE, and Cochrane Central were searched for studies comparing
conduit versus DA for RVOT reconstruction from February 20, 2025 to March
30 30, 2025. The primary outcome was early mortality; secondary outcomes
included haemodynamics, recovery, and complications. Time-to-event data
were reconstructed from Kaplan-Meier curves. Pooled hazard ratios (HRs),
risk ratios (RRs), or mean differences (MDs) with 95% confidence intervals
(CIs) were calculated using random-effects models. Results Eleven studies
(767 patients; 419 conduit, 348 DA) were included. Early mortality
(RR=0.61, 95% CI, 0.26-1.44, P=.220) and long-term survival (HR=1.11, 95%
CI, 0.61-2.02, P=.738) were similar. Reoperation was more frequent in the
conduit group (HR=1.77, 95% CI, 1.05-3.01, P=.034). Conduit repair
required longer ventilation (MD=3.44 days, P=.010) and hospitalization
(MD=4.77 days, P=.030), with comparable ICU stay and RVOT growth. Truncal
valve insufficiency (RR=0.13, P=.130 for truncal valve vs conduit) was
similar in incidence following DA. Conclusions Conduit and DA repairs
yield similar survival and postoperative complications in CAT, while DA
offers fewer reoperations and faster recovery. Data from future
prospective multicentre trials will support decision-making. Copyright
© The Author(s) 2026. Published by Oxford University Press on behalf
of the European Association for Cardio-Thoracic Surgery.

<6>
Accession Number
2043423266
Title
Clinical and Haemodynamic Outcomes in Small Versus Large Prostheses in
Surgical Aortic Valve Replacement: A Systematic Review and Meta-Analysis.
Source
Journal of Cardiac Surgery. 2026(1) (no pagination), 2026. Article Number:
9523752. Date of Publication: 2026.
Author
Hon J.J.; Rad A.A.; Harbinson O.; Al-Zubaidi F.; Sardari Nia P.; Sayeed
R.; Srivastava V.; Kourliouros A.; Athanasiou T.
Institution
(Hon, Harbinson) Faculty of Medicine, Imperial College London, London,
United Kingdom
(Rad, Al-Zubaidi, Sayeed, Srivastava, Kourliouros) Department of
Cardiothoracic Surgery, Oxford University Hospitals NHS Foundation Trust,
Oxford, United Kingdom
(Rad, Sardari Nia) Department of Cardiothoracic Surgery, Maastricht
University Medical Center, Maastricht, Netherlands
(Athanasiou) Department of Surgery and Cancer, Imperial College London,
London, United Kingdom
Publisher
John Wiley and Sons Inc
Abstract
Objectives: This systematic review and meta-analysis evaluate clinical and
haemodynamic outcomes between small (<= 21 mm) and large (>= 23 mm)
prosthetic valves in surgical aortic valve replacement (SAVR).
 Method(s): A comprehensive literature search was conducted from
inception to March 2025. Studies comparing outcomes between small and
large aortic valve prostheses were included. Primary outcome was all-cause
mortality. Secondary outcomes included short-term mortality, stroke,
reoperation, endocarditis, haemodynamic parameters and patient-prosthesis
mismatch (PPM). Random-effects models calculated pooled risk ratios (RRs)
or mean differences (MDs). Mediation analysis explored the relationships
between prosthesis size, PPM and mortality. Result(s): Twelve studies
comprising 9896 patients were included. Small prostheses were associated
with increased all-cause mortality (RR 1.23, 95% CI 1.07-1.41, p = 0.004)
and short-term mortality (RR 1.73, 95% CI 1.11-2.68, p = 0.015). No
significant differences were observed for stroke, reoperation or
endocarditis. Small prostheses demonstrated significantly lower indexed
effective orifice area (MD -0.13 cm2/m2, 95% CI
-0.24 to -0.01, p = 0.030) and higher incidence of PPM (RR 2.02, 95% CI
1.36-3.00, p < 0.0001). Mediation analysis revealed a strong correlation
(r = 0.904) between PPM and all-cause mortality effect sizes. Very small
prostheses (< 19 mm) exhibited elevated mean gradients (20.8 mmHg) and
substantial PPM incidence (33.2%). Conclusion(s): Small aortic valve
prostheses are associated with increased mortality and PPM. The strong
correlation between PPM and mortality effects suggests PPM may be the key
mechanism underlying adverse outcomes. Alternative strategies such as root
enlargement may be warranted in patients requiring small
prostheses. Copyright © 2026 Joshua J. Hon et al. Journal of
Cardiac Surgery published by John Wiley & Sons Ltd.

<7>
Accession Number
2041286515
Title
Impact of Intraoperative Hyperoxia Versus Normoxia on Mortality and Organ
Injury in Cardiac Surgery: A Systematic Review and Meta-analysis of
Randomized Clinical Trials.
Source
Journal of Cardiothoracic and Vascular Anesthesia. 40(2) (pp 509-521),
2026. Date of Publication: 01 Feb 2026.
Author
Grillo I.T.C.; de Santana E.S.P.; Passos F.S.; Tanimoto L.E.; de Melo
J.C.; Kondo A.M.; Treml R.E.; Caldonazo T.
Institution
(Grillo, Tanimoto, de Melo) University of Buenos Aires, Buenos Aires,
Argentina
(de Santana) Federal University of Bahia, Salvador, Brazil
(Passos) Department of Thoracic Surgery, Mater Dei Hospital, Salvador,
Brazil
(Kondo) Albert Einstein Israeli Faculty of Health Sciences, Sao Paulo,
Brazil
(Treml) Department of Anesthesiology, Perioperative and Pain Medicine,
Stanford University School of Medicine, Stanford, CA, United States
(Caldonazo) Department of Cardiothoracic Surgery, Jena University
Hospital, Jena, Germany
(Caldonazo) Department of Cardiothoracic Surgery, Weill Cornell Medicine,
New York, NY, United States
Publisher
W.B. Saunders
Abstract
Objective: To compare mortality and organ injury associated with
intraoperative hyperoxia and normoxia in cardiac surgery patients.
 Design(s): Systematic review and meta-analysis of randomized clinical
trials (RCTs). Setting(s): Tertiary care. Participant(s):
Patients who underwent cardiac surgery with cardiopulmonary bypass or
off-pump procedures. Intervention(s): Intraoperative hyperoxia or
normoxia. Measurements and Main Results: A systematic search of
PubMed, Embase, and the Cochrane Library identified RCTs comparing
hyperoxia versus normoxia in cardiac surgery. Primary outcomes were
in-hospital and 30-day mortality; secondary outcomes included
postoperative clinical and biochemical measures. Risk ratios (RRs), mean
differences (MDs), and standardized mean differences (SMDs) with 95%
confidence intervals (CIs) were calculated. Trial sequential analysis and
subgroup analysis based on the variable used to define oxygenation
(PaO-based v FiO-based thresholds) were performed to address heterogeneity
in oxygenation strategies. Nineteen RCTs (2,001 patients) were included,
with 982 patients (49.1%) experiencing hyperoxia. In-hospital (9/798
[1.1%] v 10/799 [1.3%], RR 0.84, 95% CI 0.36 to 1.94, p = 0.684) and
30-day mortality (1/282 [0.4%] v 4/280 [1.4%], RR 0.41, 95% CI 0.08 to
2.28, p = 0.311) were not different between the groups. However, the
normoxia group had a higher postoperative PaO<inf>2</inf>/FiO<inf>2</inf>
ratio (MD -31.49, 95% CI -47.13 to -15.85, p < 0.01), whereas creatine
kinase-MB (SMD 1.65, 95% CI 0.12 to 3.18, p = 0.03) and malondialdehyde
(SMD 3.77, 95% CI 2.99 to 4.55, p < 0.01) were higher in the hyperoxia
group. Conclusion(s): Compared with normoxia, hyperoxia during
cardiac surgery does not impact in-hospital or 30-day mortality but is
associated with worsening physiological and biochemical
parameters. Copyright © 2025 The Authors

<8>
Accession Number
2035109961
Title
Urine Output Response to a Furosemide Infusion in Infants After
Cardiopulmonary Bypass as a Predictor of Acute Kidney Injury.
Source
Pediatric Cardiology. 47(4) (pp 1520-1527), 2026. Date of Publication: 01
Apr 2026.
Author
Pierick A.R.; Luckritz K.E.; Huebschman A.; Duimstra A.; Yu S.;
Sznycer-Taub N.
Institution
(Pierick, Duimstra, Yu, Sznycer-Taub) Divison of Pediatric Cardiology,
Department of Pediatrics, University of Michigan, Ann Arbor, MI, United
States
(Luckritz) Division of Pediatric Nephrology, Department of Pediatrics,
University of Michigan, Ann Arbor, MI, United States
(Huebschman) Department of Pediatric Pharmacy, University of Michigan, Ann
Arbor, MI, United States
Publisher
Springer
Abstract
Acute kidney injury (AKI) is a common complication in infants after
cardiac surgery. Prior studies have demonstrated that urine output
response to bolus dose furosemide correlates with AKI development but have
excluded infants receiving a furosemide infusion. We sought to determine
if urine output in response to a furosemide infusion in infants after
cardiac surgery predicts AKI development. Single center retrospective
cohort study of infants post cardiac surgery requiring cardiopulmonary
bypass and received a post-operative furosemide infusion. A furosemide
response score (FRS) (urine output [mL]/furosemide delivered [mg/kg]) was
calculated. The FRS was used to determine optimal cut-offs to predict
clinically significant AKI (CS-AKI), defined as stage 2 or 3 AKI. A
furosemide infusion was started at a median of 9.4 h (interquartile range
6.6-13.6 h) after intensive care unit (ICU) admission in 155 infants. The
post-operative incidence of AKI was 76.8%, with 44.5% having CS-AKI. The
optimal FRS cut-off to correlate with AKI was 11.3 mL/mg/kg at 4 h (area
under the curve [AUC] = 0.75), 25.5 mL/mg/kg at 10 h (AUC = 0.70), and
53.3 mL/mg/kg at 24 h (AUC = 0.70) post-infusion initiation, and
independently associated with the development of AKI. Lower FRS also
correlated with increased mechanical ventilation days and ICU/hospital
length of stay. Urine output in response to a furosemide infusion in
infants following cardiac surgery is associated with post-operative
CS-AKI. The FRS can be used to predict AKI and potentially improve
hemodynamics while minimizing risks. Copyright © The Author(s)
2025.

<9>
Accession Number
2037688750
Title
The Effect of Infusion of Dexmedetomidine to the Aortic Root before Aortic
Cross-Clamp Removal on the Myocardial Protection in Patients Undergoing
Mitral Valve Surgery; A Triple-Blinded Randomized Clinical Trial.
Source
Razavi International Journal of Medicine. 14(1) (pp 22-32), 2026. Article
Number: e1427. Date of Publication: 01 Jan 2026.
Author
Amini S.; Hajipour F.; Sistani M.R.N.; Zandi Z.; Yaghubi M.
Institution
(Amini) Department of Anesthesiology, Faculty of Medicine, Mashhad
University of Medical Sciences, Mashhad, Iran, Islamic Republic of
(Hajipour) Department of Extra-Corporeal Circulation (ECC), Rajaie
Cardiovascular Medical and Research Center, Iran University of Medical
Sciences, Tehran, Iran, Islamic Republic of
(Sistani) Pediatric and Congenital Cardiology Division, Department of
Pediatrics, Faculty of Medicine, Mashhad University of Medical Sciences,
Mashhad, Iran, Islamic Republic of
(Zandi) Department of Cardiovascular disease, Faculty of Medicine, Mashhad
University of Medical Sciences, Mashhad, Iran, Islamic Republic of
(Yaghubi) Department of Extra-Corporeal Circulation (ECC), Razavi
Hospital, Imam Reza International University, Mashhad, Iran, Islamic
Republic of
Publisher
Mashhad Razavi Hospital
Abstract
Background: Myocardial protection during cardiopulmonary bypass is a
challenging dilemma. Some protective strategies have been introduced to
ameliorate ischemic-reperfusion injury, although no optimal strategy has
emerged. Objective(s): Herein, we evaluated the effect of aortic root
infusion of Dexmedetomidine before cross-clamp removal on myocardial
preservation. Method(s): This randomized, multicenter, triple-blinded
controlled trial enrolled 56 patients who underwent mitral valve surgery.
After randomization, the patients were allocated to the case group
(Dexmedetomidine infusion in the aortic root before cross-clamp removal)
and the control group (isotonic saline). Based on the study goals,
Troponin-I and Creatinine kinase-MB were measured as primary outcomes at
different time points during the study. Other clinical parameters were
also measured as secondary outcomes. Statistical analysis was performed
using SPSS software version 26.0 (Chicago, IL, USA). The significance
level was considered as P<0.05. Result(s): A total of 54 patients in
the case and control groups were included in the analysis. The main
finding of this study was that troponin-I levels at all time points showed
statistical differences between the two groups (P=0.001). Also, evaluation
of CK-MB levels showed a significant decrease at 1 hour (P=0.001), 12
hours (P=0.001), and 24 hours (P=0.001) after ICU admission, in the case
group compared with the control group. Conclusion(s): This study
found that administering a Dexmedetomidine infusion before aortic
cross-clamp removal can ameliorate ischemia-reperfusion injury-induced
myocardial damage. Copyright © 2026 The Authors.

<10>
Accession Number
2034672381
Title
Association between venous to arterial carbon dioxide tension gap and
clinical outcome in cardiac surgery patients: A systematic review and
meta-analysis.
Source
Perfusion (United Kingdom). 41(2) (pp 124-133), 2026. Date of Publication:
01 Mar 2026.
Author
Lin D.; Luo H.; Long F.; Liu M.-H.; Zhang Y.; Liu T.; Zhou R.-H.
Institution
(Lin, Long, Liu, Zhang, Liu, Zhou) Department of Anesthesiology, West
China Hospital of Sichuan University, Chengdu, China
(Luo) West China Hospital, Sichuan University/West China School of
Nursing, Sichuan University, China
Publisher
SAGE Publications Ltd
Abstract
Background: Cardiac surgery is associated with increased risk of major
adverse outcomes. Venous to arterial carbon dioxide tension gap
(Pv-aCO<inf>2</inf> gap) showed significant prognostic value of
non-cardiac surgery, while their prognostic value after cardiopulmonary
bypass (CPB) remains controversial. Method(s): We conducted a
systematic research of PubMed, MEDLINE, EMBASE and Web of science
electronic database and ClinicalTrials.gov to analysis the association
between high Pv-aCO<inf>2</inf> gap and adverse outcomes in adult cardiac
surgery patients. Random effect model was used to pool data.
 Result(s): Eight studies (n = 2136 patients) were enrolled. High
Pv-aCO<inf>2</inf> gap was mainly defined as Pv-aCO<inf>2</inf> >= 6-8
mmHg. In cardiac surgery, high Pv-aCO<inf>2</inf> gap was not associated
with increased hospital mortality (odds ratio, 0.63; 95% CI, 0.17-2.32; p
= 0.49)), but was related with higher ICU mortality (odds ratio, 5.27; 95%
CI, 2.31-12.00; p < 0.001), higher incidence of major complications (p <
0.05), longer ICU length of stay (p = 0.03) and prolonged ventilation time
in the ICU (p < 0.001). Moreover, high Pv-aCO<inf>2</inf> gap was linked
to postoperative lower cardiac index (p < 0.01) and lower ScvO<inf>2</inf>
(p < 0.001). Interesting, high Pv-aCO<inf>2</inf> gap was not associated
with increased postoperative lactate level and longer hospital length of
stay. Conclusion(s): An elevated Pv-aCO<inf>2</inf> gap seems to be
associated with adverse outcomes in very short time and indicates tissue
hypoperfusion rather than tissue hypoxia. Therefore, interventions aiming
at normalizing Pv-aCO<inf>2</inf> gap may potentially improve clinical
outcomes, while further validation is required. Copyright © The
Author(s) 2025

<11>
Accession Number
2041914433
Title
Pressure points: Hemodynamics and waitlist risk before heart transplant.
Source
Journal of Heart and Lung Transplantation. 45(3) (pp 363-364), 2026. Date
of Publication: 01 Mar 2026.
Author
Lerman J.B.; Russell S.D.
Institution
(Lerman, Russell) Division of Cardiology, Department of Medicine, Duke
University School of Medicine, Durham, NC, United States
Publisher
Elsevier Inc.

<12>
Accession Number
2041658879
Title
Ketamine in Cardiac Surgery: A Systematic Review and Meta-Analysis of
Effects on Inflammatory Markers and Clinical Outcomes.
Source
Journal of Cardiothoracic and Vascular Anesthesia. 40(2) (pp 690-698),
2026. Date of Publication: 01 Feb 2026.
Author
de Lima e Souza P.F.; Neto M.M.C.; Paz M.C.; Ponte R.V.
Institution
(de Lima e Souza) Department of Anesthesiology, Federal University of
Ceara, Fortaleza, Brazil
(Neto, Paz) School of Medicine, State University of Ceara, Fortaleza,
Brazil
(Ponte) Department of Surgery, University of Fortaleza, Fortaleza, Brazil
Publisher
W.B. Saunders
Abstract
Cardiac surgery triggers a systemic inflammatory response, especially when
cardiopulmonary bypass (CPB) is used, which may contribute to
postoperative complications. Ketamine, an NMDA receptor antagonist, has
shown anti-inflammatory potential by inhibiting nuclear factor kappa B and
reducing cytokine release, but its perioperative immunomodulatory effects
remain unclear. This systematic review and meta-analysis assessed
randomized controlled trials (RCTs) comparing intraoperative ketamine to
placebo in cardiac surgery. The primary outcome was interleukin (IL)-6
level; secondary outcomes included C-reactive protein (CRP) level,
intensive care unit (ICU) length of stay, mechanical ventilation duration,
and transfusion requirements. Eight RCTs, including a total of 377
patients, were included in the analysis. Ketamine did not significantly
reduce IL-6 levels at 24 hours postoperatively (standardized mean
difference [SMD], -0.96; 95% confidence interval [CI], -2.56 to 0.65; I2 =
96%), although a significant decrease was observed in off-pump procedures
(mean difference [MD], -59.57 pg/mL; I2 = 0%). IL-6 levels measured
immediately after CPB and CRP levels immediately after surgery also were
reduced, but findings were limited by high heterogeneity. No significant
differences were observed in ICU length of stay (MD, -0.10 days),
ventilation time (MD, -0.86 hours), or transfusion rates (risk ratio,
1.01). The certainty of the evidence was rated low to moderate owing to
imprecision and inconsistency. Although ketamine's immunomodulatory
effects were observed in selected subgroups, they did not translate into
improved clinical outcomes. Current evidence does not support the routine
use of ketamine for inflammation control in cardiac surgery, although its
effect in off-pump procedures warrants further research. Copyright
© 2025 Elsevier Inc.

<13>
Accession Number
2041169559
Title
Recombinant Factor VIIa Versus Prothrombin Complex Concentrate in Patients
Undergoing Cardiac Surgery: A Systematic Review and Meta-analysis.
Source
Journal of Cardiothoracic and Vascular Anesthesia. 40(2) (pp 676-689),
2026. Date of Publication: 01 Feb 2026.
Author
Cadd M.; Puntis D.; Bullard S.; Green S.; Kilpatrick T.; Hardy B.; Seavill
M.
Institution
(Cadd, Puntis, Green, Kilpatrick, Hardy) Anaesthetic Department, Royal
Sussex County Hospital, University Hospitals Sussex NHS Foundation Trust,
Brighton, United Kingdom
(Bullard) Department of Anaesthesia, Royal Brompton Hospital, Guy's and St
Thomas' NHS Foundation Trust, London, United Kingdom
(Seavill) Department of Anaesthesia, St George's University Hospitals NHS
Foundation Trust, London, United Kingdom
Publisher
W.B. Saunders
Abstract
Perioperative hemorrhage during cardiac surgery is a frequent occurrence
and can result in significant morbidity and mortality for patients.
Prothrombin complex concentrate (PCC) and recombinant factor VIIa (rFVIIa)
are therapies that have been used extensively in cardiac surgery with some
promise, but with some concern around acute kidney injury (AKI) and
thromboembolic disease with rFVIIa use. In this meta-analysis and
systematic review, the authors summarize the evidence regarding the
effects of PCC and rFVIIa on chest tube output, incidence of adverse
events, and mortality of adult patients undergoing cardiac surgery. A
total of 962 patients from seven retrospective observational studies were
included in the pooled analysis. There was a significant reduction in the
primary outcome: total chest tube output (mean difference: -301.01 mL, 95%
confidence interval [CI] -550.54 to -51.48). PCC was associated with a
significant reduction in total thromboembolic disease (odds ratio: 0.55,
95% CI 0.34 to 0.89), deep vein thrombosis (odds ratio 0.28, 95% CI 0.15
to 0.52), and cryoprecipitate transfusion (mean difference: -3.93, 95% CI
-7.64 to -0.21). There were no significant differences between groups in
the incidence of AKI or mortality. Five studies were deemed at moderate
risk of bias, and two at serious risk. PCC has been shown to have a
beneficial effect on reducing chest tube output and incidence of
thromboembolic disease, with no increase in AKI compared with
rFVIIa. Copyright © 2025 Elsevier Inc.

<14>
Accession Number
2041616088
Title
Outcomes of Ventricular Tachycardia Ablation in Cardiac Laminopathy: An
Updated Systematic Review and Single-Arm Meta-Analysis.
Source
Journal of Cardiovascular Electrophysiology. 37(2) (pp 268-274), 2026.
Date of Publication: 01 Feb 2026.
Author
Castrichini M.; Ferreira Felix I.; Karlinski Vizentin V.; Garmany R.;
Huynh T.; Haq I.U.; Swain W.H.; Siontis K.C.; Killu A.M.; Deshmukh A.J.;
Ackerman M.J.; Giudicessi J.R.
Institution
(Castrichini, Garmany, Haq, Swain, Siontis, Killu, Deshmukh, Ackerman,
Giudicessi) Department of Cardiovascular Medicine (Division of Heart
Rhythm Services), Mayo Clinic, Rochester, MN, United States
(Castrichini, Karlinski Vizentin, Garmany, Huynh, Ackerman, Giudicessi)
Department of Molecular Pharmacology and Experimental Therapeutics
(Windland Smith Rice Sudden Cardiac Death Genomics Laboratory), Mayo
Clinic, Rochester, MN, United States
(Ferreira Felix, Huynh) Department of Internal Medicine, Mayo Clinic,
Rochester, MN, United States
(Garmany) Mayo Clinic Medical Scientist Training Program, Mayo Clinic
Graduate School of Biomedical Sciences, Mayo Clinic Alix School of
Medicine, Rochester, MN, United States
(Ackerman) Department of Pediatric and Adolescent Medicine (Division of
Pediatric Cardiology), Mayo Clinic, Rochester, MN, United States
Publisher
John Wiley and Sons Inc
Abstract
Background: Ventricular tachycardia (VT) is a life-threatening arrhythmia
frequently observed in structural heart diseases, including LMNA-related
cardiomyopathy, a genetic disorder associated with high risk of sudden
cardiac death and progressive systolic dysfunction. While catheter
ablation is an established therapeutic option for VT, its efficacy in
cardiac laminopathy remains poorly defined. Objective(s): To
synthesize available evidence on the role and outcomes of VT ablation in
patients with cardiac laminopathy. Method(s): A systematic review and
single-arm meta-analysis was performed in accordance with PRISMA
guidelines. PubMed, Embase, and Cochrane databases were searched for
studies reporting VT ablation outcomes in LMNA-related cardiomyopathy. An
inverse variance random-effects model was applied for meta-analysis of
proportions. Result(s): Seven studies (six cohorts, one abstract)
comprising 62 patients (mean age 53.2 +/- 9.7 years; 85% male; 88% with
implantable cardioverter-defibrillator) were included. An
endocardial/endo-epicardial approach was used in 93% of cases. Acute
procedural success was achieved in 37% (95% CI: 14%-63%; I2 = 27.4%), and
28% required multiple procedures. Over a median follow-up of 26 (9-35)
months, VT recurrence occurred in 91% (95% CI: 76%-100%; I2 = 37.2%).
All-cause mortality was 54% (95% CI: 39%-70%; I2 = 28%), predominantly
from cardiac causes (51%, 95% CI: 25%-76%; I2 = 53%), and 14% (95% CI:
1%-34%; I2 = 42%) underwent heart transplantation. Conclusion(s): In
LMNA-related cardiomyopathy, catheter ablation is associated with high VT
recurrence, limited long-term success, and substantial cardiovascular
mortality and transplantation rates, underscoring the importance of ICD
implantation and the need for alternative strategies, including
variant-specific and molecularly targeted therapies. Copyright ©
2025 Wiley Periodicals LLC.

<15>
Accession Number
2030840705
Title
Electronic Glycemic Management System Improved Glycemic Control and
Reduced Complications in Patients With Diabetes Undergoing Coronary Artery
Bypass Surgery: A Randomized Controlled Trial.
Source
Journal of Diabetes Science and Technology. 20(2) (pp 308-316), 2026. Date
of Publication: 01 Mar 2026.
Author
Camara de Souza A.B.; Toyoshima M.T.K.; Cukier P.; Lottenberg S.A.; Bolta
P.M.P.; Lima E.G.; Serrano Junior C.V.; Nery M.
Institution
(Camara de Souza, Cukier, Lottenberg, Nery) Department of Endocrinology
and Metabolism, Hospital das Clinicas da Faculdade de Medicina da
Universidade de Sao Paulo, Sao Paulo, Brazil
(Toyoshima) Instituto do Cancer do Estado de Sao Paulo Octavio Frias de
Oliveira, Hospital das Clinicas da Faculdade de Medicina da Universidade
de Sao Paulo, Sao Paulo, Brazil
(Bolta, Lima, Serrano Junior) Instituto do Coracao, Hospital das Clinicas
da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil
Publisher
SAGE Publications Inc.
Abstract
Background: In-hospital hyperglycemia poses significant risks for patients
with diabetes mellitus undergoing coronary artery bypass graft (CABG)
surgery. Electronic glycemic management systems (eGMSs) like InsulinAPP
offer promise in standardizing and improving glycemic control (GC) in
these settings. This study evaluated the efficacy of the InsulinAPP
protocol in optimizing GC and reducing adverse outcomes post-CABG.
 Method(s): This prospective, randomized, open-label study was
conducted with 100 adult type 2 diabetes mellitus (T2DM) patients
post-CABG surgery, who were randomized into two groups: conventional care
(gCONV) and eGMS protocol (gAPP). The gAPP used InsulinAPP for insulin
therapy management, whereas the gCONV received standard clinical care. The
primary outcome was a composite of hospital-acquired infections, renal
function deterioration, and symptomatic atrial arrhythmia. Secondary
outcomes included GC, hypoglycemia incidence, hospital stay length, and
costs. Result(s): The gAPP achieved lower mean glucose levels (167.2
+/- 42.5 mg/dL vs 188.7 +/- 54.4 mg/dL; P = .040) and fewer patients-day
with BG above 180 mg/dL (51.3% vs 74.8%, P = .011). The gAPP received an
insulin regimen that included more prandial bolus and correction insulin
(either bolus-correction or basal-bolus regimens) than the gCONV (90.3% vs
16.7%). The primary composite outcome occurred in 16% of gAPP patients
compared with 58% in gCONV (P < .010). Hypoglycemia incidence was lower in
the gAPP (4% vs 16%, P = .046). The gAPP protocol also resulted in shorter
hospital stays and reduced costs. Conclusion(s): The InsulinAPP
protocol effectively optimizes GC and reduces adverse outcomes in T2DM
patients' post-CABG surgery, offering a cost-effective solution for
inpatient diabetes management. Copyright © 2024 Diabetes
Technology Society

<16>
Accession Number
2043751781
Title
Dexmedetomidine vs. Magnesium Sulfate as Anesthetic Adjuvants in Spine
Surgery: Effects on Inflammatory Response, Hemodynamics, Recovery, and
Opioid Use in a Randomized Controlled Trial.
Source
Archives of Anesthesiology and Critical Care. 12(2) (pp 137-142), 2026.
Date of Publication: 2026.
Author
Pulubuhu S.J.; Husain A.A.A.; Hisbullah; Salahuddin A.; Adil A.; Wirawan
N.S.
Institution
(Pulubuhu, Husain, Hisbullah, Salahuddin, Adil, Wirawan) Department of
Anesthesiology and Intensive Care, Faculty of Medicine, Hasanuddin
University, Dr. Wahidin Sudirohusodo Hospital, Makassar, Indonesia
Publisher
Tehran University of Medical Sciences
Abstract
Background: Non-cardiac surgery in patients with cardiovascular risk can
lead to Spine surgery often leads to significant postoperative pain,
inflammation, and hemodynamic instability, necessitating opioid use, which
increases the risk of side effects. Dexmedetomidine (DEX) and magnesium
sulfate (MgSO<inf>4)</inf> are anesthetic adjuvants that may enhance
recovery and reduce opioid consumption. This study aimed to compare the
effects of DEX and MgSO<inf>4</inf> as an anesthetic adjuvant on
interleukin-6 (IL-6) levels, hemodynamic stability, postoperative
recovery, and opioid consumption in spine surgery. Method(s): A
randomized controlled trial was performed on 24 patients undergoing spine
surgery under general anesthesia. Participants were randomly divided into
two groups: Group 1 received DEX (a 1 microg/kg bolus followed by a
continuous infusion of 0.3-0.5 microg/kg/h), while Group 2 was given
MgSO<inf>4</inf> (a 30-50 mg/kg bolus followed by an infusion of 10-20
mg/kg/h). Hemodynamic parameters, IL-6 levels (pre- and postoperatively),
opioid use, and recovery outcomes were analyzed. Result(s): IL-6
levels decreased significantly in both groups (p=0.001), with a greater
reduction in the DEX group (-60.5 pg/dL vs. -24.9 pg/dL), though not
statistically significant. Hemodynamic stability was comparable, but DEX
provided better pulse rate control. Opioid consumption was lower in the
DEX group at 24 and 48 hours postoperatively (p < 0.05). The DEX group
also showed higher Aldrete scores (p<0.05) and shorter hospital stays
(3.75 vs. 4.83 days, p<0.05). Conclusion(s): DEX provides superior
anti-inflammatory effects, hemodynamic stability, reduced opioid use, and
improved recovery compared to MgSO<inf>4</inf> as an anesthetic adjuvant
in spine surgery patients. Copyright © 2026 Tehran University of
Medical Sciences.

<17>
Accession Number
2043331352
Title
High-Flow Nasal Cannula Versus Conventional Oxygen Therapy in Patients
Undergoing Thoracic Surgery: A Randomized Controlled Trial.
Source
Thoracic Cancer. 17(4) (no pagination), 2026. Article Number: e70251. Date
of Publication: 01 Feb 2026.
Author
Maioli D.T.; Corbellini L.M.; Santos C.L.; Filho C.T.B.; Andrade C.F.;
Schmidt A.P.
Institution
(Maioli, Filho, Andrade, Schmidt) Programa de Pos-graduacao em Ciencias
Pneumologicas, Faculdade de Medicina, Universidade Federal do Rio Grande
do Sul (UFRGS), Rio Grande do Sul, Porto Alegre, Brazil
(Maioli, Corbellini, Santos) Clinica de Anestesiologia e Tratamento da Dor
Bento Goncalves, Hospital Tacchini, Rio Grande do Sul, Bento Goncalves,
Brazil
(Filho, Schmidt) Servico de Anestesia e Medicina Perioperatoria, Hospital
de Clinicas de Porto Alegre (HCPA), Rio Grande do Sul, Porto Alegre,
Brazil
(Schmidt) Programa de Pos-graduacao em Ciencias Cirurgicas, Faculdade de
Medicina, Universidade Federal do Rio Grande do Sul (UFRGS), Rio Grande do
Sul, Porto Alegre, Brazil
(Schmidt) Departamento de Bioquimica, Instituto de Ciencias Basicas da
Saude (ICBS), Universidade Federal do Rio Grande do Sul (UFRGS), Rio
Grande do Sul, Porto Alegre, Brazil
(Schmidt) Servico de Anestesia, Santa Casa de Porto Alegre, Universidade
Federal de Ciencias da Saude de Porto Alegre (UFCSPA), Rio Grande do Sul,
Porto Alegre, Brazil
(Schmidt) Servico de Anestesia, Hospital Nossa Senhora da Conceicao, Rio
Grande do Sul, Porto Alegre, Brazil
(Schmidt) Programa de Pos-Graduacao em Anestesiologia, Ciencias Cirurgicas
e Medicina Perioperatoria, Faculdade de Medicina da Universidade de Sao
Paulo (FMUSP), Sao Paulo, Sao Paulo, Brazil
Publisher
John Wiley and Sons Inc
Abstract
Background and Objective: Postoperative pulmonary complications (PPC) are
linked to higher morbidity and healthcare costs. High-flow nasal cannula
(HFNC) oxygen therapy may mitigate PPC by enhancing oxygenation and easing
respiratory effort. This study assessed HFNC's efficacy versus
conventional oxygen therapy in reducing PPC during anesthetic induction
and extubation in elective thoracic surgery for lung resection.
 Method(s): In a single-center randomized clinical trial, 90 patients
undergoing elective thoracic surgery were randomized (1:1) to HFNC or
conventional oxygen therapy during induction and extubation. The primary
outcome was in-hospital PPC incidence within 30 days. Secondary outcomes
included intubation hypoxemia, 30-day mortality, and ICU admission.
Poisson regression identified PPC predictors. Result(s): PPC rates
were 20.0% in the HFNC group and 26.7% in controls (relative risk [RR]
0.75, 95% CI 0.35-1.60, p = 0.455), with no significant difference.
Poisson regression revealed independent predictors: chronic obstructive
pulmonary disease, preoperative SpO<inf>2</inf> <= 94%, surgery > 2 h, and
left lung ventilation (p < 0.05). No differences occurred in intubation
hypoxemia (0% both groups), 30-day mortality (2.22% HFNC vs. 4.44%
controls, p = 0.553), or ICU admission (13.33% HFNC vs. 17.78% controls, p
= 0.526). HFNC was well-tolerated without device issues.
 Conclusion(s): HFNC, applied during intubation and extubation, did
not significantly reduce the incidence of PPC or secondary outcomes
compared to conventional oxygen therapy in patients undergoing elective
thoracic surgery. Further research is needed to explore HFNC's potential
in high-risk populations or with optimized protocols, such as extended
application periods or varied flow rates, to enhance perioperative
respiratory management. Copyright © 2026 The Author(s). Thoracic
Cancer published by John Wiley & Sons Australia, Ltd.

<18>
Accession Number
2034675102
Title
No benefit of adding mannitol to cardiopulmonary bypass priming solution
assessing cystatin C. A randomized clinical trial.
Source
Perfusion (United Kingdom). 41(2) (pp 155-164), 2026. Date of Publication:
01 Mar 2026.
Author
Skold A.; Dardashti A.; Lindstedt S.; Hyllen S.
Institution
(Skold, Dardashti, Lindstedt, Hyllen) Department of Cardiothoracic
Surgery, Anesthesia and Intensive Care, Skane University Hospital, Lund,
Sweden
(Skold, Dardashti, Lindstedt, Hyllen) Department of Clinical Sciences,
Lund, Lund University, Lund, Sweden
Publisher
SAGE Publications Ltd
Abstract
Introduction: There is no recommendation regarding the optimal prime
solution for the cardiopulmonary bypass circuit in adult cardiac surgery.
Despite the lack of scientific evidence, mannitol has frequently been
added to the prime solution with intention to prevent acute kidney injury.
The aim of this study was to investigate the impact of mannitol in
cardiopulmonary bypass circuit prime in patients with preoperative renal
dysfunction. Method(s): This prospective, randomized, double-blind
study included 70 patients, who underwent coronary artery bypass grafting.
One group received 1200 mL of a prime based on Ringer's acetate (n = 35),
and the other a prime consisting of 1000 mL Ringer's acetate and 200 mL
mannitol (n = 35). Primary endpoint were levels of Cystatin C, a renal
function biomarker. Changes in renal-related parameters, electrolytes,
osmolality and acid-base status were monitored. Result(s): The median
cystatin C on day four in the mannitol group were 1.6 mg/L (IQR 1.4-2.0
mg/L) and 1,8 mg/L (IQR 1.5-2.1 mg/L) in the Ringer's acetate group at the
same time. Using mixed model analysis, no differences in cystatin C (p =
0.442), creatinine (p = 0.203), estimated glomerular filtration rate (p =
0.264) and urea (p = 0.141) could be detected between the groups. The
mannitol group showed a more pronounced reduction in sodium levels after
cardiopulmonary bypass circuit commencement compared to the Ringer's
acetate group p < 0.001. Conclusion(s): In patients with preoperative
renal dysfunction, the addition of mannitol in the prime solution did not
show any renoprotective effect measured by cystatin C compared to a
cardiopulmonary bypass circuit prime based on Ringer's acetate. This study
was reported to ClinicalTrials.org, id: NCT03302286. Effects of Extra
Corporeal Circuit Prime on Electrolytes Balance and Clinical Outcome
Following Cardiac Surgery
https://clinicaltrials.gov/study/NCT03302286?id=NCT03302286&rank=1 Cop
yright © The Author(s) 2025

<19>
Accession Number
2043855141
Title
Single Versus Double Perclose Vascular Closure Device in Transfemoral
Transcatheter Aortic Valve Implantation: A Systematic Review and
Meta-Analysis.
Source
Angiology. (no pagination), 2026. Date of Publication: 2026.
Author
Vythoulkas-Biotis N.; Theodoropoulou T.; Gialamas I.; Lysandrou A.;
Pantelidis P.; Zakynthinos G.E.; Oikonomou E.; Katsianos E.; Vavuranakis
M.; Siasos G.; Kalogeras K.
Institution
(Vythoulkas-Biotis, Gialamas, Lysandrou, Pantelidis, Zakynthinos,
Oikonomou, Katsianos, Vavuranakis, Siasos, Kalogeras) Third Department of
Cardiology, Sotiria Chest Diseases Hospital, School of Medicine, National
and Kapodistrian University, Athens, Greece
(Theodoropoulou) First Department of Cardiology, Hippokration General
Hospital, School of Medicine, National and Kapodistrian University,
Athens, Greece
Publisher
SAGE Publications Inc.
Abstract
Complications related to vascular closure devices (VCDs) remain relatively
common after transcatheter aortic valve implantation (TAVI), while the
optimal suture-based strategy remains a subject of debate. This systematic
review and meta-analysis aim to evaluate the efficacy and safety of single
versus double Perclose VCD in patients undergoing transfemoral TAVI. A
literature search was conducted across PubMed, Scopus, and Cochrane
databases to identify appropriate studies. The primary outcome was
technical success; secondary outcomes included vascular and bleeding
complications, bailout interventions, and all-cause mortality. Seven
studies (3940 patients) fulfilled the inclusion criteria. Technical
success was comparable between the two strategies (relative risk [RR]:
.89; 95% confidence interval [CI]: .64-1.22), while the single Perclose
strategy was associated with a lower risk of major vascular complications
(RR: .61; 95% CI: .40-.92), major bleeding (RR: .28; 95% CI: .11-.73) and
bailout surgical interventions (RR: .45; 95% CI: .24-.84). There were no
differences in minor vascular complications and all-cause mortality.
Stepwise closure with the upfront single Perclose strategy demonstrated
comparable technical success and a more favorable safety profile regarding
major vascular complications and bleeding compared with the double
Perclose strategy. Additional randomized controlled trials are essential
to validate these findings. Copyright © The Author(s) 2026

<20>
Accession Number
2042867740
Title
beta-Blockers After Myocardial Infarction in Patients With Preserved
Ejection Fraction: A Meta-Analysis.
Source
JAMA Cardiology. 11(2) (pp 210-212), 2026. Date of Publication: 11 Feb
2026.
Author
Li L.; Li J.; Jiang S.; Sun P.; Wang J.-W.; Zhou X.; Yang Q.
Institution
(Li, Li, Jiang, Sun, Zhou, Yang) Department of Cardiology, Tianjin Medical
University General Hospital, Heping District, Tianjin, China
(Li, Wang) Department of Surgery, Yong Loo Lin School of Medicine,
National University of Singapore, Singapore, Singapore
(Wang) Cardiovascular Research Institute, National University Heart Centre
Singapore, Singapore, Singapore
(Wang) Nanomedicine Translational Research Program, Yong Loo Lin School of
Medicine, National University of Singapore, Singapore, Singapore
(Wang) Department of Physiology, Yong Loo Lin School of Medicine, National
University of Singapore, Singapore, Singapore
Publisher
American Medical Association

<21>
Accession Number
2042350708
Title
The Effects of Daytime Variation on Short-Term Outcomes of Cardiac
Surgical Patients: A PRISMA-Compliant Systemic Review and Meta-Analysis.
Source
Journal of Cardiothoracic and Vascular Anesthesia. 40(2) (pp 492-500),
2026. Date of Publication: 01 Feb 2026.
Author
Yao Y.-T.; Huang S.; Chao M.; More A.
Institution
(Yao, Huang) Department of Anesthesiology, Fuwai Hospital, National Center
for Cardiovascular Diseases, Peking; Union Medical College and Chinese
Academy of Medical Sciences, Beijing, China
(Yao, Huang) Evidence in Cardiovascular Anesthesia (EICA) Group, Beijing,
China
(Yao, Chao, More) Center of Outcomes Research, Department of
Anesthesiology, Critical Care and Pain Medicine, University of Texas,
Houston, TX, United States
(Yao, Chao, More) Outcomes Research Consortium, Houston, TX, United States
Publisher
W.B. Saunders
Abstract
Objective: Circadian rhythms influence cardiovascular physiology and
surgical stress responses, raising the possibility that the timing of
cardiac surgery may affect outcomes. Previous studies have reported
conflicting results regarding whether morning (AM) versus afternoon (AF)
surgery influences perioperative morbidity and mortality. The present
study aimed to systematically evaluate whether the timing of cardiac
surgery, specifically AM versus AF procedures, influences short-term
outcomes. Design(s): A meta-analysis of observational cohort studies.
 Setting(s): Cardiovascular centers. Participant(s): Patients who
underwent elective cardiac surgery. Intervention(s): The AM or the AF
group. Measurements: The primary outcome was hospitalized mortality.
Secondary outcomes included major morbidities (new-onset atrial
fibrillation, myocardial infarction, stroke, renal and infectious
complications, reexploration, mechanical circulatory support) and
postoperative recovery profiles (mechanical ventilation duration, length
of stay [LOS] in the intensive care unit and hospital). Main
Result(s): Fourteen observational studies involving 135,672 patients
(81,391 in the AM group and 54,281 in the AF group) were included. Pooled
analysis showed no significant difference in hospitalized mortality
between the two groups (1.25% [998/79,550] v 1.17% [615/52,442], OR =
1.09, 95% CI = 0.99 to 1.21; p = 0.08]. The incidences of myocardial
infarction, stroke, renal and infectious complications, reexploration, and
mechanical circulatory support use were also comparable. However, AM
surgery was associated with a modestly higher incidence of new-onset
atrial fibrillation (26.05% [2,319/8,907] v 25.50% [1,000/3,921], OR =
1.11, 95% CI = 1.01 to 1.21; p = 0.03). No significant differences were
observed in mechanical ventilation duration [MD = -0.20 hours, 95% CI =
-0.40 to 0.00; p = 0.05], intensive care unit LOS [MD = -0.35 hours, 95%
CI = -6.14 to 5.43; p = 0.90], or hospital LOS [MD = -0.10 days, 95% CI =
-0.39 to 0.19; p = 0.49]. Conclusion(s): These findings suggest that
circadian influences on elective cardiac surgical outcomes are limited.
Future multicenter prospective studies are warranted to further define the
role of surgery timing in high-risk populations. Copyright © 2025
Elsevier Inc.

<22>
Accession Number
2034671077
Title
Management of atrial fibrillation in older adults.
Source
BMJ. 386 (no pagination), 2024. Article Number: e076246. Date of
Publication: 2024.
Author
Parks A.L.; Frankel D.S.; Kim D.H.; Ko D.; Kramer D.B.; Lydston M.; Fang
M.C.; Shah S.J.
Institution
(Parks) University of Utah, Division of Hematology and Hematologic
Malignancies, Salt Lake City, UT, United States
(Frankel) Cardiovascular Division, Perelman School of Medicine, The
University of Pennsylvania, Philadelphia, PA, United States
(Kim, Ko) Hinda and Arthur Marcus Institute for Aging Research, Hebrew
SeniorLife, Harvard Medical School, Boston, MA, United States
(Ko) Richard A and Susan F Smith Center for Outcomes Research, Beth Israel
Deaconess Medical Center, Boston, MA, United States
(Ko) Boston Medical Center, Section of Cardiovascular Medicine, Boston,
MA, United States
(Kramer) Richard A and Susan F Smith Center for Outcomes Research, Beth
Israel Deaconess Medical Center, Harvard Medical School, Boston, MA,
United States
(Lydston) Massachusetts General Hospital, Treadwell Virtual Library,
Boston, MA, United States
(Fang) University of California, San Francisco, Division of Hospital
Medicine, San Francisco, CA, United States
(Shah) Massachusetts General Hospital, Division of General Internal
Medicine, Center for Aging and Serious Illness, Harvard Medical School,
Boston, MA, United States
Publisher
BMJ Publishing Group
Abstract
Most people with atrial fibrillation are older adults, in whom atrial
fibrillation co-occurs with other chronic conditions, polypharmacy, and
geriatric syndromes such as frailty. Yet most randomized controlled trials
and expert guidelines use an age agnostic approach. Given the
heterogeneity of aging, these data may not be universally applicable
across the spectrum of older adults. This review synthesizes the available
evidence and applies rigorous principles of aging science. After
contextualizing the burden of comorbidities and geriatric syndromes in
people with atrial fibrillation, it applies an aging focused approach to
the pillars of atrial fibrillation management, describing screening for
atrial fibrillation, lifestyle interventions, symptoms and complications,
rate and rhythm control, coexisting heart failure, anticoagulation
therapy, and left atrial appendage occlusion devices. Throughout, a
framework is suggested that prioritizes patients' goals and applies
existing evidence to all older adults, whether atrial fibrillation is
their sole condition, one among many, or a bystander at the end of
life. Copyright © Published by the BMJ Publishing Group Limited.

<23>
Accession Number
2043119116
Title
Erector spinae plane block in pediatric surgery: a systematic review and
meta-analysis.
Source
BMC Anesthesiology. 26(1) (no pagination), 2026. Article Number: 112. Date
of Publication: 01 Dec 2026.
Author
Reysner M.; Reysner T.; Kowalski G.; Janusz P.; Mularski A.; Daroszewski
P.; Kolasinski J.; Wieczorowska-Tobis K.
Institution
(Reysner, Reysner) Department of Clinical Anesthesiology and Pain
Management, Chair of Anesthesiology and Intensive Therapy, Poznan
University of Medical Sciences, ul. 28 Czerwca 1956 135/147, Poznan,
Poland
(Janusz) Department of Spine Disorders and Pediatric Orthopedics,
Sciences, Poznan University of Medical, Pznan, Poland
(Mularski) Department of Forensic Medicine, Institute of Medical Sciences
Collegium Medicum, University of Zielona Gora, Zielona Gora, Poland
(Daroszewski) Department of Organization and Management in Health Care,
Poznan University of Medical Sciences, Poznan, Poland
(Kolasinski) Kolasinski Clinic, Hair Clinic Poznan, Swarzedz, Poland
(Kowalski, Wieczorowska-Tobis) Department of Palliative Medicine, Poznan
University of Medical Sciences, Poznan, Poland
Publisher
BioMed Central Ltd
Abstract
Background: The Erector Spinae Plane Block (ESPB) is a well-known regional
anesthesia technique in adults. However, its effectiveness and analgesic
efficiency have yet to be fully established in children. This
meta-analysis aimed to determine the analgesic efficacy of ESPB in
pediatric surgery. Method(s): Following PRISMA guidelines, we
conducted a meta-analysis of prospective randomized clinical trials that
compared the effects of ESPB versus the control group or different
peripheral nerve blocks in pediatric surgery. Result(s): Ten
randomized controlled trials, involving 651 pediatric patients, were
included in the synthesis following critical appraisal. Compared to
no-block analgesia, ESPB significantly prolonged the time to the first
rescue analgesia (SMD 1.30, 95% CI 0.38 to 2.22; p = 0.005) and reduced
postoperative opioid consumption at 24 h (SMD -1.08, 95% CI -2.03 to
-0.13; p = 0.03). ESPB also significantly lowered pain scores at 4 h (p =
0.008) and 6 h (p = 0.0003) postoperatively compared to no-block
analgesia. However, ESPB did not significantly reduce intraoperative
fentanyl consumption (SMD -0.21, 95% CI -1.14 to 0.71; p = 0.65).
 Conclusion(s): ESPB improved analgesic efficacy in pediatric surgery,
particularly compared with caudal or no-block analgesia; however, the
overall certainty of evidence ranged from low to moderate according to the
GRADE approach. Further high-quality, methodologically robust RCTs are
required. Trial registration: The study was registered in the
International Register of Systematic Reviews (PROSPERO) and is available
online (www.crd.york.uk/prospero, CRD42023483105). Copyright ©
The Author(s) 2026.

<24>
Accession Number
2043117809
Title
PROthrombin complex concentrate versus fresh frozen Plasma for bleeding in
adults undergoing HEart SurgerY (PROPHESY-2 trial): a phase III,
randomised control trial in England and Wales.
Source
Trials. 27(1) (no pagination), 2026. Article Number: 128. Date of
Publication: 01 Dec 2026.
Author
Brown-O'Sullivan C.; Agarwal S.; Akowuah E.; Arbon E.; Gardner M.;
Hounslea E.; Hudson C.; Klein A.; Loubani M.; McCullagh J.; Murphy G.;
Murray S.; Rourke C.; Sanders J.; Simpson L.; Smith L.; Stanworth S.;
Tomini F.; Vides N.; Workman J.; Green L.
Institution
(Brown-O'Sullivan, Arbon, Gardner, Hounslea, Hudson, Rourke, Smith, Vides,
Workman) NHS Blood and Transplant Clinical Trials Unit, Cambridge, United
Kingdom
(Agarwal) Manchester University Hospital, Manchester, United Kingdom
(Akowuah) Newcastle University, Newcastle, United Kingdom
(Klein) Royal Papworth Hospital NHS Foundation Trust, Cambridge, United
Kingdom
(Loubani) Hull University Teaching Hospitals, NHS Trust, Cottingham,
United Kingdom
(McCullagh, Green) NHS Blood and Transplant and Barts Health NHS Trust,
London, United Kingdom
(McCullagh, Simpson, Tomini, Green) Queen Mary University of London,
London, United Kingdom
(McCullagh, Green) NHS Blood and Transplant and Queen Mary University of
London, London, United Kingdom
(Murphy) University of Leicester, Leicester, United Kingdom
(Murray) Patient and Public Representative, London, United Kingdom
(Sanders) King's College London, London, United Kingdom
(Stanworth) NHS Blood and Transplant, Oxford University Hospitals NHS
Trust and University of Oxford, Oxford, United Kingdom
Publisher
BioMed Central Ltd
Abstract
Background: Fresh frozen plasma (FFP) is the standard treatment for severe
bleeding following cardiac surgery. Despite increasing use of prothrombin
complex concentrate (PCC) for coagulopathic bleeding in preference to FFP
in the UK, the evidence comparing FFP versus PCC in this setting is
lacking. Hypothesis: In adults who develop severe bleeding, PCC is
superior to FFP in reducing a composite of mortality, organ failure, or
infection up to 90 days following cardiac surgery, and is more
cost-effective. Method(s): Phase III pragmatic, multicentre, parallel
group, superiority, non-blinded, open-label, two-stage group sequential
randomised controlled trial with internal pilot embedded. Participants
will be recruited by the research team at up to 20 hospitals in England
and Wales. Those who have provided informed consent and who develop
bleeding within 24 h of cardiac surgery (elective and urgent procedures)
will be randomised to PCC (1500 IU if <=70 kg or 2000 IU if >70 kg; a
maximum of 2 doses) or FFP (4 units if <=70 kg and 5 units if >70 kg; no
maximum dose). Randomisation will be stratified by site and will allocate
participants using minimisation, with a 1:1 ratio to receive PCC or FFP.
Age (>=70 and <70 years) and planned type of surgery (valve only, major
aortic surgery, coronary artery bypass graft + valve, and complex/combined
procedure) will be the minimisation factors. The primary outcome is a
composite of mortality or new onset of respiratory failure, myocardial
injury, renal failure, liver injury, intestinal injury, focal neurological
deficit, or infection at 90 days. Secondary outcomes will compare safety
(transfusion-related reactions, thrombosis), quality of life, healthcare
costs, and cost-effectiveness. A sample size of 496 participants will have
a 90% power (with a 5% significance level) to detect a relative risk of
0.7 between the two groups at 90 days. The date of the 1st patient
enrolled was 11th February 2025. Discussion(s): This trial will
provide evidence on the clinical/cost-effectiveness of PCC versus FFP in
cardiac surgery patients who bleed post-surgery. Its outcome will provide
high-quality evidence to inform the management of bleeding following
cardiac surgery. Trial registration: ISRCTN 92114384. Registered on
16/04/2024. ISRCTN-ISRCTN92114384: PROthrombin complex concentrate versus
fresh frozen Plasma for bleeding in adults undergoing HEart SurgerY
(PROPHESY-2 trial) Copyright © The Author(s) 2026.

<25>
Accession Number
2032774088
Title
Antiplatelet therapy after coronary artery bypass surgery: five year
follow-up of randomised DACAB trial.
Source
BMJ. 385 (no pagination), 2024. Date of Publication: 2024.
Author
Zhu Y.; Zhang W.; Dimagli A.; Han L.; Cheng Z.; Mei J.; Chen X.; Wang X.;
Zhou Y.; Xue Q.; Hu J.; Tang M.; Wang R.; Song Y.; Kang L.; Redfors B.;
Gaudino M.; Zhao Q.
Institution
(Zhu, Zhou, Kang, Zhao) Department of Cardiovascular Surgery, Ruijin
Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, China
(Zhang) Department of Biostatistics, School of Public Health, Fudan
University, Shanghai, China
(Dimagli, Gaudino) Department of Cardio-thoracic Surgery, Weill Cornell
Medicine, New York, NY, United States
(Han, Xue) Department of Cardiovascular Surgery, The First Affiliated
Hospital of Naval Medical University (Shanghai Changhai Hospital),
Shanghai, China
(Cheng, Hu) Department of Cardiac Surgery, Heart Centre of Henan
Provincial People's Hospital, Central China Fuwai Hospital of Zhengzhou
University, Zhengzhou, China
(Mei, Tang) Department of Cardiothoracic Surgery, Xinhua Hospital Shanghai
Jiao Tong University School of Medicine, Shanghai, China
(Chen, Wang) Department of Cardiovascular Surgery, Nanjing First Hospital,
Nanjing Medical University, Nanjing, China
(Wang, Song) Department of Cardiovascular Surgery, Jiangsu Province
Hospital, Nanjing, China
(Redfors) Department of Cardiology, Sahlgrenska University Hospital,
Gothenburg, Sweden
Publisher
BMJ Publishing Group
Abstract
OBJECTIVE To assess the effect of different antiplatelet strategies on
clinical outcomes after coronary artery bypass grafting. DESIGN Five year
follow-up of randomised Different Antiplatelet Therapy Strategy After
Coronary Artery Bypass Grafting (DACAB) trial. SETTING Six tertiary
hospitals in China; enrolment between July 2014 and November 2015;
completion of five year follow-up from August 2019 to June 2021.
PARTICIPANTS 500 patients aged 18-80 years (including 91 (18.2%) women)
who had elective coronary artery bypass grafting surgery and completed the
DACAB trial. INTERVENTIONS Patients were randomised 1:1:1 to ticagrelor 90
mg twice daily plus aspirin 100 mg once daily (dual antiplatelet therapy;
n=168), ticagrelor monotherapy 90 mg twice daily (n=166), or aspirin
monotherapy 100 mg once daily (n=166) for one year after surgery. After
the first year, antiplatelet therapy was prescribed according to standard
of care by treating physicians. MAIN OUTCOME MEASURES The primary outcome
was major adverse cardiovascular events (a composite of all cause death,
myocardial infarction, stroke, and coronary revascularisation), analysed
using the intention-to-treat principle. Time-to-event analysis was used to
compare the risk between treatment groups. Multiple post hoc sensitivity
analyses examined the robustness of the findings. RESULTS Follow-up at
five years for major adverse cardiovascular events was completed for 477
(95.4%) of 500 patients; 148 patients had major adverse cardiovascular
events, including 39 in the dual antiplatelet therapy group, 54 in the
ticagrelor monotherapy group, and 55 in the aspirin monotherapy group.
Risk of major adverse cardiovascular events at five years was
significantly lower with dual antiplatelet therapy versus aspirin
monotherapy (22.6% v 29.9%; hazard ratio 0.65, 95% confidence interval
0.43 to 0.99; P=0.04) and versus ticagrelor monotherapy (22.6% v 32.9%;
0.66, 0.44 to 1.00; P=0.05). Results were consistent in all sensitivity
analyses. CONCLUSIONS Treatment with ticagrelor dual antiplatelet therapy
for one year after surgery reduced the risk of major adverse
cardiovascular events at five years after coronary artery bypass grafting
compared with aspirin monotherapy or ticagrelor monotherapy. Copyright
© 2024 BMJ Publishing Group. All rights reserved.

<26>
Accession Number
2041116691
Title
Nonsteroidal Anti-Inflammatory Drugs as Part of a Multimodal Postoperative
Pain Management Strategy in Patients Undergoing Cardiac Surgery: A
Meta-Analysis of 11 Randomized Clinical Trials.
Source
Journal of Cardiothoracic and Vascular Anesthesia. 40(2) (pp 699-709),
2026. Date of Publication: 01 Feb 2026.
Author
Beshr M.S.; Shembesh R.H.; Salama A.H.; Kara A.O.; Arora R.C.; Abuajamieh
M.; Arhaym E.; Grant M.C.; Gregory A.J.; Elhadi M.
Institution
(Beshr) Faculty of Medicine and Health Sciences, Sana'a University,
Sana'a, Yemen
(Shembesh) Faculty of Medicine, Libyan International Medical University,
Benghazi, Libyan Arab Jamahiriya
(Salama) University of Health Sciences, Hamidiye International School of
Medicine, Istanbul, Turkey
(Kara, Arhaym) Faculty of Medicine, University of Benghazi, Benghazi,
Libyan Arab Jamahiriya
(Arora) Division of Cardiac Surgery, Harrington Heart and Vascular
Institute, University Hospitals, Cleveland, Ohio, United States
(Abuajamieh) Faculty of Medicine, Cairo University, Cairo, Egypt
(Grant) Department of Anesthesiology and Critical Care Medicine, Johns
Hopkins University School of Medicine, Baltimore, MD, United States
(Gregory) Department of Anesthesiology, Perioperative and Pain Medicine
and Libin Cardiovascular Institute, Cumming School of Medicine, University
of Calgary, Calgary, AB, Canada
(Elhadi) College of Medicine, Korea University, Seoul, South Korea, South
Korea
Publisher
W.B. Saunders
Abstract
Background: Effective and safe pain management is crucial for optimal
recovery after cardiac surgery. Traditionally, opioids have been the
mainstay for postoperative pain control, but their negative health effects
have led to a recent shift toward multimodal analgesia to minimize opioid
use. The use of nonsteroidal anti-inflammatory drugs (NSAIDs) has been
controversial owing to concerns about bleeding, acute kidney injury (AKI),
graft patency, and cardiovascular risks. Despite these concerns, many
perioperative teams continue to use NSAIDs alongside opioids as part of
multimodal analgesia. This meta-analysis evaluated the efficacy and safety
of NSAIDs as a multimodal pain management tool following cardiac surgery.
 Method(s): An electronic search was conducted on November 15, 2024,
using PubMed, Scopus, Web of Science, Embase, and Cochrane databases. Only
controlled trials that combined NSAIDs with opioids for pain management
following cardiac surgeries were included. The primary outcome was the
visual analog scale (VAS), a 0 to 10 scale measuring pain intensity
assessed at 6, 12, 18, 24, and 48 hours. Total opioid consumption was
measured at 6, 12, 24, and 48 hours. Secondary outcomes included
myocardial infarction, atrial fibrillation, kidney function,
gastrointestinal bleeding, nausea, and vomiting. The mean difference (MD)
was used for continuous outcomes, and the odds ratio (OR) was used for
dichotomous outcomes. A random-effects model was applied for the analysis.
 Result(s): Out of the 1,194 articles screened, 11 articles, totaling
1,463 patients, were included in the meta-analysis. The NSAID group
demonstrated significantly lower VAS scores at the 12-hour (MD, -1.19, 95%
confidence interval [CI], -1.83 to -0.56; p < 0.001), 24-hour (MD, -0.61;
95% CI, -0.97 to -0.24; p = 0.001), 18-hour (MD, -1.43; 95% CI, -2.58 to
-0.28; p = 0.01), and 48-hour (MD, -0.68; 95% CI, -0.87 to -0.49; p <
0.001) time points. However, no significant differences in VAS scores were
observed at the 6-hour mark. Regarding opioid consumption, the NSAID group
demonstrated significantly lower opioid consumption at the 24-hour (MD,
-8.10; 95% CI, -10.60 to -5.61; p < 0.001) and 48-hour (MD, -7.13; 95% CI,
-12.44 to -1.82; p = 0.009); however, no differences were observed at the
6-hour and 12-hour marks. Finally, there were no significant differences
between the NSAID and control groups in the incidence of gastrointestinal
bleeding, atrial fibrillation, myocardial infarction, or AKI.
 Conclusion(s): NSAID use was associated with modestly reduced VAS
scores at 12, 18, 24, and 48 hours, while opioid consumption was
significantly lower at 24 and 48 hours postoperatively. Short-term NSAID
use can be effective in reducing pain and opioid requirements. Although no
significant difference in complications was observed, the analysis was
limited by small sample sizes. More extensive randomized controlled trials
are needed to assess the effectiveness and safety of NSAIDs as part of a
multimodal analgesic strategy. Copyright © 2025 Elsevier Inc.

<27>
Accession Number
2043434210
Title
M-TEER-interventional repair of mitral valve regurgitation.
Source
Herz. (no pagination), 2026. Date of Publication: 2026.
Author
Iliadis C.; Baldus S.
Institution
(Iliadis, Baldus) Faculty of Medicine and University Hospital Cologne,
Department III for Internal Medicine, University of Cologne, Cologne,
Germany
Publisher
Springer Medizin
Abstract
Mitral valve transcatheter edge-to-edge repair (M-TEER) has emerged as an
alternative therapy for mitral regurgitation (MR), addressing the unmet
clinical need for patients with high surgical risk. Previous large
randomized controlled trials (RCTs), including EVEREST II, COAPT, and
MITRA-FR, have established the safety and efficacy of M-TEER for both
etiologies of MR: primary (PMR) and secondary MR (SMR). The field of SMR
treatment has been updated by the recent RCTs RESHAPE-HF2 and MATTERHORN,
which have expanded the recommendations of M-TEER in the current European
guidelines. This article summarizes key evidence from pivotal trials,
discusses patient selection, and presents ongoing studies in the field of
M-TEER. Copyright © The Author(s), under exclusive licence to
Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2026.

<28>
[Use Link to view the full text]
Accession Number
2032793584
Title
Factors Associated With Coronary Angiography Performed Within 6 Months of
Randomization to the Conservative Strategy in the ISCHEMIA Trial.
Source
Circulation: Cardiovascular Interventions. 17(6) (pp 457-473), 2024. Date
of Publication: 01 Jun 2024.
Author
Spertus J.A.; Broderick S.; Rockhold F.W.; Demchenko E.; Grossman G.B.;
Stone G.W.; Mancini G.B.J.; Hochman J.S.; Boden W.E.; Mavromatis K.; Doan
J.; Linefsky J.; Lee R.; Patel R.; Miller T.; Cho S.Y.; Milbrandt S.;
Shelstad D.; Banerjee S.; Kamath P.; Tejani I.; Reynolds H.R.; Newman
J.D.; Bangalore S.; Phillips L.M.; Saric M.; Abdul-Nour K.; Schley A.;
Golden H.; Stone P.H.; Osseni H.; Wiyarand C.; Douglass P.; Pomeroy H.;
Craft A.; Harvey B.; Jang J.J.; Anaya O.; Yee G.; Goold P.; Weitz S.;
Giovannone S.; Pritchard L.; Arnold S.; Gans R.; O'Keefe J.H.; Kennedy P.;
Shapiro M.D.; Ganesan S.; Schlichting D.; Naher A.; Fein S.A.; Stewart
W.L.; Torosoff M.T.; Salmi K.M.; Lyubarova R.; Mookherjee S.; Drzymalski
K.; McFalls E.O.; Garcia S.A.; Bertog S.C.; Johnson D.K.; Siddiqui R.A.;
Herrmann R.R.; Ishani A.; Hansen R.A.; Khouri M.G.; Arges K.; LeFevre M.;
Tomfohr J.; Goldberg J.L.; Byrne K.A.; Zappernick T.; Goldweit R.; Canada
S.; Kakade M.; Mieses P.; Cohen R.A.; Mirrer B.; Navarro V.; Rantinella
M.; Rodriguez J.; Mancilla O.; Winchester D.E.; Stinson S.; Kronenberg M.;
Weyand T.; Crook S.C.; Heitner J.F.; Ho J.; Khan S.; Mohamed M.; Dauber
I.M.; Soltau M.R.; Rose D.K.; Wimmer R.J.; Siegel K.E.; Derbyshire S.;
Cannan C.; Dixon M.; Leonard G.; Sudarshan S.; Heard C.; Gabriel V.;
Desire S.; Mehta P.K.; McDaniel M.; Rashid F.; Lerakis S.; Asier S.;
Quyyumi A.; Patel K.; Wenger N.K.; Hedgepeth C.M.; Gillis J.; Hurlburt H.;
Manocchia M.; Rosen A.; Moore S.; Congdon E.; Sahul Z.; Brandt G.;
Marchelletta N.; Wippler K.; Leung S.; Reda H.; Ziada K.; Setty S.;
Halverson K.E.; Roraff C.; Thorsen J.; Barua R.S.; Ojajuni A.; Olurinde
O.; Surineni K.; Hage F.; Valaiyapathi B.; Davies J.E.; Leesar M.; Heo J.;
Iskandrian A.; Al Solaiman F.; Dajani K.; Kartje C.M.; El-Hajjar M.;
Mesropian P.D.; Sacco J.; Rawlins M.; McCandless B.; Thomson J.; Orgera
M.; Sidhu M.S.; Rogge M.C.; Arif I.; Bunke J.; Kerr H.; Unterbrink K.;
Fannon J.; Burman C.; Trejo J.F.; Dubin M.F.; Fletcher G.; Lane G.E.;
Neeson L.M.; Parikh P.P.; Pollak P.M.; Shapiro B.P.; Landolfo K.;
Gemignani A.; Beaudry S.; O'Rourke D.; Meadows J.L.; Tirado S.A.; Halliday
J.; Julian P.; Call J.T.; Lane S.M.; Stanford J.L.; Hannan J.; Bojar R.;
Arsenault P.; Kumar D.; Sigel P.; Mukai J.; Martin E.T.; Brooks M.;
Vorobiof G.; Douangvila L.; Gevorgyan R.; Moor-Man A.; Ranjbaran F.; Smith
B.; Ohmart C.; Kinlay S.; Hamburger R.J.; Rocco T.P.; Ly S.; Bhatt D.L.;
Quinn M.C.; Croce K.; Temiyasathit S.; Quin J.A.; Do J.; Anumpa J.; Tobin
D.; Zenati M.; Faxon D.P.; Rayos G.; Langdon J.; Bayer M.W.; Seedhom A.;
O'Malley A.; Sullenberger L.; Orvis E.; Kumkumian G.; Murphy M.; Greenberg
A.; Iraola M.; Sedlis S.P.; Maranan L.C.; Donnino R.M.; Lorin J.;
Tamis-Holland J.E.; Malinay A.; Kornberg R.; Leber R.; Saba S.; Edillo
C.P.; Lee M.W.; Small D.R.; Nona W.; Alexander P.B.; Rehman I.; Badami U.;
Ostrander A.; Wasmiller S.; Marzo K.; Drewes W.; Patel D.; Robbins I.H.;
Levite H.A.; White J.M.; Shetty S.; Hallam A.; Patel M.; Hamroff G.S.;
Spooner B.J.; Hollenweger L.M.; Little R.W.; Little H.; Zimbelman B.D.;
Little T.; Lui C.Y.; Eskelson N.A.; Smith B.R.; Vezina D.P.; Khor L.L.;
Abraham J.D.; Bull D.A.; McKellar S.H.; Booth D.; Taul Y.; Kotter J.;
Rodgers C.; Abdel-Latif A.; Isaacs J.; Bulkley V.; Hu B.; Kaneshiro R.;
Labovitz A.J.; Berlowitz M.; Kirby B.J.; Rogal P.; Tran N.N.; McFarren C.;
Jahrsdorfer C.; Matar F.; Caldeira C.; Maron D.J.; Rodriguez F.; Yunis R.;
Schnittger I.; Patro J.; Fearon W.F.; Deedwania P.; Vega A.; Reddy K.;
Sweeny J.; Bloise-Adames H.; Jimenez S.; Vrestil N.S.; Bhandari R.;
Spizzieri C.; Schade D.; Yost R.; Hochberg C.P.; Beardsley P.; Fine D.;
Salerno W.D.; Tancredi J.; Arakelian P.; Mathus S.; O'Neill D.; Wyman R.;
Burkhardt J.; Hosino S.; Lubyanaya O.A.; Salas J.D.; Zarka A.; Aguirre M.;
Shah A.V.; Dhawan M.; Parra D.; Tran T.; Haldis T.; Fowler-Lehman K.;
Spitzer N.; Riedberger C.; Weick C.; Kohn J.A.; Girotra S.; Drum C.;
Miller-Cox K.; Ollinger A.; Almousalli O.; Capasso-Gulve E.; Loehr A.M.;
Mosley M.; Krishnam M.S.; Heydari S.; Mil-Liken J.C.; Lundeen A.M.; Patel
P.M.; Karanjah E.; Seto A.H.; Marfori W.C.; Harley K.T.; Hernandez-Rangel
E.; Gibson M.A.; Singh P.; Allen B.J.; Coram R.; Webb A.M.; Fridell E.;
Wilson H.; Thomas S.; Kim A.; Schwartz R.G.; Wilmot P.; Chen W.; El
Shahawy M.; Stevens R.; Stafford J.; Black L.; Abernethy W.B.; Hull A.B.;
Lim O.J.; Tucker H.C.; Putnam N.C.; Hall L.L.; Cauthren T.; Tucker T.;
Zurick A.; Horton H.; Orga J.; Meyer T.M.; White J.R.; Morford R.G.;
Baumann C.; Rutkin B.; Seeratan V.; Bokhari S.; Jimenez M.; Sokol S.I.;
Schultz C.; Meisner J.; Russo J.; Hamzeh I.; Misra A.; Huda Z.; Wall M.;
Boan A.; De Rosen V.L.; Alam M.; Turner M.C.; Hinton C.R.; Mulhearn T.J.;
Good A.P.; Archer B.A.; Dionne J.S.; Allardyce C.A.; Sikora L.N.; Czerniak
J.H.; Mull J.A.; Ferguson E.; Laube F.; Shammas N.W.; Shammas G.A.;
Christensen L.; Park H.; Chilton R.; Hecht J.; Nguyen P.K.; Vo D.; Hirsch
J.; Jezior M.; Bindeman J.; Salkind S.; Desimone L.-A.; Gordon P.C.;
Felix-Stern L.; Crain T.; Gomes J.; Gordon C.; Stenberg R.; Mann A.;
McCreary T.; Pedalino R.P.; Cobos S.E.; Dwyer R.R.; Espinosa D.; Quiles
K.J.; Wiesel J.; Juang G.J.; Gopaul C.; Hultberg K.; Huk T.; Hussain A.;
Al-Amoodi M.; Zambrano Y.; Rodriguez S.M.; Milner T.; Wohns D.; Mulder A.;
Van Oosterhout S.; Lader E.W.; Meyer M.; Mumma M.; Clapp N.L.; Barrentine
H.; Dharmarajan L.; Jose J.M.; Manchery J.; McGarvey J.F.X.; McKinney V.;
Schwarz L.; Downes T.R.; Kaczkowski S.M.; Luckasen G.J.; Jaskowiak A.J.;
Klitch J.; Cheong B.; Dees D.; Potluri S.; Vasquez P.; Mastouri R.A.;
Breall J.A.; Hannemann E.L.; Revtyak G.E.; Foltz J.M.; Bazeley J.W.;
DeRosa E.; Jorgenson B.; Riestenberg-Smith J.; Giedd K.; Old W.; Bariciano
R.; Burt F.; Sokhon K.; Waldron J.; Mayon M.; Gopal D.; Valeti U.S.;
Peichel G.A.; Kobashigawa J.; Starks B.; Garcia L.; Thottam M.; Anand A.;
Govindan S.C.; Raj J.; Nair R.G.; Ravindran R.; Rajalekshmi V.S.;
Manjunath C.N.; Nataraj N.; Moorthy N.; Nayak S.; Manjunath S.C.;
Mylarappa M.; Narayanappa S.; Pandit N.; Bajaj S.; Nath R.K.; Yadav V.;
Mishra G.; Dwivedi S.K.; Tewari R.; Narain V.S.; Mishra M.; Chandra S.;
Patel S.; Wander G.S.; Tandon R.; Ralhan S.; Kaur B.; Aslam N.; Gupta S.;
Pharmacy B.; Goyal A.; Bhargava B.; Suvarna C.; Karthikeyan G.;
Ramakrishnan S.; Seth S.; Yadav R.; Singh S.; Roy A.; Parakh N.; Verma
S.K.; Narang R.; Mishra S.; Naik N.; Sharma G.; Choudhary S.K.; Patel C.;
Gulati G.; Sharma S.; Bahl V.K.; Mathew A.; Kurian B.M.; Punnoose E.;
Gadkari M.A.; Karwa S.R.; Gadage S.; Kolhe S.; Pillay T.U.; Satheesh S.;
Vindhya R.J.; Jain P.; Seth A.; Meharwal Z.S.; Mathur A.; Verma A.; Bhatia
M.; Sachdeva A.; Devi T.I.; Jungla N.; Rani K.M.; Menon R.; Reddy M.S.;
Oomman A.; Sidh R.R.; Mao R.; Ramakrishnan T.; Solomon H.; Francis R.;
Priya V.P.; Khan S.P.; Preethi K.; Kumar N.; Grant P.; Hande S.; Sonawane
P.; Kachru R.; Dubey A.; Rawat K.; Kumar A.V.K.; Ganapathi S.; Jayakumar
K.; Vineeth C.P.; Sivadasanpillai H.; Chacko M.; Sasidharan B.; Babu S.;
Kapilamoorthy T.R.; Christopher J.; Reddy S.; Polamuri P.; Rani M.; Kaul
U.; Arambam P.; Singh B.; Senior R.; Fox K.A.A.; Carruthers K.; Elghamaz
A.; Gurunathan S.; Karogiannis N.; Young G.M.; Shah B.N.; Kinsey C.;
Trimlett R.H.J.; Kavalakkat R.; Rubens M.B.; Evans J.; Nicol E.D.; Hassan
I.; Mittal T.K.; Hampson R.; Gamma R.A.; Williams S.; Holland K.; Swan K.;
de Belder M.A.; Atkinson B.; Thambyrajah J.; Nageh T.; Kunhunny S.; Davies
J.R.; Lindsay S.J.; Atkinson C.; Kurian J.; Krannila C.; Jamil H.; Vinod
M.; Raheem O.; Hoye A.; Chaytor L.; Cox L.; Morrow J.; Rowe K.; Donnelly
P.; Kelly S.; Valecka B.; Regan S.; Turnbull D.; Chauhan A.; Fleming C.;
Ghosh A.; Gratrix K.; Preston S.; Barr C.; Cartwright A.; Alfakih K.;
Knighton A.; Byrne J.; Martin K.; Webb I.; Henriksen P.; Flint L.;
Harrison J.; OKane P.; Lake-Man N.; Ljubez A.; de Silva R.; Conway D.S.G.;
Wright J.; Exley D.; Sirker A.A.; Andiapen M.; Richards A.J.; Hoole S.P.;
Wong L.; Witherow F.N.; Munro M.J.; Harbinson M.; McEvoy M.; Walsh S.; Bao
B.; Brown C.; Douglas H.; Luckie M.; Charles T.; Kolakaluri L.; Phillips
H.; Sobolewska J.; Morby L.; Hallett K.; Corbett C.; Winstanley L.;
Jeetley P.; Smit A.; Patel N.; Kotecha T.; Travill C.; Gent S.; Karimullah
I.; Hussain N.; Al-Bustami M.; Braganza D.; Haines F.; Taaffe J.;
Henderson R.; Burton J.; Pointon K.; Colton M.; Naik S.; King R.; Mathew
T.; Brown A.; Docherty A.; Berry C.; McCloy L.; Collison D.; Robb K.;
Roditi G.; Paterson C.; Crawford W.; Kelly J.; McGregor L.; Moriarty A.J.;
Mackin A.; Glover J.D.; Knight J.P.; Pradhan J.; Mikhail G.; Bose T.;
Francis D.P.; Dzavik V.; Proietti A.; Brousseau M.; Corfias M.; Blaise P.;
Harvey L.; Diaz A.; Rheault P.; Barrero M.; Gagne C.-E.; Alarie P.;
Pepin-Dubois Y.; Arcand L.; Costa R.; Roy I.; Sia Y.T.; Montpetit E.;
Lemay C.; Gisbert A.; Gervais P.; Rheault A.; Drouin K.; Phaneuf D.C.;
Bergeron C.; Gosselin G.; Shelley C.; Masson C.; Garg P.; Carr S.; Bone
C.; Chow B.J.W.; Moga E.; Hessian R.C.; Kourzenkova J.; Beanlands R.S.;
Walter O.; Davies R.F.; Bainey K.R.; Hogg N.; Welsh S.; Bagai A.; Wald R.;
Goodman S.; Graham J.J.; Peterson M.; Bello O.; Chow C.-M.; Abramson B.;
Cheema A.N.; Syed I.; Vakani M.T.; Hussain M.; Kushniriuk K.; Cha J.; Otis
J.; Otis R.; Howarth A.G.; Seib M.M.; Rivest S.M.; Sandonato R.; Chow J.;
Starovoytov A.; Uchida N.; Meadows N.; Uxa A.; Asif N.; Tavares S.;
Galiwango P.; Bozek B.; Kassam S.; Shier M.; Mukherjee A.; Larmand L.-A.;
Ricci A.J.; Janmohamed A.; Hart B.; Lam A.; Marucci J.; Tai S.; Mehta S.;
Brons S.; Beck C.; Wong G.; Etherington K.; Arumairajah T.; Udell J.;
Aprile M.; Karlsson S.; Webber S.; Genereux P.; Mercure C.; Hameed A.;
Aedy N.; Daba L.; Farquharson F.; Siddiqui A.; Lopes R.D.; Hueb W.;
Takiuti M.E.; Rezende P.C.; Silva E.E.R.; Hueb A.C.; Smanio P.E.P.;
Caetano L.P.; de Quadros A.S.; Kalil R.A.K.; Deiro A.P.; da Costa Vieira
J.L.; Muller A.M.; Grossmann G.; de Moraes M.A.P.; de Oliveira P.P.;
Ascoli B.M.; Bridi L.; Poletti S.Z.; Savaris S.; Vitola J.V.; Cerci R.J.;
Zier S.S.; Farias F.R.; Veiga V.; Fernandes M.M.; Marin-Neto J.A.; Schmidt
A.; de Oliveira Lima Filho M.; da Cunha D.F.; Oliveira R.M.; Chierice
J.R.A.; Polanczyk C.A.; Rucatti G.G.; Furtado M.V.; Igansi F.; Smidt L.F.;
Haeffner M.P.; Carvalho A.C.; Almeida V.; Pucci G.; de Souza G.S.; Lyra
F.; Alves A.R.; Almeida M.; dos Santos V.; Dracoulakis M.D.A.; Oliveira
N.S.; Lima R.G.S.D.; Figueiredo E.; Azevedo B.E.P.; Caramori P.R.; Santos
M.B.; Germann A.; Gomes V.; Homem R.; Magedanz E.; Tumelero R.; Laimer R.;
Tognon A.; Dall'Orto F.; Mesquita C.T.; Santos R.P.; Colafranseschi A.S.;
Oliveira A.C.; Carvalho L.A.; Palazzo I.C.; Sousa A.S.; da Silva E.E.R.;
de Barros e Silva P.G.M.; Okada M.Y.; de Padua Silva Baptista L.; Batista
A.P.; Rodrigues M.J.; Rabaca A.N.; de Resende M.V.C.; Saraiva J.F.; Trama
L.M.; de Souza Ormundo C.T.; Vicente C.; Costantini C.; Pinheiro C.; Komar
D.; Ruzyllo W.; Demkow M.; Pracon R.; Kepka C.; Teresinska A.; Walesiak
O.; Kryczka K.; Malinowska K.; Henzel J.; Solecki M.; Kaczmarska E.;
Mazurek T.; Maksym J.; Wojtera K.; Fojt A.; Szczerba E.; Drozdz J.;
Czarniak B.; Frach M.; Szymczyk K.; Niedzwiecka I.; Sobczak S.; Ciurus T.;
Jakubowski P.; Misztal-Teodorczyk M.; Teodorczyk D.; Swiderek M.; Fratczak
A.; Wojtala E.; Szkopiak M.; Lebioda P.; Wlodarczyk M.; Plachcinska A.;
Kusmierek J.; Miller M.; Marciniak H.; Wojtczak-Soska K.; Luczak K.;
Tarchalski T.; Cichocka-Radwan A.; Szwed H.; Karwowski J.; Szulczyk G.A.;
Witkowski A.; Kukula K.; Celinska-Spodar M.; Zalewska J.; Gajos G.; Bury
K.; Pruszczyk P.; Labyk A.; Roik M.; Szramowska A.; Zdonczyk O.;
Loboz-Grudzien K.; Jaroch J.; Sokalski L.; Brzezinska B.; Lesiak M.;
Lanocha M.; Reczuch K.W.; Kolodziej A.; Kalarus Z.; Swiatkowski A.; Szulik
M.; Musial W.J.; Marcinkiewicz-Siemion M.; Bockeria O.; Bockeria L.;
Petrosyan K.; Kudzoeva Z.; Trifonova T.; Aripova N.; Chernyavskiy A.M.;
Naryshkin I.A.; Kretov E.I.; Kuleshova A.; Grazhdankin I.O.; Malaev D.;
Bershtein L.L.; Sayganov S.A.; Subbotina I.; Kuzmina-Krutetskaya A.M.;
Gumerova V.; Zbyshevskaya E.V.; Katamadze N.O.; Demchenko E.A.; Nikolaeva
O.B.; Kozlov P.S.; Kozulin V.Y.; Lubinskaya E.I.; Lopez-Sendon J.L.;
Lopez-Sendon J.; Fernandez-Figares V.; Castro A.; Salicio E.R.; Guzman G.;
Galeote G.; Valbuena S.; Peteiro J.; Martinez-Ruiz M.D.; Perez-Fernandez
R.; Blanco-Calvo M.; Cuenca-Castillo J.J.; Alonso-Alvarez E.; Flores-Rios
X.; Garcia-Gonzalez P.; Prada-Delgado O.; Barge-Caballero G.; Juanatey
J.R.G.; Amigo J.S.; Bayarri M.S.; Nunez V.P.; Sanchez R.O.; Alvarez B.C.;
Gil C.P.; Monzonis A.M.; Sionis A.; Martinez A.F.; Perales M.V.; Padro
J.M.; Penaranda A.S.; Picart J.G.; Iglesias A.G.; Marimon X.G.-M.; Llado
G.P.; Costa F.C.; Miro V.; Igual B.; Diez J.L.; Calvillo P.; Ortuno F.M.;
Chavarri M.V.; Giner M.Q.; Montolliu A.T.; Aniorte A.I.R.; Bermudez E.P.;
Caravaca J.M.R.; De La Morena G.; Blancas M.G.; Canavate O.; Guerrero S.;
Riera S.; Luena J.E.C.; Lasala M.; Fernandez-Aviles F.; Lorenzo M.;
Sobrino O.; Vazquez A.; Jiang L.; Chen J.; Dong H.; He P.; Xia C.; Yang
J.; Zhong Q.; Wu Y.; Tian Y.; Li D.; Ma Y.; Yang Y.; Ma X.; Yu Z.; Zhao
Q.; Ji Z.; Li C.; Zhu B.; Yang X.; Chen M.; Chi H.; Zhang J.; Lin W.; Jing
R.; Liu J.; Zeng H.; Zhou Q.; Xu C.; Li Z.; Xiong L.; Fu X.; Gao D.; Jiang
D.; Leng R.; Yuan Q.; Zhang L.; Bai Z.; Li J.; Qi J.; Wang F.; Wang H.;
Yang B.; Yue Z.; Zhang Z.; Wang S.; Dong Y.; Mao J.; Zhang B.; Cheng G.;
Li X.; Yao X.; Zhong N.; Zhou N.; Huang Y.; Zhou P.; Fang X.; Su W.; Zeng
Q.; Kunwu Y.; Peng Y.; Su X.; Wang C.; Zhao Y.; Li Q.; Geng Y.; Wang Y.;
Nie S.-P.; Fan J.-Y.; Feng S.-T.; Wang X.; Yan Y.; Zhang H.-M.; Yu Q.; Chi
L.; Liu F.; Chen H.; Jiang J.; Li H.; Wang J.; Han Y.; Xu L.; Zhang S.;
Liu Z.; Chen G.; Hu R.; Perna G.P.; Pietrucci F.; Marini M.; Gabrielli G.;
Provasoli S.; Di Donato A.; Verna E.; Monti L.; Nardi B.; Di Chiara A.;
Pezzetta F.; Mortara A.; Casali V.; Galvani M.; Attanasio C.; Ottani F.;
Sicuro M.; Leone G.; Pisano F.; Bare C.; Calabro P.; Fimiani F.; Formisano
T.; Tarantini G.; Barioli A.; Cucchini U.; Ramani F.; Andres A.L.; Racca
E.; Rolfo F.; Goletto C.; Briguori C.; De Micco F.; Amati R.; Di Marco S.;
Vergoni W.; Tricoli M.; Russo A.; Villella M.; Fanelli R.; Poh K.-K.; Chai
P.; Lau T.; Loh J.P.; Tay E.L.; Teoh K.; Tan S.-Y.V.; Teo L.L.; Sia W.C.;
Ong C.-C.; Leong A.W.; Wong R.C.; Loh P.-H.; Kofidis T.; Chan W.X.; Chan
K.H.; Foo D.; Yan L.H.; Kong J.L.K.; Er C.M.; Jafary F.-H.H.; Chua T.;
Ismail N.; Kyaw M.T.; Yip D.; Doerr R.; Stumpf J.; Grahl D.; Matschke K.;
Guenther F.; Simonis G.; Bonin K.; Kadalie C.T.; Sechtem U.; Wenzelburger
I.; Ong P.; Gruensfelder S.; Schulze P.C.; Goebel B.; Lenk K.; Nickenig
G.; Sinning J.-M.; Weber M.; Werner N.; Schuchlenz H.; Steinmaurer G.;
Weikl S.; Lang I.M.; Winter M.-P.; Andric T.; Huber K.; Maximilian T.;
Gabriele J.-K.; Claudia W.; Bernhard J.; Florian E.; Keltai M.; Vertes A.;
Sebo J.; Davidovits Z.; Matics L.; Varga A.; Agoston G.; Fontos G.; Dekany
G.; Merkely B.; Bartykowszki A.; Maurovich-Horvat P.; Kerecsen G.; Jakal
A.; Hinic S.; Djokic J.; Zdravkovic M.; Mudrenovic V.; Crnokrak B.;
Beleslin B.D.; Boskovic N.N.; Djordjevic-Dikic A.D.; Petrovic M.T.; Giga
V.L.; Dobric M.R.; Stepanovic J.J.; Markovic Z.Z.; Mladenovic A.S.;
Cemerlic-Adjic N.; Velicki L.; Pupic L.; Davidovic G.; Simovic S.M.; Vucic
R.; Dekleva M.N.; Martinovic M.S.; Stevanovic G.; Stankovic G.; Dobric M.;
Apostolovic S.; Martinovic S.S.; Stanojevic D.; Escobedo J.; de
Jesus-Perez R.; Juarez B.; Baleon-Espinosa R.; Campos-Santaolalla A.S.;
Duran-Cortes E.; Flores-Palacios J.M.; Garcia-Rincon A.; Jimenez-Santos
M.; Penafiel J.V.; Ortega-Ramirez J.A.; Valdespino-Estrada A.; Rosas E.A.;
Brassetti M.F.C.; Anaya D.A.V.; Garcia M.P.; Juarez I.E.C.; Rovalo M.M.;
Rodriguez E.D.M.; Selvanayagam J.B.; Rankin J.; Murphy D.; Lee S.; Joseph
M.X.; Thomas P.; Thambar S.T.; Chaplin M.D.; Boer S.C.; Beltrame J.F.;
Stansborough J.K.; Black M.; Hillis G.S.; Bonner M.M.; Ireland K.F.;
Venn-Edmonds C.; Steg P.-G.; Thobois C.; Thuaire C.; Tachot E.; Dutoiu T.;
Laure C.; Vassaliere C.; Steg P.G.; Abergel H.; Juliard J.-M.; Fuentes A.;
Slama M.S.; Eliahou L.; Mahmoud R.E.; Dubourg O.; Michaud P.; Nicollet E.;
Hadjih S.; Goube P.; Brito P.; Barone-Rochette G.; Furber A.; Cornet C.;
Biere L.; Rautureau J.; Juceviciene A.; Kalibataite-Rutkauskiene I.;
Keinaite L.; Laucevicius A.; Laukyte M.; Celutkiene J.; Mikolaitiene G.;
Smigelskaite A.; Tamasauskiene I.; Urboniene A.; Kedhi E.; Timmer J.;
Bouwhuis I.; Hermanides R.; Nijmeijer L.; Kaplan E.; Riezebos R.K.; Samadi
P.; Schoep J.J.M.; van Dongen E.; Janzen E.M.; Niehe S.R.; Suryapranata
H.; Ahoud S.; van Vugt S.; Ramos R.; Cacela D.; Santana A.; Fiarresga A.;
Sousa L.; Marques H.; Patricio L.; Selas M.; Bernanrdes L.; Silva F.; Rio
P.; Freixo C.; Carvalho R.; Ferreira R.; Silva T.; Rodrigues I.; Modas P.;
Portugal G.; Fragata J.; Pinto F.J.; Cabrita I.Z.; Menezes M.N.; Rocha A.;
Lopes G.C.; Figueiras F.P.; Almeida A.G.; Coelho A.; Silva P.C.; Capinha
M.; Nobre A.; Caetano M.I.; Francisco A.R.; Silva S.; Ferreira N.; Lopes
R.L.; Diaz R.; Guzman L.; Tinnirello V.; Figal J.C.; Mungo M.N.; Mendiz
O.; Cortes C.; Favaloro R.R.; Alvarez C.; Garcia M.; Courtis J.; Godoy V.;
Zeballos G.; Schiavi L.; Actis M.V.; Rubio M.; Scaro G.; Devlin G.P.; Low
L.; Fisher R.; Scales J.; Abercrombie K.; Stewart R.A.H.; Howell L.;
Patten C.; Benatar J.; Kedev S.; Mitevska I.P.; Kostovska E.S.; Pejkov H.;
Held C.; Eggers K.; Frostfelt G.; Bjorklund C.; Johnston N.; Andreasson
M.; Olsowka M.; Essermark M.; Akerblom A.; Soveri I.; Aspberg J.; Persson
L.; Beyar R.; Nikolsky E.; Sharir T.; Harel O.; Elian D.; Kerner A.;
Bentzvi M.; Massalha S.; Helmer L.; Fukuda K.; Ueda I.; Kohsaka S.; Fujita
J.; Yasuda S.; Furukawa A.; Nagai T.; Otsuka F.; Nishimura S.; Nakano S.;
Goetschalckx K.; Robesyn V.; Van de Werf F.; Claes K.; Hung C.-L.; Yang
Y.-H.; Yun C.-H.; Hou C.J.-Y.; Kuo J.-Y.; Yeh H.-I.; Hung T.-C.; Li J.-Y.;
Chien C.-Y.; Tsai C.-T.; Liu C.-C.; Yu F.-C.; Lin Y.-H.; Lan W.-R.; Yen
C.-H.; Tsai J.-P.; Sung K.-T.; Ntsekhe M.; Pandie S.; Philander C.;
Viljoen C.A.; Mtana N.; De Andrade M.; Maggioni A.P.; Moccetti T.; Anesini
A.; Rossi M.G.; Maspoli S.; Mombelli M.; Abdelhamid M.; Talaat A.; Adel
A.; Kamal A.; Mahrous H.; El Kaffas S.; El Fishawy H.; Pop C.; Claudia M.;
Popescu B.A.; Ginghina C.; Rosca M.; Deleanu D.; Beladan C.C.; Iliescu
V.A.; Al-Mallah M.H.; Zahrani S.; Aljzeeri A.; Najm H.; Alghamdi A.; Ramos
W.E.M.; Davila M.A.M.; Kuanprasert S.; Prommintikul A.; Nawarawong W.;
Khwakhong S.; Woragidpoonpol S.; Chaiyasri A.; Tepsuwan T.; Mekara W.;
Taksaudom N.; Kulthawong S.; Rimsukcharoenchai C.; Amaritakomol A.;
Euathrongchit J.; Wannasopha Y.; Yamwong S.; Panpunuan P.; Sritara P.;
Aramcharoen S.; Meemuk K.; White H.D.; Alsweiler C.; Khairuddin A.;
Mokhtar N.S.; Hadi H.A.; Basri N.A.; Yahaya S.A.; Yusnida I.; Hashim H.;
Bugiardini R.
Institution
(Pracon, Ruzyllo) National Institute of Cardiology, Warsaw, Poland
(Spertus) Saint Luke's Mid America Heart Institute, University of
Missouri-Kansas City, Durham, NC, United States
(Broderick, Rockhold) Duke Clinical Research Institute, Durham, NC, United
States
(Bangalore, Newman, Reynolds, Hochman) Cardiovascular Clinical Research
Center, New York University Grossman School of Medicine, Durham, NC,
United States
(Rockhold) Department of Biostatistics and Bioinformatics, Duke University
School of Medicine, Durham, NC, United States
(Demchenko) Almazov National Medical Research Centre, Saint Petersburg,
Russian Federation
(Nageh) Southend University Hospital, United Kingdom
(Grossman) Moinhos de Vento Hospital, Porto Alegre, Brazil
(Grossman) Cardionuclear Clinic, Porto Alegre, Brazil
(Mavromatis) Emory University, Atlanta VA Healthcare System, GA, United
States
(Manjunath) Sri Jayadeva Institute of Cardiovascular Sciences and
Research, Bengaluru, India
(Smanio) Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil
(Stone) Icahn School of Medicine at Mount Sinai, New York, NY, United
States
(Mancini) Center for Cardiovascular Innovation, The University of British
Columbia, Vancouver, Canada
(Boden) VA New England Healthcare System, Boston University School of
Medicine, MA, United States
(Maron) Department of Medicine, Stanford University, CA, United States
(Boden, Mavromatis, Doan) Atlanta VA Medical Center, Decatur, GA, United
States
(Linefsky, Lee, Patel, Miller, Cho) Mayo Clinic, Rochester, MN, United
States
(Milbrandt, Shelstad, Banerjee, Kamath) V.A. North Texas Health Care
System, Dallas, TX, United States
(Tejani) NYU Langone Medical Center-Bellevue Hospital, New York, NY,
United States
(Reynolds, Newman, Bangalore, Donnino, Phillips, Saric, Abdul-Nour,
Schley) Henry Ford Health System, Detroit, MI, United States
(Golden, Stone, Osseni) Brigham & Women's Hospital, Harvard Medical
School, Boston, MA, United States
(Wiyarand, Douglass, Pomeroy, Craft, Harvey, Jang, Anaya) Kaiser
Permanente San Jose, San Jose, CA, United States
(Yee, Goold, Weitz, Giovannone) Cardiology Associates of Schenectady P.C.,
Schenectady, NY, United States
(Pritchard, Arnold, Gans) Saint Luke's Hospital, Kansas City, MO, United
States
(O'Keefe, Kennedy, Shapiro, Ganesan) Oregon Health & Science University,
Portland, OR, United States
(Schlichting, Naher) Albany Medical Center Hospital, Albany, NY, United
States
(Fein, Stewart, Torosoff, Salmi, Lyubarova, Mookherjee, Drzymalski,
McFalls) Minneapolis VAMC, Minneapolis, MN, United States
(Garcia, Bertog, Johnson, Siddiqui, Herrmann, Ishani, Hansen, Khouri,
Arges) Duke University Medical Center, Durham, NC, United States
(LeFevre, Tomfohr, Goldberg, Byrne) Louis Stokes Cleveland Veterans
Affairs Medical Center, Cleveland, OH, United States
(Zappernick, Goldweit, Canada) Englewood Hospital and Medical Center,
Englewood, NJ, United States
(Kakade) NYU-HHC Woodhull Hospital, Brooklyn, NY, United States
(Mieses, Cohen, Mirrer, Navarro, Rantinella, Rodriguez, Mancilla,
Winchester, Stinson) Malcom Randall VAMC, Gainesville, FL, United States
(Kronenberg, Weyand) Vanderbilt University Medical Center, Nashville, TN,
United States
(Rogal, Crook, McFarren, Heitner, Ho) New York -Presbyterian/Brooklyn
Methodist Hospital, Brooklyn, NY, United States
(Khan, Mohamed, Dauber, Soltau) South Denver Cardiology Associates, P.C.,
Littleton, CO, United States
(Rose, Wimmer, Siegel, Derbyshire, Cannan, Dixon) Providence Heart and
Vascular Institute, Portland, OR, United States
(Leonard, Sudarshan, Heard) Wichita Falls Heart Clinic, Wichita Falls, TX,
United States
(Gabriel, Desire, Mehta) Emory University, Atlanta, GA, United States
(McDaniel, Rashid, Lerakis, Asier, Quyyumi, Patel, Wenger, Hedgepeth,
Gillis) Kent Hospital, Warwick, RI, United States
(Hurlburt, Manocchia, Rosen, Moore, Congdon, Sahul, Brandt) Michigan
Heart, PC, Ypsilanti, MI, United States
(Marchelletta, Wippler, Booth, Taul) University of Kentucky, Lexington,
KY, United States
(Leung, Isaacs, Abdel-Latif, Bulkley, Reda, Rodgers, Ziada, Setty,
Halverson) Gundersen Lutheran Medical Center, La Crosse, WI, United States
(Roraff, Thorsen, Barua, Ojajuni) Kansas City VA Medical Center, Kansas
City, MO, United States
(Olurinde, Surineni, Hage, Valaiyapathi) UAB Vascular Biology and
Hypertension Program, Birmingham, AL, United States
(Caldeira, Davies, Leesar, Heo, Iskandrian, Al Solaiman, Singh, Dajani,
Kartje) Loyola University Medical Center, Maywood, IL, United States
(El-Hajjar) Samuel Stratton VA Medical Center of Albany NY, Albany, NY,
United States
(Mesropian, Sacco, Rawlins, McCandless, Thomson, Orgera, Sidhu, Rogge)
Cincinnati VA Medical Center, Cincinnati, OH, United States
(Arif, Bunke, Kerr, Unterbrink, Fannon, Burman, Trejo, Dubin) Mayo Clinic
Florida, Jacksonville, FL, United States
(Fletcher, Lane, Neeson, Parikh, Pollak, Shapiro, Landolfo, Gemignani,
Beaudry) VAMC-White River Junction, White River Junction, VT, United
States
(O'Rourke, Meadows, Tirado) VA Connecticut Healthcare System, West Haven,
CT, United States
(Halliday, Julian, Call, Lane) Winchester Cardiology and Vascular
Medicine, PC, Winchester, VA, United States
(Stanford, Hannan) Saint Vincent Hospital, Worcester Medical Center,
Worcester, MA, United States
(Bojar, Arsenault, Kumar, Sigel, Mukai, Martin, Brooks) Oklahoma Heart
Institute, Tulsa, OK, United States
(Vorobiof, Douangvila) Ronald Reagan UCLA Medical Center, Los Angeles, CA,
United States
(Gevorgyan, Moor-Man, Ranjbaran) University of Washington Medical Center,
Seattle, WA, United States
(Smith, Ohmart, Kinlay) VA Boston Healthcare System, West Roxbury, MA,
United States
(Hamburger, Rocco, Ly, Bhatt, Quinn, Croce, Temiyasathit, Quin, Do,
Anumpa, Tobin, Zenati, Faxon, Rayos, Langdon) Daytona Heart Group, Daytona
Beach, FL, United States
(Bayer, Seedhom, O'Malley) Capital Cardiology Associates, Albany, NY,
United States
(Sullenberger, Orvis, Kumkumian, Murphy) NIH Heart Center, Suburban
Hospital, Bethesda, MD, United States
(Greenberg, Iraola, Sedlis, Maranan) VA New York Harbor Health Care
System, New York, NY, United States
(Donnino, Lorin, Tamis-Holland, Malinay) Mount Sinai Saint Luke's
Hospital, Ridgewood, NJ, United States
(Kornberg, Leber, Saba, Edillo) Providence - Providence Park Hospital,
Southfield, MI, United States
(Lee, Small, Nona, Alexander, Rehman, Badami, Ostrander) Covenant Medical
Center, Inc., Saginaw, MI, United States
(Wasmiller, Marzo, Drewes) NYU Winthrop, Mineola, NY, United States
(Patel, Robbins) AtlantiCare Regional Medical Center, Pomona, NJ, United
States
(Levite, White, Shetty, Hallam, Patel, Hamroff, Spooner) NYP Medical
Medical Group Hudson Valley Cardiology, Cortlandt Manor, NY, United States
(Hollenweger, Little, Little) Houston Heart & Vascular Associates,
Houston, TX, United States
(Zimbelman, Little, Lui, Eskelson) Salt Lake City VA Medical Center, Salt
Lake City, UT, United States
(Smith, Vezina, Khor, Abraham, Bull, McKellar, Booth, Taul) Lexington VA
Medical Center, Lexington, KY, United States
(Kotter, Rodgers, Abdel-Latif, Isaacs, Bulkley, Hu, Kaneshiro) Palo Alto
Medical Foundation Research Institute, Palo Alto, CA, United States
(Labovitz) University of South Florida, Tampa, FL, United States
(Berlowitz, Kirby, Rogal, Tran, McFarren, Jahrsdorfer, Matar, Caldeira,
Maron) Stanford University School of Medicine, Stanford, CA, United States
(Rodriguez, Yunis, Schnittger, Patro, Fearon, Deedwania, Vega) UCSF -
Fresno Community Regional Medical Center, Fresno, CA, United States
(Reddy, Sweeny, Bloise-Adames) Icahn School of Medicine at Mount Sinai,
New York, NY, United States
(Jimenez, Vrestil, Bhandari, Spizzieri, Schade) Holy Spirit Hospital
Cardiovascular Institute, Camp Hill, PA, United States
(Yost, Hochberg, Beardsley) Boston Medical Center, Boston, MA, United
States
(Fine, Salerno, Tancredi) Hackensack University Medical Center, Saddle
Brook, NJ, United States
(Arakelian, Mathus, O'Neill, Wyman, Burkhardt) Torrance Memorial Medical
Center, Torrance, CA, United States
(Hosino, Lubyanaya) Coastal Heart Medical Group, Santa Ana, CA, United
States
(Salas, Zarka, Aguirre, Shah, Dhawan, Parra, Tran, Haldis, Weick) Sanford
Health, Fargo, ND, United States
(Fowler-Lehman, Spitzer, Riedberger, Weick, Kohn) NYU New York Medical
Associates, New York, NY, United States
(Cobos, Quiles, Girotra, Drum) University of Iowa Hospitals and Clinics,
Iowa City, IA, United States
(Miller-Cox, Ollinger, Almousalli, Capasso-Gulve) Advanced Heart Care
Group, Fairview Heights, IL, United States
(Loehr, Mosley, Krishnam, Heydari) University of California Irvine Medical
Center, Orange, CA, United States
(Mil-Liken, Lundeen, Patel, Karanjah, Seto, Marfori, Harley,
Hernandez-Rangel, Gibson, Singh, Allen, Coram, Webb) University of
Louisville, Louisville, KY, United States
(Fridell, Wilson, Thomas, Kim) University of Rochester, Rochester, NY,
United States
(Schwartz, Wilmot, Chen, El Shahawy, Stevens) Cardiovascular Center of
Sarasota, Sarasota, FL, United States
(Stafford, Black) University of Maryland Medical Center, Baltimore, MD,
United States
(Abernethy, Hull) Asheville Cardiology Associates, Asheville, NC, United
States
(Lim, Tucker, Putnam, Hall, Cauthren, Tucker, Zurick, Horton) Saint Thomas
Hospital, Nashville, TN, United States
(Orga, Meyer, White) Stroobants Cardiovascular Center, Lynchburg, VA,
United States
(Morford, Baumann, Rutkin, Seeratan) Northwell Health - Manhasset,
Manhasset, NY, United States
(Bokhari, Jimenez) Columbia University Medical Center, New York, NY,
United States
(Sokol, Schultz) Jacobi Medical Center, Bronx, NY, United States
(Meisner, Russo, Hamzeh) Baylor College of Medicine, Houston, TX, United
States
(Misra, Huda, Wall, Boan, De Rosen, Alam, Turner, Hinton) Cardiovascular
Specialists of Southwest Louisiana, Lake Charles, LA, United States
(Mulhearn, Good, Archer) Ohio Health Grant Medical Center, Columbus, OH,
United States
(Dionne, Allardyce, Sikora, Czerniak, Mull, Ferguson, Laube, Shammas,
Shammas) Midwest Cardiovascular Research Foundation, Davenport, IA, United
States
(Christensen, Park, Chilton, Hecht) Audie Murphy V.A., San Antonio, TX,
United States
(Nguyen, Vo) VA Palo Alto Healthcare System, Palo Alto, CA, United States
(Hirsch, Jezior, Bindeman) Walter Reed National Military Medical Center,
Bethesda, MD, United States
(Salkind, Espinosa) Miriam Hospital, Providence, RI, United States
(Desimone, Gordon, Felix-Stern, Crain, Gomes, Gordon, Stenberg, Mann)
Conemaugh Valley Memorial Hospital, Johnstown, PA, United States
(McCreary, Pedalino, Cobos) NYU-HHC Kings County Hospital Center,
Brooklyn, NY, United States
(Dwyer, Espinosa, Quiles, Wiesel) New York University - Langone
Cardiovascular Associates, Flushing, NY, United States
(Juang, Gopaul) Coney Island Hospital, Brooklyn, NY, United States
(Hultberg, Huk, Hussain, Al-Amoodi, Zambrano) Yuma Regional Medical
Center, Yuma, AZ, United States
(Rodriguez, Milner, Wohns, Mulder) Spectrum Health, Grand Rapids, MI,
United States
(Van Oosterhout, Lader, Meyer) Mid Valley Cardiology, Kingston, NY, United
States
(Mumma, Clapp) Sarasota Memorial Hospital, Sarasota, FL, United States
(Barrentine, Dharmarajan, Jose) NYU-HHC Lincoln Medical and Mental Health
Center, Bronx, NY, United States
(Manchery, McGarvey, McKinney) Doylestown Health Cardiology, Doylestown,
PA, United States
(Schwarz, Downes, Kaczkowski) Medical Center of the Rockies, Loveland, CO,
United States
(Luckasen, Jaskowiak, Klitch, Cheong, Dees) Baylor St. Luke's Medical
Center, Houston, TX, United States
(Potluri, Vasquez) Baylor Research Institute, Legacy Heart Center, Plano,
TX, United States
(Mastouri) Indiana University, Krannert Institute of Cardiology,
Indianapolis, IN, United States
(Breall, Hannemann, Revtyak, Foltz, Bazeley, Li, DeRosa) HealthEast Saint
Joseph's Hospital, St. Paul, MN, United States
(Jorgenson, Riestenberg-Smith, Giedd) Beth Israel Medical Center, New
York, NY, United States
(Old, Bariciano) Cardiovascular Associates, Ltd., Chesapeake, VA, United
States
(Burt) Saint Luke's Hospital and Health Network, Bethlehem, PA, United
States
(Sokhon, Waldron) Medicus Alliance Clinical Research Org., Inc., Sugar
land, TX, United States
(Mayon, Gopal) The Heart Hospital Baylor, Plano, TX, United States
(Valeti, Peichel) University of Minnesota, Minneapolis, MN, United States
(Kobashigawa, Starks) Cedars Sinai Medical Center, Beverly Hills, CA,
United States
(Garcia, Thottam, Bhargava, Anand) Government Medical College, Calicut,
India
(Govindan, Raj, Nair, Ravindran, Rajalekshmi, Manjunath, Nataraj) Sri
Jayadeva Institute of Cardiovascular Sciences and Research, Bengaluru,
India
(Moorthy, Nayak, Manjunath, Mylarappa, Narayanappa, Pandit, Bajaj) Dr Ram
Manohar Lohia Hospital, New Delhi, India
(Nath, Yadav, Mishra, Dwivedi, Tewari) King George's Medical University,
Department of Cardiology, Lucknow, India
(Narain, Mishra, Chandra, Patel, Singh, Wander) Hero DMC Heart Institute,
Dayanand Medical College and Hospital, Ludhiana, India
(Tandon, Ralhan, Kaur, Aslam, Gupta, Pharmacy, Goyal, Bhargava, Suvarna)
All India Institute of Medical Sciences, New Delhi, India
(Karthikeyan, Ramakrishnan, Seth, Yadav, Singh, Roy, Parakh, Verma,
Narang, Mishra, Naik, Sharma, Choudhary, Patel, Gulati, Sharma, Bahl,
Mathew, Kurian) MOSC Medical College Hospital, Kolenchery, India
(Punnoose, Gadkari, Karwa) KEM Hospital Pune, Pune, India
(Gadage, Kolhe, Pillay, Satheesh, Vindhya) Jawaharlal Institute of
Postgraduate Medical Education & Research (JIPMER), Pondicherry, India
(Jain) Fortis Escort Heart Institute, New Delhi, India
(Seth, Meharwal, Mathur, Verma, Kaul, Bhatia, Sachdeva, Devi, Jungla,
Christopher, Rani) Gurunanak CARE Hospital, Hyderabad, India
(Menon, Reddy, Kumar, Preethi, Oomman, Sidh) Apollo Research and
Innovation, Chennai, India
(Mao, Ramakrishnan, Solomon, Francis, Naik, Priya) Apollo Research &
Innovations, Hyderabad, India
(Khan, Christopher, Preethi) CARE Nampally, Hyderabad, India
(Kumar, Grant, Hande) Ruby Hall Clinic, Grant Medical Foundation, Pune,
India
(Sonawane, Kachru, Dubey) Fortis Healthcare Fl.t Lt. Rajan Dhall Hospital,
New Delhi, India
(Rawat, Kumar) Sree Chitra Tirunal Institute for Medical Sciences and
Technology, Trivandrum, India
(Ganapathi, Jayakumar, Vineeth, Sivadasanpillai, Chacko, Sasidharan, Babu,
Kapilamoorthy, Christopher, Reddy) CARE Hospital, Hyderabad, India
(Polamuri, Rani, Kaul, Arambam) Batra Hospital and Medical Research Centre
(BHMRC), New Delhi, India
(Singh, Senior, Fox, Young, Carruthers) Northwick Park Hospital Harrow,
Royal Brompton Hospital London, Harrow, United Kingdom
(Elghamaz, Gurunathan, Karogiannis, Young, Shah, Kinsey, Trimlett,
Kavalakkat, Rubens, Evans, Nicol, Hassan, Mittal, Hampson, Gamma,
Williams) Broomfield Hospital, Chelmsford, United Kingdom
(Holland, Swan, de Belder, Atkinson) The James Cook University Hospital,
Middlesbrough, Middlesbrough, United Kingdom
(Thambyrajah, Nageh, Kunhunny) Southend University Hospital, Westcliffe on
Sea, United Kingdom
(Davies, Lindsay, Atkinson) Bradford Royal Infirmary, Bradford, United
Kingdom
(Kurian, Krannila, Jamil, Vinod, Raheem, Hoye, Chaytor) The University of
Hull, Castle Hill Hospital, Cottingham, United Kingdom
(Cox, Morrow, Rowe, Donnelly, Kelly) South Eastern Health and Social Care,
Belfast, United Kingdom
(Valecka, Regan, Turnbull, Chauhan, Fleming) Blackpool Teaching Hospitals,
Blackpool, United Kingdom
(Ghosh, Gratrix, Preston, Barr, Cartwright) Russells Hall Hospital,
Dudley, United Kingdom
(Alfakih, Knighton) King's College NHS Foundation Hospital, London, United
Kingdom
(Byrne, Martin, Webb, Henriksen, Flint) Royal Infirmary of Edinburgh,
Edinburgh, United Kingdom
(Harrison, OKane, Lake-Man) Royal Bournemouth Hospital, Bourneouth, United
Kingdom
(Ljubez, de Silva) Bedford Hospital NHS Trust, Bedford, United Kingdom
(Conway, Wright) Pinderfields Hospital, Wakefield, United Kingdom
(Exley, Sirker, Andiapen) University College London Hospitals NHS
Foundation Trust, London, United Kingdom
(Richards) BartsHealth NHS Trust, United Kingdom
(Hoole, Wong) Papworth Hospital, Cambridge, United Kingdom
(Witherow, Munro) Dorset County Hospital, Dorchester, United Kingdom
(Johnston, Bao) Belfast Trust, Belfast, United Kingdom
(Harbinson, Bao, McEvoy, Walsh, Bao, Brown, Douglas, Luckie, Charles)
Central Manchester University Hospital, Manchester, United Kingdom
(Kolakaluri, Phillips, Sobolewska, Morby) The Pennine Acute Hospitals NHS
Trust, Oldham, United Kingdom
(Hallett, Corbett, Winstanley, Jeetley, Smit) Royal Free London NHS
Foundation Trust, London, United Kingdom
(Patel, Kotecha, Travill, Gent) Luton and Dunstable University Hospital
NHS FT, Luton, United Kingdom
(Karimullah, Hussain, Al-Bustami, Braganza, Haines) Peterborough City
Hospital, Peterborough, United Kingdom
(Taaffe, Henderson, Burton) Nottingham University Hospitals, Nottingham,
United Kingdom
(Pointon, Colton, Naik, King, Mathew, Brown) University of Glasgow,
Clydebank, United Kingdom
(Docherty, Berry, McCloy, Collison, Robb, Roditi, Paterson, Crawford,
Kelly, McGregor, Moriarty, Mackin) Cardiovascular Research Unit, Craigavon
Area Hospital, Craigavon, United Kingdom
(Glover, Knight) Hampshire Hospitals NHS Foundation Trust, Basingstoke,
United Kingdom
(Pradhan, Mikhail, Bose) Imperial College Healthcare NHS Trust, London,
United Kingdom
(Francis, Dzavik, Goodman, Gosselin, Proietti) Montreal Heart Institute,
Montreal, QC, Canada
(Brousseau, Corfias, Blaise, Harvey, Diaz) Centre Hospitalier de Regional
Trois-Rivieres, Trois-Rivieres, QC, Canada
(Rheault, Barrero, Gagne, Alarie, Pepin-Dubois, Arcand, Costa, Roy, Sia,
Montpetit, Lemay, Gisbert, Gervais, Rheault, Drouin) CISSSL - Hopital
Pierre-Le Gardeur, Terrebonne, QC, Canada
(Phaneuf, Bergeron, Gosselin, Shelley, Masson, Garg, Carr) London Health
Sciences Centre, London, ON, Canada
(Bone, Chow, Moga) University of Ottawa Heart Institute, Ottawa, ON,
Canada
(Hessian, Kourzenkova, Beanlands, Walter, Davies, Bainey, Hogg) University
of Alberta, Edmonton, AB, Canada
(Welsh, Cheema) St. Michael's Hospital, Toronto, ON, Canada
(Bagai, Wald, Goodman, Kushniriuk, Graham, Hussain, Peterson, Bello, Chow,
Abramson, Cheema, Syed) Dixie Medical Group, Mississauga, ON, Canada
(Vakani, Hussain, Kushniriuk, Cha, Otis) Dr James Cha, Oshawa, ON, Canada
(Otis, Howarth, Seib) University of Calgary, Calgary, AB, Canada
(Rivest, Sandonato, Wong, Chow) Vancouver General Hospital, Vancouver, BC,
Canada
(Starovoytov, Uchida, Meadows, Uxa, Asif) University Health Network,
Toronto, ON, Canada
(Tavares, Galiwango, Bozek) Scarborough Cardiology Research, Scarborough,
ON, Canada
(Kassam, Shier, Mukherjee, Larmand, Ricci, Janmohamed, Hart, Lam, Marucci)
West Lincoln Memorial Hospital East Grimsby, ON, Canada
(Tai, Mehta, Brons) Hamilton General Hospital, Hamilton, ON, Canada
(Beck, Wong, Etherington, Arumairajah, Udell, Aprile) Women's College
Hospital, Toronto, ON, Canada
(Karlsson, Webber, Genereux, Mercure) Centre Integre Universitaire de
Sante et de Services Sociaux du Montreal, Montreal, QC, Canada
(Hameed, Aedy) Saint Catharines General Hospital, Catharines, ON, Canada
(Daba, Farquharson) Northwest GTA Cardiovascular and Heart Rhythm Program,
Vaughan, ON, Canada
(Siddiqui, Carvalho, Lopes, Hueb, Takiuti) Heart Institute (InCor),
University of Sao Paulo, Sao Paulo, Brazil
(Rezende, Silva, Hueb, Smanio, Caetano) Instituto Dante Pazzanese de
Cardiologia, Sao Paulo, Brazil
(de Quadros) Instituto de Cardiologia de Porto Alegre, Porto Alegre,
Brazil
(Kalil, Deiro, da Costa Vieira, Muller, Grossmann, de Moraes, de Oliveira,
Ascoli, Bridi, Poletti, Savaris, Vitola) Quanta Diagnostico & Terapia,
Curitiba, Brazil
(Cerci, Zier, Farias, Veiga, Fernandes, Marin-Neto) Hospital das Clinicas
da Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo,
Ribeirao Preto, Brazil
(Schmidt, de Oliveira Lima Filho, da Cunha, Oliveira, Chierice, Polanczyk,
Rucatti) Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil
(Furtado, Igansi, Smidt, Haeffner, Carvalho, Almeida) Unifesp - Hospital
Sao Paulo, Sao Paulo, Brazil
(Pucci, de Souza, Lyra, Alves, Almeida) Fundacao Bahiana de Cardilogia,
Salvador, Brazil
(dos Santos, Dracoulakis, Oliveira) Hospital da Bahia, Salvador, Brazil
(Lima, Figueiredo, Azevedo) Hospital Lifecenter, Belo Horizonte, Brazil
(Caramori, Santos) Hospital Sao Lucas da Pontificia Universidade Catolica
do Rio Grande do Sol, Porto Alegre, Brazil
(Germann, Gomes, Homem, Magedanz, Tumelero, Laimer) Hospital Sao Vicente
de Paulo Fundo, Brazil
(Tognon, Dall'Orto) Hospital Maternidade e Pronto Socorro Santa Lucia,
Pocos de Caldas, Brazil
(Mesquita, Santos) Hospital Pro-Cardiaco Botafogo, Brazil
(Colafranseschi, Oliveira, Carvalho, Palazzo, Sousa, da Silva) Hospital
TotalCor, Sao Paulo, Brazil
(de Barros e Silva, Okada, de Padua Silva Baptista, Batista, Rodrigues,
Rabaca, de Resende, Saraiva, Trama) Hospital Celso Pierro, Sao Paulo,
Brazil
(Silva, de Souza Ormundo, Vicente, Costantini, Pinheiro, Pracon) Hospital
Cardiologico Costantini, Curitiba, Brazil
(Komar, Ruzyllo, Szwed, Demkow, Pracon) Coronary and Structural Heart
Diseases Department, Institute of Cardiology, Warsaw, Poland
(Kepka, Teresinska, Walesiak, Kryczka, Malinowska, Henzel, Solecki,
Kaczmarska, Mazurek, Maksym) Medical University of Warsaw, Warszawa,
Poland
(Wojtera, Fojt, Szczerba, Drozdz) Cardiology Clinic, Medical University in
Lodz, Lodz, Poland
(Czarniak, Frach, Szymczyk, Niedzwiecka, Sobczak, Ciurus, Jakubowski,
Misztal-Teodorczyk, Teodorczyk, Swiderek, Fratczak, Wojtala, Szkopiak,
Lebioda, Wlodarczyk, Plachcinska, Kusmierek, Miller, Marciniak,
Wojtczak-Soska, Luczak, Tarchalski, Cichocka-Radwan, Szwed, Karwowski)
National Institute of Cardiology, Warsaw, Warsaw, Poland
(Szulczyk, Witkowski) Department of Interventional Cardiology & Angiology,
Institute of Cardiology, Warsaw, Poland
(Kukula, Celinska-Spodar, Zalewska, Gajos) Department of Coronary Disease,
John Paul II Hospital, Jagiellonian University Medical College, Krakow,
Poland
(Bury, Pruszczyk, Labyk) Department of Internal Medicine and Cardiology,
Infant Jesus Teaching Hospital, Medical University of Warsaw, Warszawa,
Poland
(Roik, Szramowska, Zdonczyk, Loboz-Grudzien, Jaroch) T.Marciniak Hospital,
Wroclaw, Poland
(Sokalski, Brzezinska, Lesiak) Szpital Kliniczny Przemienienia Panskiego,
Poznan, Poland
(Lanocha, Reczuch, Kolodziej) Military Hospital, Medical University,
Wroclaw, Poland
(Kalarus) Medical University of Silesia, School of Medicine, The Division
of Dentistry, Department of Cardiology, Congenital Heart Diseases and
Electrotherapy, Silesian Center for Heart Diseases, Zabrze, Poland
(Swiatkowski, Szulik, Musial, Marcinkiewicz-Siemion) University Hospital
in Bialystok, Bialystok, Poland
(Bockeria, Bockeria) National Medical Research Center for Cardiovascuar
Surgery, Moscow, Russian Federation
(Petrosyan, Kudzoeva, Trifonova, Aripova, Chernyavskiy, Naryshkin)
E.Meshalkin National Medical Research Center, The Ministry of Health of
the Russian Federation, Novosibirsk, Russian Federation
(Kretov, Kuleshova, Grazhdankin, Malaev, Bershtein) North-Western State
Medical University, Saint Petersburg, Russian Federation
(Sayganov, Subbotina, Kuzmina-Krutetskaya, Gumerova, Zbyshevskaya,
Katamadze, Demchenko, Nikolaeva) Federal Almazov North-West Medical
Research Centre, Saint Petersburg, Russian Federation
(Kozlov, Kozulin, Lubinskaya, Lopez-Sendon, Castro, Lopez-Sendon,
Fernandez-Figares) Hospital La Paz. IdiPaz, Madrid, Spain
(Castro, Salicio, Guzman, Galeote, Valbuena, Peteiro) Complexo
Hospitalario Universitario A Coruna (CHUAC) Sergas, Department of
Cardiology, INIBIC A Coruna. CIBER-CV., Universidad de A Coruna, A Coruna,
Spain
(Martinez-Ruiz, Perez-Fernandez, Blanco-Calvo, Cuenca-Castillo,
Alonso-Alvarez, Flores-Rios, Garcia-Gonzalez, Prada-Delgado,
Barge-Caballero, Juanatey, Amigo) Hospital Clinico Universitario de
Santiago, Santiago de Compostela, Spain
(Bayarri, Nunez, Sanchez, Alvarez, Gil, Monzonis, Sionis, Martinez)
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
(Perales, Padro, Penaranda, Picart, Iglesias, Marimon, Llado, Costa, Miro,
Igual) Hospital Universitario y Politecnico La Fe, Valencia, Spain
(Diez, Calvillo, Ortuno) HUVA, Hospital Clinico Universitario Virgen De La
Arrixaca, Murcia, Spain
(Chavarri, Giner, Montolliu, Aniorte, Bermudez, Caravaca, De La Morena,
Blancas, Canavate) Hospital De Bellvitge, Barcelona, Spain
(Guerrero, Riera, Luena, Luena) Hospital Universitario Miguel Servet,
Zaragoza, Spain
(Lasala, Fernandez-Aviles, Lorenzo) Hospital General Universitario
Gregorio Maranon, Madrid, Spain
(Sobrino, Vazquez, Jiang, Chen, Dong) Guangdong General Hospital,
Guangzhou, China
(He, Xia, Yang, Zhong, Wu, Tian) Chinese Academy of Medical Sciences,
Fuwai Hospital, Beijing, China
(Li) First Affiliated Hospital of Xinjiang Medical University, Urumqi,
China
(Ma, Li, Yang, Ma, Yu, Zhao, Ji, Li) Tangshan Gongren Hospital, Tangshan,
China
(Zhang, Zhao, Zhu, Yang, Chen) Beijing Chao-yang Hospital, Capital Medical
University, Beijing, China
(Chi, Wang, Zhang, Lin, Jing) TEDA International Cardiovascular Hospital,
Tianjing, China
(Liu, Zeng, Zhou) Tongji Medical College, Wuhan, China
(Xu, Li, Li, Xiong, Fu, Gao) The First Affiliated Hospital of Zhengzhou
University, Zhengzhou, China
(Jiang, Leng, Wang, Yuan, Zhang, Yang, Bai) Shanxi Cardiovascular
Hospital, Taiyuan, China
(Li, Qi, Wang, Wang, Yang, Yue, Zhang, Wang, Dong) Qingdao Fuwai Hospital,
Qingdao, China
(Mao, Zhang, Cheng, Li) Shanxi Provincial People's Hospital, Xian, China
(Yao, Zhong, Zhou, Zhao, Huang) The Second Affiliated Hospital of
Zhengzhou University, Zhengzhou, China
(Zhou, Fang, Su) Liangxiang Hospital, Beijing, Fangshan District, Beijing,
China
(Zeng, Kunwu) Wuhan Union Hospital, Tongji Medical College, Huazhong
Science and Tech University, Wuhan, China
(Peng, Su, Su, Wang) Wuhan Asia Heart Hospital, Wuhan, China
(Zhao, Li, Geng) Affiliated Hospital of Jining Medical University, Jining,
China
(Wang, Nie, Fan) Beijing Anzhen Hospital, Beijing, China
(Feng, Wang, Yan, Zhang, Yu, Chi) Affiliated Zhongshan Hospital of Dalian
University, Dalian, China
(Liu, Wang, Chen) The Second Affiliated Hospital Zhejiang University
School of Medicine, Hangzhou, China
(Jiang, Li, Wang, Han) Peking Union Medical College Hospital, Beijing,
China
(Xu, Zhang, Liu, Liu, Chen, Hu, Maggioni, Perna, Pietrucci) Cardiology and
CCU - Ospedali Riuniti Ancona, Ancona, Italy
(Marini, Gabrielli, Provasoli, Di Donato) Ospedale di Circolo e Fondazione
Macchi, Varese, Italy
(Verna, Monti) Humanitas Research Hospital, Rozzano (MI), Rozzano, Italy
(Nardi, Di Chiara, Pezzetta) Azienda Servizi Sanitaria n.3 Alto
Friuli-Collinare-Medio Friuli, Tolmezzo, Italy
(Mortara, Casali) Policlinico di Monza, Monza, MB, Monza, Italy
(Galvani, Attanasio) Ospedale "G.B. Morgagni - L. Pierantoni" Forli (AUSL
della Romagna), Forli, Italy
(Ottani, Sicuro, Leone) Ospedale Regionale Umberto Parini, Aosta, Italy
(Pisano, Bare, Calabro, Fimiani) AORN Dei Colli "V. Monaldi" UOC
Cardiologia Universita della Campania "L.Vanvitelli", Napoli, Italy
(Formisano, Tarantini, Barioli) University of Padua- Cardiology Clinic,
Padua, Italy
(Cucchini, Ramani, Andres, Racca, Rolfo) Azienda Ospedaliera S. Croce e
Carle, Cuneo, Italy
(Goletto, Briguori, De Micco) Clinica Mediterranea, Naples, Italy
(Amati, Di Marco) UO Cardiologia Ospedale SS Cosma e Damiano, Pescia,
Italy
(Vergoni, Tricoli, Russo, Villella) IRCCS "Casa Sollievo della
Sofferenza", San Giovanni Rotondo, Italy
(Fanelli, White, Alsweiler, Poh) National University Heart Center
Singapore, Singapore, Singapore
(Chai, Lau, Loh, Tay, Teoh, Tan, Teo, Sia, Ong, Leong, Wong, Loh, Kofidis,
Chan, Chan, Foo, Yan) Tan Tock Seng Hospital, Singapore, Singapore
(Kong, Er, Jafary, Chua, Ismail) National Heart Centre Singapore,
Singapore, Singapore
(Kyaw, Yip, Doerr) Praxisklinik Herz und Gefaesse, Dresden, Germany
(Stumpf, Grahl, Matschke, Guenther, Simonis, Bonin, Kadalie, Sechtem,
Wenzelburger) Robert-Bosch-Krankenhaus, Stuttgart, Germany
(Ong, Gruensfelder, Schulze) University Hospital Jena, Jena, Germany
(Goebel, Lenk, Nickenig, Sinning) Universitatsklinikum Bonn, Bonn, Germany
(Weber, Werner, Lang, Huber, Schuchlenz, Steinmaurer) LKH Graz West, Graz,
Austria
(Weikl, Lang, Winter) Medical University of Vienna, Department of
Cardiology, Vienna, Austria
(Andric) Wilhelminen Hospital Vienna, Vienna, Austria
(Huber, Maximilian, Gabriele, Claudia, Bernhard, Florian, Keltai, Vertes,
Sebo) Eszszk- Szent Istvan Hospital, Budapest, Hungary
(Davidovits, Matics, Varga, Agoston) University of Szeged, Szeged, Hungary
(Fontos, Dekany) George Gottsegen National Institute of Cardiology,
Budapest, Hungary
(Merkely, Bartykowszki) Heart and Vascular Center, Semmelweis University,
Budapest, Hungary
(Maurovich-Horvat, Kerecsen, Jakal) Military Hospital, Budapest, Budapest,
Hungary
(Hinic, Djokic) University Hospital Center Bezanijska Kosa, Belgrade,
Serbia
(Zdravkovic, Mudrenovic, Crnokrak, Beleslin) Faculty of Medicine,
University of Belgrade, Cardiology Clinic, Clinical Center of Serbia,
Belgrade, Serbia
(Boskovic, Djordjevic-Dikic, Petrovic, Giga, Dobric, Stepanovic, Markovic,
Mladenovic, Cemerlic-Adjic, Velicki) Institute of Cardiovascular Diseases
Vojvodina, Sremska Kamenica, Serbia
(Pupic, Davidovic, Simovic) Clinical Center Kragujevac, Kragujevac, Serbia
(Vucic, Dekleva, Martinovic) University Clinical Hospital Zvezdara,
Belgrade, Serbia
(Stevanovic, Stankovic, Dobric) Clinical Center of Serbia, Belgrade,
Serbia
(Apostolovic, Martinovic) Clinic for Cardiovascular Diseases, Clinical
Center Nis, Nis, Serbia
(Stanojevic, Escobedo, de Jesus-Perez, Juarez) Instituto Mexicano del
Seguro Social, Mexico
(Baleon-Espinosa, Campos-Santaolalla, Duran-Cortes, Flores-Palacios,
Garcia-Rincon, Jimenez-Santos, Penafiel, Ortega-Ramirez,
Valdespino-Estrada, Rosas, Brassetti, Selvanayagam) Instituto Nacional de
Cardiologia "Ignacio Chavez", Mexico City, Mexico
(Anaya, Garcia, Juarez, Rovalo, Rodriguez, Selvanayagam, Rankin, Murphy,
Lee) Flinders Medical Centre, Adelaide, Australia
(Joseph, Thomas, Thambar, Chaplin) John Hunter Hospital, New Lambton
Heights, Australia
(Boer, Beltrame, Stansborough) The Queen Elizabeth Hospital, Woodville
South, Australia
(Black, Hillis, Bonner) Royal Perth Hospital, Perth, Australia
(Ireland, Venn-Edmonds, Steg, Abergel, Juliard, Thobois) C.H. Louis
Pasteur, Chartres, France
(Thuaire, Tachot, Dutoiu, Laure, Vassaliere, Steg, Abergel) Bichat
Hospital, Paris, France
(Juliard, Fuentes, Slama, Eliahou) Antoine-Beclere Hospital, Clamart,
France
(Mahmoud, Dubourg) Ambroise Pare Hospital, Boulogne, France
(Michaud, Nicollet, Hadjih) Centre Hospitalier Sud Francilien,
Corbeil-Essonnes, France
(Goube, Brito, Barone-Rochette, Barone-Rochette) Grenoble University
Hospital, Grenoble, France
(Furber, Cornet) Centre Hospitalier Universitaire d'Angers, Angers, France
(Biere, Rautureau, Juceviciene) Vilnius University Hospital Santariskes
Clinic, Vilnius, Lithuania
(Kalibataite-Rutkauskiene, Keinaite, Laucevicius, Laukyte, Celutkiene,
Mikolaitiene, Smigelskaite, Tamasauskiene, Urboniene, Kedhi) Isala
Klinieken, Zwolle, Netherlands
(Timmer, Bouwhuis, Hermanides, Nijmeijer, Kaplan, Riezebos) Cardio
Research Hartcentrum OLVG, Amsterdam, Netherlands
(Samadi, Schoep, van Dongen, Janzen, Niehe, Suryapranata, Ahoud)
Radboudumc, Nijmegen, Netherlands
(van Vugt, Ramos) Hospital de Santa Marta, Lisbon, Portugal
(Cacela, Santana, Fiarresga, Sousa, Marques, Patricio, Selas, Bernanrdes,
Silva, Rio, Freixo, Carvalho, Ferreira, Silva, Rodrigues, Modas, Portugal,
Fragata, Pinto, Cabrita) Santa Maria University Hospital, Cardiology
Department, CHLN, Lisbon, Portugal
(Menezes, Rocha, Lopes, Figueiras, Almeida, Coelho, Silva, Capinha, Nobre,
Caetano, Francisco, Silva, Ferreira) Centro Hospitalar de Vila Nova de
Gaia/Espinho, EPE, Vila Nova de Gaia, Portugal
(Lopes, Diaz, Guzman, Tinnirello) Instituto Medico DAMIC, Cordoba,
Argentina
(Figal, Mungo) Fundacion Favaloro, Ciudad Autonoma de Buenos Aires,
Argentina
(Mendiz, Cortes, Favaloro, Alvarez, Garcia) Hospital Italiano Regional del
Sur Bahia Blanca, Bahia Blanca, Argentina
(Courtis, Godoy) Clinica Romagosa and Clinica De La Familia, Cordoba,
Spain
(Zeballos, Schiavi, Actis) Clinica Del Prado, Cordoba, Spain
(Rubio) Clinica Privada Velez Sarsfield, Cordoba, Spain
(Scaro, Devlin, Low) Waikato Hospital, Hamilton, New Zealand
(Fisher, Scales, Abercrombie, Stewart) Auckland City Hospital, Auckland,
New Zealand
(Howell, Patten, Benatar, Kedev, Held) University Clinic of Cardiology,
Skopje, North Macedonia
(Mitevska, Kostovska, Pejkov, Held) Uppsala University, Uppsala, Sweden
(Eggers, Frostfelt, Bjorklund, Johnston, Andreasson, Olsowka, Essermark,
Akerblom, Soveri, Aspberg, Persson, Sharir) Karolinska Institutet,
Danderyd Hospital, Stockholm, Sweden
(Beyar, Nikolsky, Sharir, Harel) Assuta Medical Centers, Tel-Aviv, Israel
(Elian, Kerner, Bentzvi) Rambam Medical Center, Haifa, Israel
(Massalha, Helmer, Kohsaka, Fukuda, Ueda) Keio University, Shinjuku-ku,
Japan
(Kohsaka, Fujita, Yasuda, Furukawa) National Cerebral and Cardiovascular
Center, Kanae Hirase, RN, -4, Suita-shi, Japan
(Nagai, Otsuka, Nishimura, Nakano) Saitama Medical University, Hidaka,
Japan
(Van de Werf, Goetschalckx, Robesyn) University Hospital Leuven, Leuven,
Belgium
(Van de Werf, Claes, Hung, Yang) Mackay Memorial Hospital, Taipei City,
Taiwan (Republic of China)
(Yun, Hou, Kuo, Yeh, Hung, Li, Chien, Tsai, Liu, Yu, Lin, Lan, Yen, Tsai,
Sung, Ntsekhe) Groote Schuur Hospital, University of Cape Town, Cape Town,
South Africa
(Pandie, Philander, Viljoen, Mtana, De Andrade, Maggioni, Moccetti,
Anesini) Cardiocentro, Lugano, Switzerland
(Rossi, Maspoli, Mombelli, Abdelhamid, Talaat) Cairo University, Cairo,
Egypt
(Adel, Kamal, Mahrous, El Kaffas, El Fishawy, Pop) Emergency County
Hospital Baia Mare, Bucharest, Romania
(Claudia, Popescu) Emergency Institute of Cardiovascular Diseases ''Prof.
Dr. C. C. Iliescu'', Bucharest, Romania
(Ginghina, Rosca, Deleanu, Beladan, Iliescu, Al-Mallah, Zahrani) King
AbdulAziz Cardiac Center, Central Province, Saudi Arabia
(Aljzeeri, Najm, Alghamdi, Ramos) Instituto Neuro Cardiovascular De Las
Americas, Mirafloes, Peru
(Davila, Kuanprasert) Maharaj Nakorn Chiang Mai Hospital, Chiang Mai,
Thailand
(Prommintikul, Nawarawong, Khwakhong, Woragidpoonpol, Chaiyasri, Tepsuwan,
Mekara, Taksaudom, Kulthawong, Rimsukcharoenchai, Amaritakomol,
Euathrongchit, Wannasopha, Yamwong, Panpunuan) Ramathibodi Hospital,
Bangkok, Thailand
(Sritara, Aramcharoen, Meemuk, White, Alsweiler, Khairuddin, Mokhtar)
Institut Jantung Negara, Kuala Lumpur, Malaysia
Publisher
Lippincott Williams and Wilkins
Abstract
BACKGROUND: ISCHEMIA (International Study of Comparative Health
Effectiveness With Medical and Invasive Approaches) did not find an
overall reduction in cardiovascular events with an initial invasive versus
conservative management strategy in chronic coronary disease; however,
there were conservative strategy participants who underwent invasive
coronary angiography early postrandomization (within 6 months).
Identifying factors associated with angiography in conservative strategy
participants will inform clinical decision-making in patients with chronic
coronary disease. METHOD(S): Factors independently associated with
angiography performed within 6 months of randomization were identified
using Fine and Gray proportional subdistribution hazard models, including
demographics, region of randomization, medical history, risk factor
control, symptoms, ischemia severity, coronary anatomy based on
protocol-mandated coronary computed tomography angiography, and medication
use. RESULT(S): Among 2591 conservative strategy participants,
angiography within 6 months of randomization occurred in 8.7% (4.7% for a
suspected primary end point event, 1.6% for persistent symptoms, and 2.6%
due to protocol nonadherence) and was associated with the following
baseline characteristics: enrollment in Europe versus Asia (hazard ratio
[HR], 1.81 [95% CI, 1.14-2.86]), daily and weekly versus no angina (HR,
5.97 [95% CI, 2.78-12.86] and 2.63 [95% CI, 1.51-4.58], respectively),
poor to fair versus good to excellent health status (HR, 2.02 [95% CI,
1.23-3.32]) assessed with Seattle Angina Questionnaire, and new/more
frequent angina prerandomization (HR, 1.80 [95% CI, 1.34-2.40]). Baseline
low-density lipoprotein cholesterol <70 mg/dL was associated with a lower
risk of angiography (HR, 0.65 [95% CI, 0.46-0.91) but not baseline
ischemia severity nor the presence of multivessel or proximal left
anterior descending artery stenosis >70% on coronary computed tomography
angiography. CONCLUSION(S): Among ISCHEMIA participants randomized to
the conservative strategy, angiography within 6 months of randomization
was performed in <10% of patients. It was associated with frequent or
increasing baseline angina and poor quality of life but not with objective
markers of disease severity. Well-controlled baseline low-density
lipoprotein cholesterol was associated with a reduced likelihood of
angiography. These findings point to the importance of a comprehensive
assessment of symptoms and a review of guideline-directed medical therapy
goals when deciding the initial treatment strategy for chronic coronary
disease. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique
identifier: NCT01471522. GRAPHIC ABSTRACT: A graphic abstract is available
for this article. Copyright © 2024 American Heart Association,
Inc.

<29>
Accession Number
2042706576
Title
Effect of single-injection thoracic paravertebral block with liposomal
bupivacaine on the quality of recovery after thoracic surgery: a protocol
for an open-label, randomized controlled trial.
Source
Frontiers in Medicine. 12 (no pagination), 2026. Article Number: 1734331.
Date of Publication: 2026.
Author
Ma W.; Wang L.; Zhang H.; Zou M.; Feng S.; Liu Y.; Wang P.
Institution
(Ma, Wang, Zhang, Zou, Feng, Liu, Wang) Department of Anesthesiology, The
Affiliated Hospital of Qingdao University, Qingdao, China
(Ma, Feng) Department of Clinical Medicine, Qingdao University, Shandong,
Qingdao, China
Publisher
Frontiers Media SA
Abstract
Background: Postoperative pain management plays a crucial role in
determining the quality of recovery following thoracic surgery. However,
achieving high-quality postoperative analgesia that facilitates
satisfactory recovery remains challenging due to suboptimal pain control
and side effects associated with conventional analgesic strategies. This
study aims to evaluate the effect of single-injection thoracic
paravertebral block with liposomal bupivacaine on the overall quality of
recovery in patients undergoing thoracic surgery. Method(s): This
single-center, open-label, randomized controlled trial will enroll 162
patients scheduled for video-assisted thoracic surgery. Participants will
be randomly allocated in a 1:1:1 ratio to three groups (n=54 each): Group
L will receive ultrasound-guided thoracic paravertebral block with
liposomal bupivacaine; Group R will receive ropivacaine-based
paravertebral block combined with opioid-based patient-controlled
intravenous analgesia; and Group P will receive opioid-based
patient-controlled intravenous analgesia alone. The primary outcome is the
quality of recovery assessed by patient-reported Quality of Recovery-15
scores on postoperative days 1-3. Between-group differences will be
analyzed using generalized estimating equations. Secondary outcomes
include: pain-free interval; resting and cough-induced pain intensity at
6, 12, 24, 48, and 72h; worst pain scores at 24, 48, and 72h;
perioperative opioid use; time to first rescue analgesia and times of
request; patient confidence in coughing and ambulation; anxiety and sleep
quality at 24, 48, and 72h; patient satisfaction; postoperative nausea and
vomiting incidence/severity and rescue antiemetic use. Safety outcomes
comprise block-related complications and postoperative complications. All
adverse events will be documented throughout the study.
 Discussion(s): This study aims to provide high-quality evidence on
the efficacy of a single-injection thoracic paravertebral block with
liposomal bupivacaine for post-thoracic surgery analgesia, compared with
opioid-based intravenous analgesia alone and the combination of
ropivacaine paravertebral block with systemic opioid analgesia. Clinical
trial registration: Identifier: ChiCTR2500107787. Copyright ©
2026 Ma, Wang, Zhang, Zou, Feng, Liu and Wang.

<30>
Accession Number
2043311790
Title
Understanding the etiologies of meralgia Paresthetica: An In-Depth review
and Meta-Analysis of iatrogenic causes.
Source
Journal of Clinical Neuroscience. 147 (no pagination), 2026. Article
Number: 111938. Date of Publication: 01 May 2026.
Author
Fortuniak J.; Hupalo M.; Jaskolski D.J.; Karuga F.F.; Wanibuchi S.; Szmyd
B.
Institution
(Fortuniak, Hupalo, Jaskolski, Szmyd) Department of Neurosurgery and
Neuro-Oncology, Medical University of Lodz, Barlicki University Hospital,
Kopcinskiego St. 22, Lodz, Poland
(Karuga) Department of Gynecology and Gynecological Oncology, Center for
Postgraduate Medical Education, Warsaw, Poland
(Karuga) Department of Sleep Medicine and Metabolic Disorders, Medical
University of Lodz, Lodz, Poland
(Wanibuchi) Department of Plastic and Reconstructive Surgery, Aichi
Medical University, Nagakute, Japan
Publisher
Churchill Livingstone

<31>
Accession Number
636912019
Title
Efficacy and Safety of Aspirin for Primary Cardiovascular Risk Prevention
in Younger and Older Age: An Updated Systematic Review and Meta-analysis
of 173,810 Subjects from 21 Randomized Studies.
Source
Thrombosis and Haemostasis. 122(3) (pp 445-455), 2022. Date of
Publication: 04 Mar 2022.
Author
Calderone D.; Greco A.; Ingala S.; Agnello F.; Franchina G.; Scalia L.;
Buccheri S.; Capodanno D.
Institution
(Calderone, Greco, Ingala, Agnello, Franchina, Scalia, Capodanno) Division
of Cardiology, Azienda Ospedaliero-Universitaria Policlinico G. Rodolico -
San Marco, University of Catania, Catania, Italy
(Buccheri) Department of Medical Sciences, Uppsala University, Uppsala,
Sweden
(Buccheri) Uppsala Clinical Research Center, Uppsala University, Uppsala,
Sweden
Publisher
Georg Thieme Verlag
Abstract
Aims The efficacy and safety of aspirin for primary cardiovascular disease
(CVD) prevention is controversial. The aim of this study was to
investigate the efficacy and safety of aspirin in subjects with no overt
CVD, with a focus on age as a treatment modifier. Methods and Results
Randomized trials comparing aspirin use versus no aspirin use or placebo
were included. The primary efficacy outcome was all-cause death. The
primary safety outcome was major bleeding. Secondary ischemic and bleeding
outcomes were explored. Subgroup analyses were conducted to investigate
the consistency of the effect sizes in studies including younger and older
individuals, using a cut-off of 65 years. A total of 21 randomized trials
including 173,810 individuals at a mean follow-up of 5.3 years were
included. Compared with control, aspirin did not reduce significantly the
risk of all-cause death (risk ratio: 0.96; 95% confidence interval:
0.92-1.00, p = 0.057). Major adverse cardiovascular events were
significantly reduced by 11%, paralleled by significant reductions in
myocardial infarction and transient ischemic attack. Major bleeding,
intracranial hemorrhage, and gastrointestinal bleeding were significantly
increased by aspirin. There was a significant age interaction for death (p
for interaction = 0.007), with aspirin showing a statistically significant
7% relative benefit on all-cause death in studies including younger
patients. Conclusion The use of aspirin in subjects with no overt CVD was
associated with a neutral effect on all-cause death and a modest lower
risk of major cardiovascular events at the price of an increased risk in
major bleeding. The benefit of aspirin might be more pronounced in younger
individuals. Copyright © 2022 Georg Thieme Verlag. All rights
reserved.

<32>
Accession Number
2043048786
Title
Colchicine for Secondary Prevention in Cardiovascular Diseases: A
Systematic Review and Meta-Analysis of RCTs.
Source
SN Comprehensive Clinical Medicine. 8(1) (no pagination), 2026. Article
Number: 22. Date of Publication: 01 Dec 2026.
Author
Tanashat M.; Khalefa B.B.; Eletrreby A.; Abuelazm M.; Abouzid M.; Ayyad
M.; Arnaout M.; Altobaishat O.; Bataineh O.A.; Hariri M.; Manasrah A.;
Bataineh Z.; Galy R.
Institution
(Tanashat) Faculty of Medicine, Yarmouk University, Irbid, Jordan
(Khalefa) Faculty of Medicine, Ain Shams University, Cairo, Egypt
(Eletrreby) Faculty of Medicine, Mansoura University, Mansour, Egypt
(Abuelazm) Faculty of Medicine, Tanta University, Tanta, Egypt
(Abouzid) Department of Physical Pharmacy and Pharmacokinetics, Faculty of
Pharmacy,, Poznan University of Medical Sciences, Rokietnicka 3 St,
Poznan, Poland
(Abouzid) Doctoral School, Poznan University of Medical Sciences, Poznan,
Poland
(Ayyad) Department of Internal Medicine, Rutgers New Jersey Medical
School, Newark, NJ, United States
(Arnaout) Faculty of Medicine, Aleppo University, Aleppo, Syrian Arab
Republic
(Altobaishat, Bataineh, Bataineh) Faculty of Medicine, Jordan University
of Science and Technology, Irbid, Jordan
(Hariri) College of Medicine, Alfaisal University, Riyadh, Saudi Arabia
(Manasrah) Mayo Clinic, Rochester, MN, United States
(Manasrah) Internal Medicine Department, UHS-Wilson Medical Center,
Johnson City, NY, United States
(Galy) University of Missouri-Kansas City, Kansas City, MO, United States
Publisher
Springer Nature
Abstract
Background: Colchicine has gained attention for its potential
cardiovascular benefits, particularly in patients at high cardiovascular
risk. This study aims to assess the impact of colchicine on these primary
outcomes in adults with high cardiovascular risk. Method(s):
Following the PRISMA (Preferred Reporting Items for Systematic Reviews and
Meta-Analyses) guidelines, we searched four electronic databases (PubMed,
EMBASE, Cochrane Library, and Web of Science) to identify eligible studies
reported up to December 16, 2024. Using Review Manager software, we
reported outcomes as risk ratios (RRs) and confidence intervals (CIs). A
p-value < 0.05 is considered statistically significant. The study was
registered on PROSPERO (CRD42024589252). Result(s): The meta-analysis
included a total of 12 studies with 24,412 patients. Overall, the results
showed insignificant differences in all-cause mortality 1.04 (RR 1.04, 95%
CI: 0.88-1.24, p = 0.63), or cardiovascular mortality (RR 0.82, 95% CI:
0.61-1.11, p = 0.20) between colchicine and placebo. However, compared to
placebo, colchicine significantly reduced the risk of myocardial
infarction (RR = 0.75, 95% CI: 0.60-0.92, p < 0.01), major adverse cardiac
and cerebrovascular events (RR = 0.77, 95% CI: 0.68-0.87, p < 0.01),
revascularization (RR = 0.61, 95% CI: 0.42-0.89, p = 0.01) and incidence
of ischemic stroke - only in patients with acute coronary syndrome (RR
0.35, 95% CI: 0.16-0.74, p < 0.01). Conclusion(s): Incorporating
colchicine into standard secondary prevention regimens for patients with
coronary artery disease or acute coronary syndrome has been shown to
reduce the incidence of cardiovascular and cerebrovascular events
effectively. Copyright © The Author(s), under exclusive licence
to Springer Nature Switzerland AG 2026.

<33>
Accession Number
2043781523
Title
Predictive Value of Preoperative Left Atrial Strain Parameters on
Postoperative Atrial Fibrillation in Adults Undergoing Cardiac Surgery: A
Systematic Review and Meta-Analysis.
Source
Interdisciplinary Cardiovascular and Thoracic Surgery. 41(2) (no
pagination), 2026. Article Number: ivag035. Date of Publication: 01 Feb
2026.
Author
Misra S.; Das D.; Patra T.K.; Borde D.P.; Srinivasan A.
Institution
(Misra) Department of Anesthesiology and Critical Care, All India
Institute of Medical Sciences (AIIMS), Odisha, Bhubaneswar, India
(Das, Patra) Department of Anesthesiology (Burn Centre), AIIMS, Odisha,
Bhubaneswar, India
(Borde) Department of Cardiac Anesthesia, Ozone Anesthesia Group,
Maharashtra, Aurangabad, India
(Srinivasan) Department of Pharmacology, AIIMS, Odisha, Bhubaneswar, India
Publisher
Oxford University Press
Abstract
Objectives Preoperative left atrial (LA) strain parameters measured by
2-dimensional speckle tracking echocardiography have been used to predict
postoperative atrial fibrillation (POAF) after cardiac surgery. The aim of
this meta-analysis was to determine whether preoperative LA strain
parameters predict POAF after cardiac surgery. Methods PubMed, Embase,
Cochrane database, and Google Scholar were searched manually until January
31, 2025. Studies where preoperative LA strain was used to predict POAF
following cardiac surgery in adults were considered. Reviews, case series,
case reports, and studies where patients were in preoperative atrial
fibrillation were excluded. Results Twenty-four observational studies
involving 2242 patients were included. Preoperative LA reservoir strain
was significantly lower in patients with POAF vs those without POAF
(standardized mean difference [SMD] -2.37; 95% confidence interval [CI]
-3.87 to -0.88; I2 = 94.5%). Preoperative LA conduit (SMD
-0.73; 95% CI, -1.06 to -0.39; I2 = 41.5%) and contraction (SMD
-1.04; 95% CI, -1.81 to -0.27; I2 = 92.2%) strain were
significantly lower in patients with POAF while preoperative LA reservoir,
conduit, and contraction strain rates were not different in patients with
POAF vs no POAF. Meta regression for heterogeneity in reservoir strain was
significant for gender, vendor platform, and filling pressures (E/e'). The
cut-off value of LA reservoir strain for predicting POAF was 22 to 25%
(area under curve 0.69, specificity 0.679 [95% CI, 0.645 to 0.711],
sensitivity 0.713 [95% CI, 0.675 to 0.743]). Conclusions Preoperative LA
reservoir, conduit, and contraction strain predict POAF in adults
undergoing cardiac surgery. Prospero registration no
CRD42024606011. Copyright © The Author(s) 2026. Published by
Oxford University Press on behalf of the European Association for
Cardio-Thoracic Surgery.

<34>
Accession Number
638001941
Title
Clinical Outcomes of Different Warfarin Self-Care Strategies: A Systematic
Review and Network Meta-Analysis.
Source
Thrombosis and Haemostasis. 122(4) (pp 492-505), 2022. Date of
Publication: 17 May 2022.
Author
Dhippayom T.; Boonpattharatthiti K.; Thammathuros T.; Dilokthornsakul P.;
Sakunrag I.; Devine B.
Institution
(Dhippayom, Boonpattharatthiti, Thammathuros, Sakunrag) Department of
Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan
University, Phitsanulok, Thailand
(Boonpattharatthiti) Division of Clinical Pharmacy, Faculty of
Pharmaceutical Sciences, Burapha University, Chon Buri, Thailand
(Dilokthornsakul) Department of Pharmacy Practice, Center of
Pharmaceutical Outcomes Research, Faculty of Pharmaceutical Sciences,
Naresuan University, Phitsanulok, Thailand
(Devine) The Comparative Health Outcomes, Policy, and Economics Institute,
School of Pharmacy, University of Washington, Seattle, WA, United States
Publisher
Georg Thieme Verlag
Abstract
Aim To compare the effects of different strategies for warfarin self-care.
Methods PubMed, EMBASE, CENTRAL, CINAHL, ProQuest Dissertations & Theses,
and OpenGrey were searched from inception to August 2021. Randomized
controlled trials (RCTs) of warfarin self-care, either patient
self-testing (PST) or patient self-management (PSM), were included.
Self-care approaches were classified based on the TIP framework (theme,
intensity, provider): (1) PST >=1/week via e-Health (PST/High/e-Health);
(2) PST >=1/week by health care practitioner (PST/High/HCP); (3) PST
<1/week via e-Health (PST/Low/e-Health); (4) PSM >=1/week by e-Health
(PSM/High/e-Health); (5) PSM >=1/week by patient (PSM/High/Pt); (6) PSM
<1/week by patient (PSM/Low/Pt); and (7) PSM with flexible frequency by
patient (PSM/Flex/Pt). Mean differences (MDs) and risk ratios (RRs) with
95% confidence interval (CI) were estimated using frequentist network
meta-analyses with a random-effects model. The certainty of evidence was
evaluated using CINeMA (Confidence in Network Meta-Analysis). Results
Sixteen RCTs involving 5,895 participants were included. When compared
with usual care, time in therapeutic range was higher in PSM/High/Pt and
PST/High/e-Health with MD [95% CI] of 7.67% [0.26-15.08] and 5.65%
[0.04-11.26], respectively. The certainty of evidence was rated as
moderate for these findings. The risk of thromboembolic events was lower
in the PSM/Flex/Pt group when compared with PST/High/e-Health (RR: 0.39
[0.20-0.77]) and usual care (RR: 0.38 [0.17-0.88]) with low and very low
level of evidence, respectively. There was no significant difference in
the proportion of international normalized ratio (INR) values in range,
major bleeding, and all-cause mortality among different self-care
features. Conclusion Patient self-care (either PST or PSM) by measuring
INR values at least once weekly is more effective in controlling the INR
level. Copyright © 2022 Georg Thieme Verlag. All rights reserved.

<35>
Accession Number
635319371
Title
Safety and Efficacy of Different Antithrombotic Strategies after
Transcatheter Aortic Valve Implantation: A Network Meta-Analysis.
Source
Thrombosis and Haemostasis. 122(2) (pp 216-225), 2022. Article Number:
210095. Date of Publication: 07 Feb 2022.
Author
Navarese E.P.; Grisafi L.; Spinoni E.G.; Mennuni M.G.; Rognoni A.;
Ratajczak J.; Podhajski P.; Koni E.; Kubica J.; Patti G.
Institution
(Navarese, Kubica) Department of Cardiology and Internal Medicine,
Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland
(Grisafi, Spinoni, Patti) Department of Translational Medicine, University
of Eastern Piedmont, Via Solaroli 17, Novara, Italy
(Grisafi, Spinoni, Mennuni, Rognoni, Patti) Department of Thoracic, Heart
and Vascular Diseases, Maggiore della Carita Hospital, Novara, Italy
(Ratajczak) Department of Health Promotion, Nicolaus Copernicus
University, Bydgoszcz, Poland
(Ratajczak, Podhajski) Department of Cardiology and Internal Medicine,
Nicolaus Copernicus University, Bydgoszcz, Poland
(Koni) Department of Interventional Cardiology, Santa Corona Hospital,
Pietra Ligure, Italy
Publisher
Georg Thieme Verlag
Abstract
Background The optimal pharmacological therapy after transcatheter aortic
valve implantation (TAVI) remains uncertain. We compared efficacy and
safety of various antiplatelet and anticoagulant approaches after TAVI by
a network meta-analysis. Methods A total of 14 studies (both observational
and randomized) were considered, with 24,119 patients included. Primary
safety endpoint was the incidence of any bleeding complications during
follow-up. Secondary safety endpoint was major bleeding. Efficacy
endpoints were stroke, myocardial infarction, and cardiovascular
mortality. A frequentist network meta-analysis was conducted with a
random-effects model. The following strategies were compared: dual
antiplatelet therapy (DAPT), single antiplatelet therapy (SAPT), oral
anticoagulation (OAC), and OAC + SAPT. The mean follow-up was 15 months.
Results In comparison to DAPT, SAPT was associated with a 44% risk
reduction of any bleeding (odds ratio [OR]: 0.56 [95% confidence interval,
CI: 0.39-0.80]). SAPT was ranked as the safest strategy for the prevention
of any bleeding (p -score: 0.704), followed by OAC alone (p -score: 0.476)
and DAPT (p -score: 0.437). Consistent results were observed for major
bleeding. The incidence of cardiovascular death and secondary ischemic
endpoints did not differ among the tested antithrombotic approaches. In
patients with indication for long-term anticoagulation, OAC alone showed
similar rates of stroke (OR: 0.92 [95% CI: 0.41-2.05], p = 0.83) and
reduced occurrence of any bleeding (OR: 0.49 [95% CI: 0.37-0.66], p <
0.01) versus OAC + SAPT. Conclusion The present network meta-analysis
supports after TAVI the use of SAPT in patients without indication for OAC
and OAC alone in those needing long-term anticoagulation. Copyright
© 2022 American Institute of Physics Inc.. All rights reserved.

<36>
Accession Number
2042788237
Title
Effects of Levosimendan in Patients with Severe Mitral Insufficiency and
Left Ventricular Dysfunction Undergoing Transcatheter Edge-to-Edge Repair:
A Systematic Review and Meta-Analysis.
Source
Journal of Cardiovascular Development and Disease. 13(1) (no pagination),
2026. Article Number: 40. Date of Publication: 01 Jan 2026.
Author
Kuhne S.G.; Patrignani A.; Wolbert S.; Harmel E.; Penev D.; Elvinger S.;
Chiarito M.; Raake P.W.J.; Bongiovanni D.
Institution
(Kuhne, Wolbert, Harmel, Penev, Elvinger, Raake, Bongiovanni) Department
of Internal Medicine I, Cardiology, University Hospital Augsburg,
University of Augsburg, Augsburg, Germany
(Patrignani, Chiarito) Department of Cardiovascular Medicine, Humanitas
Clinical and Research Center IRCCS and Humanitas University, Milan,
Rozzano, Italy
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Severe mitral regurgitation (MR) is one of the most common valvular heart
diseases and is frequently associated with advanced left ventricular (LV)
systolic dysfunction. Transcatheter edge-to-edge repair (TEER) offers
effective symptom relief but may induce abrupt hemodynamic changes leading
to afterload mismatch and acute LV failure. Levosimendan may help mitigate
this complication by improving contractility, yet evidence supporting its
use in this setting is scarce. Therefore, the aim of this study was to
systematically evaluate the evidence on the effects of Levosimendan in
patients with severe MR and LV dysfunction undergoing TEER. We performed a
comprehensive search of PubMed, Embase, Scopus, and Google Scholar.
Primary outcomes were postprocedural LV ejection fraction (LVEF) and
systolic pulmonary artery pressure (sPAP). Secondary outcomes included
procedural success, procedure duration, and in-hospital complications.
Five studies comprising 315 patients (n = 141 Levosimendan, n = 174
controls) met the inclusion criteria. Pooled analysis showed no
significant difference in postprocedural LVEF between Levosimendan-treated
patients and controls (mean difference 0.45%, 95% CI [-1.46-2.35] p =
0.65) and no significant change from baseline. Similarly, postprocedural
sPAP did not differ significantly. Procedural success was higher with
Levosimendan, and procedure duration was shorter. These
hypothesis-generating findings highlight the need for larger, prospective
randomized trials to clarify the role of Levosimendan in this
setting. Copyright © 2026 by the authors.

<37>
Accession Number
2043799870
Title
The Predictive Value of Machine Learning for Postoperative Delirium in
Cardiac Surgery: Systematic Review and Meta-Analysis.
Source
Journal of Medical Internet Research. 28 (no pagination), 2026. Article
Number: e72304. Date of Publication: 2026.
Author
Guo Y.; Xu H.; Wang A.; Zhang M.; Zhang S.; Xie P.
Institution
(Guo, Wang, Zhang, Zhang) Department of Anesthesiology, Norinco General
Hospital, Xi'an, China
(Xu) Department of Operating Room, Norinco General Hospital, Xi'an, China
(Xie) Department of Hepatobiliary and Vascular Surgery, Norinco General
Hospital, Xi'an, China
Publisher
JMIR Publications Inc.
Abstract
Background: Postoperative delirium (POD) following cardiac surgery is a
severe complication, and early identification of delirium risk remains a
challenge in clinical practice. While machine learning (ML) has garnered
increasing attention in health care applications, effective early
prediction tools remain limited in current clinical practice. Recent
investigations have explored the effectiveness of ML-based methods for
identifying the risk of POD in patients undergoing cardiac surgery.
However, more evidence is required to validate the feasibility of these
methods. Objective(s): This study aims to ascertain the performance
of ML in identifying the risk of POD following cardiac surgery, providing
evidence for the development or updating of future ML-based assessment
tools. Method(s): A comprehensive literature search was conducted
across 4 databases-PubMed, the Cochrane Library, Embase, and Web of
Science-through August 30, 2024, to identify studies investigating
individual POD risk prediction using ML approaches and nomograms. The risk
of bias of the models in the included studies was assessed leveraging the
Prediction Model Bias Risk Assessment Tool. Subgroup analyses were
performed based on datasets, validation methods, study types, risk of
bias, and model types. Result(s): The analysis incorporated 28
original studies comprising 80,143 patients undergoing cardiac surgery, of
whom 6326 developed POD. Meta-analysis revealed that, in validation
datasets, the c-index, sensitivity, and specificity for delirium
prediction reached 0.805 (95% CI 0.759-0.852), 0.72 (95% CI 0.65-0.79),
and 0.78 (95% CI 0.71-0.83), respectively. Logistic regression was the
primary modeling method. In validation datasets, the c-index, sensitivity,
and specificity reached 0.773 (95% CI 0.724-0.823), 0.73 (95% CI
0.64-0.80), and 0.70 (95% CI 0.65-0.74), respectively. Conclusion(s):
ML-based prediction tools for POD following cardiac surgery demonstrate
promising performance. However, the limited number of studies and
validation approaches necessitate cautious interpretation of these
findings. Future multicenter studies are warranted to develop more robust
ML-based prediction tools, enabling precise risk stratification and
targeted preventive interventions for POD. Copyright © Yi Guo,
Hong Xu, Ankui Wang, Mingming Zhang, Shuai Zhang, Peng Xie.

<38>
Accession Number
2043154196
Title
Cardiothoracic Transplant Surgery and Enhanced Recovery: Recent Advances
and Perspectives.
Source
Journal of Clinical Medicine. 15(3) (no pagination), 2026. Article Number:
1179. Date of Publication: 01 Feb 2026.
Author
Aggarwal R.; Hutson J.; Zapata D.; Massey H.; Taylor B.; Griffith B.;
Robinson J.
Institution
(Aggarwal, Hutson, Robinson) College of Human Medicine, Michigan State
University, Grand Rapids, MI, United States
(Zapata, Massey, Taylor, Griffith, Robinson) Department of Surgery,
University of Maryland School of Medicine, Baltimore, MD, United States
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Introduction: Cardiothoracic transplant surgery represents a critical
intervention for patients with end-stage heart and/or lung failure. While
advancements in surgical techniques and perioperative management have
enhanced survival rates, these procedures remain associated with
significant morbidity, extended hospitalizations, and complex recovery
trajectories. Background/Objectives: Enhanced Recovery After Surgery
(ERAS) protocols, originally developed for colorectal surgery, have shown
promise in optimizing perioperative care across various surgical
disciplines. However, their application in cardiac and thoracic
transplantation is still emerging. This article evaluates recent
advancements in ERAS protocols tailored to cardiac and thoracic transplant
patients, focusing on preoperative, intraoperative, and postoperative
interventions. Result(s): Evidence highlights the potential of ERAS
to reduce complications, shorten hospital stays, and improve long-term
outcomes. Key strategies include preoperative optimization through
nutritional and psychosocial prehabilitation, intraoperative adoption of
minimally invasive techniques and refined anesthesia practices, and
postoperative protocols emphasizing opioid-sparing pain management, early
mobilization, and nutritional recovery. Conclusion(s): This review
identifies gaps in current research and offers recommendations for the
broader implementation and standardization of ERAS protocols in
cardiothoracic surgery, with emphasis on cardiothoracic transplantation,
aiming to improve outcomes for this high-risk population. Copyright
© 2026 by the authors.

<39>
Accession Number
2041161321
Title
Ventricular Assist Devices in Adults With Transposition of the Great
Arteries and Systemic Right Ventricle: Systematic Literature Review.
Source
World Journal for Pediatric and Congenital Heart Surgery. 17(2) (pp
263-269), 2026. Date of Publication: 01 Mar 2026.
Author
Abdelkader A.E.A.; Guglin M.
Institution
(Abdelkader, Guglin) Section of Heart Failure/Heart Transplantation/MCS
Services, Indiana University School of Medicine, Indianapolis, IN, United
States
Publisher
SAGE Publications Inc.
Abstract
Background: In adult patients with transposition of the great arteries
(TGA) and systemic right ventricle (sRV), the use of ventricular assist
devices (VADs) is uncommon. Method(s): We conducted a systematic
review of published studies to examine the indications, hemodynamic
effects, and outcomes of VADs in this patient population. We reviewed
English-language literature for case reports, case series, and reviews
that included individual patient data, such as demographics, hemodynamic
parameters, types of implanted VADs, and outcomes. Result(s): We
identified 107 patients, 76% (81/107) males, mean age 40.2 +/- 10.6 at the
time of implantation, 38.3% (41/107) with left TGA (L-TGA), and 61.7%
(66/107) with dextro-TGA (D-TGA). The VAD support resulted in hemodynamic
improvement, including a decrease in the mean pulmonary arterial pressure
(45 +/- 15 mm Hg before implantation to 25 +/- 9.3 mm Hg afterwards, P <
.001), pulmonary vascular resistance (6.3 +/- 4.9 Wood units (WU) to 2.4
+/- 1.35 WU, P < .001), right atrial pressure (16.4 +/- 7.3 mm Hg to 9.5
+/- 3.7 mm Hg, P = .009), and pulmonary capillary wedge pressure (25.45
+/- 7.12 mm Hg to 14.25 +/- 5.6 mm Hg, P < .001). The cardiac index
increased from 2.0 +/- 0.5 L/min/m2 to 2.8 +/- 0.6 L/min/m2 (P = .004).
The 1-year survival rate was 80.5%. Eventually, 31 (29%) underwent heart
transplantation, and 48 (54%) remained on VAD at the time of publication.
 Conclusion(s): Durable VADs provide hemodynamic improvement and
excellent survival in adults with a systemic right ventricle. Expanding
the use of VADs for this patient population would be
justified. Copyright © The Author(s) 2025

<40>
Accession Number
649275425
Title
Effectiveness of intermittent pneumatic compression cushion in preventing
sacrococcygeal intraoperative acquired pressure injuries during cardiac
surgery: a randomized controlled trial.
Source
Intensive & critical care nursing. 93 (pp 104278), 2026. Date of
Publication: 01 Apr 2026.
Author
Gao W.; Zhang Y.; Lin Y.; Chen N.; Sun C.; Hu Y.; Chen H.; Xu M.; Wang W.
Institution
(Zhang, Chen, Sun, Hu, Chen) Department of the Operating Room, First
Affiliated Hospital of Wenzhou Medical University, Zhejiang Province,
Wenzhou, China
(Gao, Zhang, Lin, Wang) Department of Anaesthesiology, First Affiliated
Hospital of Wenzhou Medical University, Zhejiang Province, Wenzhou, China
(Xu) Department of the Operating Room, First Affiliated Hospital of
Wenzhou Medical University, Zhejiang Province, Wenzhou, China
Abstract
BACKGROUND: Intraoperative Acquired Pressure Injury (IAPI) is a common
complications in cardiac surgery, with reported incidence rates of
14.3-30%. Conventional pressure redistribution methods have limited
effectiveness during lengthy procedures. This study evaluated the efficacy
of intermittent pneumatic compression (IPC) cushions in preventing
sacrococcygeal IAPI in cardiac surgery patients and developed a predictive
nomogram for risk assessment. METHOD(S): In this prospective,
single-center randomized controlled trial, patients undergoing cardiac
surgery with cardiopulmonary bypass (CPB) were randomized to receive
either IPC cushion (n = 94) or standard gel pad (n = 95). The primary
outcome was the incidence of sacrococcygeal IAPI. Secondary outcomes
included intraoperative changes in regional tissue oxygen saturation
(rSO2) and postoperative skin temperature differentials (DELTAT). Risk
factors were identified through logistic regression analysis, and a
predictive nomogram was constructed and validated. RESULT(S): The
IAPI incidence was significantly lower in the IPC group compared to the
control group (3.19 % vs. 18.95 %, P = 0.001). The IPC group demonstrated
higher sacrococcygeal rSO2 values during CPB and rewarming phases (P <
0.05). Postoperative sacrococcygeal DELTAT was significantly lower in the
IPC group [0.0 (-0.1, 0.1) vs 0.3 (-0.3, 0.5); P = 0.001]. Multivariate
logistic regression identified lower preoperative sacrococcygeal rSO2 (OR
= 0.94, 95 % CI: 0.90-0.98), absence of IPC intervention (OR = 0.06, 95 %
CI: 0.01-0.28), and diabetes mellitus (OR = 7.98, 95 % CI: 2.20-29.01) as
independent risk factors for IAPI. The nomogram demonstrated excellent
discrimination (AUC = 0.857, 95 % CI: 0.776-0.937) and calibration (chi2 =
1.09, P = 0.997). CONCLUSION(S): IPC cushions effectively reduce IAPI
incidence during cardiac surgery by improving sacrococcygeal tissue
perfusion. Skin temperature differentials correlate with IAPI risk and may
serve as early indicators for prevention. The validated predictive
nomogram offers a practical tool for risk assessment and targeted
preventive strategies in clinical practice. IMPLICATIONS FOR CLINICAL
PRACTICE: This study introduced an innovative application of IPC for
preventing intraoperative IAPI in cardiac surgery patients, demonstrating
its effectiveness in lowering the incidence of IAPI. Copyright ©
2025 Elsevier Ltd. All rights reserved.

<41>
[Use Link to view the full text]
Accession Number
2038848693
Title
Continued Versus Interrupted Oral Anticoagulation During Transcatheter
Aortic Valve Replacement in Patients With Atrial Fibrillation: A
Meta-Analysis.
Source
American Journal of Therapeutics. 33(1) (pp e31-e38), 2026. Date of
Publication: 2026.
Author
Jain H.; Patel N.; Daoud Tariq M.; Al-Shammari A.S.; Khan R.; Jain J.;
Patel R.; Ahmed F.; Ahmed R.; Alexander T.
Institution
(Jain, Patel, Jain) Department of Cardiology, All India Institute of
Medical Sciences (AIIMS), Jodhpur, India
(Daoud Tariq) Department of Internal Medicine, Foundation University
Medical College, Islamabad, Pakistan
(Al-Shammari) Department of Medicine, College of Medicine, University of
Baghdad, Baghdad, Iraq
(Khan) Department of Internal Medicine, University of Pittsburgh Medical
Center, Harrisburg, PA
(Patel) Department of Internal Medicine, University of North Carolina
Health Blue Ridge, Morganton, NC
(Ahmed) Department of Cardiology, Duke University Hospital, Durham, NC
(Ahmed) Department of Cardiology, National Heart and Lung Institute,
Imperial College London, London, United Kingdom
(Alexander) Department of Cardiology, Corpus Christi Medical Center,
Corpus Christi, TX
Publisher
Lippincott Williams and Wilkins
Abstract
Introduction: - A substantial number of patients undergoing transcatheter
aortic valve replacement (TAVR) require long-term oral anticoagulants
(OAC) owing to comorbidities. This study examined whether continuing oral
anticoagulation periprocedurally during TAVR is as safe and effective as
interrupting it. Method(s): - A systematic search of the major
databases was performed to identify relevant studies. Effect estimates
were calculated using risk ratios (RR) and 95% CIs by pooling the data
using the inverse-variance random effects model. Statistical significance
was set at P < 0.05. Result(s): - Four studies were included, with
2962 patients undergoing TAVR with continued OAC (n = 1318) and
interrupted OAC (n = 1644). The pooled analysis demonstrated that TAVR
with continued OAC had comparable risks for all-cause mortality (RR: 0.91;
95% CI, 0.62-1.34; P = 0.64), cardiovascular mortality (RR: 0.89; 95% CI,
0.43-1.84; P = 0.76), stroke (RR: 0.67; 95% CI, 0.42-1.08; P = 0.09),
closure device failure (RR: 0.86; 95% CI, 0.47-1.59; P = 0.64),
major/life-threatening bleeding (RR: 0.93; 95% CI, 0.74-1.15; P = 0.49),
and major vascular complications (RR: 0.97; 95% CI, 0.79-1.20; P = 0.80)
compared with TAVR with interrupted OAC. Conclusion(s): - In patients
undergoing TAVR, continued OAC showed comparable safety and efficacy with
interrupted OAC. These findings demonstrate that continuing OAC in the
periprocedural period may be a viable option in patients with atrial
fibrillation because of comorbidities requiring
anticoagulants. Copyright © 2025

<42>
Accession Number
2043152985
Title
Preoperative Nutrition-Based Interventions in Children Undergoing Cardiac
Surgeries-A Systematic Review and Meta-Analysis.
Source
Nutrients. 18(3) (no pagination), 2026. Article Number: 544. Date of
Publication: 01 Feb 2026.
Author
Strozyk A.; Halicki P.; Kolodziej M.; Horvath A.; Buczynski M.; Pietrzak
R.
Institution
(Strozyk, Kolodziej, Horvath) Department of Pediatrics, Medical University
of Warsaw, Warsaw, Poland
(Halicki, Pietrzak) Department of Pediatric Cardiology and General
Pediatrics, Medical University of Warsaw, Warsaw, Poland
(Buczynski) Department of Cardiothoracic Surgery and Transplantology,
Medical University of Warsaw, Warsaw, Poland
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Objective: This systematic review aimed to evaluate the efficacy and
safety of preoperative nutrition-based interventions on pre-, intra-, and
postoperative outcomes in children undergoing cardiac surgical procedures.
 Method(s): CENTRAL, MEDLINE, and EMBASE were systematically searched
for interventional and observational studies comparing any nutritional
preoperative intervention with a control or alternative strategy in
pediatric patients undergoing cardiac surgery, up to July 2025. The main
outcome was the postoperative length of stay in the intensive care unit
(ICU). The certainty of evidence was assessed using the GRADE approach.
 Result(s): Nineteen studies were included (8 randomized controlled
trials [RCTs], 1 non-randomized trial, and 10 observational studies),
evaluating heterogeneous interventions or exposures, including fatty
acids, vitamin D supplementation, and structured preoperative nutritional
protocols. Two RCTs demonstrated shorter ICU and hospital stays with
extended preoperative nutritional support (2 weeks vs. 1 week; n = 40; and
1 month vs. no support; n = 80). Observational data indicated an
association between preoperative nutritional support and reduced hospital
length of stay (meta-analysis of four studies; n = 278), as well as fewer
days to achieve full enteral feeding postoperatively (meta-analysis of
three studies; n = 138). No significant difference in postoperative ICU
stay was observed between groups (meta-analysis of two studies; n = 175).
No intervention-related serious adverse events were reported. The overall
certainty of evidence was very low. Conclusion(s): This systematic
review provides very low-certainty evidence suggesting that preoperative
nutrition-based interventions in children undergoing cardiac surgery are
safe and may offer clinical benefits. Substantial heterogeneity across
studies underscores the need for well-designed trials and standardized
preoperative nutritional protocols. PROSPERO number:
CRD420251085196. Copyright © 2026 by the authors.

<43>
Accession Number
2043110211
Title
Efficacy and Safety of Ciprofol for Sedation in Critically Ill Patients
After Cardiac Surgery: A Single-Center, Prospective, Randomized Controlled
Trial.
Source
Drug Design, Development and Therapy. 20 (no pagination), 2026. Article
Number: 12475780. Date of Publication: 2026.
Author
Guo L.; Hong M.; Li P.; Du W.; Li Y.; Li J.
Institution
(Guo, Hong, Du, Li) The Xuzhou Clinical College of Xuzhou Medical
University, Jiangsu, Xuzhou, China
(Li, Li) Xuzhou Clinical College of Xuzhou Medical University, Xuzhou
Medical University, Jiangsu, Xuzhou, China
Publisher
Dove Medical Press Ltd
Abstract
Purpose: This study aimed to compare the efficacy and safety of ciprofol
and propofol for sedation in critically ill patients after cardiac
surgery. Patients and Methods: In this prospective, randomized
controlled trial, 123 patients undergoing coronary artery bypass grafting
(CABG) and/or valve surgery were randomly assigned to receive either
ciprofol (Group C) or propofol (Group P) for postoperative sedation in the
intensive care unit (ICU). Midazolam was administered if additional
sedation was required, and remifentanil was used for analgesia. Sedation
and analgesia were titrated to a target Richmond Agitation-Sedation Scale
(RASS) score of -2 to +1 and a Critical-Care Pain Observation Tool (CPOT)
score < 3. The primary endpoint was the mean sedation compliance rate,
defined as the percentage of RASS scores within the target range during
the initial 24 hours. Secondary endpoints included safety events,
extubation time, length of ICU stay, mortality, delirium incidence, and
postoperative recovery. Result(s): In the per-protocol (PP)
population, sedation compliance was 92.77% (Group C) and 94.30% (Group P).
Ciprofol showed non-inferior sedation to propofol in cardiac surgery
patients; the lower limit of the one-sided 95% confidence interval (CI)
for rate difference (RD) exceeded the -8% non-inferiority margin in both
PP and intention-to-treat (ITT) populations. The incidence of hypotension
was numerically lower in Group C (31.3% vs 40.7%; P = 0.276), with no
significant differences in other safety or secondary outcomes (all P >
0.05). Conclusion(s): In summary, ciprofol provides non-inferior
sedation efficacy and a comparable safety profile to propofol in
critically ill patients following cardiac surgery. A numerical trend
toward lower hypotension incidence was observed with ciprofol, which
warrants further validation in future studies. Copyright © 2026
Guo et al.

<44>
Accession Number
2039541360
Title
Representativeness of surgical controls in aortic valve replacement
trials: Comparison with routine surgical cohorts.
Source
Heart. 112(5) (pp 239-245), 2026. Date of Publication: 01 Mar 2026.
Author
Tomsic A.; Velders B.J.J.; Kawczynski M.J.; Schoones J.W.; Klautz R.J.M.;
Palmen M.; Sardari Nia P.; Owais T.; Girdauskas E.; Heuts S.
Institution
(Tomsic, Owais, Girdauskas) Department of Cardiothoracic Surgery, Augsburg
University Medical Centre, Ausburg, Germany
(Velders, Klautz, Palmen) Department of Cardiothoracic Surgery, Leiden
University Medical Centre, Leiden, Netherlands
(Kawczynski, Sardari Nia, Heuts) Department of Cardiothoracic Surgery,
Maastricht University Medical Centre, Maastricht, Netherlands
(Kawczynski, Sardari Nia, Heuts) Cardiovascular Research Institute
Maastricht (CARIM), Maastricht University, Maastricht, Netherlands
(Schoones) Directorate of Research Policy, Leiden University Medical
Center, Zuid-Holland, Leiden, Netherlands
(Klautz) Department of Cardiothoracic Surgery, Amsterdam University
Medical Centre, Amsterdam, Netherlands
Publisher
BMJ Publishing Group
Abstract
Background Randomised controlled trials (RCTs) comparing transcatheter
aortic valve implantation (TAVI) and surgical aortic valve replacement
(SAVR) have significantly influenced treatment guidelines for aortic
stenosis, expanding the use of TAVI into lower risk populations. However,
the patients enrolled in the SAVR arms of these trials may differ from
those typically undergoing SAVR in routine clinical practice. This study
aims to critically assess the representativeness of SAVR patients in these
RCTs by comparing their characteristics and outcomes to those of patients
undergoing SAVR in routine clinical practice. Methods A systematic
literature review was conducted across PubMed, Embase, Web of Science,
Emcare and the Cochrane Library, focusing on RCTs and large prospective
studies (n>=500 SAVR patients), enrolling low-risk or intermediate-risk
patients since 2010. Patient characteristics, early outcomes and 5-year
survival were compared between RCT SAVR cohorts and those treated in
routine clinical practice settings. Meta-Analyses of pooled data and
reconstructed Kaplan-Meier survival analyses were performed, with
stratification by risk category. Results Nineteen studies (9 RCTs and 10
studies describing routine clinical practice), encompassing 74 797 SAVR
patients, were included. SAVR patients in routine clinical practice
demonstrated comparable early mortality to SAVR patients in RCTs but
experienced fewer periprocedural complications, including lower rates of
stroke, pacemaker implantation and myocardial infarction. At 5 years,
overall survival was notably higher in patients treated in routine
clinical practice compared to those in the SAVR arms of RCTs, both for
low-risk (HR 0.64, 95% CI 0.55 to 0.75) and intermediate-risk patients (HR
0.55, 95% CI 0.470.64). Conclusions Compared with typical SAVR patients
treated in routine practice, RCT SAVR patients experienced higher
complication rates and worse long-Term survival, despite similar or lower
surgical risk scores. These findings question the external validity of
SAVR versus TAVI trials. Copyright © 2026 BMJ Publishing Group.
All rights reserved.

<45>
Accession Number
2042962926
Title
Bidirectional nexus between metabolic disease and aortic valve
calcification: from pathogenic mechanisms to integrated multimorbidity
management.
Source
Expert Opinion on Therapeutic Targets. 30(2) (pp 147-162), 2026. Date of
Publication: 2026.
Author
Wang X.; Yu M.; Chen J.; Xu J.; Liu Y.; Wang Z.
Institution
(Wang, Yu, Chen, Xu, Liu, Wang) Department of Cardiology, Affiliated
Hospital of Jiangsu University, Zhenjiang, China
(Wang, Yu, Chen, Xu, Liu, Wang) Institute of Cardiovascular Diseases,
Jiangsu University, Zhenjiang, China
Publisher
Taylor and Francis Ltd.
Abstract
Introduction: Calcified aortic valve disease (CAVD) imposes a severe
global health burden, and there is currently no effective pharmacotherapy,
which urgently requires a new understanding of pathophysiology to guide
treatment. Areas covered: This review systematically evaluates the
epidemiological association and common mechanistic pathways between
metabolic diseases and aortic valve calcification (AVC) through the
proposed 'calcification-metabolic axis' framework. We conducted a
comprehensive literature search, covering the PubMed database up to
December 2025, with a focus on studies related to CAVD, metabolism,
inflammation, and calcification signaling. Expert opinion: Future
management strategies must transition toward early, multi-disease
co-governance strategies. At the same time, targeted drugs will be
developed for specific pathways on this axis, surpassing the current
treatment status of relying solely on valve replacement
surgery. Copyright © 2026 Informa UK Limited, trading as Taylor &
Francis Group.

<46>
Accession Number
2042931235
Title
Epidural Anesthesia as a Protective Factor in Cardiac Surgery: A
Prospective Randomized Study.
Source
Anesthesiology Research and Practice. 2026(1) (no pagination), 2026.
Article Number: 1869099. Date of Publication: 2026.
Author
Sanchez D.N.; Diez E.R.; Renna N.F.
Institution
(Sanchez) Head of Anesthesiology Service, Hospital Central de Mendoza,
Mendoza, Argentina
(Sanchez) Department of Surgery, School of Medicine, UNCuyo, Mendoza,
Argentina
(Diez) Area of Physiology, Department of Scientific Foundations in Health,
School of Medicine, UNCuyo, IMBECU-CONICET, Mendoza, Argentina
(Renna) Area of Pathological Physiology, Department of Scientific
Foundations in Health, School of Medicine, UNCuyo, IMBECU-CONICET,
Mendoza, Argentina
(Renna) Department of Cardiology, Hospital Espanol de Mendoza, Mendoza,
Argentina
Publisher
John Wiley and Sons Ltd
Abstract
Background: Epidural anesthesia (EA) has gained prominence in rapid
postoperative recovery protocols for cardiac surgery, aiming to reduce
opioid use, shorten intensive care stays, and improve patient outcomes.
This prospective randomized controlled trial evaluated the protective
effects of EA combined with general anesthesia (GA + EA) compared to GA
alone in patients undergoing off-pump coronary artery bypass grafting
(CABG). Method(s): Sixty male patients undergoing elective off-pump
CABG were randomized into two groups: GA (n = 30) and GA + EA (n = 30).
Surgical procedures were standardized using bilateral internal mammary
arteries skeletonized with an ultrasonic scalpel. Patients in the GA + EA
group received thoracic EA at the T2-T3 level, confirmed radiologically,
with continuous bupivacaine infusion. Result(s): Significant benefits
were observed in the GA + EA group, including shorter mechanical
ventilation duration (4.59 vs. 5.72 h; p = 0.011) and reduced hospital
stay (5.43 vs. 6.73 days; p = 0.001). Internal mammary artery blood flow
measurements were significantly higher in the GA + EA group (p < 0.001).
Plasma aldosterone levels were significantly lower in GA + EA patients,
indicating reduced stress-induced hormonal responses (left artery: 13.38
vs. 17.68 ng/dL, p = 0.005; right artery: 12.77 vs. 18.37 ng/dL, p =
0.003). Long-term outcomes demonstrated superior major adverse
cardiovascular event (MACE)-free survival in the GA + EA group (p <
0.001). Cox regression analysis confirmed that GA + EA independently
reduced cardiovascular risk, even after adjusting for age, ejection
fraction, and dopamine levels (HR = 0.0118, p < 0.001). Higher aldosterone
levels significantly correlated with increased MACE risk (p < 0.05).
 Conclusion(s): The study highlights aldosterone suppression as a
potential mechanism underlying EA's cardioprotective effects, emphasizing
its role in enhancing recovery and reducing cardiovascular complications.
Despite limitations such as small sample size and single-center design,
findings strongly support integrating EA into cardiac surgical
practice. Copyright © 2026 Diego Nicolas Sanchez et al.
Anesthesiology Research and Practice published by John Wiley & Sons Ltd.

<47>
Accession Number
2043362704
Title
Current rat models of extracorporeal life support following global
ischaemia: a scoping review.
Source
Intensive Care Medicine Experimental. 14(1) (no pagination), 2026. Article
Number: 19. Date of Publication: 01 Dec 2026.
Author
Dinkelaker J.; Pooth J.-S.; Trummer G.; Broer S.; Busch H.-J.; Schimmel
M.; Wollborn J.; Brixius S.J.
Institution
(Dinkelaker) Center for Experimental Models and Transgenic Service
CEMT-FR, Medical Center, Faculty of Medicine, University of Freiburg,
Breisacher Str. 66, Freiburg, Germany
(Pooth, Trummer, Busch, Brixius) Department of Emergency Medicine, Medical
Center, Faculty of Medicine, University of Freiburg, Hugstetter Strasse
55, Freiburg, Germany
(Broer) Institute of Pharmacology and Toxicology, School of Veterinary
Medicine, Freie Universitat Berlin, Berlin, Germany
(Wollborn) Department of Anesthesiology, Mass General Brigham, Brigham and
Women's Hospital, Harvard Medical School, Boston, United States
(Schimmel) Department of Cardiovascular Surgery, Faculty of Medicine,
University Heart Center Freiburg-Bad Krozingen, University of Freiburg,
Hugstetter Strasse 55, Freiburg, Germany
Publisher
Springer Nature
Abstract
Introduction: Small animal models are indispensable in cardiovascular
research. This scoping review aims to provide an overview of contemporary
rat models for extracorporeal life support (ECLS) after global ischaemia.
 Material(s) and Method(s): A systematic search was conducted in
PubMed, Web of Science and Embase to identify studies involving rat models
of global ischaemia followed by ECLS from January 2000 to December 2024.
Title and abstracts were screened by two independent reviewers, and the
remaining full text was included in predefined data extraction forms.
 Result(s): A total of 79 studies met the inclusion criteria. Male
Sprague Dawley rats were predominantly used (82%), with limited reporting
on animal age and inconsistent use of analgesia. The majority of studies
employed ECLS configurations with roller pumps (71%), custom-made
oxygenators (41%), venous drainage via the jugular vein (96%) and arterial
inflow via the femoral (53%) or caudal (35%) artery. Three distinct
clinical scenarios were identified: extracorporeal cardiopulmonary
resuscitation (41%), emergency preservation and resuscitation (13%), and
deep hypothermic circulatory arrest (47%). Substantial methodological
heterogeneity was observed across models, particularly in ischaemia
induction, ECLS protocols, outcome measures, and reporting standards.
 Conclusion(s): Rat models are increasingly used in ECLS research and
offer valuable opportunities for investigating pathophysiological
mechanisms and advantages for translational studies. To utilize their full
potential, improved standardization and adherence to existing guidelines
are needed to enhance their reproducibility and clinical
relevance. Copyright © The Author(s) 2026.

<48>
Accession Number
2042352020
Title
Driving Pressure-Guided Tidal Volume Titration Reduces Lung Injury in
Thoracic Surgery With One-Lung Ventilation: A Randomized Clinical Trial.
Source
Journal of Cardiothoracic and Vascular Anesthesia. 40(2) (pp 652-659),
2026. Date of Publication: 01 Feb 2026.
Author
Yan Y.; Liu X.; Liu Z.; Li Z.; Cai H.; Li W.; Zhao J.
Institution
(Yan, Li, Cai, Zhao) Department of Anesthesiology, China-Japan Friendship
Hospital, Chinese Academy of Medical Sciences and Peking Union Medical
College, Beijing, China
(Yan, Liu, Liu, Li, Cai, Li, Zhao) Department of Anesthesiology,
China-Japan Friendship Hospital, Beijing, China
Publisher
W.B. Saunders
Abstract
Objective: The optimal tidal volume for patients undergoing thoracic
surgery with one-lung ventilation (OLV) remains unclear. This study aimed
to evaluate whether driving pressure-guided tidal volume titration could
reduce lung injury in these patients. Design(s): Prospective,
single-center, randomized controlled trial. Setting(s): Single-center
academic hospital in China. Participant(s): A total of 96 patients
undergoing thoracic surgery with OLV. Intervention(s): Patients were
randomly assigned to either the driving pressure-guided tidal volume group
(n = 46) or the control group (n = 50). In the control group, tidal volume
was set at 8 mL/kg of predicted body weight (PBW) during OLV. In the
driving pressure-guided group, tidal volume was adjusted to maintain a
driving pressure between 8 and 10 cm H<inf>2</inf>O, with modifications
within 4 to 8 mL/kg PBW during OLV. Measurements and Main Results:
The primary outcome was the concentration of interleukin 6 (IL-6) in the
dependent lung following OLV. The tidal volume in the driving
pressure-guided group was 4.65 [4.23-5.65] mL/kg at 15 minutes and 4.58
[4.27-5.41] mL/kg at 45 minutes of OLV. The concentration of IL-6 in the
dependent lung after OLV was significantly lower in the driving pressure
group (5.31 [3.62]) compared to the control group (7.37 [5.21]) (mean
difference: -0.46 [-0.86 to -0.05] cm H<inf>2</inf>O; p = 0.025). There
were no significant differences between groups in the incidence of
postoperative pulmonary complications or in the oxygenation index 45
minutes after the start of OLV. Conclusion(s): Driving
pressure-guided tidal volume titration significantly reduces IL-6 levels
in bronchoalveolar lavage fluid from the dependent lung following OLV in
patients undergoing thoracic surgery, compared to conventional ventilation
using 8 mL/kg PBW. Copyright © 2025 Elsevier Inc.

<49>
Accession Number
2042451101
Title
Use of Video Laryngoscope to Reduce Complications of Transesophageal
Echocardiography Probe Insertion in Children.
Source
Journal of Cardiothoracic and Vascular Anesthesia. 40(2) (pp 613-619),
2026. Date of Publication: 01 Feb 2026.
Author
Gayathri G.; Divya Jacob P.; Nayanar V.K.N.; Vipin Raj V.; Babu S.;
Unnikrishnan K.P.; Koshy T.
Institution
(Gayathri, Divya Jacob, Nayanar, Vipin Raj, Babu, Unnikrishnan, Koshy)
Division of Cardiothoracic and Vascular Anaesthesia, Sree Chitra Tirunal
Institute for Medical Sciences and Technology, Thiruvananthapuram, India
Publisher
W.B. Saunders
Abstract
Objectives: To test the hypothesis of whether using a video laryngoscope
reduces complications related to transesophageal echocardiography (TEE)
probe insertion in children. Design(s): Randomized controlled study.
 Setting(s): Pediatric cardiac surgical operating rooms in a tertiary
care level hospital. Participant(s): One hundred thirty children aged
0 to 18 years undergoing elective cardiac surgery. Intervention(s):
TEE probe insertion. Measurements and Main Results: The patients were
randomized into 2 groups: conventional (C) group (n = 64) and video
laryngoscopy (VL) group (n = 66). The primary endpoint of the study was
the incidence of oropharyngeal injury. The secondary endpoints were the
number of attempts required for successful TEE probe insertion and the
relation between the esophageal inlet and the larynx. The overall
incidence of oropharyngeal injuries was 7.7%, with 4 injuries (6.3%)
occurring in the C group and 6 injuries (9.1%) occurring in the VL group
(p = 0.543). Most children (90.8%) required only 1 attempt to insert the
TEE probe, with no significant difference between groups (p = 0.579). A
higher percentage increase in mean blood pressure during probe insertion
and a higher heart rate increase after probe insertion were observed in
the VL group (p < 0.05). The most common relationship with the larynx was
posterior (62%), followed by left posterolateral (20.9%) and right
posterolateral (17.1%). Conclusion(s): VL does not demonstrate
superiority over conventional methods of TEE probe insertion in children
regarding injury incidence or first-attempt success rate. Copyright
© 2025 Elsevier Inc.

<50>
Accession Number
2043667237
Title
Antithrombotic strategies and DOAC dosing following left atrial appendage
occlusion: a network meta-analysis.
Source
European Heart Journal - Cardiovascular Pharmacotherapy. 12(1) (pp 38-51),
2026. Date of Publication: 01 Jan 2026.
Author
Samaras A.; Karakasis P.; Feidakis A.; Giannakoulas G.; Fragakis N.;
Nielsen-Kudsk J.-E.; Freixa X.; Nair D.G.; Freeman J.V.; Bergmann M.;
Landmesser U.; Tzikas A.
Institution
(Samaras, Tzikas) School of Medicine, Faculty of Health Sciences,
Aristotle University of Thessaloniki, Thessaloniki, Greece
(Samaras, Karakasis, Fragakis, Tzikas) Second Department of Cardiology,
Thessaloniki, Greece
(Feidakis) Department of Cardiology, Heart Center, University of Cologne,
Germany
(Giannakoulas) First Department of Cardiology, AHEPA University Hospital
of Thessaloniki, Thessaloniki, Greece
(Nielsen-Kudsk) Department of Cardiology, Aarhus University Hospital,
Aarhus, Denmark
(Freixa) Department of Cardiology, Institut Cardiovascular, IDIBAPS,
Barcelona, Spain
(Nair) Department of Cardiac Electrophysiology, St Bernard's Heart and
Vascular Center, Jonesboro, AR, United States
(Freeman) Section of Cardiovascular Medicine, Yale University School of
Medicine, New Haven, CT, United States
(Freeman) Center for Outcomes Research and Evaluation, Yale-New Haven
Hospital, New Haven, CT, United States
(Bergmann) Department of Cardiology and Intensive Care Medicine, Asklepios
Klinik Altona, Hamburg, Germany
(Landmesser) BerlinGermany
(Landmesser) German Centre for Cardiovascular Research (DZHK), Partner
Site Berlin, Berlin, Germany
(Landmesser) Department of Cardiology, Angiology and Intensive Care
Medicine, Deutsches Herzzentrum Charite, Campus Benjamin Franklin, Germany
(Landmesser) Berlin Institute of Health, Berlin, Germany
(Tzikas) European Interbalkan Medical Center, Thessaloniki, Greece
Publisher
Oxford University Press
Abstract
Aims The optimal short-term antithrombotic strategy following left atrial
appendage occlusion (LAAO) remains uncertain, with the need to balance
thromboembolic prevention and bleeding risk presenting a critical
challenge. Recent evidence suggests that direct oral anticoagulants
(DOACs) may provide a favourable safety-efficacy profile, with low-dose
regimens showing potential benefits during the device endothelialization
period. This network meta-analysis (NMA) aimed to compare the efficacy and
safety of various antithrombotic strategies, including DOAC dosing,
following LAAO. Methods and results A systematic review and NMA were
conducted following Cochrane and PRISMA guidelines. Eligible studies
included randomized controlled trials (RCT) and observational studies
comparing at least two antithrombotic regimens in patients with
non-valvular atrial fibrillation undergoing percutaneous LAAO. Primary
outcomes were major bleeding and thromboembolism. Secondary outcomes
included device-related thrombosis (DRT) and all-cause mortality. Pairwise
and network meta-analyses were performed using a random-effects model. A
total of 52 studies (49 observational and 3 RCTs) involving 69 751
patients were included. DOACs were consistently associated with
significantly lower rates of major bleeding and all-cause mortality than
other antithrombotic regimens. Low-dose DOACs showed a potential advantage
over standard-dose DOACs in reducing major bleeding risk (odds ratio 0.45,
95% confidence interval: 0.22-0.92). For thromboembolism and DRT,
standard-dose DOAC significantly reduced risk compared with single
antiplatelet therapy (SAPT) but not with dual antiplatelet therapy (DAPT),
whereas low-dose DOAC significantly reduced both outcomes compared with
SAPT, DAPT, and vitamin K antagonists plus SAPT. In ranking analysis,
DOACs emerged as the most effective and safest antithrombotic strategy,
with low-dose DOACs demonstrating further safety benefits in bleeding
outcomes. Conclusion DOACs provide a superior safety-efficacy profile
compared with other antithrombotic strategies following LAAO,
significantly reducing the risks of major bleeding, thromboembolic events,
and mortality. While low-dose DOACs may offer additional bleeding risk
reduction without compromising efficacy, further research is warranted to
confirm their role in clinical practice. Copyright © The
Author(s) 2025. Published by Oxford University Press on behalf of European
Society of Cardiology.

<51>
Accession Number
638963099
Title
Self-expanding Transcatheter vs Surgical Aortic Valve Replacement in
Intermediate-Risk Patients: 5-Year Outcomes of the SURTAVI Randomized
Clinical Trial.
Source
JAMA Cardiology. 7(10) (pp 1000-1008), 2022. Date of Publication: 01 Oct
2022.
Author
Van Mieghem N.M.; Deeb G.M.; Sondergaard L.; Grube E.; Windecker S.; Gada
H.; Mumtaz M.; Olsen P.S.; Heiser J.C.; Merhi W.; Kleiman N.S.; Chetcuti
S.J.; Gleason T.G.; Lee J.S.; Cheng W.; Makkar R.R.; Crestanello J.;
George B.; George I.; Kodali S.; Yakubov S.J.; Serruys P.W.; Lange R.;
Piazza N.; Williams M.R.; Oh J.K.; Adams D.H.; Li S.; Reardon M.J.
Institution
(Van Mieghem, Serruys) Department of Interventional Cardiology, Erasmus
University Medical Center, Rotterdam, Netherlands
(Deeb, Chetcuti) Department of Interventional Cardiology, University of
Michigan, Ann Arbor, United States
(Deeb) Department of Cardiac Surgery, University of Michigan, Ann Arbor,
United States
(Sondergaard, Olsen) Department of Cardiology, Heart Center,
Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
(Grube) Department of Interventional Cardiology, University of Bonn, Bonn,
Germany
(Windecker) Department of Cardiology, Inselspital, University of Bern,
Bern, Switzerland
(Gada, Mumtaz) Department of Interventional Cardiology, University of
Pittsburgh Medical Center Pinnacle Health, Harrisburg, PA, United States
(Gada, Mumtaz) Department of Cardiothoracic Surgery, University of
Pittsburgh Medical Center Pinnacle Health, Harrisburg, PA, United States
(Heiser, Merhi) Department of Interventional Cardiology, Spectrum Health,
Grand Rapids, Michigan, United States
(Heiser, Merhi) Department of Cardiothoracic Surgery, Spectrum Health,
Grand Rapids, MI, United States
(Kleiman, Reardon) Department of Interventional Cardiology, Houston
Methodist DeBakey Heart and Vascular Center, Houston, TX, United States
(Kleiman, Reardon) Department of Cardiothoracic Surgery, Houston Methodist
DeBakey Heart and Vascular Center, Houston, TX, United States
(Gleason, Lee) Department of Interventional Cardiology, University of
Pittsburgh, Pittsburgh, PA, United States
(Gleason) Now with Division of Cardiac Surgery, Department of Surgery,
University of Maryland School of Medicine, Baltimore, United States
(Gleason, Lee) Department of Cardiothoracic Surgery, University of
Pittsburgh, Pittsburgh, PA, United States
(Cheng, Makkar) Department of Interventional Cardiology, Cedars-Sinai
Medical Center, Los Angeles, CA, United States
(Cheng, Makkar) Department of Cardiothoracic Surgery, Cedars-Sinai Medical
Center, Los Angeles, CA, United States
(Crestanello, George) Department of Interventional Cardiology, Ohio State
University Wexner Medical Center, Columbus, United States
(Crestanello) Now with Mayo Clinic, Rochester, MN, United States
(Crestanello, George) Department of Cardiovascular Surgery, Ohio State
University Wexner Medical Center, Columbus, United States
(George, Kodali) Department of Interventional Cardiology, New York
Presbyterian Hospital-Columbia University Irving Medical Center, New York,
United States
(George, Kodali) Department of Cardiothoracic Surgery, New York
Presbyterian Hospital-Columbia University Irving Medical Center, New York,
United States
(Yakubov) Department of Interventional Cardiology, OhioHealth Riverside
Methodist Hospital, Columbus, United States
(Serruys) Now with National University of Ireland, Galway, Ireland
(Lange) Department of Cardiac Surgery, German Heart Center, Munich,
Germany
(Piazza) Department of Interventional Cardiology, McGill University Health
Centre, Montreal, QC, Canada
(Williams) Department of Interventional Cardiology and Cardiac Surgery,
Langone-New York University, New York, United States
(Oh) Echocardiography Core Laboratory, Mayo Clinic, Rochester, MN, United
States
(Adams) Department of Cardiovascular Surgery, Mount Sinai Health System,
New York, NY, United States
(Li) Clinical Research, Medtronic, Minneapolis, MN, United States
Publisher
American Medical Association
Abstract
Importance: In patients with severe aortic valve stenosis at intermediate
surgical risk, transcatheter aortic valve replacement (TAVR) with a
self-expanding supra-Annular valve was noninferior to surgery for
all-cause mortality or disabling stroke at 2 years. Comparisons of
longer-Term clinical and hemodynamic outcomes in these patients are
limited. Objective(s): To report prespecified secondary 5-year
outcomes from the Symptomatic Aortic Stenosis in Intermediate Risk
Subjects Who Need Aortic Valve Replacement (SURTAVI) randomized clinical
trial. Design, Setting, and Participant(s): SURTAVI is a prospective
randomized, unblinded clinical trial. Randomization was stratified by
investigational site and need for revascularization determined by the
local heart teams. Patients with severe aortic valve stenosis deemed to be
at intermediate risk of 30-day surgical mortality were enrolled at 87
centers from June 19, 2012, to June 30, 2016, in Europe and North America.
Analysis took place between August and October 2021. Intervention(s):
Patients were randomized to TAVR with a self-expanding, supra-Annular
transcatheter or a surgical bioprosthesis. Main Outcomes and
Measures: The prespecified secondary end points of death or disabling
stroke and other adverse events and hemodynamic findings at 5 years. An
independent clinical event committee adjudicated all serious adverse
events and an independent echocardiographic core laboratory evaluated all
echocardiograms at 5 years. Result(s): A total of 1660 individuals
underwent an attempted TAVR (n = 864) or surgical (n = 796) procedure. The
mean (SD) age was 79.8 (6.2) years, 724 (43.6%) were female, and the mean
(SD) Society of Thoracic Surgery Predicted Risk of Mortality score was
4.5% (1.6%). At 5 years, the rates of death or disabling stroke were
similar (TAVR, 31.3% vs surgery, 30.8%; hazard ratio, 1.02 [95% CI,
0.85-1.22]; P =.85). Transprosthetic gradients remained lower (mean [SD],
8.6 [5.5] mm Hg vs 11.2 [6.0] mm Hg; P <.001) and aortic valve areas were
higher (mean [SD], 2.2 [0.7] cm2vs 1.8 [0.6] cm2; P
<.001) with TAVR vs surgery. More patients had moderate/severe
paravalvular leak with TAVR than surgery (11 [3.0%] vs 2 [0.7%]; risk
difference, 2.37% [95% CI, 0.17%-4.85%]; P =.05). New pacemaker
implantation rates were higher for TAVR than surgery at 5 years (289
[39.1%] vs 94 [15.1%]; hazard ratio, 3.30 [95% CI, 2.61-4.17]; log-rank P
<.001), as were valve reintervention rates (27 [3.5%] vs 11 [1.9%]; hazard
ratio, 2.21 [95% CI, 1.10-4.45]; log-rank P =.02), although between 2 and
5 years only 6 patients who underwent TAVR and 7 who underwent surgery
required a reintervention. Conclusions and Relevance: Among
intermediate-risk patients with symptomatic severe aortic stenosis, major
clinical outcomes at 5 years were similar for TAVR and surgery. TAVR was
associated with superior hemodynamic valve performance but also with more
paravalvular leak and valve reinterventions. Copyright © 2022
American Medical Association. All rights reserved.

<52>
Accession Number
2041513885
Title
Use of the win ratio approach to assess outcomes in the DapaTAVI trial.
Source
Revista Espanola de Cardiologia. 79(3) (pp 215-225), 2026. Date of
Publication: 01 Mar 2026.
Author
Rossello X.; Gonzalez-Manzanares R.; Amat-Santos I.; Peral Disdier V.;
Nieto Roca L.; Lopez Otero D.; Nombela Franco L.; Gheorge L.; Sanz-Sanchez
J.; Gomez Herrero J.; Gonzalez Ferreiro R.; Munoz Garcia A.J.; Vilalta V.;
Ojeda S.; Veiga Fernandez G.; Cordoba Soriano J.G.; Regueiro A.; Sandin
Rollan M.; Flores Rios X.; Uribarri A.; Martin Reyes R.; Romaguera R.;
Avanzas P.; Garcia Blas S.; Franco-Pelaez J.A.; Martin Moreiras J.;
Gonzalez Juanatey J.R.; Tirado G.; Calle G.; Diez J.L.; Santos-Martinez
S.; Melendo Viu M.; Carrillo Suarez X.; Sanmartin X.; Gonzalo N.;
Gutierrez Barrios A.; Gonzalez Bermudez I.; Real C.; Fuster V.; Ibanez B.;
Raposeiras-Roubin S.
Institution
(Rossello, Peral Disdier, Nieto Roca) Unidad de Cardiologia, Institut
d'Investigacio Sanitaria Illes Balears (IdISBa), Hospital Universitari Son
Espases, Palma de Mallorca, Baleares, Spain
(Rossello, Peral Disdier, Nieto Roca) Facultad de Medicina, Universitat de
les Illes Balears (UIB), Palma de Mallorca, Baleares, Spain
(Rossello, Peral Disdier, Nieto Roca, Real, Fuster, Ibanez,
Raposeiras-Roubin) Departamento de Investigacion Clinica, Centro Nacional
de Investigaciones Cardiovasculares (CNIC), Madrid, Spain
(Gonzalez-Manzanares, Ojeda) Unidad de Cardiologia, Hospital Universitario
Reina Sofia, Cordoba, Spain
(Gonzalez-Manzanares, Ojeda) Instituto Maimonides de Investigacion
Biomedica de Cordoba (IMIBIC), Cordoba, Spain
(Gonzalez-Manzanares, Amat-Santos, Gomez Herrero, Avanzas, Garcia Blas,
Gonzalez Juanatey, Santos-Martinez, Ibanez) Centro de Investigacion
Biomedica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de
Salud Carlos III, Madrid, Spain
(Amat-Santos, Gomez Herrero, Santos-Martinez) Unidad de Cardiologia,
Hospital Clinico Universitario de Valladolid, Valladolid, Spain
(Lopez Otero, Sanmartin) Unidad de Cardiologia, Hospital Universitario
Montecelo, Pontevedra, Spain
(Lopez Otero, Gonzalez Juanatey, Sanmartin) Unidad de Cardiologia,
Hospital Clinico Universitario de Santiago, Santiago de Compostela, A
Coruna, Spain
(Lopez Otero, Gonzalez Ferreiro, Melendo Viu, Gonzalez Bermudez,
Raposeiras-Roubin) Instituto de Investigacion Sanitaria Galicia Sur, Vigo,
Pontevedra, Spain
(Nombela Franco, Tirado, Gonzalo, Real) Unidad de Cardiologia, Hospital
Clinico Universitario San Carlos, Madrid, Spain
(Gheorge, Calle, Gutierrez Barrios) Unidad de Cardiologia, Hospital Puerta
del Mar, Cadiz, Spain
(Sanz-Sanchez, Diez) Unidad de Cardiologia, Hospital Universitario La Fe,
Valencia, Spain
(Gonzalez Ferreiro, Melendo Viu, Gonzalez Bermudez, Raposeiras-Roubin)
Unidad de Cardiologia, Hospital Universitario Alvaro Cunqueiro, Vigo,
Pontevedra, Spain
(Munoz Garcia) Unidad de Cardiologia, Hospital Universitario Virgen de la
Victoria, Malaga, Spain
(Vilalta, Carrillo Suarez) Unidad de Cardiologia, Hospital Universitario
German Trias i Pujol, Badalona, Barcelona, Spain
(Ojeda) Departamento de Ciencias Medicas y Quirurgicas. Universidad de
Cordoba, Cordoba, Spain
(Veiga Fernandez, Sanmartin) Unidad de Cardiologia, Hospital Universitario
Marques de Valdecilla, Santander, Spain
(Veiga Fernandez) Instituto de Investigacion Valdecilla (IDIVAL),
Santander, Spain
(Cordoba Soriano) Unidad de Cardiologia, Hospital Universitario de
Albacete, Albacete, Spain
(Regueiro) Unidad de Cardiologia, Hospital Clinic, Barcelona, Spain
(Sandin Rollan) Unidad de Cardiologia, Hospital General Universitario de
Alicante, Alicante, Spain
(Flores Rios) Unidad de Cardiologia, Hospital Universitario Juan Canalejo,
A Coruna, Spain
(Uribarri) Unidad de Cardiologia, Hospital Universitario Vall d'Hebron,
Barcelona, Spain
(Martin Reyes) Unidad de Cardiologia, Hospital Universitario QuironSalud
La Luz, Madrid, Spain
(Romaguera) Unidad de Cardiologia, Hospital Universitario de Bellvitge,
L'Hospitalet de Llobregat, Barcelona, Spain
(Avanzas) Unidad de Cardiologia, Hospital Universitario Central de
Asturias, Oviedo, Spain
(Avanzas) Instituto de Investigacion Sanitaria del Principado de Asturias
(ISPA), Oviedo, Spain
(Avanzas) Departamento de Medicina, Universidad de Oviedo, Oviedo, Spain
(Garcia Blas) Hospital Clinico Universitario de Valencia, Valencia, Spain
(Garcia Blas) Instituto de Investigacion Sanitaria INCLIVA, Valencia,
Spain
(Franco-Pelaez, Ibanez) Unidad de Cardiologia, Hospital Universitario
Fundacion Jimenez Diaz, Madrid, Spain
(Martin Moreiras) Unidad de Cardiologia, Hospital Clinico Universitario de
Salamanca, Salamanca, Spain
(Gonzalez Juanatey) Instituto de Investigacion Sanitaria de Santiago
(IDIS), Santiago de Compostela, A Coruna, Spain
(Gonzalez Juanatey, Raposeiras-Roubin) Facultad de Medicina, Universidad
de Santiago de Compostela, Santiago de Compostela, A Coruna, Spain
(Fuster) Cardiovascular Institute, Icahn School of Medicine at Mount
Sinai, Nueva York, United States
Publisher
Ediciones Doyma, S.L.
Abstract
Introduction and objectives: The win ratio (WR) approach is used to assess
composite endpoints in a hierarchical fashion. This novel method offers an
excellent opportunity to assess the robustness of the findings yielded by
landmark trials, such as the DapaTAVI trial. Method(s): We applied
the WR method to evaluate the treatment effect of dapagliflozin in
hierarchically ordered clinical outcomes. Several combinations of outcomes
were tested, including time-to-event, binary, and continuous endpoints.
 Result(s): The WR of the original primary endpoint was 1.36 (95%CI,
1.03-1.78; P = .028), comparable to the reciprocal of the original hazard
ratio (1/HR, 1.38; 95%CI, 1.06-1.81). The win difference was 4.84% (95%CI,
0.55-9.12), confirming consistent findings in terms of absolute effect.
Alternative combinations of the primary outcome with different
prioritization of its components yielded similar treatment effects and
statistical significance. Ignoring a time-to-event approach and including
recurrent events did not substantially affect treatment efficacy and its
statistical significance. In contrast, the inclusion of the total length
of stay for heart failure hospitalizations in the hierarchy shifted the
point estimate toward the null. Including New York Heart Association
functional class improved the precision of the estimate (WR = 1.31; 95%CI,
1.09-1.56; P = .003). Conversely, including quality of life through Kansas
City Cardiomyopathy Questionnaire comparisons shifted the overall estimate
toward the null (WR = 1.10; 95%CI, 0.94-1.30; P = .236).
 Conclusion(s): The WR approach is a solid method to assess treatment
efficacy. We observed consistent findings using this approach in the
DapaTAVI trial. Copyright © 2025 Sociedad Espanola de Cardiologia

<53>
Accession Number
2043375593
Title
Incidence and risk factors of hypoxemia after general anesthesia in
children undergoing non-cardiac surgery: a systematic review and
meta-analysis.
Source
Pediatric Surgery International. 42(1) (no pagination), 2026. Article
Number: 105. Date of Publication: 01 Dec 2026.
Author
Zhang D.; Yu X.; Cui Y.
Institution
(Zhang, Cui) Department of Anesthesiology, School of Medicine, Chengdu
Women's and Children's Central Hospital, University of Electronic Science
and Technology of China, Sichuan, Chengdu, China
(Yu) Department of Clinical Laboratory, School of Medicine, Chengdu
Women's and Children's Central Hospital, University of Electronic Science
and Technology of China, Sichuan, Chengdu, China
Publisher
Springer Science and Business Media Deutschland GmbH
Abstract
Background: Postoperative hypoxemia is a critical complication in
pediatric (<= 18 years) patients undergoing non-cardiac surgeries with
endotracheal intubation, which will potentially lead to poorer outcomes.
Despite its clinical significance, systematic approaches to ascertain
prevalence and risk factors are lacking. Thus, our study aims to conduct a
systematic review and meta-analysis to assess the prevalence of
postoperative hypoxemia in pediatric patients following endotracheal
intubation for non-cardiac procedures and to identify associated risk
factors. Method(s): A comprehensive search of PubMed, Ovid, Embase,
Web of Science, and Cochrane Library was conducted from inception to
November 30, 2024, using terms related to children, postoperative, and
hypoxemia. Observational and interventional studies reporting
postoperative hypoxemia in pediatric patients undergoing non-cardiac
surgeries with endotracheal intubation were included. Two reviewers
independently extracted data. Random-effects meta-analysis estimated
pooled prevalence. Subgroup analyses examined age, publication year, and
geographic region. Meta-regression examined surgical types. The primary
outcome was the overall incidence of postoperative hypoxemia. The
secondary outcomes were the risk factors related to postoperative
hypoxemia. Result(s): A total of 37 studies involving 14,597 patients
were identified. The pooled prevalence of postoperative hypoxemia was
10.1% (95% CI: 0.066-0.142). Infants (< 1 year) had a higher prevalence
than older children (17.5% vs. 7.4%; p = 0.025). Studies published before
2010 reported higher rates (15.4-20.6%) than post-2010 studies (5.5-6.7%).
No significant variations were observed across World Health Organization
regions, World Bank income classifications or surgical types.
 Conclusion(s): This study provides a global estimation of
postoperative hypoxemia prevalence in pediatric patients undergoing
non-cardiac surgeries with endotracheal intubation. Standardizing the
definition of hypoxemia in future research is crucial to enhance
comparability and clinical relevance. Trial registration: The review
protocol was registered in advance with PROSPERO (ID CRD42025631572), date
of registration: Dec 26 2024. Copyright © The Author(s), under
exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature
2026.

<54>
Accession Number
650185990
Title
A randomized controlled trial of artificial intelligence-based analytics
for clinical deterioration.
Source
Scientific reports. 16(1) (no pagination), 2026. Date of Publication: 05
Feb 2026.
Author
Keim-Malpass J.; Ratcliffe S.J.; Clark M.T.; Krahn K.N.; Monfredi O.J.;
Hamil S.; Yousefvand G.; Jones M.K.; Nelson A.; Moorman L.P.; Moorman
J.R.; Bourque J.M.
Institution
(Keim-Malpass) Center for Advanced Medical Analytics, School of Medicine,
University of Virginia, Charlottesville, VA, United States
(Keim-Malpass) Department of Pediatrics, Hematology-Oncology Division,
School of Medicine, University of Virginia, Charlottesville, VA, United
States
(Keim-Malpass) Pediatric Hematology-Oncology, University of Virginia, P.O.
Box 800386, Charlottesville, VA, United States
(Ratcliffe, Jones) Department of Public Health Sciences, Biostatistics
Division, University of Virginia, Charlottesville, VA, United States
(Clark, Moorman) Nihon Kohden Digital Health Solutions, Irvine, CA, United
States
(Krahn, Hamil, Yousefvand, Moorman, Bourque) Center for Advanced Medical
Analytics, School of Medicine, University of Virginia, Charlottesville,
VA, United States
(Krahn, Monfredi, Hamil, Yousefvand, Nelson, Moorman, Bourque) Department
of Internal Medicine, Cardiovascular Division, School of Medicine,
University of Virginia, Charlottesville, VA, United States
Abstract
This pragmatic randomized controlled trial aimed to assess the effect of a
passive display of artificial intelligence (AI)-based predictive analytics
on hours free of clinical deterioration events among medical and surgical
patients in an acute care cardiology medical-surgical ward. 10,422
inpatient visits were randomly assigned by cluster to the intervention
group of a display of risk trajectories or to a control group of usual
medical care. The trial was undertaken on an 85-bed inpatient cardiology
and cardiac surgery ward of an academic hospital with a substantial
implementation and education plan. This was a passive display with no
specific response mandated. The primary analysis compared events of
clinical deterioration (death, emergent ICU transfer, emergent
endotracheal intubation, cardiac arrest, or emergent surgery) and compared
mortality 21 days after admission. Patients with a large spike in risk
score had, on average, twice the length of hospital stay (6.8 compared to
3.4 days). There was no change in the primary outcome between groups.
Among those who had a clinical event, there were more event-free hours in
the intervention/display-on group compared to the
standard-of-care/display-off, but this did not reach statistical
significance. Clinicians chose to transfer 11% of patients into or out of
display beds, a censoring event removing them from the analysis, thereby
undermining aspects of the randomized nature of the study. Predictive
analytics monitoring incorporating continuous cardiorespiratory monitoring
and displays of risk trajectories coupled with an education plan did not
improve patient outcomes. While necessary to conduct the study, the
pragmatic design allowed for significant movement towards
intervention/displayed beds for sicker patients. Design considerations in
the future must focus on understanding clinicians' interpretation, care
processes, and communication practices.Clinical trial registration number:
NCT04359641 Registered 4/24/20. Copyright © 2026. The Author(s).

<55>
Accession Number
2043351864
Title
Renal Protection at a Metabolic Cost: A Systematic Review and
Meta-Analysis of Perioperative Use of Sodium-Glucose Cotransporter 2
Inhibitors.
Source
Endocrinology, Diabetes and Metabolism. 9(2) (no pagination), 2026.
Article Number: e70180. Date of Publication: 01 Mar 2026.
Author
Balbaa E.; Gadelmawla A.F.; Ibrahim A.; Manasrah A.; Elbataa A.; Shubietah
A.; Elgendy M.S.; Sobhy A.; Mansour A.; Awashra A.; Elguindy N.N.;
Bazzazeh M.; Ben-Selma A.
Institution
(Balbaa, Ibrahim, Bazzazeh) Faculty of Medicine, Alexandria University,
Alexandria, Egypt
(Gadelmawla) Faculty of Medicine, Menoufia University, Menoufia, Egypt
(Gadelmawla) Medical Research Group of Egypt, Negida Academy, Arlington,
MA, United States
(Manasrah, Ben-Selma) Department of Internal Medicine, United Health
Services-Wilson Medical Center, Johnson city, NY, United States
(Elbataa, Mansour) Faculty of Medicine, Al-Azhar University, Cairo, Egypt
(Shubietah) Department of Medicine, Advocate Illinois Masonic Medical
Center, Chicago, IL, United States
(Elgendy) Faculty of Medicine, Tanta University, Tanta, Egypt
(Sobhy) Faculty of Medicine, Kafr Elshiekh University, Kafr el-Sheikh,
Egypt
(Awashra) Department of Medicine, An Najah National University, Nablus,
Palestine
(Elguindy) Faculty of Medicine, Ainshams University, Cairo, Egypt
Publisher
John Wiley and Sons Inc
Abstract
Introduction: Concerns about diabetic ketoacidosis (DKA) and euglycemic
ketoacidosis (eKA) are balanced against possible organ-protective benefits
in the debated perioperative management of sodium-glucose cotransporter-2
(SGLT2) inhibitors. This meta-analysis compared the perioperative clinical
and laboratory outcomes associated with perioperative exposure to SGLT2i.
 Method(s): Through July 31, 2025, we searched PubMed, Web of Science,
Scopus, and CENTRAL for observational studies and randomised controlled
trials comparing the outcomes of preoperative use of SGLT2 inhibitors with
non-use in patients undergoing cardiac or non-cardiac surgery. We pooled
data using a random-effects model and investigated heterogeneity using
leave-one-out sensitivity analyses. PROSPERO-ID: CRD420251155809.
 Result(s): There were 10 studies comprising 246,242 patients. Due to
considerable heterogeneity, the primary pooled analysis revealed no
significant association between SGLT2 inhibitor use and either eKA (OR
4.86; p = 0.11) or DKA (OR 2.21; p = 0.11). However, a significant
increase in the risk of eKA (OR 1.11; p < 0.001) and DKA (OR 5.33; p <
0.001) was observed using leave-one-out sensitivity analysis to identify
outliers. On the other hand, the usage of SGLT2 inhibitors was associated
with a statistically significant decrease in both mortality (OR 0.73; p =
0.006) and acute renal injury (OR 0.68; p < 0.0001). The SGLT2 inhibitor
group had significantly lower perioperative pH, base excess, and blood
glucose levels. Conclusion(s): The use of perioperative SGLT2
inhibitors poses a clinical paradox between significant renoprotection and
survival advantages and a latent risk of ketoacidosis concealed by
considerable heterogeneity. While metabolic monitoring is essential,
current surgeries requiring more prolonged withholding may need to weigh
metabolic risk against the drug's significant benefit in reducing acute
kidney injury and mortality. Copyright © 2026 The Author(s).
Endocrinology, Diabetes & Metabolism published by John Wiley & Sons Ltd.

<56>
Accession Number
2041850517
Title
Prothrombin Complex Concentrate in Cardiac Surgery-Associated Bleeding: On
the Verge of Routine Use.
Source
Journal of Cardiothoracic and Vascular Anesthesia. 40(2) (pp 765-766),
2026. Date of Publication: 01 Feb 2026.
Author
Kaddoura R.; Omar A.S.
Institution
(Kaddoura, Omar) Pharmacy Department, Heart Hospital, Hamad Medical
Corporation, Doha, Qatar
(Omar) Department of Cardiothoracic Surgery/Cardiac Anaesthesia & ICU
Section, Heart Hospital, Hamad Medical Corporation, Doha, Qatar
(Omar) Weill Cornell Medical College-Qatar, Doha, Qatar
(Omar) Department of Critical Care Medicine, Beni Suef University, Egypt
Publisher
W.B. Saunders

<57>
Accession Number
2043229537
Title
Femoral versus radial arterial pressure monitoring in cardiac surgery
patients: protocol for a randomised controlled multicentric superiority
trial (FERARI).
Source
BMJ Open. 16(1) (no pagination), 2026. Article Number: e111663. Date of
Publication: 28 Jan 2026.
Author
Guinot P.-G.; Bronnert R.; Grelet T.; Bouhemad B.; Nguyen M.; Besch G.
Institution
(Guinot, Bouhemad, Nguyen) Department of Anesthesiology and Intensive
Care, University Hospital Centre Dijon Bourgogne Francois Mitterrand
Hospital, Dijon, France
(Guinot, Bouhemad, Nguyen) University of Burgundy Europe, Dijon, France
(Guinot, Bouhemad, Nguyen) Center for Translational and molecular Medicine
(CTM), Lipness Team, UMR1231, Dijon, France
(Bronnert, Besch) Universite Marie et Louis Pasteur, SINERGIES (EA 4662),
Besancon, France
(Bronnert, Besch) CHU de Besancon, Departement d'Anesthesie Reanimation
Chirurgicale, Besancon, France
(Bronnert, Besch) Inserm CIC 1431, Besancon, France
(Grelet) Universite Marie et Louis Pasteur, Besancon, France
Publisher
BMJ Publishing Group
Abstract
Background Accurate arterial pressure monitoring is critical in cardiac
surgery to guide haemodynamic management and vasopressor therapy. Radial
arterial pressure monitoring may systematically underestimate central
aortic pressure compared with femoral monitoring, potentially leading to
inappropriate vasopressor escalation and associated complications. Recent
evidence demonstrates that excessive norepinephrine exposure is associated
with acute kidney injury and increased mortality in cardiac surgery
patients. Objective To determine whether femoral arterial pressure
monitoring reduces norepinephrine use compared with radial monitoring in
cardiac surgery patients. Methods and analysis This is a prospective,
randomised, controlled, single-blind, superiority trial conducted at two
French university hospitals (CHU Besancon and CHU Dijon). Adult patients
undergoing cardiac surgery with cardiopulmonary bypass will be randomised
1:1 to receive either femoral or radial arterial pressure monitoring. The
primary endpoint is the proportion of patients treated with norepinephrine
from anaesthetic induction to postoperative day 7. Secondary endpoints
include acute kidney injury according to KDIGO criteria, cardiac
complications, vasoactive-inotropic scores, duration of vasopressor
therapy, vascular complications, and 7-day and 30-day mortality. Sample
size calculation indicates 340 patients (170 per group) are needed to
detect a 15% absolute reduction in norepinephrine use with 90% power and
alpha=0.05, and an anticipated loss to follow-up rate of 5%. Ethics and
dissemination The study has been approved by the French Ethics Committee
(Comite de Protection des Personnes Nord-Ouest II, no. 2024/897) and will
be conducted according to the Declaration of Helsinki and Good Clinical
Practice guidelines. Results will be submitted for publication in
peer-reviewed journals and presented at international
conferences. Copyright © Author(s) (or their employer(s)) 2026.

<58>
[Use Link to view the full text]
Accession Number
2039857026
Title
Left Atrial Appendage Closure Versus Oral Anticoagulation for Stroke
Prevention in Atrial Fibrillation: An Updated Systematic Review and
Meta-Analysis.
Source
American Journal of Therapeutics. 33(1) (pp e74-e77), 2026. Date of
Publication: 2026.
Author
Naeem F.; Qamar U.; Waqas M.; Tabassum S.; Munir M.B.; Asad Z.U.A.
Institution
(Naeem) Department of Cardiology, Massachusetts General Hospital, Harvard
Medical School, Boston, MA
(Qamar) Department of Internal Medicine, Mayo Clinic, Rochester, NY
(Waqas) Department of Internal Medicine, Wah Medical College, Wahcantt,
Pakistan
(Tabassum) Department of Internal Medicine, King Edward Medical
University, Lahore, Pakistan
(Munir) Division of Cardiovascular Medicine, University of California
Davis, Sacramento, CA
(Asad) Department of Medicine, Cardiovascular Section, University of
Oklahoma Health Sciences Center, Oklahoma City, OK
Publisher
Lippincott Williams and Wilkins

<59>
Accession Number
2037676518
Title
Regional analgesia for postoperative pain control after thoracic surgery:
a narrative review.
Source
Journal of Yeungnam Medical Science. 42 (no pagination), 2025. Article
Number: 80. Date of Publication: 2025.
Author
Park S.-J.; Choi E.K.
Institution
(Park, Choi) Department of Anesthesiology and Pain Medicine, Yeungnam
University College of Medicine, Daegu, South Korea
Publisher
Yeungnam University School of Medicine and College of Medicine
Abstract
Effective management of post-thoracotomy pain is essential to prevent
pulmonary complications and reduce the risk of developing chronic pain
syndrome. Although systemic opioids remain a common option, their use is
limited by significant adverse effects, making regional analgesia the
cornerstone of postoperative pain management. Thoracic epidural analgesia,
historically regarded as the gold standard, provides potent postoperative
pain relief but carries risks of hypotension and, in rare cases, severe
neurological events. Thoracic paravertebral block (PVB) has emerged as the
primary alternative, offering comparable analgesic efficacy and an
improved safety profile, particularly in maintaining hemodynamic
stability. However, PVB is technically demanding and associated with a
higher failure rate and localized procedural complications such as
pneumothorax. Fascial plane blocks have recently been developed to
prioritize safety. The erector spinae plane block is technically simpler,
using the transverse process as a "bony backstop" to minimize the risk of
pleural injury; however, its analgesic potency may be lower than that of
PVB. The intertransverse process block seeks to combine the efficacy of
PVB with enhanced safety; however, supporting evidence remains limited.
Alternative regional techniques, such as serratus anterior plane block,
intercostal nerve block, and continuous wound instillation, typically
provide insufficient analgesia for the comprehensive pain associated with
open thoracotomy. No regional analgesic technique has demonstrated
universal superiority. The optimal approach should be individualized,
balancing the distinct risk-benefit profile of each block with patient
comorbidities, surgical factors, and institutional
expertise. Copyright © 2025 Yeungnam University College of
Medicine, Yeungnam University Institute of Medical Science.

<60>
Accession Number
630154198
Title
Diffuse endoscopically visible, predominantly low grade dysplasia in
Barrett's esophagus (with video).
Source
Endoscopy International Open. 7(12) (pp E1742-E1747), 2019. Date of
Publication: 10 Dec 2019.
Author
Tsoi E.H.; Fehily S.; Williams R.; Desmond P.; Taylor A.
Institution
(Tsoi, Fehily, Desmond, Taylor) St. Vincent's Hospital, Department of
Gastroenterology, Fitzroy, VIC, Australia
(Tsoi, Desmond, Taylor) University of Melbourne, Faculty of Medicine,
Dentistry and Health Sciences, VIC, Australia
(Williams) St. Vincent's Hospital, Department of Pathology, Fitzroy, VIC,
Australia
Publisher
Georg Thieme Verlag
Abstract
Background Low grade dysplasia (LGD) in Barrett's esophagus (BE) has
generally been considered as undetectable endoscopically. Aim To describe
a phenotype which consists of diffuse, endoscopically visible,
predominantly low grade dysplasia in Barrett's esophagus (DEVLB), with
often subtle but visible endoscopic changes seen with high definition
white light (HDWL) and narrow-band imaging (NBI). Method A systematic
search of a prospectively collected database for patients satisfying
predefined criteria for DEVLB and a review of endoscopic and histological
features of biopsies and endoscopic mucosal resection (EMR) specimens.
Results Out of a total of 419 patients referred to our expert center for
assessment of dysplastic Barrett's esophagus during the period January
2009 to March 2018, there were 7 patients (1.7%) who satisfied the
criteria defined for DEVLB, identified on their initial assessment
endoscopy. All patients were treated by EMR of visible abnormal mucosa
during their assessment endoscopy at our tertiary referral center. There
was a total of 47 EMR specimens obtained, with a median of 6 (IQR 5-9) EMR
resection pieces per patient, of which 36 (77%) contained LGD, 8 (17%)
high grade dysplasia (HGD), 2 (4%) non-dysplastic Barrett's esophagus
(NDBE), and 1 (2%) contained early esophageal adenocarcinoma (EAC).
Conclusion DEVLB is a distinct phenotype seen in a small but significant
proportion of individuals with dysplastic Barrett's esophagus. Patients
with DEVLB have widespread LGD, with many having areas of focal HGD or
early cancer within this area. We believe these patients are best treated
with extensive EMR of the visibly abnormal area. Copyright © 2019
Georg Thieme Verlag KG Stuttgart * New York.

<61>
Accession Number
2043371464
Title
Ticagrelor-Based antiplatelet therapy versus aspirin alone after coronary
artery bypass grafting: A systematic review and Meta-Analysis with trial
sequential analysis.
Source
Journal of Thrombosis and Thrombolysis. (no pagination), 2026. Date of
Publication: 2026.
Author
Bacha Z.; Khalid A.A.; Sikandar M.; Siddique K.; Rashid A.Z.; Shah Z.A.;
Qazi K.; Javed J.; Khan N.A.
Institution
(Bacha, Sikandar, Shah, Khan) Department of Medicine, Khyber Medical
College, Peshawar, Pakistan
(Khalid) Department of Medicine, Peshawar Medical College, Peshawar,
Pakistan
(Siddique) Department of Medicine, Nishtar Medical University, Multan,
Pakistan
(Rashid) Department of Medicine, Allama Iqbal Medical College, Lahore,
Pakistan
(Qazi, Javed) Department of Medicine, Jinnah Sindh Medical University,
Karachi, Pakistan
Publisher
Springer
Abstract
Introduction: Coronary artery bypass grafting (CABG) is a common surgical
treatment for coronary artery disease; however, long-term success is
limited by saphenous vein graft (SVG) occlusion. Aspirin remains the
standard lifelong antiplatelet therapy; however, graft failure and adverse
events persist after its use. More potent agents, such as ticagrelor, have
been proposed, although the evidence is inconsistent, and concerns about
bleeding risk remain. We conducted a systematic review and meta-analysis
of randomized controlled trials (RCTs) comparing ticagrelor-based therapy
with aspirin monotherapy in patients who underwent CABG. A comprehensive
literature search of major databases was performed until August 2025. The
primary endpoints were major bleeding, MACE, and all-cause mortality. The
secondary outcomes included saphenous vein graft failure, stroke,
myocardial infarction, and repeat revascularization. Pooled risk ratios
(RR) with 95% confidence intervals (CI) were calculated using a
random-effects model. Five randomized controlled trials comprising 4,208
patients (ticagrelor-based therapy = 2,108; aspirin monotherapy = 2,100)
were included. Across the primary clinical endpoints, ticagrelor-based
therapy showed no significant advantage over aspirin, with comparable
rates of MACE (RR 1.05, 95% CI 0.78-1.41; p = 0.75; I2 = 20%), all-cause
mortality (RR 1.02, 95% CI 0.74-1.40; p = 0.93; I2 = 0%), and major
bleeding (RR 1.09, 95% CI 0.68-1.74; p = 0.73; I2 = 51%). Similarly, no
significant differences were observed for stroke (RR 1.10, 95% CI
0.70-1.75; p = 0.67; I2 = 0%), myocardial infarction (RR 1.52, 95% CI
0.94-2.46; p = 0.09; I2 = 27%), or repeat revascularization (RR 1.02, 95%
CI 0.71-1.45; p = 0.93; I2 = 7%). In contrast to the neutral clinical
outcomes, ticagrelor-based therapy was associated with a significant
reduction in saphenous vein graft (SVG) failure compared with aspirin
monotherapy (RR 0.62, 95% CI 0.50-0.78; p < 0.0001; I2 = 0%). Subgroup
analysis revealed no meaningful differences between ticagrelor monotherapy
and ticagrelor plus aspirin for major clinical events. Ticagrelor-based
therapy did not reduce major clinical outcomes (MACE, mortality, MI,
stroke, revascularization, or major bleeding) compared with aspirin after
CABG, although it was associated with improved SVG patency. Routine use
cannot be recommended; ticagrelor may be considered in selected high-risk
patients. Further large, long-term trials are needed to determine whether
patency benefits translate into improved clinical outcomes. Copyright
© The Author(s), under exclusive licence to Springer Science+Business
Media, LLC, part of Springer Nature 2026.

<62>
Accession Number
2043078317
Title
Dexmedetomidine for opioid-sparing postoperative analgesia: a systematic
review and meta-analysis.
Source
BMC Anesthesiology. 26(1) (no pagination), 2026. Article Number: 103. Date
of Publication: 01 Dec 2026.
Author
Sun Y.; Yao Y.; Li Y.; Deng W.
Institution
(Sun, Yao, Li) Department of Anesthesiology, The Affiliated Hospital of
Changchun, University of Traditional Chinese Medicine, No. 1478 Gongnong
Avenue, Jilin, Changchun, China
(Deng) Department of Orthopedics, The Affiliated Hospital of Changchun
University of Traditional Chinese Medicine, No. 1478 Gongnong Avenue,
Jilin, Changchun, China
Publisher
BioMed Central Ltd
Abstract
Introduction: Postoperative opioid use is associated with adverse effects
and increased risk of long-term dependence. Dexmedetomidine (Dex), a
selective alpha-2 adrenergic agonist, has analgesic and sedative
properties and may reduce opioid requirements when used perioperatively.
This systematic review assessed its efficacy in reducing postoperative
opioid consumption and improving recovery outcomes in adult surgical
patients. Method(s): A systematic search of PubMed, Embase, and the
Cochrane Library (to 1 May 2025) identified randomised controlled trials
comparing intravenous Dex with placebo or standard opioid-based analgesia
in adults undergoing surgery. The primary outcome was cumulative opioid
consumption in the first 24 h postoperatively. Secondary outcomes included
pain intensity, postoperative nausea and vomiting, sedation, haemodynamic
events, and indicators of recovery. Data were synthesised using a
random-effects model. Risk of bias and certainty of evidence were assessed
using the Cochrane Risk of Bias 2 tool and GRADE approach, respectively.
This review was prospectively registered in PROSPERO (CRD420251126259).
 Result(s): Twenty studies involving 1,793 patients met inclusion
criteria. Dex was administered intraoperatively (bolus 0.5-1 microg per
kilogram; infusion 0.2-0.7 microg per kilogram per hour) or via
patient-controlled analgesia (PCA). Compared with control, Dex
significantly reduced 24-hour opioid consumption (mean difference - 7.7
milligrams morphine equivalents; 95% confidence interval - 9.5 to - 6.0; P
< 0.001; I2 = 46%). Pain scores were lower, and incidence of postoperative
nausea and vomiting was reduced. Bradycardia and hypotension were more
frequent but typically transient and manageable. Discussion(s): Dex
is an opioid sparing adjunct that modestly reduces postoperative opioid
requirements and is associated with lower pain scores and less
postoperative nausea and vomiting. Haemodynamic monitoring is advised
during administration, and Dex should be integrated into wider multimodal
analgesia pathways rather than used as a stand alone solution to opioid
reduction. Prospero registration: CRD420251126259. Copyright ©
The Author(s) 2026.

<63>
Accession Number
2043080153
Title
Does postoperative heparin-induced thrombocytopenia worsen outcomes
following cardiac surgery? A meta-analytic review.
Source
Cardiothoracic Surgeon. 34(1) (no pagination), 2026. Article Number: 6.
Date of Publication: 01 Dec 2026.
Author
Anosike U.G.; Amador W.F.O.; de Assis T.C.C.; Maciel R.B.; Etumudon S.I.;
Montanhesi P.K.
Institution
(Anosike) Faculty of Medicine, Nnamdi Azikiwe University College of Health
Sciences, Awka, Nigeria
(Amador) Universidade Federal de Campina Grande, Cajazeiras, Paraiba,
Brazil
(de Assis) School of Medical Sciences, University of Campinas, Campinas,
Brazil
(Maciel) School of Medicine, Universidade Nove de Julho, Sao Paulo, Brazil
(Etumudon) Lagos University Teaching Hospital, Lagos, Nigeria
(Montanhesi) Division of Cardiac Surgery, St. Michael's Hospital,
University of Toronto, Toronto, Canada
Publisher
Springer Science and Business Media Deutschland GmbH
Abstract
Background: Heparin-induced thrombocytopenia (HIT) after cardiac surgery
is a life-threatening complication despite the low reported incidence. The
impact of HIT on perioperative outcomes in cardiac surgery remains
controversial, with limited and conflicting evidence regarding its effects
on cardiopulmonary bypass time, length of hospital stay, complication
rates, and mortality. Our meta-analysis aims to clarify the influence of
postoperative HIT on outcomes in cardiac surgery. Method(s): We
systematically searched PubMed, Embase, and Cochrane Library to identify
studies comparing outcomes in patients with and without postoperative HIT
after cardiac surgery. Pooled odds ratios (ORs) and mean differences (MDs)
with 95% confidence intervals (CIs) were calculated using a random effects
model. Heterogeneity was assessed with I2 statistics. R
software was used for statistical analysis. Result(s): Nine studies
encompassing 266,099 cardiac surgery patients were included, among whom
1,204 patients (0.45%) were diagnosed with HIT postoperatively. The pooled
incidence of HIT was 1.68% [95% CI 0.13-4.88; Prediction Interval
0.00-20.85]. HIT was associated with higher in-hospital mortality [OR =
2.57; 95% CI 1.02-6.46; p < 0.0001], longer hospital stay [MD 10.02 days,
95% CI 3.87 to 16.17, p = 0.001], increased thromboembolic events [OR
5.13, 95% CI 2.10 to 12.53, p < 0.01], and stroke [OR 2.33, 95% CI 1.40 to
3.89, p < 0.01]. However, cardiopulmonary bypass time and postoperative
complications including 30-day mortality, acute limb ischemia, pulmonary
embolism, renal complications, renal replacement therapy, and sepsis did
not differ significantly between HIT and non-HIT groups.
 Conclusion(s): HIT after cardiac surgery is associated with higher
in-hospital mortality, longer duration of hospital stay, increased
thromboembolic events, and stroke. Despite consistent signals of harm, the
very low certainty of evidence necessitates cautious interpretation and
highlights an urgent need for higher-quality prospective studies.
Systematic review registration: PROSPERO CRD420251175827 Copyright
© The Author(s) 2026.

<64>
Accession Number
2043190467
Title
Mobile applications in enhanced recovery after surgery: a systematic
review of protocol adherence and outcomes.
Source
mHealth. 12 (pp 1-11), 2026. Date of Publication: 30 Jan 2026.
Author
D'Ambrosio P.D.; Passos F.S.; Oliveira R.E.N.D.N.; Alvarenga-Bezerra V.;
Hirayama P.; Kawano A.H.A.; Terra R.M.; Moretti-Marques R.
Institution
(D'Ambrosio) Department of Thoracic Surgery, Hospital das Clinicas,
Faculty of Medicine, University of Sao Paulo (FMUSP), Sao Paulo, Brazil
(Passos) Department of Thoracic Surgery, Mater Dei Hospital, Salvador,
Brazil
(Oliveira) Department of Thoracic Surgery, Barretos Cancer Hospital,
Barretos, Brazil
(Alvarenga-Bezerra, Moretti-Marques) Department of Gynecology Oncology,
Hospital Israelita Albert Einstein, Sao Paulo, Brazil
(Hirayama, Kawano) Einstein Surgical Network, Hospital Israelita Albert
Einstein, Sao Paulo, Brazil
(Terra) Department of Thoracic Surgery, Hospital Israelita Albert
Einstein, Sao Paulo, Brazil
Publisher
AME Publishing Company
Abstract
Background: Enhanced recovery after surgery (ERAS) programs are designed
to reduce postoperative complications and accelerate recovery. Despite
their proven benefits, maintaining patient adherence to these protocols
remains a significant challenge. Mobile health (mHealth) applications have
been introduced as potential tools to support adherence and improve
perioperative outcomes; however, their effectiveness within ERAS pathways
has not been clearly established. This review aims to evaluate the impact
of mobile applications on protocol compliance, recovery, and clinical
outcomes among surgical patients enrolled in ERAS programs.
 Method(s): PubMed, EMBASE, and the Cochrane Library were
systematically searched through February 2025 to identify studies
comparing ERAS care with and without mobile application support. Due to
heterogeneity in study design, outcomes, and app functionalities, a
meta-analysis was not performed. The primary outcome was adherence to ERAS
protocols. Secondary outcomes included quality of recovery, patient and
clinician satisfaction, postoperative complication rates, hospital length
of stay (LOS), and readmissions. Result(s): Eight studies
encompassing 1,623 patients were included. Mobile app use was associated
with improved adherence to ERAS components, particularly early
mobilization and oral intake. Some studies reported higher Quality of
Recovery-15 (QoR-15) scores and greater patient satisfaction, although
these differences were not always statistically significant. The clinician
reported reductions in unnecessary visits and improved communication. No
study reported an increased rate of complications. One study found that
non-adherent patients had a significantly higher risk of 30-day
readmission; another reported reduced infection rates and better pain
control. The risk of bias was moderate in most studies.
 Conclusion(s): mHealth applications integrated into ERAS protocols
may improve adherence, recovery quality, and patient engagement without
increasing adverse outcomes. However, the overall quality of evidence
remains limited due to heterogeneity and a predominance of non-randomized
studies. Copyright © (2026), (AME Publishing Company). All rights
reserved.

<65>
Accession Number
2042880857
Title
Balloon Lithotripsy Added to Conventional Preparation Before Stent
Implantation in Severely Calcified Coronary Lesions.
Source
JACC: Cardiovascular Interventions. 19(3) (pp 331-341), 2026. Date of
Publication: 09 Feb 2026.
Author
Kristensen A.T.; Christiansen E.H.; Holm N.R.; Kelbaek H.; Engstrom T.;
Veien K.; Raungaard B.; Kleveland O.; Bennett J.; Laanmets P.; Jakobsen
L.; Havndrup O.; Lonborg J.T.; Ahlehoff O.; Iversen A.; Vatwani A.K.;
Stottrup N.B.; Jensen L.O.; Christensen M.K.; Haahr-Pedersen S.A.; Charlot
M.G.; Gabriel E.E.; Olsen N.T.
Institution
(Kristensen, Engstrom, Lonborg, Ahlehoff, Iversen, Vatwani,
Haahr-Pedersen, Charlot, Olsen) Department of Cardiology, Copenhagen
University Hospital Rigshospitalet, Copenhagen, Denmark
(Kristensen, Iversen, Vatwani, Haahr-Pedersen, Charlot, Olsen) Department
of Cardiology, Copenhagen University Hospital Herlev and Gentofte,
Gentofte, Denmark
(Christiansen, Holm, Jakobsen, Stottrup) Department of Cardiology, Aarhus
University Hospital, Aarhus, Denmark
(Kelbaek, Havndrup) Department of Cardiology, Zealand University Hospital,
Roskilde, Denmark
(Veien, Jensen) Department of Cardiology, Odense University Hospital,
Odense, Denmark
(Raungaard, Christensen) Department of Cardiology, Aalborg University
Hospital, Aalborg, Denmark
(Kleveland) Clinic of Cardiology, St. Olavs Hospital, Trondheim, Norway
(Bennett) Department of Cardiovascular Medicine, University Hospitals
Leuven, Leuven, Belgium
(Laanmets) Department of Cardiology, North-Estonia Medical Center,
Tallinn, Estonia
(Gabriel) Section of Biostatistics, Department of Public Health,
University of Copenhagen, Copenhagen, Denmark
(Olsen) Department of Clinical Medicine, University of Copenhagen,
Copenhagen, Denmark
Publisher
Elsevier Inc.
Abstract
Background Percutaneous coronary intervention in severely calcified
lesions is associated with an increased risk for procedural complications
and impaired clinical outcomes. Intravascular lithotripsy is a
balloon-based technique that uses pressure waves to fracture calcified
plaques. However, no randomized evidence supports the routine use of
lithotripsy in clinical practice. Objectives The aim of this study was to
evaluate the efficacy and safety of adding lithotripsy to conventional
lesion preparation in severely calcified lesions. Methods In an
international and assessor-blinded trial, patients with severely calcified
coronary lesions were randomized to lesion preparation with vs without
lithotripsy before stent implantation. The primary composite endpoint
consisted of procedural failure (failed or no stent delivery, or residual
area stenosis >=20% by optical coherence tomography) or target vessel
failure (cardiac death, myocardial infarction, or clinically driven
revascularization) at 1 year. Results Ninety-nine patients were randomized
to lithotripsy and 101 patients to conventional lesion preparation. The
primary endpoint occurred in 35 patients (35%) in the lithotripsy group vs
52 patients (52%) in the conventional group (RR: 0.69; 95% CI: 0.48-0.97;
P = 0.02). Residual area stenosis >=20% was the most frequent component of
the primary endpoint and occurred in 32 patients (32%) in the lithotripsy
group vs 45 patients (45%) in the conventional group (RR: 0.73; 95% CI:
0.49-1.04). Safety endpoints did not differ between groups. Conclusions
Adding lithotripsy to lesion preparation using conventional techniques
before stent implantation in severely calcified lesions reduced the
combined incidence of procedural failure or target vessel failure at 1
year. The reduced incidence was driven primarily by a reduction in
residual area stenosis >=20%. (Balloon Lithoplasty for Preparation of
Severely Calcified Coronary Lesions [BALI]; NCT04253171 ) Copyright
© 2026 The Authors.

<66>
Accession Number
2043470914
Title
Phase III cardiac rehabilitation improves left ventricular ejection
fraction in patients with coronary artery disease and mildly reduced
ejection fraction after percutaneous coronary intervention.
Source
International Journal of Cardiology. 450 (no pagination), 2026. Article
Number: 134219. Date of Publication: 01 May 2026.
Author
Cai M.-L.; Shi W.-X.; Li J.; Li T.; Zhang W.; Lin C.-B.; Wang X.-Y.; Huang
Y.-T.; Qing X.-M.
Institution
(Cai, Li, Li, Zhang) Department of Cardiology, People's Liberation Army
Joint Logistic Support Force 924th Hospital, Guilin, China
(Shi) School of Public Health, Guilin Medical University, Guilin, China
(Cai, Lin, Wang, Huang, Qing) Department of Cardiology, the Second
Affiliated Hospital of Guilin Medical University, Guilin, China
Publisher
Elsevier Ireland Ltd
Abstract
Background: Exercise-based cardiac rehabilitation (ExCR) is standard for
secondary prevention in coronary artery disease (CAD), yet its efficacy in
patients with heart failure with mildly reduced ejection fraction (HFmrEF)
after percutaneous coronary intervention (PCI) remains unclear.
 Method(s): In this single-center RCT, 120 stable CAD patients with
HFmrEF (LVEF 40-49%) post-PCI were randomized 1:1 to receive either
guideline-directed medical therapy (GDMT) plus a 52-week structured ExCR
program (intervention) or GDMT alone (control). Primary outcomes-LDL-C,
TG, LVEF, and LVEDD-were assessed at 4, 12, 24, and 52 weeks. Linear Mixed
Models analyzed longitudinal intervention effects. Result(s): A
significant Group x Time interaction was observed for LVEF (p = .032),
indicating superior recovery in the ExCR group. At 52 weeks, the ExCR
group showed greater improvement in LVEF (+5.0% vs. +4.0%, p = .023) and
greater reduction in LDL-C (-1.43 mmol/L vs. -1.04 mmol/L, p = .030)
versus control. No between-group differences were found in TG or LVEDD.
 Conclusion(s): A 52-week structured ExCR program significantly
enhances cardiac recovery and lipid control in HFmrEF patients post-PCI,
providing incremental benefits beyond GDMT alone. Sustained ExCR should be
considered essential in comprehensive management for this
population. Copyright © 2026

<67>
Accession Number
2043251250
Title
Safety and efficacy of remimazolam in critical illness.
Source
Journal of Intensive Care. 14(1) (no pagination), 2026. Article Number:
16. Date of Publication: 01 Dec 2026.
Author
Obara S.; Yoshida K.; Inoue S.
Institution
(Obara, Yoshida, Inoue) Department of Anesthesiology, Fukushima Medical
University, 1 Hikarigaoka, Fukushima, Fukushima, Japan
Publisher
BioMed Central Ltd
Abstract
Sedation is essential in intensive care units (ICUs) for invasive
procedures and mechanical ventilation; however, commonly used agents are
limited by hemodynamic instability, delayed recovery of consciousness, and
delirium. Remimazolam, an ultra-short-acting benzodiazepine, introduced in
2020, is rapid metabolized by hepatic carboxylesterase 1 and enables
predictable recovery after prolonged administration, suggesting potential
advantages for sedation in critical illness despite limited ICU-specific
evidence. A narrative review was conducted based on evidence derived from
randomized controlled trials, meta-analyses, and observational studies,
which indicated that remimazolam provides sedation efficacy comparable to
that of conventional hypnotics across surgical anesthesia, procedural
sedation, and ICU settings. Multiple meta-analyses have suggested that
remimazolam is associated with favorable hemodynamic tolerance and does
not increase the incidence of postoperative or ICU delirium compared with
propofol or other sedative agents. Delirium risk appears to be more
strongly influenced by patient severity, surgical characteristics, and
sedation depth than by hypnotic choice alone, although the heterogeneity
across studies may partly reflect differences in delirium diagnostic
tools. In ICU patients requiring mechanical ventilation, remimazolam
demonstrated safety and efficacy comparable to those of propofol or
midazolam, with acceptable hemodynamic stability and no consistent signs
of increased mortality. Several studies have also suggested that the
predictable recovery profile associated with flumazenil may facilitate
ventilator weaning or recovery of consciousness, although the
interpretation of recovery outcomes requires caution, particularly in
studies involving routine flumazenil administration. Pharmacokinetic data
in ICU populations remain limited but suggest preserved dose linearity
with reduced clearance in patients with severe hepatic dysfunction.
Remimazolam may be a promising sedative option for critically ill
patients, offering a predictable recovery and generally favorable
hemodynamic profiles. However, its optimal role in ICU sedation requires
confirmation through high-quality international multicenter studies,
particularly regarding prolonged mechanical ventilation, neurocognitive
outcomes, and cost-effectiveness. Copyright © The Author(s) 2026.

<68>
Accession Number
2041098938
Title
Anomalous left coronary artery from the pulmonary artery in adults: a
systematic review of clinical presentation, diagnosis, and outcomes.
Source
International Journal of Cardiovascular Imaging. 42(2) (pp 161-174), 2026.
Date of Publication: 01 Feb 2026.
Author
Suchodolski A.; Krolikowska M.; Kowal A.; Glowacki J.; Szulik M.
Institution
(Suchodolski, Szulik) Department of Cardiology and Electrotherapy,
Silesian Center for Heart Diseases, Faculty of Medical Sciences in Zabrze,
Medical University of Silesia, Marii Sklodowskiej-Curie 9 Zabrze,
Katowice, Poland
(Suchodolski) Doctoral School of the Medical University of Silesia in
Katowice, Katowice, Poland
(Krolikowska, Kowal) Student Research Group, Faculty of Medical Sciences
in Zabrze, Medical University of Silesia, Katowice, Poland
(Szulik) Collegium Medicum-Faculty of Medicine, Department of Medical and
Health Sciences, Faculty of Applied Sciences, Dabrowa Gornicza, Poland
(Glowacki) Computed Tomography Laboratory, Silesian Centre for Heart
Diseases, Zabrze, Poland
Publisher
Springer Science and Business Media B.V.
Abstract
Abnormal left coronary artery from the pulmonary artery (ALCAPA) is a rare
congenital coronary anomaly, occurring in approximately 1 in 300 000 live
births and accounting for roughly 0,5 per cent of all congenital heart
defects. Without surgical correction, in more than 90% of cases, the
defect leads to death in the first year of life. However, a small subgroup
of individuals survive into adulthood. In adults, it can manifest as
dyspnoea, angina, palpitations and eventually leads to heart failure,
arrhythmia and sudden cardiac death. We summarised 60 years of case
reports of ALCAPA syndrome in adults and identified 279 patients, the
majority of whom were women. In most cases, the diagnosis was based on
coronary angiography. The most common symptom was dyspnoea and the least
frequent were palpitations. Surgery was performed in 194 patients with a
mean age at surgery of 37,46 years. The aim of this study is to obtain
clinically relevant information that would be unattainable even in large
multicentre clinical trials, given the rarity of this anomaly. This is the
first review juxtaposing all ALCAPA cases in adults published in 60
years. Copyright © The Author(s) 2025.

<69>
Accession Number
2043630880
Title
Novel molecular biomarkers in kidney diseases: bridging the gap between
early detection and clinical implementation.
Source
Journal of Pharmacy and Pharmacology. 78(2) (no pagination), 2026. Article
Number: rgaf096. Date of Publication: 01 Feb 2026.
Author
Choudhary B.B.; Puri B.; Gaikwad A.B.
Institution
(Choudhary, Puri, Gaikwad) Department of Pharmacy, Birla Institute of
Technology and Science Pilani, Pilani Campus, Vidya Vihar, Rajasthan,
Pilani, India
Publisher
Oxford University Press
Abstract
Background: Kidney diseases affect over 850 million people globally and
are a significant cause of morbidity and mortality. Traditional biomarkers
like serum creatinine, blood urea nitrogen, and proteinuria have limited
sensitivity and specificity, often detecting damage only after substantial
renal function loss. Even U.S. Food and Drug Administration (FDA)-approved
biomarkers, such as kidney injury molecule-1, neutrophil
gelatinase-associated lipocalin, and cystatin C, have limitations because
their levels can be influenced by inflammation, infections, or disease
stage. There is an urgent need for reliable, non-invasive biomarkers for
early diagnosis and treatment guidance. Objective(s): This review
provides an updated overview of emerging biomarkers for early detection
and monitoring of kidney diseases (acute kidney injury, chronic kidney
disease, diabetic kidney disease, polycystic kidney disease, lupus
nephritis, renal cell carcinoma). Method(s): A comprehensive
literature review focused on studies from the past decade on urine and
blood-based biomarkers that reflect key pathological processes, including
inflammation, tubular injury, fibrosis, and immune activation.
 Result(s): Promising biomarkers include collectrin, olfactomedin 4,
activin A, follistatin, USP18, galectin-3, fetuin-A, sestrin-2,
podocalyxin, copeptin, anti-C1q, p-cresol glucuronide, serum CD206,
lncRNAs, and miRNAs. Conclusion(s): These biomarkers may enhance
early diagnosis, enable personalized therapy, and improve kidney disease
outcomes. Their integration into clinical practice may bridge the gap
between early detection and effective intervention, potentially improving
long-term outcomes in patients with kidney disease. Copyright ©
The Author(s) 2025. Published by Oxford University Press on behalf of the
Royal Pharmaceutical Society. All rights reserved.

<70>
Accession Number
2043351710
Title
Intravenous Bolus Fluid Therapy Versus No Fluid Therapy Prior to
Pericardiocentesis in Dogs: A Randomized Controlled Trial in 30 Dogs.
Source
Journal of Veterinary Emergency and Critical Care. (no pagination), 2026.
Date of Publication: 2026.
Author
Jones N.; Humm K.; Tinson E.W.
Institution
(Jones, Humm, Tinson) Veterinary Clinical Science and Services, The Royal
Veterinary College, London, United Kingdom
Publisher
John Wiley and Sons Inc
Abstract
Objective: To determine the cardiovascular and respiratory effects of
bolus IV isotonic crystalloid fluid therapy before pericardiocentesis in
dogs with pericardial effusion. Design(s): Prospective, randomized,
nonblinded clinical trial (January 2021 to November 2022).
 Setting(s): University teaching hospital. Animals: Thirty dogs
diagnosed with pericardial effusion. Intervention(s): Dogs were
randomized to receive a 10-mL/kg IV bolus of compound sodium lactate (IV
fluid bolus [IVFB] group) or no fluid bolus (no-IVFB group) over 10 min
before pericardiocentesis. Measurements and Main Results:
Cardiovascular parameters, respiratory rate, peripheral blood lactate
concentration, and point-of-care ultrasound (POCUS) findings were
assessed. Shock index (SI) was calculated as heart rate divided by
systolic blood pressure. Measurements were recorded at four time points
(T): baseline (T0), 15 min later (T1, after fluid bolus for the IVFB
group), immediately after pericardiocentesis (T2), and 4 h after
pericardiocentesis (T3). Significant decreases in SI were observed in the
no-IVFB group between T1 and T2 and between T1 and T3, and in the IVFB
group between T1 and T3 (p = 0.034, p = 0.003, and p = 0.027,
respectively). No differences in SI were found between the groups when
compared at the same time point. Administration of an IVFB did not result
in adverse respiratory effects, as no dogs required supplemental oxygen by
T3, and there were no differences in respiratory rate. The no-IVFB group
had a higher incidence of new B-lines compared with the IVFB group (60%
vs. 20%), but the median B-line score was <=1 at all POCUS sites at T0 and
T3. Twenty-four dogs survived to hospital discharge with no difference in
survival between groups. Conclusion(s): Administering an IVFB of 10
mL/kg isotonic crystalloid before pericardiocentesis in dogs with
pericardial effusion did not alter SI. This dose appears to be safe, with
no adverse respiratory effects seen. However, the current study was
underpowered to detect a significant difference, and further studies are
needed. Copyright © 2026 Veterinary Emergency and Critical Care
Society.

<71>
Accession Number
2042900695
Title
Perioperative dexmedetomidine and renal outcomes in adult cardiac surgery:
an updated systematic review and meta-analysis.
Source
Frontiers in Medicine. 12 (no pagination), 2026. Article Number: 1737121.
Date of Publication: 2026.
Author
Wen J.; Jiang F.
Institution
(Wen) Department of Emergency, Clinical Medical College & Affiliated
Hospital of Chengdu University, Sichuan, Chengdu, China
(Jiang) Department of Nursing, Pengzhou Peoples's Hospital, Sichuan,
Pengzhou, China
Publisher
Frontiers Media SA
Abstract
Background: Acute kidney injury (AKI) is a common complication following
cardiac surgery, associated with increased morbidity and mortality.
Dexmedetomidine (DEX), a highly selective alpha-2 adrenoceptor agonist,
has shown potential renal protective effects, but evidence remains
inconsistent. This study aims to evaluate the efficacy of DEX in
preventing AKI and improving renal outcomes in cardiac surgery patients
through a systematic review and meta-analysis of randomized controlled
trials (RCTs). Method(s): A comprehensive search of PubMed, Cochrane
Library, Embase, and Web of Science was conducted until April 2025. PICOS
criteria were applied to select studies comparing DEX with placebo/normal
saline in cardiac surgery patients. Primary outcomes included AKI
incidence; secondary outcomes encompassed intraoperative parameters,
postoperative recovery, and complications. Result(s): Bibliometric
analysis highlighted China and the USA as leading contributors, with
emerging trends in pediatric and mechanistic research. Among 16 RCTs
(n=2,882), DEX significantly reduced AKI incidence [RR 0.58; 95% CI 0.37
to 0.91; I2 =74%, p=0.02], particularly at 0.6-0.1mug/kg/h
doses [RR 0.43; 95% CI 0.26 to 0.71; I2 =0%, p=0.001]. Subgroup
analysis revealed 0.4mug/kg/h doses failed to yield a statistically
significant benefit [RR 0.65; 95% CI 0.36 to 1.17; I2 =84%;
p=0.15]. DEX also shortened ICU stay [MD -1.23; 95% CI -2.17 to -0.30;
I2 =93%; p=0.01], mechanical ventilation duration [MD -1.24;
95% CI -2.15 to -0.33; I2 =97%; p=0.008], and hospital stays
[MD -0.33; 95% CI -0.54 to -0.13; I2 =86%; p=0.01]. However, it
did not affect mortality or intraoperative times. Conclusion(s): DEX
demonstrates significant renal protection and improves postoperative
recovery in cardiac surgery patients, though optimal dosing requires
further investigation. These findings support its integration into
perioperative protocols but underscore the need for standardized dosing
regimens. Systematic review registration: Identifier,
INPLASY2025120019. Copyright © 2026 Wen and Jiang.

<72>
Accession Number
650151426
Title
Randomized trial of smartphone application and bed sensor for atrial
fibrillation detection in high-risk patients.
Source
Scientific reports. 16(1) (pp 7088), 2026. Date of Publication: 03 Feb
2026.
Author
Lehto J.; Nuotio J.; Relander A.; Jaakkola J.; Lahdenoja O.; Vasankari T.;
Anzanpour A.; Elnaggar I.; Rekola R.; Sandelin J.; Hurnanen T.; Airaksinen
J.K.; Koivisto T.; Kiviniemi T.O.
Institution
(Lehto, Nuotio, Relander, Jaakkola, Vasankari, Airaksinen) Heart Center,
Turku University Hospital and University of Turku, Turku, Finland
(Lahdenoja, Anzanpour, Elnaggar, Rekola, Sandelin, Hurnanen, Koivisto)
Department of Computing, University of Turku, Turku, Finland
(Kiviniemi) Heart Center, Turku University Hospital and University of
Turku, Turku, Finland
(Kiviniemi) Heart Center, Turku University Hospital and University of
Turku T-hospital, Hameentie 11, Turku, Finland

<73>
Accession Number
2043346969
Title
Invasive and medical management approaches to non-acute myocardial
ischaemic syndromes.
Source
Nature Reviews Cardiology. (no pagination), 2026. Date of Publication:
2026.
Author
Chiu N.; Bhatt D.L.; De Caterina R.; Doenst T.; Kirov H.; Dayan V.; Faxon
D.P.; Kaul S.; Perera D.; Puskas J.D.; Steg P.G.; Boden W.E.
Institution
(Chiu, Faxon) Brigham and Women's Hospital Heart and Vascular Center,
Harvard Medical School, Boston, MA, United States
(Bhatt) Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at
Mount Sinai, New York, NY, United States
(De Caterina) Cardiovascular Division, Pisa University Hospital -
University of Pisa, Pisa, Italy
(Doenst, Kirov) Department of Cardiothoracic Surgery, Jena University
Hospital, Friedrich Schiller University, Jena, Germany
(Dayan) Centro Cardiovascular Universitario, Hospital de Clinicas,
Universidad de la Republica, Montevideo, Uruguay
(Kaul) Division of Cardiology, Cedars-Sinai Heart Institute, Cedars-Sinai
Medical Center, David Geffen School of Medicine, University of California,
Los Angeles, CA, United States
(Perera) British Heart Foundation Centre for Research Excellence, School
of Cardiovascular and Metabolic Medicine and Sciences, King's College,
London, United Kingdom
(Puskas) Emory Heart and Vascular Center, Emory University School of
Medicine, Atlanta, GA, United States
(Steg) Universite Paris-Cite, Assistance Publique - Hopitaux de Paris,
INSERM U1148 and FACT (French Alliance of Cardiovascular Trials), Paris,
France
(Boden) VA Boston Healthcare System, Boston University School of Medicine,
Boston, MA, United States
Publisher
Nature Research
Abstract
Over the past two decades, approaches to managing patients with coronary
artery disease have improved substantially with advances in percutaneous
coronary intervention (PCI), coronary artery bypass graft (CABG) surgery,
pharmacological secondary prevention, anti-anginal agents and lifestyle
interventions. Accordingly, clinical management choices in non-acute
myocardial ischaemic syndromes (NAMIS) remain a timely and important
topic. The risks and benefits of an invasive strategy combined with
optimal medical therapy (OMT) versus a conservative strategy of OMT alone
should be discussed with patients to facilitate shared clinical decision
making. The findings from high-quality, randomized, controlled trials in
the era of modern OMT form an essential platform for these informed
conversations. In totality, the evidence from randomized, controlled
trials supports OMT as the first-line therapeutic approach in patients
with NAMIS, whereas selected patients at high anatomical risk or those
with persistent anginal symptoms despite initial OMT often derive further
symptom relief from invasive therapy with PCI. In patients with high-risk
NAMIS, including those with multivessel disease and diabetes mellitus,
CABG surgery improves survival, whereas the benefit is less clear for PCI.
In this Review, we discuss the findings from contemporary trials
evaluating outcomes in patients with NAMIS treated invasively or
conservatively with OMT alone, and we conclude with proposed management
pathways. Copyright © This is a U.S. Government work and not
under copyright protection in the US; foreign copyright protection may
apply 2026.

<74>
Accession Number
2040952834
Title
A Novel Competency-Based Simulation Model for Thoracoscopic Lung
Resection.
Source
Thoracic and Cardiovascular Surgeon. 74(2) (pp 174-180), 2026. Date of
Publication: 01 Mar 2026.
Author
Liu G.; Yang F.; Zhou Z.; Jiang G.
Institution
(Liu, Yang, Zhou, Jiang) Department of Thoracic Surgery, Peking University
People's Hospital, Beijing, China
(Liu, Yang, Zhou, Jiang) Institute of Advanced Clinical Medicine, Peking
University, Beijing, China
Publisher
Georg Thieme Verlag
Abstract
Background Simulation-based thoracic surgery training is increasingly
incorporating physical models to enhance traditional learning methods.
Conventional box trainers, though useful for basic skills, often lack
anatomical accuracy and tactile feedback, limiting their relevance for
complex procedures like thoracoscopic lung resection. High-fidelity
3D-printed lung models offer realistic anatomy and procedural flow, but
their educational impact remains underexplored. Methods Fifty-two surgical
residents without prior thoracoscopic experience were randomly assigned to
a high-fidelity lung model group or a conventional Fundamentals of
Laparoscopic Surgery (FLS) box trainer group. All participants completed a
baseline thoracic anatomy test and received standardized educational
materials. The lung model group received structured simulation training on
procedural anatomy and operative steps, while the FLS group practiced
fundamental laparoscopic tasks. After training, participants repeated the
anatomy test and performed a thoracoscopic lung wedge resection in a live
animal model. Performance was assessed using the Objective Structured
Assessment of Technical Skill (OSATS) and a 5-point confidence scale.
Results A total of 52 surgical residents participated in the study, with
26 assigned to the high-fidelity lung model group and 26 to the FLS
trainer group. Baseline anatomy scores were similar between groups
(65.42+/- 6.10 vs. 66.12+/- 5.92; p = 0.710). Posttraining, the lung model
group showed greater gains in anatomy comprehension (87.60+/- 4.75 vs.
78.19+/- 5.54; p < 0.001), higher OSATS scores (19.18+/- 2.43 vs. 15.41+/-
2.41; p < 0.001), and increased confidence (3.13+/- 0.61 vs. 2.27+/- 0.68;
p = 0.002). Conclusion High-fidelity 3D-printed lung models significantly
enhance anatomical understanding, thoracoscopic skills, and confidence
compared with conventional box trainers. These results support integrating
anatomically accurate simulation into thoracic surgical education to
improve both cognitive and psychomotor outcomes. Copyright © 2026
Georg Thieme Verlag. All rights reserved.

<75>
Accession Number
2036018403
Title
Overall Accuracy of the Modified Duke Criteria-A Systematic Review and
Meta-analysis.
Source
Thoracic and Cardiovascular Surgeon. 74(2) (pp 92-98), 2026. Date of
Publication: 01 Mar 2026.
Author
Caldonazo T.; Tasoudis P.; Doenst T.; Moris D.; Kang L.; Moschovas A.;
Kirov H.; Treml R.E.; Sa M.P.; Hagel S.; Diab M.
Institution
(Caldonazo, Doenst, Moschovas, Kirov, Diab) Department of Cardiothoracic
Surgery, Friedrich-Schiller-University Jena, Germany
(Tasoudis) Division of Cardiothoracic Surgery, University of North
Carolina, Chapel Hill, United States
(Moris, Kang) Department of Surgery, Duke University Hospitals, Durham,
NC, United States
(Treml) Department of Anesthesiology and Intensive Care Medicine,
Friedrich-Schiller-University Jena, Jena, Germany
(Sa) Department of Cardiothoracic Surgery, University of Pittsburgh,
Pittsburgh, PA, United States
(Sa) Upmc Heart and Vascular Institute, University of Pittsburgh Medical
Center, Pittsburgh, PA, United States
(Hagel) Institute for Infectious Diseases and Infection Control,
Friedrich- Schiller-University Jena, Germany
(Diab) Department of Cardiac Surgery, Herz- und Kreislaufzentrum,
Rotenburg an der Fulda, Germany
Publisher
Georg Thieme Verlag
Abstract
Background Rapid and accurate diagnosis of infective endocarditis (IE)
allows timely management of this life-threatening disease and improves
outcome. The Duke criteria have traditionally been the clinical method for
diagnosing IE. These criteria were reformulated at different timepoints.
We aimed to evaluate the real accuracy of the modified Duke criteria based
on several studies that concluded the diagnosis of IE. Methods Three
databases were assessed. Studies were considered for inclusion if they
reported the use of modified Duke criteria as the initial approach and the
confirmation of the diagnosis with the gold standard methods. The
meta-analysis of diagnostic test accuracy was performed after fitting the
hierarchical summary receiver operating characteristic model (HSROC) with
bivariate model and displaying the summarized measures of sensitivity and
specificity, and positive and negative likelihood ratios. Results A total
of 11 studies were included. Accuracy in the included studies ranged from
62.3 to 92.2%, sensitivity ranged from 58.3 to 84.0%, and specificity
ranged from 50.0 to 100%. The combined overall sensitivity and specificity
were 85% (95% CI: 0.77-0.90) and 98% (95% CI: 0.89-0.99), respectively.
The positive likelihood ratio was 40.2 (95% CI: 7.26-220.74) and the
negative likelihood ratio was 0.15 (95% CI: 0.01-0.23). Conclusion The
analysis reveals that the modified Duke criteria have a high positive
likelihood ratio, suggesting a robust correlation between a positive test
result and the existence of IE, and a very good overall specificity at
98%. The latter aspect holds significant importance in order to prevent
unnecessary overtreatment, given the intricacies involved in managing
IE. Copyright © 2026 Georg Thieme Verlag. All rights reserved.

<76>
Accession Number
2043429896
Title
Comparing the Direct Oral Anticoagulants versus Vitamin K Antagonists in
Bioprosthetic Valves: A Systematic Review and Meta-Analysis of Randomized
Controlled Trials.
Source
Clinical and Applied Thrombosis/Hemostasis. 32 (no pagination), 2026. Date
of Publication: 01 Jan 2026.
Author
Waseem M.H.; Abideen Z.U.; Cheema A.H.; Farhan K.; Raja H.A.A.; Tahir
M.Z.; Saleem F.; Nadeem A.; Thada P.K.
Institution
(Waseem) Allama Iqbal Medical College, Lahore, Pakistan
(Abideen) King Edward Medical University, Lahore, Pakistan
(Cheema) University of Texas Southwestern, Dallas, TX, United States
(Farhan) Jinnah Sindh Medical University, Karachi, Pakistan
(Raja) Rawalpindi Medical University, Rawalpindi, Pakistan
(Tahir, Saleem, Nadeem) Punjab Medical College, Faisalabad, Pakistan
(Thada) Sotang Primary Hospital, Solukhumbu, Nepal
Publisher
SAGE Publications Inc.
Abstract
Background: Replacing bioprosthetic valves is common but can cause
coagulation issues. This study assesses the safety and efficacy of Direct
oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) in
bioprosthetic valve procedures. Method(s): PubMed, Cochrane Central,
and ScienceDirect were searched till May 2025. The risk ratios (RRs) were
pooled with 95% confidence intervals (CIs) under the random effects model
using Review Manager software. The quality assessment was conducted using
the Cochrane risk of bias (RoB 2.0) tool. Result(s): Eight randomized
controlled trials involving 3863 patients were included in the
meta-analysis. DOACs were associated with a significant reduction in the
risk of stroke or systemic embolism compared with VKAs (RR = 0.48; 95%CI:
[0.26, 0.88]; p = .02). The rate of major bleeding was similar between the
DOACs and VKAs (RR = 0.92; 95%CI: [0.49, 1.72]; p = .79). There was no
significant difference in the incidence of any stroke between the two
groups (RR = 0.65; 95%CI: [0.32, 1.31]; p = .23). The occurrence of
clinically relevant non-major bleeding (RR = 1.17; 95%CI: [0.97, 1.40]; p
= .10), all-cause mortality (RR = 0.94; 95%CI: [0.75, 1.17]; p = .57), and
intracranial hemorrhage (ICH) (RR = 0.71; 95%CI: [0.40, 1.26]; p = .25)
were comparable between the groups. Conclusion(s): DOACs seem safe
after bioprosthetic valve implantation, lowering the risk of stroke or
systemic embolism. However, rates of major bleeding, clinically relevant
non-major bleeding, any stroke, ICH, and all-cause mortality were
comparable between DOACs and VKAs. Copyright © The Author(s)
2026. This article is distributed under the terms of the Creative Commons
Attribution-NonCommercial 4.0 License
(https://creativecommons.org/licenses/by-nc/4.0/) which permits
non-commercial use, reproduction and distribution of the work without
further permission provided the original work is attributed as specified
on the SAGE and Open Access page
(https://us.sagepub.com/en-us/nam/open-access-at-sage).

<77>
Accession Number
2042831566
Title
Effectiveness and Safety of Hybrid Comprehensive Telerehabilitation in
Women with Heart Failure-A Subanalysis of the TELEREH-HF Randomized
Clinical Trial.
Source
Journal of Clinical Medicine. 15(2) (no pagination), 2026. Article Number:
694. Date of Publication: 01 Jan 2026.
Author
Piotrowicz E.; Glowczynska R.; Szalewska D.; Kowalik I.; Orzechowski P.;
Pluta S.; Kalarus Z.; Mierzynska A.; Jaworska I.; Irzmanski R.; Piotrowicz
R.
Institution
(Piotrowicz, Orzechowski) Telecardiology Center, National Institute of
Cardiology, Warsaw, Poland
(Glowczynska) 1st Chair, Department of Cardiology, Medical University of
Warsaw, Warsaw, Poland
(Szalewska) Clinic of Rehabilitation Medicine, Faculty of Health Sciences,
Medical University of Gdansk, Gdansk, Poland
(Kowalik, Mierzynska, Piotrowicz) National Institute of Cardiology,
Warsaw, Poland
(Pluta, Kalarus, Jaworska) Department of Cardiology, Congenital Heart
Diseases and Electrotherapy, Silesian Center for Heart Diseases, Silesian
Medical University, Zabrze, Poland
(Irzmanski) Department of Internal Medicine and Cardiac Rehabilitation,
Medical University of Lodz, Lodz, Poland
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Background/Objectives: Despite the known benefits of cardiac
rehabilitation, it remains underutilized among women. In particular,
little is known about the effectiveness of hybrid comprehensive
telerehabilitation (HCTR) in women with heart failure (HF). The purpose of
this study was to assess effectiveness and safety of HCTR in women with
HF. Method(s): This analysis formed part of the TELEREH-HF
multicenter, randomized trial that enrolled 850 HF patients (NYHA I-III,
LVEF <= 40%). Patients were randomized 1:1 to HCTR plus usual care (UC) or
UC alone. Patients underwent either HCTR (1 week in hospital and 8 weeks
at home, five times weekly) or UC with observation. The effectiveness of
HCTR was assessed by changes in peak oxygen consumption
(VO<inf>2</inf>peak), workload duration (t) in cardiopulmonary exercise
test and quality of life (QoL) based on Medical Outcome Survey Short Form
36 Questionnaire (SF-36). Measurements were taken before and after
intervention/observation. Result(s): Women constituted 11.5% of the
TELEREH-HF study population. Forty women in the HCTR group and 44 women in
the UC group completed program and observation, respectively. HCTR
resulted in a significant improvement in VO<inf>2</inf>peak (13.4 +/- 4.3
vs. 14.3 +/- 4.6; 95%CI 0.91 [0.05; 1.77], p = 0.038), workload duration
(301 +/- 162.3 vs. 334 +/- 156.6; 95%CI 33 [5; 60], p = 0.022) and SF-36
overall score (85.9 +/- 13.6 vs. 89.9 +/- 13.5; 95%CI 4.0 [0.6; 7.4], p =
0.024). These favorable results were not observed in the UC group
VO<inf>2</inf>peak (14.2 +/- 4.8 vs. 14.2 +/- 4.8; 95%CI 0.02 [-1.20;
1.24], p = 0.971) and SF-36 overall score (89.1 +/- 17.4 vs. 89.5 +/-
15.8; 95%CI 4.0 [-2.1; 2.8], p = 0.796), except for an increase workload
duration (268 +/- 138.4 vs. 300 +/- 130.1; 95%CI 32 [2; 62], p = 0.036).
The HCTR group showed a significantly greater improvement in the physical
component of QoL than the UC group. In neither group were there deaths nor
major adverse events related to exercise training. Conclusion(s):
Among women with heart failure, hybrid comprehensive telerehabilitation
appears safe and leads to statistically significant although moderate
improvements in physical capacity and quality of life. However, due to the
small sample size, further studies in larger female populations are needed
to confirm these findings. Copyright © 2026 by the authors.

<78>
Accession Number
2036018406
Title
HTK Solution Cardioplegia in Pediatric Patients: A Meta-analysis.
Source
Thoracic and Cardiovascular Surgeon. 74(2) (pp 164-173), 2026. Date of
Publication: 01 Mar 2026.
Author
Galvao L.K.C.S.; De Farias Santos A.C.F.; Dos Santos N.P.; Zamora F.V.;
Biavatti B.B.V.; Salles J.P.C.E.A.; Mendonca H.S.
Institution
(Galvao, Zamora) Federal University of Minas Gerais Medicine School, Belo
Horizonte, Brazil
(De Farias Santos) Unicid, Sao Paulo, Brazil
(Dos Santos, Salles) Unirio, Rio de Janeiro, Brazil
(Biavatti) Unicamp, Campinas, Sao Paulo, Brazil
(Mendonca) Prevent Senior Private Health Operator, Sao Paulo, Brazil
Publisher
Georg Thieme Verlag
Abstract
Introduction Cardioplegia, a therapy designed to induce reversible cardiac
arrest, revolutionized cardiovascular surgery. Among the various
pharmacological approaches is the histidine-tryptophan-ketoglutarate (HTK)
solution. Despite numerous studies, no meta-analysis has investigated the
efficacy of the HTK solution in the pediatric population. Therefore, we
aim to conduct a meta-analysis comparing HTK and other cardioplegia
solutions in pediatric patients undergoing cardiovascular surgery. Methods
PubMed, Embase, and Cochrane databases were searched from inception
through April 2024. Endpoints were computed in odds ratios (OR) with 95%
confidence intervals (CI) for dichotomous variables, whereas continuous
variables were compared using mean differences (MD) with 95% CI. Results A
total of 11 studies comprising 1,349 patients were included, of whom 677
(50.19%) received HTK cardioplegia. The results were similar between
groups regarding mortality (OR 0.98; 95% CI 0.29, 3.29), length of
hospital stay (MD 0.32 days; 95% CI -0.88, 1.51), Mechanical ventilation
(MV) (MD -17.72 hours; 95% CI -51.29, 15.85), arrhythmias (OR 1.27; 95% CI
0.83, 1.95), and delayed sternal closure (OR 0.89; 95% 0.56, 1.43).
However, transfusion volume was lower in the HTK group (MD -452.39; 95% CI
-890.24, -14.53; p = 0.04). Conclusion The use of HTK solution was
demonstrated to be similar regarding its clinical efficacy to other
approaches for cardioplegia, and it may present advantages to patients
prone to hypervolemia. Copyright © 2026 Georg Thieme Verlag. All
rights reserved.

<79>
Accession Number
2043331614
Title
The effect of transcutaneous electrical nerve stimulation (TENS) on pain
and vital signs during chest tube removal.
Source
Pakistan Journal of Medical Sciences. 42(2) (pp 345-351), 2026. Date of
Publication: 01 Feb 2026.
Author
Turkmen A.; Avci A.; Tura I.; Erden S.
Institution
(Turkmen, Tura, Erden) Department of Nursing, Faculty of Health Sciences,
Cukurova University, Adana, Turkey
(Avci) Department of Thoracic Surgery, Faculty of Medicine, Cukurova
University, Adana, Turkey
Publisher
Professional Medical Publications
Abstract
Objective: The aim of the study was to determine the effects of
transcutaneous electrical nerve stimulation (TENS) on pain and vital signs
during chest tube removal (CTR). Methodology: This randomized controlled
study was conducted with a group of patients treated in the thoracic
surgery unit of a university hospital between May 2023 to September 2023.
Participants were equally allocated using simple randomization. This
randomized-controlled study collected data 60 thoracic surgery patients
using Patient Information Form (PIF) and the Numerical Rating Scale (NRS).
TENS was applied for a total of one hour, 2-3 cm from the chest tube site.
The pain level and vital signs of the patients were assessed at
immediately before (T1), during (T2) and immediately after (T3) the CTR in
all groups. Result(s): Pain levels were significantly lower in the
TENS group compared to the control group (p < 0.05). In addition, a
significance was found between the groups at T2 for Heart Rate (HR), T2-T3
for Systolic Blood Pressure (SBP) and T2-T3 for Respiratory Rate (RR). HR,
SBP and RR were statistically significant at T2 time (p<0.05) in this
group. Conclusion(s): TENS effectively reduces acute procedural pain
and provide maintain stable vital signs as a safe complementary method in
multimodal pain management. Copyright © 2026, Professional
Medical Publications. All rights reserved.

<80>
Accession Number
2043093532
Title
Climate change and the immune system.
Source
Expert Review of Clinical Immunology. 22(1) (pp 61-77), 2026. Date of
Publication: 2026.
Author
Rijkers G.T.; Timraliyeva Z.; Mackie E.; Lupusoara M.
Institution
(Rijkers, Timraliyeva, Mackie, Lupusoara) Department of Health, Cognition,
and Behavior, University College Roosevelt, Middelburg, Netherlands
Publisher
Taylor and Francis Ltd.
Abstract
Introduction: Climate change and global warming have major consequences
for human health, including effects on the immune system. Areas covered:
The impact of global warming on vector transmitted infectious diseases,
such as West Nile Virus and dengue. Changes in pollen grain composition
and pollen season duration, along with increased frequencies of dust
storms, have detrimental impacts on asthmatic and allergic patients. The
direct and indirect effects of climate change on autoimmune and
cardiovascular diseases are also discussed. Literature on climate and the
immune system was retrieved from PubMed and Google Scholar up to 21 July
2025. Expert opinion: Climate change will lead to the spread of tropical
infectious diseases toward moderate climate regions. Recommended
vaccination schedules should be adapted to include these diseases. The
changing climate has also extended pollen season and increased both the
frequency and severity of dust storms, which impacts asthmatic patients.
There are indications that next to extreme heath, pollen exposure
contributes to acute cardiac events and complications after cardiovascular
surgery. More insight into the underlying mechanisms of the negative
effects of climate changes on the immune system could allow to take the
appropriate measures and interventions to mitigate climate-associated
immune-mediated diseases. Copyright © 2026 The Author(s).
Published by Informa UK Limited, trading as Taylor & Francis Group.

<81>
Accession Number
2043340493
Title
The impact of acute normovolemic hemodilution on blood transfusions in
cardiac surgery: a GRADE-assessed systematic review and meta-analysis of
30 randomized controlled trials with trial sequential analysis.
Source
Naunyn-Schmiedeberg's Archives of Pharmacology. (no pagination), 2026.
Date of Publication: 2026.
Author
Alam U.; Rath S.; Ansab M.; Khattak F.; Siddiqui H.T.; Burhan M.; Moiz A.;
Sabir V.; Afridi Z.A.K.
Institution
(Alam, Khattak, Sabir, Afridi) Khyber Medical College, Peshawar, Pakistan
(Rath) All India Institute of Medical Sciences Bhubaneswar, Bhubaneswar,
India
(Ansab) Services Institute of Medical Sciences, Lahore, Pakistan
(Siddiqui) Jinnah Sindh Medical University, Karachi, Pakistan
(Burhan) Dow University of Health Sciences, Sindh, Karachi, Pakistan
(Moiz) Bacha Khan Medical College, Mardan, Pakistan
Publisher
Springer Science and Business Media Deutschland GmbH
Abstract
Acute normovolemic hemodilution (ANH) is an intraoperative blood
conservation technique that involves removing a portion of the patient's
blood after anesthesia induction and replacing it with fluids to maintain
normovolemia. The purpose of this systematic review and meta-analysis was
to assess the efficacy and safety of ANH in reducing transfusion
requirements and improving hemorrhagic outcomes in adult cardiac surgery
patients. Studies were identified through systematic searches of PubMed,
Embase, and Cochrane Central databases. Effect estimates were calculated
using random-effects models, with heterogeneity assessed using the
I2 statistic. Trial sequential analysis (TSA) was employed to
evaluate the robustness of cumulative evidence. randomized controlled
trials (RCTs) involving 4473 patients were included for further analysis.
ANH was associated with a 27% relative reduction in the incidence of
allogeneic blood transfusions (RR = 0.73, 95% CI = 0.60 to 0.88; p =
0.0008) and a decrease in the volume of allogeneic red blood cell units
transfused (MD = - 0.75 units, 95% CI = - 1.41 to - 0.08; p = 0.020).
Fresh frozen plasma transfusion requirements were also significantly
reduced (MD = - 0.21 units, 95% CI = - 0.39 to - 0.03; p = 0.0248), along
with total blood loss (MD = - 64.35 mL, 95% CI = - 114.57 to - 14.13; p =
0.012). However, chest tube drainage, surgical revision, and stroke
incidence showed no significant differences between ANH and usual care.
This meta-analysis demonstrates that ANH significantly reduces the need
for allogeneic blood transfusions and improves outcomes such as red blood
cell and fresh frozen plasma usage during cardiac surgery. The findings
highlight ANH's potential as an effective blood conservation strategy,
though variability in outcomes and heterogeneity warrant further
high-quality research to optimize its application in contemporary cardiac
surgical practices. Copyright © The Author(s), under exclusive
licence to Springer-Verlag GmbH Germany, part of Springer Nature 2026.

<82>
Accession Number
2043566337
Title
Totally Endoscopic Approach for Aortic Valve Replacement: A Systematic
Review and Single-Arm Meta-Analysis.
Source
Medicina (Lithuania). 62(2) (no pagination), 2026. Article Number: 339.
Date of Publication: 01 Feb 2026.
Author
Anghel F.; Bistriceanu M.I.A.; Toma C.V.; Ursu C.G.; Danet A.; Blindaru
A.D.C.; Popescu M.-A.; Paun M.-A.; Parsan V.-I.; Margineanu T.C.; Cristea
D.I.; Cristea C.F.; Ceausu A.-M.; Boboruta R.A.; Udrea V.-N.A.; Andreescu
D.I.; Badiu C.-C.
Institution
(Anghel, Danet, Blindaru, Badiu) Department of Cardiovascular Surgery,
Emergency University Hospital of Bucharest, Bucharest, Romania
(Anghel, Bistriceanu, Toma, Ursu, Danet, Blindaru, Popescu, Paun, Parsan,
Margineanu, Cristea, Cristea, Ceausu, Boboruta, Udrea, Andreescu, Badiu)
Faculty of Medicine, Carol Davila University of Medicine and Pharmacy,
Bucharest, Romania
(Anghel) Curtin Medical School, Curtin University, Perth, Australia
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Background and Objectives: Totally endoscopic aortic valve replacement
(TE-AVR) is a minimally invasive technique offering potential benefits of
reduced surgical trauma and faster recovery compared with median
sternotomy or other minimally invasive access. While isolated aortic valve
replacement (AVR) is well established through conventional and minimally
invasive access, large-scale evidence for the totally endoscopic approach
remains limited. This meta-analysis aimed to systematically assess the
safety and feasibility of TE-AVR by aggregating perioperative outcomes,
including mortality, stroke, conversion, bleeding, paravalvular leak
(PVL), and atrial fibrillation (AF). Material(s) and Method(s): A
systematic search of PubMed, Embase, and the Cochrane Library was
performed, following PRISMA 2020 guidelines. Observational studies and
randomized controlled trials reporting outcomes of totally endoscopic or
thoracoscopic AVR were eligible. After independent screening and
selection, data were analyzed using a single-arm proportion model.
Leave-one-out sensitivity analyses were performed to evaluate the
influence of individual studies. The protocol was registered in PROSPERO
(CRD42024610128). Result(s): A total of 11 studies comprising 1135
patients were included. The pooled perioperative mortality was 0.00% (95%
CI 0.00-0.23; I2 = 0.0%), indicating highly consistent results
across cohorts. The stroke incidence was 0.69% (95% CI 0.00-2.07;
I2 = 42.7%), confirming the low cerebrovascular risk of this
approach. Conversion to sternotomy occurred in 0.00% of cases (95% CI
0.00-0.17; I2 = 0.0%), with no statistical heterogeneity
observed. Reintervention for bleeding occurred in 1.75% (95% CI 0.34-3.85;
I2 = 43.4%), while PVL was reported in 1.24% (95% CI 0.00-4.22;
I2 = 64.0%). AF incidence was 10.54% (95% CI 3.79-19.70;
I2 = 90.5%), with substantial between-study heterogeneity,
likely related to non-standardized definitions of new-onset AF and
variability in postoperative rhythm monitoring and reporting across
studies. Conclusion(s): TE-AVR is a safe and feasible technique
associated with very low perioperative mortality, bleeding, and stroke
rates, as well as low PVL incidence. The absent conversion rate in our
pooled analysis highlights the technical reliability of the procedure.
Variability in AF reporting underscores the need for future randomized
studies with harmonized definitions. Overall, TE-AVR offers a promising
minimally invasive alternative for aortic valve replacement, with
potential advantages in recovery (pooled ICU stay 1.86 days), hospital
stay (pooled 7.98 days), and aesthetic outcomes. Copyright © 2026
by the authors.

<83>
Accession Number
2043866703
Title
Perioperative high-dose selenium supplementation in open thoracic aortic
surgery: a post hoc subgroup analysis of the SUSTAIN CSX trial.
Source
Journal of Thoracic Disease. 18(2) (no pagination), 2026. Article Number:
72. Date of Publication: 28 Feb 2026.
Author
Catena D.; Stoppe C.; Mohsen G.; Germinario L.; Kleine-Brueggeney M.;
O'Brien B.; Ott S.; Hagen X.A.; Orsenigo A.; Hellner N.; Landoni G.;
Belletti A.; Ortalda A.; Muller M.; Nersesian G.; Kempfert J.; Pitts L.
Institution
(Catena, Stoppe, Mohsen, Germinario, Kleine-Brueggeney, O'Brien, Ott,
Hagen, Orsenigo, Hellner) Department of Cardiac Anesthesiology and
Intensive Care Medicine, Deutsches Herzzentrum der Charite-Medical Heart
Center of Charite, German Heart Institute Berlin, Berlin, Germany
(Catena, Stoppe, Mohsen, Germinario, Kleine-Brueggeney, O'Brien, Ott,
Hagen, Orsenigo, Hellner, Muller, Nersesian, Kempfert, Pitts) Freie
Universitat Berlin, Humboldt-Universitat zu Berlin,
Charite-Universitatsmedizin Berlin, Berlin, Germany
(Catena, Stoppe, Kleine-Brueggeney, O'Brien, Ott, Nersesian, Kempfert,
Pitts) German Centre for Cardiovascular Research (DZHK), Partner Site
Berlin, Berlin, Germany
(Stoppe) Department of Anesthesiology, Intensive Care, Emergency and Pain
Medicine, University Hospital Wurzburg, Wurzburg, Germany
(O'Brien) Department of Perioperative Medicine, St Bartholomew's Hospital,
Barts Heart Centre, London, United Kingdom
(Ott, Muller, Nersesian, Kempfert, Pitts) Department of Cardiothoracic and
Vascular Surgery, Deutsches Herzzentrum der Charite-Medical Heart Center
of Charite, German Heart Institute Berlin, Berlin, Germany
(Hellner) Department of Anesthesiology, University Hospital Basel, Basel,
Switzerland
(Landoni, Belletti, Ortalda) Department of Anesthesia and Intensive Care,
IRCCS San Raffaele Scientific Institute, Milan, Italy
(Landoni) School of Medicine, Vita-Salute San Raffaele University, Milan,
Italy
Publisher
AME Publishing Company
Abstract
Background: Open surgery on the thoracic aorta is associated with a
variable and often pronounced postoperative inflammatory response, which
contributes to organ injury and prolonged intensive care unit (ICU) stays.
Various anti-inflammatory strategies have been proposed as a way to
modulate this response and therefore improve clinical outcomes. The
SUSTAIN-CSX randomized controlled trial investigated the effect of
perioperative high-dose selenium supplementation on mortality and organ
dysfunction in cardiac surgery patients. In this post hoc analysis, we
examined its effect on 30-day mortality and organ dysfunction in patients
undergoing open thoracic aortic surgery. Method(s): We conducted a
post hoc analysis of patients who underwent open thoracic aortic surgery
within the SUSTAIN-CSX trial, a multicenter randomized controlled trial
evaluating perioperative intravenous high-dose selenium supplementation in
cardiac surgery. The selenium regimen consisted of 2,000 microg sodium
selenite at anesthesia induction, 2,000 microg immediately
postoperatively, and 1,000 microg daily for up to 10 days in the ICU.
Patients treated with endovascular interventions of the thoracic aorta
were excluded. Result(s): A total of 287 patients were included, with
144 randomized to selenium and 143 to placebo. The primary outcome, 30-day
mortality, did not differ significantly between groups (selenium 2.8% vs.
placebo 3.5%; P=0.73). Clinically relevant postoperative atrial
fibrillation (POAF) occurred more frequently in the selenium group
(selenium 18.1% vs. placebo 10.5%; P=0.03). Non-cardiac organ dysfunction,
including acute kidney injury (AKI), postoperative delirium and Sequential
Organ Failure Assessment (SOFA) scores, was comparable between groups.
Postoperative inflammatory and organ injury markers were overall
comparable, although patients receiving selenium showed a non-significant
trend toward lower creatine kinase-myocardial band (CK-MB) levels
(selenium 18.9 microg/L vs. placebo 28.3 microg/L; P=0.07). Six-month
survival, ICU and hospital length of stay, readmission rates, and measures
of functional recovery did not differ between groups. Conclusion(s):
Perioperative intravenous high-dose selenium supplementation did not
improve 30-day mortality and was associated with an increased incidence of
clinically relevant POAF in this exploratory subgroup analysis. Routine
selenium supplementation in this setting cannot be
recommended. Copyright © AME Publishing Company.

<84>
Accession Number
2043876458
Title
Early Versus Late Extubation in Pediatric Cardiac Surgery: A Systematic
Review.
Source
World Journal for Pediatric and Congenital Heart Surgery. (no
pagination), 2026. Date of Publication: 2026.
Author
Usmani S.U.R.; Javed H.; Sajid A.; Shahzad M.; Siddiqui A.; Ziaulhaq A.
Institution
(Usmani, Javed, Sajid, Shahzad, Siddiqui, Ziaulhaq) Dow Medical College,
Dow University of Health Sciences, Karachi, Pakistan
Publisher
SAGE Publications Inc.
Abstract
Background: Early extubation (EE) and immediate extubation (IE) after
pediatric cardiac surgery are increasingly being studied with the aim of
lowering hospital and intensive care unit (ICU) stays, and postoperative
complications. The aim of this systematic review was to assess the
outcomes of EE and IE versus traditional delayed extubation (DE) in
children undergoing surgery for congenital heart disease. Method(s):
This study was conducted in line with the PRISMA guidelines. Articles
comparing outcomes of EE versus DE in pediatric patients undergoing
cardiac surgery between 2014 and 2023 were identified using PubMed, Web of
Science, and CENTRAL. The Newcastle-Ottawa scale was employed to assess
the quality of the included studies. Result(s): A total of 22 studies
including 8359 patients were included. Two IE studies and 6 EE studies
reported significantly higher reintubation rates as compared with DE,
indicating variability across populations and practices. The ICU length of
stay was notably shorter for the IE group in 7 studies and for the EE
group in 7 studies as compared with DE; 1 IE study reported a longer ICU
stay. Six studies in the IE group and 5 in the EE group showed
significantly shorter hospital stays as compared with DE. Lastly, 2
studies in the EE group showed higher mortality than in the DE group.
 Conclusion(s): In a selective population, EE proved advantageous with
quicker recovery and less use of resources. However, to optimize patient
selection and outcomes, standardization of the procedures and additional
prospective research are needed. Copyright © The Author(s) 2026

<85>
[Use Link to view the full text]
Accession Number
650401195
Title
Integrating the PRECEDE-PROCEED Model Into Postoperative Rehabilitation:
Impacts on Exercise Self-Efficacy and Quality of Life in Patients With
Abdominal Aortic Aneurysm.
Source
The Journal of cardiovascular nursing. (no pagination), 2026. Date of
Publication: 24 Feb 2026.
Author
Han R.; Chen Y.; Zhang J.; Jia Y.; Gao M.
Institution
(Han) Ruoqian Han, MN, RN, School of Nursing, Inner Mongolia Medical
University, Hohot, Inner Mongolia, China
(Chen) Yan Chen, MN, RN, The Affiliated Hospital of Inner Mongolia Medical
University, Hohot, Inner Mongolia, China
(Zhang) Jiaqi Zhang, MN, RN, School of Nursing, Inner Mongolia Medical
University, Hohot, Inner Mongolia, China
(Jia) Yuxin Jia, MN, RN, School of Nursing, Inner Mongolia Medical
University, Hohot, Inner Mongolia, China
(Gao) Min Gao, MN, RN, School of Nursing, Inner Mongolia Medical
University, Hohot, Inner Mongolia, China
Abstract
BACKGROUND: Health education is a beneficial nursing approach for patients
with cardiovascular disease, but it is unclear whether this approach is
effective for patients with abdominal aortic aneurysms who abandon
beneficial physical activity due to concerns. In this study, we aimed to
evaluate the effectiveness of a health education intervention based on the
PRECEDE-PROCEED model in enhancing exercise self-efficacy and quality of
life among patients with abdominal aortic aneurysms. OBJECTIVE(S): In
this study, our aim was to investigate the impact of exercise
rehabilitation health education based on the PRECEDE-PROCEED model on the
quality of life and exercise self-efficacy of patients with abdominal
aortic aneurysms. METHOD(S): This randomized controlled trial
enrolled 70 patients admitted to the Department of Cardiovascular Surgery
at a tertiary Grade-A hospital between June 2024 and June 2025.
Participants were equally allocated to either the intervention group (n =
35) receiving exercise rehabilitation health education based on the
PRECEDE-PROCEED model or the control group (n = 35) receiving standard
cardiac surgical rehabilitation guidance. Outcomes were assessed using the
36-Item Short-Form Health Survey (SF-36) and the Chinese self-efficacy for
exercise scale at baseline, discharge, and 3-month follow-up.
 RESULT(S): No statistically significant differences in baseline
scores were observed between the groups (all P > .05). Postintervention,
the intervention group demonstrated significantly higher SF-36 scores and
Chinese self-efficacy scores both at discharge and at the 3-month
follow-up (all P < .05). CONCLUSION(S): The application of exercise
rehabilitation health education based on the PRECEDE-PROCEED model
effectively improves quality of life and enhances exercise self-efficacy,
providing empirical support for standardized postoperative rehabilitation
protocols. Copyright © 2026 Wolters Kluwer Health, Inc. All
rights reserved.

<86>
Accession Number
2043626591
Title
Sex-related differences in long-term mortality after coronary artery
bypass graft surgery: A systematic review and meta-analysis.
Source
International Journal of Cardiology: Cardiovascular Risk and Prevention.
29 (no pagination), 2026. Article Number: 200611. Date of Publication: 01
Jun 2026.
Author
Zhang D.T.; Dhaliwal S.; Tajeshwar N.; Stevens G.A.; Al-Sadawi M.; Tao M.
Institution
(Zhang, Dhaliwal) Division of Cardiology, Department of Medicine, Stony
Brook Medicine, Stony Brook, NY, United States
(Tajeshwar) Division of Cardiology, Department of Medicine, Albany Medical
Center, Albany, NY, United States
(Stevens) University of Massachusetts Chan Medical School, Worcester, MA,
United States
(Al-Sadawi) Cardiovascular Division, Department of Medicine, University of
Minnesota, Minneapolis, MN, United States
(Tao) Heart & Vascular Institute, Hartford Healthcare Medical Group,
Hartford, CT, United States
Publisher
Elsevier B.V.
Abstract
Background This meta-analysis assessed the sex-related differences in
long-term mortality (>=7 years) after coronary artery bypass graft (CABG)
surgery. Methods We searched the databases Ovid MEDLINE, Embase, and Web
of Science for studies reporting sex-specific differences in mortality
following CABG. The search was not restricted to time or publication
status. The primary endpoint of interest was long-term mortality (>=7 year
or longer). Results A total of 1289 studies resulted from literature
search. A total of 19 studies with 277,224 patients (60,858 women and
216,369 men) were included. The mean age was higher in women than men
(66.5 vs. 63.1 years). Our analysis demonstrated that female sex was
associated with higher long-term mortality (>=7 years) following CABG
(odds ratio 1.17; 95% confidence interval 1.05-1.30; p < 0.01).
Conclusions Our results suggest that women had higher long-term mortality
following CABG compared with men. It is the largest study to date of
sex-specific differences in long-term mortality (>=7 years). Copyright
© 2026 The Authors.

<87>
Accession Number
2043866689
Title
Research progress on imaging prediction of pleural adhesion: a narrative
review.
Source
Journal of Thoracic Disease. 18(2) (no pagination), 2026. Article Number:
162. Date of Publication: 28 Feb 2026.
Author
Wang Y.; Lyu D.; Tu W.; Zhou X.; Xiao Y.; Fan L.; Liu S.
Institution
(Wang, Lyu, Tu, Zhou, Xiao, Fan, Liu) Department of Radiology, The Second
Affiliated Hospital of Navy Medical University, Shanghai, China
(Fan, Liu) Department of Radiology, The Second Affiliated Hospital of Navy
Medical University, No. 415 Fengyang Road, Huangpu District, Shanghai,
China
Publisher
AME Publishing Company
Abstract
Background and Objective: Pleural adhesion is a significant risk factor
that can lead to a poor prognosis in thoracic surgery. The extent of these
adhesions directly affects the selection of preoperative surgical
approaches, the progress of the intraoperative surgical process, and the
occurrence of serious postoperative complications. Accurate preoperative
judgment of pleural adhesions and their severity is of great significance
for formulating perioperative treatment plans and achieving precision
medicine. This article focuses on summarizing and synthesizing various
imaging methods for preoperative prediction of pleural adhesions and
discusses the challenges and prospects facing future research. The aim is
to improve preoperative diagnostic accuracy and risk stratification,
thereby enhancing surgical safety and efficacy. Method(s): A
comprehensive, non-systematic review of the latest literature was carried
out in order to investigate the progress of predicting pleural adhesions.
PubMed database was being examined, and the last run was on December
17th 2025. Key Content and Findings: This article reviews the
definition, classification, and clinical significance of pleural
adhesions, and summarizes the latest research progress of imaging
prediction of pleural adhesions in the past 10 years. It was found that
ultrasound, chest X-ray, computed tomography (CT), and
18F-fluorodeoxyglucose (18F-FDG) positron emission
tomography (PET)/CT can all effectively predict the pleural adhesion
status before the operation. Conclusion(s): Pleural adhesions
influence the survival prognosis of patients with thoracic surgery.
Effective preoperative prediction of the state of pleural adhesions can
help to improve the preoperative surgical plan formulation and reduce the
occurrence of postoperative complications. Ultrasound, chest X-ray, CT,
and 18F-FDG PET/CT have their advantages and disadvantages in
predicting pleural adhesions, and artificial intelligence (AI) may be the
direction of future research. Copyright © AME Publishing Company.

<88>
Accession Number
2043570799
Title
Near Misses as Signals of System Vulnerability in Thoracic Surgery: A
Narrative Review on Quality Improvement and Patient Safety.
Source
Healthcare (Switzerland). 14(4) (no pagination), 2026. Article Number:
423. Date of Publication: 01 Feb 2026.
Author
Magouliotis D.E.; Androutsopoulou V.; Zotos P.-A.; Xanthopoulos A.; Cioffi
U.; Sicouri N.; Solli P.; Scarci M.
Institution
(Magouliotis) Department of Cardiac Surgery Research, Lankenau Institute
for Medical Research, Wynnewood, PA, United States
(Magouliotis, Xanthopoulos) Department of Cardiology, University of
Thessaly, Biopolis, Larissa, Greece
(Androutsopoulou, Zotos) Department of Cardiothoracic Surgery, University
of Thessaly, Biopolis, Larissa, Greece
(Cioffi) Department of Surgery, University of Milan, Milan, Italy
(Sicouri) Department of Neuroscience Pittsburgh Campus, University of
Pittsburgh, Pittsburgh, PA, United States
(Solli) Department of Thoracic Surgery, Fondazione IRCCS Istituto
Nazionale dei Tumori Milano, Via Giacomo, Venezian 1, Milan, Italy
(Scarci) Department of Cardiothoracic Surgery, Hammersmith Hospital,
Imperial College Healthcare, National Health Service (NHS) Trust, London,
United Kingdom
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Near misses-clinical events that could have resulted in patient harm but
did not-are increasingly recognized as critical yet underutilized sources
of insight in surgical quality improvement. In thoracic surgery, where
procedures are physiologically demanding and care pathways are highly
interdependent, near misses frequently precede major complications and
expose latent system vulnerabilities rather than isolated technical
errors. A structured narrative review methodology was employed, including
a targeted literature search of major biomedical databases and thematic
synthesis of relevant studies. This narrative review synthesizes evidence
from patient safety science, surgical quality literature, and thoracic
surgery-specific outcomes research to examine how near misses can be
systematically leveraged to improve care. We discuss the transition from
individual-centered explanations of adverse events to system-based models
that emphasize human factors, communication, escalation pathways, and
organizational culture. Particular attention is given to contemporary
quality frameworks such as failure to rescue and textbook outcome, which
highlight the importance of early recognition, coordinated response, and
recovery from complications rather than complication avoidance alone. We
further explore the central role of psychological safety and leadership
behaviors in enabling meaningful learning from near misses. By reframing
near misses as actionable data rather than anecdotal "close calls,"
quality improvement emerges as a core professional responsibility in
thoracic surgery. We conclude that excellence in thoracic surgery should
be defined not by the absence of complications, but by the capacity of
surgical systems to learn, adapt, and prevent future harm. Copyright
© 2026 by the authors.

<89>
Accession Number
2043417383
Title
Direct oral anticoagulants versus vitamin K antagonists after heart valve
bioprosthetic replacement or repair: A systematic review and
meta-analysis.
Source
Archives of Cardiovascular Diseases. (no pagination), 2026. Date of
Publication: 2026.
Author
Bruno V.D.; Lester T.; Poletti E.; Celmeta B.; Viva T.; Bisogno A.; Miceli
A.; Glauber M.
Institution
(Bruno, Celmeta, Viva, Bisogno, Miceli, Glauber) Department of Minimally
Invasive Cardiac Surgery, IRCCS Galeazzi-Sant'Ambrogio Hospital, Milan,
Italy
(Lester) School of Medicine, University of Bristol, Bristol, United
Kingdom
(Poletti) Department of Cardiology, Hartcentrum Middelheim ZNA, Antwerp,
Belgium
Publisher
Elsevier Masson s.r.l.
Abstract
Vitamin K antagonists are used as a temporary anticoagulation method after
bioprosthetic valve replacement or repair. However, the novel direct oral
anticoagulants may be a preferred method of anticoagulation because of
their improved patient compliance. This meta-analysis aimed to evaluate
the safety of direct oral anticoagulants versus vitamin K antagonists
after biological valve replacement or repair. A systematic review and
meta-analysis were performed for studies reporting the effect of direct
oral anticoagulants versus vitamin K antagonists after biological valve
replacement or repair. The inclusion criteria were studies of adults
undergoing bioprosthetic mitral or aortic valve replacement or repair,
comparing direct oral anticoagulants versus vitamin K antagonists in the
early postoperative period. The main outcomes were thromboembolic and
bleeding events, and short- and mid-term death rates. Six observational
studies and one randomized controlled trial were included, with a total of
2994 direct oral anticoagulant recipients and 16,894 vitamin K antagonist
recipients. There were no significant differences between the groups in
terms of thromboembolic events (odds ratio: 0.82, 95% confidence interval:
0.45-1.49; P = 0.52) or bleeding events (odds ratio: 0.89, 95% confidence
interval: 0.70-1.14, P = 0.36). Higher 30-day and mid-term death rates
were observed in patients receiving direct oral anticoagulants, but this
analysis was reported inconsistently, and was heavily influenced by a
single study. In a mixed population of individuals undergoing
bioprosthetic valve replacement or repair, there was no statistically
significant difference between direct oral anticoagulants and vitamin K
antagonists in terms of reducing thromboembolic or bleeding events.
Further studies are needed to establish the optimal anticoagulation
regimen in this context. Copyright © 2026 Elsevier Masson SAS.

<90>
[Use Link to view the full text]
Accession Number
650383846
Title
Extracorporeal Membrane Oxygenation Following Acute Type A Aortic
Dissection Repair: A Systematic Review and Meta-Analysis.
Source
ASAIO journal (American Society for Artificial Internal Organs : 1992).
72(3) (pp 233-241), 2026. Date of Publication: 01 Mar 2026.
Author
Papakonstantinou N.A.; Antonopoulos C.N.
Institution
(Papakonstantinou) From the 2nd Cardiac Surgery Department, Onassis
Cardiac Surgery Center, Athens, Greece
(Antonopoulos) 1st Department of Vascular Surgery, Attikon University
Hospital, National and Kapodistrian University of Athens, Athens, Greece
Abstract
Acute type A aortic dissection (ATAAD) is a life-threatening
cardiovascular emergency. Despite the well-established role of
veno-arterial extracorporeal membrane oxygenation (VA-ECMO) after
postcardiotomy cardiogenic shock in cardiac surgery patients, its
application in the context of ATAAD has been controversial. The goal of
this study is to evaluate the role of postcardiotomy ECMO subsequent to
ATAAD repair. A meta-analysis of nine retrospective studies approaching
this topic was conducted. Finally, a total of 318 patients were analyzed.
Despite a successful weaning from ECMO rate of 48.3% (95% confidence
interval [CI]: 30.6-66.2), not all of them finally survived, resulting in
a higher overall in-hospital mortality of 72.4% (95% CI: 61.9-81.9). Acute
kidney injury requiring continuous renal replacement therapy rate was
60.5% (95% CI: 43.9-76.0), neurologic complications rate as a consequence
of stroke was 24.4% (95% CI: 13.9-36.3), limb ischemia rate was 7.6% (95%
CI: 1.7-16.2) and bleeding requiring reoperation rate was 29.2% (95% CI:
10.3-52.2). We estimated a pooled 6.04 days mean duration on ECMO support
(95% CI: 3.88-8.20) and a pooled 24.26 days mean length of stay (95% CI:
18.81-29.71). Concerning medium-term outcomes, a pooled incidence rate of
late mortality of 5.8% per 100 person-years (95% CI: 0.8-13.4) was
recorded. Despite high mortality and complication rates, postcardiotomy
ECMO after ATAAD repair may be reasonable, but it depends on further
multicenter research to determine which patients could
benefit. Copyright © ASAIO 2025.

<91>
Accession Number
650379212
Title
Effectiveness of hypotension prediction index in reducing postoperative
organ hypoperfusion-related complications in non-cardiac surgery: a
meta-analysis of randomized controlled trials.
Source
Minerva anestesiologica. (no pagination), 2026. Date of Publication: 24
Feb 2026.
Author
Ding Y.; Jia H.; Xu J.-S.; Liao Q.-G.; Dai J.-Y.; Wei X.; Pan C.; Fu H.-L.
Institution
(Ding, Jia, Xu, Liao, Dai, Wei, Pan) Department of Anesthesiology,
Shanghai Changzheng Hospital, Second Affiliated Hospital of Naval Medical
University, Shanghai, China
(Fu) Department of Anesthesiology, Shanghai Changzheng Hospital, Second
Affiliated Hospital of Naval Medical University, Shanghai, China
Abstract
INTRODUCTION: Intraoperative hypotension during non-cardiac surgery is
associated with postoperative complications such as acute kidney injury
(AKI), myocardial injury, and stroke, which may increase mortality and
severe adverse outcomes. Although the Hypotension Prediction Index (HPI)
may help reduce intraoperative hypotension, its clinical value in lowering
the incidence of these complications remains uncertain. This meta-analysis
evaluates whether HPI-guided hemodynamic management reduces major
postoperative complications (including AKI, cardiorenal, and
cerebrovascular events) in adult patients undergoing non-cardiac surgery.
EVIDENCE ACQUISITION: A systematic search was conducted in PubMed, EMBASE,
Cochrane Library, and Web of Science, to identify RCTs assessing HPI in
non-cardiac surgery. The outcomes encompassed the incidence of
postoperative complications such as AKI, myocardial injury after
non-cardiac surgery (MINS), stroke and 30-day mortality. Pooled effect
estimates, including odds ratios (ORs) with 95% confidence intervals (95%
CIs), were calculated using either fixed-effects or random-effects models
based on heterogeneity assessments. Sensitivity analyses were performed by
excluding trials with a high or unclear risk of bias to evaluate the
robustness of the findings. EVIDENCE SYNTHESIS: A total of 10 RCTs
involving 1746 participants were included. The results revealed no
statistically significant difference in incidence of AKI (OR: 0.85; 95%CI:
0.65 to 1.10; P=0.21), MINS(OR: 0.62; 95%CI: 0.36 to 1.06; P=0.08), stroke
(OR: 0.63; 95%CI: 0.20 to 1.98; P=0.42), and 30-day mortality (OR: 0.87;
95%CI: 0.32 to 2.34; P=0.78) between HPI group and control group.
 CONCLUSION(S): Hemodynamic management guided by the HPI in adults
undergoing non-cardiac surgery does not significantly reduce the incidence
of major postoperative complications compared to standard care.

<92>
Accession Number
650369561
Title
Effectiveness of the Preschool Children eHealth Cardiac Rehabilitation
Program After Congenital Heart Surgery: Randomised Controlled Trial.
Source
Congenital Heart Disease. Conference: The 5th Asian Associations for
Pediatric and Congenital Heart Surgery Annual Meeting. Bali Indonesia.
20(Supplement 1) (pp 48-49), 2025. Date of Publication: 2025.
Author
Luo W.; Chen L.; Cai X.; Xu Y.; Zhang H.; Xu Z.
Institution
(Luo, Chen, Cai, Xu, Zhang, Xu) Shanghai Children's Medical Center,
Cardiovascular Intensive Care Unit, China
Publisher
Tech Science Press
Abstract
Aim: To develop the Preschool Children eHealth Cardiac Rehabilitation
(PCeCR) program for pediatric rehabilitation after congenital heart
disease surgery, based on the Interaction Model of Client Health Behavior,
and to evaluate the effects of the program. Design(s): A parallel
two-arm randomised controlled trial was conducted. Method(s):
Participants were recruited from July 2022 to June 2023 and randomly
assigned to either the intervention or control group. The intervention
group participated in a six-month PCeCR program, while the control group
received routine care. Outcomes were measured at baseline, 3-month at the
end of the intervention, and 6-month after the intervention. The baseline
study included 84 children, with 44 in the control group and 40 in the
intervention group. Among the 84 participants, 80 finished all 6-month of
follow-up. Result(s): The two groups showed significant differences
in the ICF-CY-CHDS score, LVEF and the distance achieved in the 6-Minute
Walk Test (p < 0.001). The intervention group exhibited a significantly
higher amount of vigorous physical activity compared to the control group
(p < 0.001). Parents in the intervention and control groups exhibited
significant variations in knowledge, attitude, behavior, and healthcare
relationship trust levels (p < 0.001). The proportion of parents with
anxiety in the intervention group significantly decreased
post-intervention at 6-month (p < 0.001). Conclusion(s): The PCeCR
program is helpful for the cardiac rehabilitation of preschool children
after congenital heart disease surgery.

<93>
Accession Number
2043808394
Title
Adult heart transplantation in the USA and Western Europe: state of the
art review.
Source
European Heart Journal. 47(8) (pp 916-926), 2026. Date of Publication: 21
Feb 2026.
Author
Chen C.W.; Saeed D.; Woo Y.J.
Institution
(Chen, Woo) Department of Cardiothoracic Surgery, Stanford University
School of Medicine, 300 Pasteur Drive, Palo Alto, CA, United States
(Saeed) Department of Cardiovascular Surgery, Heart Center Niederrhein,
Health and Medical University Krefeld, Krefeld, Germany
Publisher
Oxford University Press
Abstract
Heart transplantation has made remarkable strides since its inception in
the 1960s. While the transplant volume in the USA has steadily increased
over the last decade, significant disparities exist in Europe, fuelled by
cultural and legislative differences. Recent advancements such as donation
after circulatory death and use of hepatitis C positive donors are
embraced to differing degrees among countries. This review serves to
summarize the current state and ongoing challenges of heart
transplantation in the USA and Europe. Copyright © The Author(s)
2025. Published by Oxford University Press on behalf of the European
Society of Cardiology. All rights reserved.

<94>
Accession Number
2043467344
Title
Efficacy and safety of a Venus A valve among Chinese patients undergoing
transcatheter aortic valve replacement: a systematic review and single-arm
meta-analysis.
Source
Frontiers in Cardiovascular Medicine. 13 (no pagination), 2026. Article
Number: 1725106. Date of Publication: 2026.
Author
Sun Z.; Shan D.; Wang J.; Jiang B.; Chen T.; Zhang Y.; Han T.; Wang W.;
Guo J.; Liu C.
Institution
(Sun, Shan, Wang, Jiang, Chen, Zhang, Han, Guo, Liu) Senior Department of
Cardiology, The Sixth Medical Center of PLA General Hospital, Beijing,
China
(Wang) Department of Cardiology, The First Medical Center of PLA General
Hospital, Beijing, China
Publisher
Frontiers Media SA
Abstract
Background: The Venus A valve is a first-generation self-expanding valve
used in China for transcatheter aortic valve replacement (TAVR). However,
data on its efficacy and safety remain limited. The present study assessed
the efficacy and safety of the Venus A valve in Chinese patients
undergoing TAVR. Method(s): A single-arm meta-analysis was performed,
and relevant studies were systematically retrieved from PubMed, Embase,
Web of Science, the Cochrane Library, ClinicalTrials.gov, and Google
Scholar from inception until 1 June 2022. Domestic libraries were not
searched due to data overlap. All study types evaluating the Venus A valve
were considered for inclusion, except case reports or reviews. Non-English
language studies or those without corresponding data were excluded. The
Newcastle-Ottawa scale (NOS) was used to evaluate the included
retrospective studies, and the methodological index for non-randomized
studies (MINORS) was used to assess the included non-randomized study
(single-arm study). The random-effects model was used to calculate the
combined proportion and 95% confidence interval (CI) when I2
was >50%; otherwise, a fixed-effect model was used. Publication bias was
assessed using the Egger test, with P < 0.05 indicating potential bias.
 Result(s): This meta-analysis included 15 studies involving 1,144
Chinese patients who underwent TAVR with a Venus A valve. The
device/procedure success rate was 90%. The mean transvalvular gradient
decreased from 58.52 to 10.85 mmHg, and the peak jet velocity decreased
from 4.86 s to 2.23 m/s. At the 30-day follow-up evaluation, the all-cause
mortality rate was 3%. The requirement for a second valve accounted for
12% of cases. Major vascular complications were uncommon, as were major
bleeding, stroke, acute kidney injuries, and new-onset atrial
fibrillation. At the 1-year follow-up evaluation, the all-cause mortality
rate was 7%. The incidence of new permanent pacemaker implantation in
patients with bicuspid aortic valves was 16%, and the all-cause mortality
rate was 8% at the 30-day follow-up evaluation. Conclusion(s):
Despite its relatively high requirement for a second valve, the Venus A
valve is feasible for Chinese patients undergoing TAVR. Its effectiveness
and safety were demonstrated by a high device/procedure success rate,
immediate hemodynamic improvement, and low incidence of
complications. Copyright 2026 Sun, Shan, Wang, Jiang, Chen, Zhang,
Han, Wang, Guo and Liu.

<95>
Accession Number
2043551603
Title
Clinical Application of Inhaled Nitric Oxide in Conditions of Excessive
Right Heart Load: A Review from Neonatal Pulmonary Hypertension to
Perioperative Cardiac Surgery Management.
Source
Journal of Cardiovascular Development and Disease. 13(2) (no pagination),
2026. Article Number: 81. Date of Publication: 01 Feb 2026.
Author
Hu C.; Chen Z.; Lv L.; Zhu Y.; Chen Y.; Wang Q.
Institution
(Hu, Chen, Lv, Wang) Department of Pediatric Cardiac Surgery, Beijing
Anzhen Hospital, Capital Medical University, No. 2 Anzhen Street, Chaoyang
District, Beijing, China
(Zhu, Chen) Department of ICU in Pediatric Cardiology, Beijing Anzhen
Hospital, Capital Medical University, No. 2 Anzhen Street, Chaoyang
District, Beijing, China
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Excessive right heart load imposes an acute or chronic injury on the right
ventricle (RV), predisposing critically ill neonates and cardiac surgical
patients to RV failure, low cardiac output syndrome, and death. Inhaled
nitric oxide (iNO) is a selective pulmonary vasodilator that improves
ventilation-perfusion matching and unloads the RV without systemic
hypotension; nonetheless, its application beyond established neonatal
indications remains contentious. Our review synthesizes current
mechanistic, translational, and clinical evidence regarding iNO use in
three major settings characterized by excessive RV load: (1) neonatal
pulmonary hypertension, particularly PPHN; (2) acute and chronic RV
overload in older children and adults, including secondary pulmonary
hypertension, acute respiratory distress syndrome (ARDS), and acute
pulmonary embolism; and (3) perioperative and post-cardiopulmonary bypass
(CPB) management in congenital and adult cardiac surgery. In term and
near-term infants with hypoxic respiratory failure, pivotal randomized
trials show that iNO consistently improves oxygenation and reduces
extracorporeal membrane oxygenation (ECMO) use, but this has little effect
on survival and long-term neurodevelopment. In ARDS and other adult
critical-care indications, iNO provides transient improvements in gas
exchange and RV performance without reducing mortality or ventilator
duration, and meta-analyses signal an increased risk of acute kidney
injury, particularly with prolonged use. In contrast, perioperative
studies around CPB demonstrate that prophylactic postoperative iNO and
intra-CPB nitric oxide administration can attenuate pulmonary hypertensive
crises, facilitate separation from CPB, shorten ventilation and intensive
care stay, and, in selected high-risk cohorts, may reduce cardiac
surgery-associated acute kidney injury, although survival benefits remain
unproven. Across these scenarios, iNO should be used judiciously and in a
pathophysiology-driven manner as a time-limited, targeted adjunct to
stabilize patients with documented or anticipated RV strain rather than a
disease-modifying therapy. Future work should refine patient selection,
timing, dosing, and weaning strategies, and define the long-term safety
and cost-effectiveness of iNO within contemporary multimodal RV support
pathways. Copyright © 2026 by the authors.

<96>
Accession Number
2043499697
Title
Patient-Controlled Analgesia in ICU: A Scoping Review.
Source
Journal of Personalized Medicine. 16(2) (no pagination), 2026. Article
Number: 109. Date of Publication: 01 Feb 2026.
Author
Califano A.; Caldonazzo R.; Gotti M.; Sabbatini G.; Galimberti A.; Angelo
P.; Formenti P.
Institution
(Califano, Caldonazzo) School of Medicine and Surgery, University of
Milano-Bicocca, Milano, Italy
(Gotti, Sabbatini, Galimberti, Angelo, Formenti) SC Anestesia,
Rianimazione e Terapia Intensiva, ASST Nord Milano, Ospedale Bassini,
Cinisello Balsamo, Italy
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Background/Objectives: Patient-Controlled Analgesia (PCA) is a
well-established strategy for managing postoperative pain, but its use in
the Intensive Care Unit (ICU) remains poorly defined, poorly standardized,
and fragmented. The aim of this scoping review is to map the extent,
nature, and characteristics of the available evidence on the use of PCA in
ICU patients, identifying key areas of uncertainty and knowledge gaps that
require further study. Method(s): Scoping review reported according
to the PRISMA-ScR guidelines. Result(s): 12 relevant studies were
identified. Available evidence suggests that PCA can provide pain control
comparable to traditional techniques in post-cardiac surgery patients in
the ICU, while data on its use in non-surgical patients are limited. The
studies reported good feasibility and a generally favorable safety
profile, with a low incidence of significant respiratory events thanks to
intensive monitoring. Methodological variability prevents direct
comparisons between studies. Conclusion(s): PCA supports personalized
pain management based on patient-specific clinical conditions and
response. However, more standardized studies are needed to define its
role. Copyright © 2026 by the authors.

<97>
Accession Number
2043603063
Title
Ross Procedure Renaissance: A Contemporary Review of Patient Selection,
Technique, and Long-Term Outcomes in Adults.
Source
Journal of the American Heart Association. 15(1) (no pagination), 2025.
Article Number: e044454. Date of Publication: 30 Dec 2025.
Author
Bloom J.P.; Nam L.; Sa M.P.; Williams E.; Ouzounian M.; El-Hamamsy I.;
Hopkins W.; Yeh D.D.
Institution
(Bloom, Nam, Sa) Division of Cardiac Surgery, Massachusetts General
Hospital, Boston, MA, United States
(Williams, El-Hamamsy) Division of Cardiovascular Surgery, Mount Sinai
Hospital, Icahn School of Medicine at Mount Sinai, New York, NY, United
States
(Ouzounian) Division of Cardiovascular Surgery, University of Toronto,
Toronto, ON, Canada
(Hopkins) Division of Cardiology, University of Vermont Medical Center,
Burlington, VT, United States
(Yeh) Division of Cardiology, Massachusetts General Hospital, Boston, MA,
United States
Publisher
American Heart Association Inc.
Abstract
Renewed interest in the Ross procedure, driven by compelling evidence of
superior long- term outcomes, has led to increased international use. This
review outlines a comprehensive framework for understanding the Ross
procedure within the broader context of aortic valve replacement. Topics
include procedural overview, patient selection and contraindications,
diagnostic imaging, technical modifications to promote durability,
clinical outcomes, postoperative management, and future directions. The
Ross procedure remains the only valve replacement strategy capable of
restoring life expectancy in selected young and middle- aged adults,
making it an imperative option for multidisciplinary
consideration. Copyright © 2025 The Author(s). Published on
behalf of the American Heart Association, Inc., by Wiley.

<98>
Accession Number
2043551605
Title
The Present and Future of Zone 0 Endovascular Arch Reconstruction.
Source
Journal of Cardiovascular Development and Disease. 13(2) (no pagination),
2026. Article Number: 93. Date of Publication: 01 Feb 2026.
Author
Guo M.H.; Doonan R.-J.; Rockley M.
Institution
(Guo) Division of Cardiac Surgery, University of Ottawa Heart Institute,
Ottawa, ON, Canada
(Doonan) Division of Vascular Surgery, McGill University, Montreal, QC,
Canada
(Rockley) Division of Vascular Surgery, University of Calgary, Calgary,
AB, Canada
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Thoracic aortic pathology involving the aortic arch is most commonly
treated with open total arch replacement. However, open surgery is still
associated with significant risk of mortality and morbidity, particularly
in the elderly, patients with high-risk comorbidities, and those with
previous cardiac surgery. Multiple endovascular approaches to enable zone
0 arch reconstruction have been developed, including custom-made,
physician-modified, and off-the-shelf fenestrated/branched endografts. The
initial experiences of this approach have been plagued by high incidence
of stroke; although improvements have been made over the past decade, it
remains suboptimal. Several factors contribute to this stagnation,
including limited descriptive studies with small sample sizes,
heterogeneous patient populations, varied techniques, and lack of data
granularity and standardization. These limitations reduce the ability to
analyze factors that could improve patient selection, device design, and
procedural techniques. In addition, consistent follow-ups have not been
reported, and the long-term outcome of these interventions are unknown. To
address these issues, a randomized controlled trial of open versus
endovascular arch repair or multicenter registry with standardized data
reporting, follow-up protocol, and sufficient sample size would be needed.
High-quality data will help identify patient clinical or anatomical
features as well as procedural factors that can improve
outcomes. Copyright © 2026 by the authors.

<99>
Accession Number
650369609
Title
Long-term outcomes of biventricular repair in double outlet right
ventricle: A network meta-analysis of multicenter studies.
Source
Congenital Heart Disease. Conference: The 5th Asian Associations for
Pediatric and Congenital Heart Surgery Annual Meeting. Bali Indonesia.
20(Supplement 1) (pp 29-30), 2025. Date of Publication: 2025.
Author
Arta G.J.; Yasa K.P.; Harta K.A.P.
Institution
(Arta) Medical Faculty of Udayana University, Bali, Denpasar, Indonesia
(Yasa, Harta) Ngoerah General Hospital, Bali, Denpasar, Indonesia
Publisher
Tech Science Press
Abstract
Objective: Management of Double Outlet Right Ventricle (DORV), a difficult
congenital cardiac anomaly, frequently necessitates biventricular repair
interventions to get good long-term results. Four frequently employed
surgical interventions for DORV include the Arterial Switch Operation
(ASO), Nikaidoh procedure, Rastelli procedure, and Revised Procedure
(REV). While clinical decisions rely on multiple criteria, such as
surgical proficiency and patient-specific attributes, assessing the
comparative efficacy of different treatments has proven difficult Method:
This study intends to perform a Network Meta-Analysis (NMA) to evaluate
the long-term outcomes of these four surgical procedures utilizing a
Bayesian hierarchical model. A comprehensive literature analysis was
performed to identify studies that compared a minimum of two out of the
four treatments for DORV and gave hazard ratios (HR) along with their 95%
confidence intervals (CIs) Result: The SUCRA scores indicated that ASO and
Nikaidoh achieved the highest ratings, between 85-90%, signifying a
greater likelihood of being the most effective interventions for DORV.
Conversely, Rastelli and REV therapies exhibited lower SUCRA ratings of
approximately 60-70%, indicating they were less probable to be the optimal
selection. The forest plot of the hazard ratios (HRs) revealed that
although most comparisons exhibited HRs near 1, the 95% confidence
intervals (CIs) for each research intersect with 1, indicating an absence
of a significant statistical difference between the treatments. This
discovery underscores the statistical ambiguity in the data.
 Conclusion(s): The NMA results show that ASO and Nikaidoh are the
most advantageous interventions for DORV, as evidenced by elevated SUCRA
scores; however, the absence of substantial differences between
treatments, demonstrated by overlapping confidence intervals, underscores
the statistical uncertainty inherent in the analysis. Additional extensive
investigations with more substantial data are required to validate these
conclusions. Clinical decision-making must consistently account for
patient-specific characteristics and surgical proficiency when determining
the most effective treatment.

<100>
Accession Number
650379134
Title
Interventions to promote patient utilisation of cardiac rehabilitation.
Source
The Cochrane database of systematic reviews. 2 (pp CD007131), 2026. Date
of Publication: 24 Feb 2026.
Author
Long L.; Lin C.Z.; Davies P.; Wells V.; Grace S.L.; Taylor R.S.
Institution
(Long, Wells) School of Health and Wellbeing, University of Glasgow,
Glasgow, United Kingdom
(Lin) School of Medicine, Dentistry & Nursing, University of Glasgow,
Glasgow, United Kingdom
(Davies) Population Health Sciences, Bristol Medical School, University of
Bristol, Bristol, United Kingdom
(Grace) School of Kinesiology and Health Science, York University,
Toronto, Canada
(Grace) Toronto Rehabilitation Institute, University Health Network,
Toronto, Canada
(Taylor) Robertson Centre for Biostatistics and General Practice & Primary
Care, School of Health and Wellbeing, University of Glasgow, Glasgow,
United Kingdom
Abstract
RATIONALE: Clinical practice guidelines routinely recommend that cardiac
patients participate in rehabilitation programmes as part of comprehensive
secondary prevention of heart disease. However, only a small proportion of
these patients utilise rehabilitation across global health systems. This
is an update of a Cochrane review last published in 2019.
 OBJECTIVE(S): Primary objective To assess the effects of
interventions provided to increase patient enrolment in, adherence to, and
completion of cardiac rehabilitation (CR) for people with myocardial
infarction (MI), with angina, following coronary artery bypass graft
(CABG) surgery or percutaneous coronary intervention (PCI), or with heart
failure (HF) who were eligible for CR in an inpatient or outpatient
setting. Secondary objectives To assess intervention costs and associated
harms with interventions intended to promote CR utilisation. SEARCH
METHOD(S): We searched the Cochrane Central Register of Controlled Trials
(CENTRAL) in the Cochrane Library (Wiley), MEDLINE (Ovid), Embase (OVID),
CINAHL Cumulative Index to Nursing and Allied Health Literature (EBSCO),
and Conference Proceedings Citation Index - Science (CPCI-S) via Web of
Science (Clarivate Analytics). We checked the reference lists of relevant
systematic reviews for additional studies and searched two clinical trial
registers. We did not apply any language restrictions. The date of search
was 02 March 2025. ELIGIBILITY CRITERIA: We included randomised controlled
trials (RCTs) and quasi-RCTs in adults with MI, with angina, undergoing
CABG surgery or PCI, or with HF who were eligible for CR in an inpatient
or outpatient setting. Interventions had to aim to increase patient
utilisation of CR, and we included any study that aimed to increase
patient enrolment in, adherence to, or completion of CR. OUTCOME(S):
Critical outcome measures were CR programme enrolment, CR programme
adherence, and CR programme completion. Important outcome measures
included serious adverse events (SAEs) and costs. RISK OF BIAS: We used
the Cochrane RoB 1 tool to assess the risk of bias in eligible trials.
SYNTHESIS METHODS: One review author extracted trial data into piloted
data extraction forms, which were checked by a second review author. We
pooled outcome data across included studies using random-effects
meta-analysis, and used meta-regression to explore the potential impact of
prespecified intervention characteristics on intervention effects.
INCLUDED STUDIES: We included 47 studies (58 comparisons) with 10,803
participants. Trials were conducted over a range of geographical settings,
principally North America and Europe or other high-income economies. No
studies from low- and middle-income country settings were included.
Participants in most of the included studies were primarily male. The
median percentage of females across studies was 40% (range 0% to 100%).
Sixteen studies included patients with HF. We assessed most studies as
having low or unclear risk of bias. Studies tested a variety of strategies
to increase utilisation of CR. The most common intervention strategies
tested were: education/self-management training/motivational interviewing
(nine trials); switch from traditional centre-based CR to alternative
models of delivery - home/digital/hybrid (eight trials); letters/messaging
invites (seven trials); peer support strategies (five trials); women-only
programmes (two studies); and use of financial incentives (two studies).
SYNTHESIS OF RESULTS: Interventions to promote patient utilisation of CR
may increase programme enrolment (risk ratio (RR) 1.19, 95% confidence
interval (CI) 1.11 to 1.29; 27 trials (31 comparisons), 7216 participants;
low-certainty evidence). Meta-regression showed no evidence of significant
differences in prespecific trial-level covariates, except for the
intervention target where there was weak evidence of somewhat higher
impact of interventions in trials where the intervention target was the
patient. Interventions to promote patient utilisation of CR likely
increase programme adherence (standardised mean difference (SMD) 0.32, 95%
CI 0.15 to 0.49; 18 trials (21 comparisons), 3024 participants;
moderate-certainty evidence). Meta-regression showed no evidence of
significant differences in prespecific trial-level covariates and the
impact of interventions. Interventions to promote patient utilisation of
CR likely increase programme completion (RR 1.22, 95% CI 1.10 to 1.35; 19
trials (23 comparisons), 5432 participants; moderate-certainty evidence).
Meta-regression showed no evidence of significant differences in
prespecific trial-level covariates and the impact of interventions. There
was strong evidence of small study bias for enrolment, and weak evidence
of small study bias for completion. There was no evidence of small study
bias for adherence. There was likely no increase in the incidence of SAEs
with interventions to promote utilisation of CR (RR 0.82, 95% CI 0.44 to
1.51; 6 trials (6 comparisons), 716 participants; moderate-certainty
evidence). Little information (four trials) was available on the costs or
cost-effectiveness of interventions to promote utilisation of CR. AUTHORS'
 CONCLUSION(S): This updated Cochrane review shows that a range of
interventions may increase utilisation of CR in terms of CR enrolment, and
likely increase CR adherence and completion. The certainty of the evidence
was low to moderate due to high statistical heterogeneity across trials,
which was likely due to the range of included interventions and the
differences in outcome collection and reporting. FUNDING: This Cochrane
review was funded by the National Institute for Health Research (NIHR)
under its Research and Innovation for Global Health Transformation (RIGHT)
Programme (Grant reference: NIHR205540). LL, RST, and VW undertook this
research as University of Glasgow-funded staff. REGISTRATION: Protocol
(2008): DOI 10.1002/14651858.CD007131/full Original review (2010): DOI
10.1002/14651858.CD007131.pub2 Review updates (2014): DOI
10.1002/14651858.CD007131.pub3; (2019): DOI
10.1002/14651858.CD007131.pub4. Copyright © 2026 The Cochrane
Collaboration. Published by John Wiley & Sons, Ltd.

<101>
Accession Number
2043421353
Title
Effect of levosimendan treatment in cardiac surgery: a network
meta-analysis of randomized controlled trials.
Source
Frontiers in Cardiovascular Medicine. 12 (no pagination), 2026. Article
Number: 1673410. Date of Publication: 2026.
Author
Zhu B.; Zhao W.; Li Y.
Institution
(Zhu, Zhao, Li) Department of Pediatrics, West China Second University
Hospital, Sichuan University, Sichuan, Chengdu, China
Publisher
Frontiers Media SA
Abstract
Background: The prophylactic administration of levosimendan in patients
undergoing cardiac surgery remains clinically contentious, particularly
regarding its efficacy and safety in improving key postoperative outcomes,
such as cardiac function, renal protection, and mortality in high-risk
surgical populations. Existing randomized controlled trials (RCTs) are
heterogeneous in sample size, timing, and dosing of levosimendan and
comparator inotropes and have yielded neutral or conflicting results for
these endpoints. Moreover, prior meta-analyses have predominantly used
pairwise comparisons and have not systematically compared levosimendan
with all major inotropic alternatives (e.g., dobutamine, milrinone, and
standard therapy) across multiple clinically relevant outcomes. As a
result, the relative benefits and harms of levosimendan vs. other
perioperative inotropic strategies in cardiac surgery remain unclear. To
evaluate the potential benefits and risks of perioperative levosimendan
therapy, we conducted a systematic network meta-analysis of available
evidence. Method(s): A comprehensive literature search was conducted
in PubMed, Embase, the Cochrane Library, and other databases for RCTs
evaluating perioperative levosimendan vs. placebo or alternative inotropic
therapies, published up to 31 December 2024. Primary outcomes included
cardiac index, central venous pressure (CVP), mean arterial pressure
(MAP), intensive care unit (ICU) length of stay, and creatinine levels.
The frequentist surface under the cumulative ranking curve (SUCRA) was
calculated for each outcome to rank competing interventions.
 Result(s): A total of 29 RCTs encompassing 4,509 patients were
included. Levosimendan was associated with higher postoperative CI
[standardized mean difference (SMD) 1.16, 95% CI 0.04-2.29] compared with
placebo and lower postoperative MAP (SMD -0.93, 95% CI -1.62 to -0.23)
compared with dobutamine. Milrinone had lower CVP compared with dobutamine
(SMD -0.66, 95% CI -1.22 to -0.10) and placebo (SMD -0.46, 95% CI -0.83 to
-0.09), and levosimendan (SMD 0.40, 95% CI 0.05-0.75) had higher CVP
compared with milrinone. Both levosimendan (SMD -0.68, 95% CI -1.13 to
-0.24) and milrinone (SMD -0.71, 95% CI -1.25 to -0.17) significantly
shortened ICU stays compared with dobutamine. No significant differences
in creatinine levels were identified across interventions in the network
meta-analysis. Conclusion(s): Levosimendan improved postoperative
hemodynamic parameters, showing a higher cardiac index than placebo and
shorter ICU stays than dobutamine, but it did not provide significant
renal protection as assessed by creatinine levels. Systematic Review
Registration: https://www.crd.york.ac.uk/PROSPERO/recorddashboard,
identifier CRD42024612151. Copyright 2026 Zhu, Zhao and Li.

<102>
Accession Number
650372673
Title
Investigations into the clinical significance of treatmentemergent
antibodies to amustaline/glutathione pathogen-reduced red blood cells.
Source
Vox Sanguinis. Conference: 35th Regional Congress of the ISBT. Milan
Italy. 120(Supplement 1) (pp 374-375), 2025. Date of Publication: 01 May
2025.
Author
Karim C.; Erickson A.; Corash L.; Mufti N.; Benjamin R.
Institution
(Karim, Erickson, Corash, Mufti, Benjamin) Cerus Corporation, Concord, CA,
United States
Publisher
John Wiley and Sons Inc
Abstract
Background: Subjects exposed to Amustaline/Glutathione Pathogen- Reduced
Red Blood Cells (PR-RBCs) in the ReCePI Phase III randomized, controlled
clinical trial developed treatment-emergent antibodies specific for
PR-RBCs. Aim(s): We investigated the clinical significance of the
antibodies. Method(s): ReCePI study subjects received Test or Control
study RBCs during and for 7 days after complex cardiac or thoracic aorta
surgery and were screened using an indirect antiglobulin test (IAT) for
PR-RBCspecific antibodies at baseline, whenever a routine IAT test was
performed, and at 28-and 75-days post-surgery. Subjects with positive
antibody screens were followed at 2-week intervals and investigated for
clinical evidence of hemolysis. Serological confirmation was performed at
Versiti Blood Center (Milwaukee, WI) and monocyte monolayer assays (MMA)
at American Red Cross (Pomona, CA). Circulating PR-RBCs were characterized
by flow cytometry for surface-bound immunoglobulin and for acridine, a
residual component of amustaline treatment, using a specific mouse
monoclonal antibody (2S197-2M1). Antigen density was determined using a
commercial calibrated Phycoeryththrin (PE) bead panel (QuantiBrite PE, BD
Biosciences CA). Result(s): Five of 159 Test (3.1%,) and 0 of 162
Control subjects (P = 0.015) developed IgG PR-RBC specific antibodies,
first detected on Days 26-80 after surgery after receipt of 1 to 3 study
RBC units. Antibody titers were low (titer <=8) and decreased over time. A
MMA for clinically relevant antibodies was either non-reactive (3/5
subjects) or indeterminate (2/5 subjects) and the DAT was negative in 4 of
5 subjects. One subject (011-011) had a weak positive DAT (IgG +, C3-)
with an eluate specific for PR-RBCs. Three of the four antibodies tested
were inhibited by free acridine (S-300, a breakdown component of
amustaline) and one was not inhibited, suggesting two epitope
specificities. No clinical or laboratory evidence of hemolysis was
observed. Flow cytometry of frozen patient blood samples revealed
circulating acridine-positive PR-RBCs in all cases at levels consistent
with the expected post transfusion proportions (Table) considering RBC
dose, hemorrhagic loss, RBC survival and dilution by hematopoietic
recovery after surgery. RBC surface human IgG was detected at low levels
in 3 of 5 cases. RBC acridine surface density on transfused PR-RBCs in
vivo was substantially lower (200-300 acridine/ cell) than on PR-RBCs
before transfusion (7,500 acridine/cell) and decreased over time,
suggesting in vivo acridine loss from the RBC surface. (Table present)
Summary/Conclusions: PR-RBC-specific antibodies occurred in 3.1% of Test
subjects. Circulating PR-RBCs were detected by flow cytometry in all cases
with a progressive loss of RBC surface acridine expression. Antibodies
were IgG isotype and low titer. There was no clinical evidence of
hemolysis or any in vitro properties indicative of clinical significance.

<103>
Accession Number
650371862
Title
Reduced hemoglobin use with amustaline/ glutathione pathogen-reduced red
cells in complex cardiac surgery: Results of a randomized, controlled
phase III trial.
Source
Vox Sanguinis. Conference: 35th Regional Congress of the ISBT. Milan
Italy. 120(Supplement 1) (pp 41), 2025. Date of Publication: 01 May 2025.
Author
Benjamin R.J.; Corash L.; Liu K.; Mufti N.
Institution
(Benjamin, Liu, Mufti) Cerus Corporation, Concord, CA, United States
(Corash) University of California, San Francsico, United States
Publisher
John Wiley and Sons Inc
Abstract
Background: The Red Cell Pathogen Inactivation (ReCePI) trial was a Phase
III, double-blinded, randomized non-inferiority study comparing
amustaline/glutathione pathogen-reduced (PR) and conventional red blood
cells (RBCs) for the support of acute anemia in complex cardiac surgery.
 Aim(s): Blood utilization was compared between the study arms.
 Method(s): Complex cardiac or thoracic-aorta surgery patients were
randomized to receive conventional (Control) or PR RBCs (Test) during and
for 7 days after surgery. Patient hemoglobin (Hb) levels were assessed at
baseline, daily for 7 days and at 28 days after surgery. Surgical and
post-operative blood loss were estimated from medical records. The primary
endpoint was the incidence of acute kidney injury (AKI) measured as change
in serum creatinine from baseline within 48 h of surgery, a strong
predictor of adverse postoperative outcomes. Blood utilization (number of
components and total red cell Hb transfused [measured as volume x Hb
concentration of each RBC]) was prospectively assessed as one indicator of
efficacy. Result(s): Five-hundred and eighty-one subjects were
randomized in 18 US hospitals and 321 (55%) (159 Test and 162 Control) RBC
transfused recipients constituted the modified intent-to-treat (mITT)
population. Test and Control subjects had similar medical histories and
baseline characteristics, underwent similar types of surgery with similar
median [IQR] total blood loss (Test 1500 [940-2475] mL, Control 1733
[1060- 2880] mL, p = 0.310) over seven days and had comparable hemoglobin
levels at baseline, immediately post-surgery (median (IQR] 9.8 [8.9- 10.9]
g/dL Test, 9.6 [8.6-10.6] g/dL Control, p = 0.157) and for 28 days after
surgery. PR RBC units contained 5% less mean total Hb (median [IQ] Test
58.0 (53.0-62.0) g Hb vs. Control 61.0 (57.0-66.0) g Hb, p < 0.001). Test
RBC were slightly older at the time of transfusion (median [IQR] Test 23.8
(16.9-29.4) days vs. Control 21.8 (15.0-28.3) days, p < 0.001). The PR RBC
arm was transfused with 10% less total red cell Hb, measured as total
study plus non-study Hb transfused over 7-days (median [IQR] Test 169.0
[102.0-240.0] g Hb vs. Control 188.0 [126.0-295.0] g Hb, p = 0.008). Both
groups received a median of three (3) RBC components. However, 48/162
(29.6%) Control and 32/ 159 Test (20.1%) subjects required 5 or more RBC
units within 7 days (p = 0.05), and more Control subjects required
non-study RBC transfusions after exceeding the available supply of study
RBCs [Test 35/159 (22.0%) subjects vs. Control 45/162 (27.8%) subjects].
Plasma utilization was significantly less in the Test group (median [IQR]
Test 2 (1-3) units vs. Control 2 (2-4) units, p = 0.021) while platelet
and cryoprecipitate use were not different. The incidence of AKI was 29.3%
(46/157) for Test and 28.0% (45/161) for Control subjects in the modified
intention- to treat group. Non-inferiority for the incidence of AKI was
achieved in both the mITT (p < 0.001) and the per protocol analyses (p =
0.03). Adverse events, serious adverse events and deaths on study were not
different. Summary/Conclusions: PR RBCs and conventional RBCs demonstrated
equivalent support for acute bleeding patients undergoing cardiac or
thoracic-aorta surgery while using fewer plasma units and 10% less
transfused total red cell Hb. The incidence of AKI, the primary efficacy
endpoint, in patients transfused with PR RBCs was noninferior to that
observed with conventional RBCs.

<104>
Accession Number
2043602571
Title
Echocardiographic Results of Transcatheter Versus Surgical Aortic Valve
Replacement in Women With Severe Aortic Stenosis: The RHEIA Trial.
Source
Journal of the American Heart Association. 15(1) (no pagination), 2025.
Article Number: e047196. Date of Publication: 30 Dec 2025.
Author
Silva I.; Alperi A.; Hecht S.; Zanuttini A.; Theron A.; Giuliani C.;
Camacho B.; Dahou A.; Mares J.; Bax J.; Bonaros N.; Windecker S.;
Messika-Zeitoun D.; Wesselink W.; Rakova R.; Bramlage P.; Tchetche D.;
Eltchaninoff H.; Pibarot P.
Institution
(Silva, Alperi, Rakova) Department of Cardiology, Hospital Universitario
Central de Asturias, Instituto de Investigacion Sanitaria del Principado
de Asturias, Oviedo, Spain
(Silva, Alperi, Hecht, Zanuttini, Theron, Giuliani, Rakova, Pibarot)
Quebec Heart & Lung Institute, Laval University, Quebec City, QC, Canada
(Theron) Department of Cardiology, Assistance Publique, Hopitaux de
Marseille, Marseille, France
(Camacho) Interventional Cardiology, Hospital Arnau de Vilanova, Lerida,
Spain
(Dahou) Division of Cardiovascular Imaging, St. Francis Hospital and Heart
Center, Catholic Health, New York, NY, United States
(Dahou) Division of Cardiology, Massachusetts General Hospital/Harvard
Medical School, Boston, MA, United States
(Mares) Department of Data Science, Institute for Clinical and
Experimental Medicine, Prague, Czechia
(Bax) Department of Cardiology, Leiden University Medical Center, Leiden,
Netherlands
(Bonaros) Department of Cardiac Surgery, Medical University of Innsbruck,
Innsbruck, Austria
(Windecker) Department of Cardiology, Inselspital University Hospital of
Bern, University of Bern, Bern, Switzerland
(Messika-Zeitoun) Division of Cardiology, University of Ottawa Heart
Institute, Ottawa, ON, Canada
(Wesselink) Edwards Lifesciences Prague, Prague, Czechia
(Bramlage) Institute for Pharmacology and Preventive Medicine Cloppenburg,
Cloppenburg, Germany
(Tchetche) Clinique Pasteur, Toulouse, France
(Eltchaninoff) Department of Cardiology, Univ Rouen Normandie, INSERM
U1096, CHU Rouen, Rouen, France
Publisher
American Heart Association Inc.
Abstract
BACKGROUND: In the RHEIA (Randomized Research in Women All Comers With
Aortic Stenosis) trial, the incidence of the primary end point of death,
stroke, or rehospitalization at 1 year was lower with transcatheter aortic
valve implantation (TAVI) than with surgical aortic valve replacement. The
objective of this substudy was to compare echocardiographic findings in
women with severe aortic stenosis following surgical aortic valve
replacement or TAVI. METHOD(S): At 48 European centers, 443 women
underwent randomization 1:1, and 420 were treated as randomized.
Echocardiograms were available in 356 patients and were analyzed by a core
laboratory. RESULT(S): Rates of or greater moderate paravalvular
regurgitation was low (<1%) and similar between groups. At 30 days, TAVI
was associated with higher mean transprosthetic gradient and smaller
aortic valve area, but the rate of severe patient-prosthesis mismatch (3.0
versus 2.6%; P=1) was low and not different between groups. Valve
hemodynamics were stable at 1 year. The rate of residual left ventricular
hypertrophy (45.3 versus 28.6%; P=0.004) at 1 year was significantly
higher with TAVI, whereas the rate of right ventricular systolic
dysfunction (14.5 versus 40.7%; P<0.001) and evolution of cardiac damage
stage (improved in 21.8 versus 18.1%; worsened in 16.8 versus 47.0%;
P=0.001) were better with TAVI. CONCLUSION(S): Among women with
severe aortic stenosis, both TAVI and surgical aortic valve replacement
achieve excellent valve hemodynamic results with low and similar rates of
moderate or greater paravalvular regurgitation or severe
patient-prosthesis mismatch. Surgical aortic valve replacement was
associated with lower gradients and more pronounced regression of left ven
tricular hypertrophy, whereas TAVI was associated with better right
ventricular systolic function and evolution of cardiac damage
stage. Copyright © 2025 The Author(s). Published on behalf of the
American Heart Association, Inc., by Wiley.

<105>
Accession Number
2043554402
Title
Effect of Reversal Agents on Postoperative Cognitive Disorders Following
General Anesthesia in the Elderly Population: A Systematic Review and
Meta-Analysis.
Source
Diagnostics. 16(4) (no pagination), 2026. Article Number: 535. Date of
Publication: 01 Feb 2026.
Author
Chan J.Y.; Singh B.S.S.; Nachiappan R.; Mohd Faizal N.F.J.; Song Z.X.;
Mohd F.H.; Abdullah F.H.; Izaham A.
Institution
(Chan, Singh, Nachiappan, Mohd Faizal, Song, Mohd, Abdullah, Izaham)
Department of Anaesthesiology and Intensive Care, Faculty of Medicine,
Universiti Kebangsaan Malaysia, Jalan Yaacob Latif, Bandar Tun Razak,
Cheras, Kuala Lumpur, Malaysia
(Abdullah, Izaham) Department of Anaesthesiology and Intensive Care,
Hospital Canselor Tuanku Muhriz, Jalan Yaacob Latif, Bandar Tun Razak,
Cheras, Kuala Lumpur, Malaysia
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Background/Objectives: Perioperative neurocognitive disorders (PND),
including postoperative delirium and cognitive dysfunction (POCD),
represent significant complications in elderly surgical patients
undergoing general anesthesia. The choice of neuromuscular blockade
reversal agent may influence POCD risk through different mechanisms and
side effects. This systematic review and meta-analysis evaluated the
comparative effect of neostigmine versus sugammadex on POCD incidence in
elderly patients. Method(s): A systematic search of PubMed, Web of
Science, Scopus, and Google Scholar was conducted from database inception
to September 2025, following PRISMA 2020 guidelines with PROSPERO
registration (CRD420251058187). Randomized controlled trials involving
elderly patients (>=60 years) undergoing general anesthesia with
neuromuscular blockade were included, comparing neostigmine and sugammadex
for reversal. Primary outcomes included POCD incidence, assessed using
validated cognitive tools, including the Mini-Mental State Examination and
Montreal Cognitive Assessment. Meta-analysis was performed using Review
Manager 5.4.1, with results expressed as odds ratios (ORs) and 95%
confidence intervals (CIs). Result(s): Six randomized controlled
trials involving 795 elderly patients published between 2017 and 2024 met
the inclusion criteria. Studies encompassed non-cardiac surgery,
robotic-assisted radical cystectomy, and pars plana vitrectomy. Pooled
meta-analysis showed neostigmine was associated with a higher risk of POCD
than sugammadex (OR 1.74, 95% CI 1.00-3.02, p = 0.05), with low
heterogeneity (I2 = 39%). Secondary outcomes, including
prevention of POCD, management strategies, and related complications, were
inconsistently reported and unavailable across all six RCTs. Subgroup
analysis stratified by neostigmine dosage demonstrated that administration
of a higher dose (>=0.04 mg/kg) was associated with reduced POCD incidence
compared to a lower dose (<0.04 mg/kg) (OR 0.31, 95% CI 0.15-0.63, p =
0.001), with negligible heterogeneity (I2 = 0%).
 Conclusion(s): This meta-analysis suggests that sugammadex may be
associated with reduced early postoperative neurocognitive disorders
compared to neostigmine in elderly patients, likely through rapid
neuromuscular blockade reversal that minimizes residual paralysis and
respiratory complications. Copyright © 2026 by the authors.

<106>
Accession Number
2043457224
Title
Simulation in robotic-assisted thoracic surgery: a systematic review.
Source
Journal of Robotic Surgery. 20(1) (no pagination), 2026. Article Number:
296. Date of Publication: 01 Dec 2026.
Author
Walji H.D.; de Rosenzweig P.G.-D.S.; Jesani H.; Martin-Ucar A.;
Hernandez-Arenas L.
Institution
(Walji, de Rosenzweig, Jesani, Martin-Ucar, Hernandez-Arenas) Department
of Cardio-Thoracic Surgery, University Hospitals Coventry and
Warwickshire, Clifford Bridge Road, Coventry, United Kingdom
Publisher
Springer Nature
Abstract
Method: A literature search was conducted across three databases using
terms: robot* AND simulat* AND thora* OR chest* from January 2010 to
December 2025. Themes regarding development of a robotic surgical program
were identified. The papers were critically appraised and scored using the
MMERSQI tool. Result(s): Out of 455 articles, 24 full-text articles
were reviewed, and ten included in the final review. Three themes emerged:
competency assessment, skills development, and MDT education. Studies
indicated minimally invasive surgery skills can predict robotic skill
acquisition. There is conflicting evidence on whether simulation sets a
benchmark for competency or enhances surgical skills. Translation of
improvements from simulation to clinical practice remains unclear.
Simulation was also highlighted as a method to ensure team members develop
together and offer organisations learning opportunities.
 Conclusion(s): Recommendations on incorporating simulation into a
RATS program include: prioritize surgeons experienced in minimally
invasive techniques for early introduction to RATS via simulation; avoid
using simulation benchmarking as the sole marker of competence; use
virtual simulation-based learning for familiarity with robotic systems but
do not accept it as surgical experience for certification; and emphasize
MDT simulation for improved teamwork and organizational
learning. Copyright © The Author(s), under exclusive licence to
Springer-Verlag London Ltd., part of Springer Nature 2026.

<107>
Accession Number
2043577450
Title
Clinical Impact of Diabetes Mellitus After Intravascular Imaging-Guided
PCI vs Coronary Artery Bypass Grafting.
Source
JACC: Cardiovascular Interventions. 19(5) (pp 555-567), 2026. Date of
Publication: 09 Mar 2026.
Author
Gim D.H.; Cho Y.H.; Sung K.; Kim W.S.; Lee S.-J.; Kwon W.; Lee J.-Y.; Lee
S.H.; Shin D.; Lee S.Y.; Kim S.M.; Yun K.H.; Cho J.Y.; Kim C.J.; Ahn
H.-S.; Nam C.-W.; Yoon H.-J.; Park Y.H.; Lee W.S.; Choi K.H.; Park T.K.;
Yang J.H.; Choi S.-H.; Gwon H.-C.; Song Y.B.; Hahn J.-Y.; Jeong D.S.; Lee
J.M.
Institution
(Gim, Lee, Choi, Park, Yang, Choi, Gwon, Song, Hahn, Lee) Division of
Cardiology, Department of Medicine, Heart Vascular Stroke Institute,
Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul,
South Korea
(Cho, Sung, Kim, Jeong) Department of Thoracic and Cardiovascular Surgery,
Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan
University School of Medicine, Seoul, South Korea
(Lee, Kwon, Lee) Kangbuk Samsung Hospital, Sungkyunkwan University School
of Medicine, Seoul, South Korea
(Lee) Department of Internal Medicine and Cardiovascular Center, Chonnam
National University Hospital, Gwangju, South Korea
(Shin) Department of Cardiology, St. Francis Hospital and Heart Center,
Roslyn, NY, United States
(Lee, Kim) Chungbuk National University Hospital, Chungbuk National
University College of Medicine, Cheongju, South Korea
(Lee) Chung-Ang University College of Medicine, Chung-Ang University
Gwangmyeong Hospital, Gwangmyeong, South Korea
(Yun, Cho) Wonkwang University Hospital, Iksan, South Korea
(Kim, Ahn) The Catholic University of Korea, Uijeongbu St. Mary's
Hospital, Seoul, South Korea
(Nam, Yoon) Keimyung University Dongsan Hospital, Daegu, South Korea
(Park) Samsung Changwon Hospital, Sungkyunkwan University School of
Medicine, Changwon, South Korea
(Lee) Chung-Ang University College of Medicine, Chung-Ang University
Hospital, Seoul, South Korea
Publisher
Elsevier Inc.
Abstract
Background Coronary artery bypass grafting (CABG) is the standard
revascularization method for patients with diabetes mellitus (DM) and
complex coronary artery disease. However, with significant advances in
percutaneous coronary intervention (PCI), particularly the use of
intravascular imaging (IVI), it is uncertain whether contemporary
IVI-guided PCI can achieve clinical outcomes comparable with those of
CABG. Objectives The aim of this study was to compare the clinical
outcomes of IVI-guided PCI, angiography-guided PCI, and CABG in DM
patients with left main or 3-vessel disease. Methods A total of 3,402 DM
patients with left main or 3-vessel disease were included from individual
patient-level data of the RENOVATE-COMPLEX-PCI (Randomized Controlled
Trial of Intravascular Imaging Guidance Versus Angiography-Guidance on
Clinical Outcomes After Complex Percutaneous Coronary Intervention) trial
and the institutional registries of Samsung Medical Center (n = 6,962).
The primary outcome, which was a composite of all-cause death, nonfatal
myocardial infarction, or stroke at 3 years was compared among IVI-guided
PCI, angiography-guided PCI, and CABG. Results In the DM population, the
cumulative incidence of the primary outcome at 3 years was 20.1% for
angiography-guided PCI, 11.4% for IVI-guided PCI, and 12.4% for CABG. PCI
was associated with a significantly higher risk for primary outcome (17.0%
vs 12.4%; HR: 1.91; 95% CI: 1.50-2.44; P < 0.001). However, the risk for
the primary outcome was comparable between the IVI-guided PCI and CABG
groups (11.4% vs 12.4%; HR: 0.88; 95% CI: 0.58-1.32; P = 0.525). A
propensity score-matched analysis yielded similar results (HR: 0.85; 95%
CI: 0.53-1.36; P = 0.507). Conclusions In this hypothesis-generating
study, PCI was associated with significantly higher risk for all-cause
death, nonfatal myocardial infarction, or stroke at 3 years than CABG in
DM patients with left main or 3-vessel disease. However, IVI-guided PCI
had comparable risk for clinical events compared with CABG in DM patients.
Further randomized controlled trial is needed to confirm this finding.
(Randomized Controlled Trial of Intravascular Imaging Guidance Versus
Angiography-Guidance on Clinical Outcomes After Complex Percutaneous
Coronary Intervention [RENOVATE-COMPLEX-PCI], NCT03381872 ; institutional
cardiovascular catheterization database of Samsung Medical Center
[Long-Term Outcomes and Prognostic Factors in Patient Undergoing CABG or
PCI], NCT03870815 ; institutional CABG database of Samsung Medical Center,
NCT03870815 ) Copyright © 2026 American College of Cardiology
Foundation.

<108>
Accession Number
2043574070
Title
Efficacy of SGLT2 Inhibitors on Clinical Outcomes After Transcatheter
Aortic Valve Replacement: A Systematic Review and Meta-Analysis.
Source
Endocrinology, Diabetes and Metabolism. 9(2) (no pagination), 2026.
Article Number: e70184. Date of Publication: 01 Mar 2026.
Author
Daniyal S.M.; Khatoon N.M.; Rasool A.; Gul I.; Tabish S.; Asifa S.; Khalid
A.; Aftab Z.; Burhan M.; Fahim S.L.; Gondal H.T.; Nadir M.A.; Ahmed S.Z.;
Ashraf D.A.; Ahmed S.
Institution
(Daniyal, Khatoon, Rasool, Gul, Tabish, Asifa, Khalid, Aftab, Burhan,
Fahim, Gondal, Ahmed) Department of Medicine, Dow University of Health
Sciences, Karachi, Pakistan
(Nadir) Department of Medicine, Allama Iqbal Medical College, Lahore,
Pakistan
(Ashraf) Department of Medicine, TruGift Health LLC, Wilmington, DE,
United States
(Ahmed) Department of Medicine, Sir Salimullah Medical College, Dhaka,
Bangladesh
Publisher
John Wiley and Sons Inc
Abstract
Background: Sodium-glucose cotransporter 2 (SGLT2) inhibitors improve
cardiovascular (CV) outcomes in patients with heart failure (HF) and type
2 diabetes. Their effect in patients undergoing transcatheter aortic valve
replacement (TAVR) for severe aortic stenosis (AS), however, remains
unclear. This study evaluated whether SGLT2 inhibitors reduce all-cause
mortality and HF hospitalisations after TAVR. Method(s): A systematic
search of PubMed, ScienceDirect, Cochrane (CENTRAL), Scopus and Embase was
performed through April 2025 for studies comparing post-TAVR outcomes
between SGLT2 inhibitor users and non-users. Outcomes of interest included
a composite of all-cause mortality or heart failure (HF) hospitalisation,
along with the individual components of all-cause mortality and HF
hospitalisation. All outcomes were extracted at 1 year. Pooled hazard
ratios (HRs) with 95% confidence intervals (CIs) were calculated using a
random-effects model. Heterogeneity was quantified using I2
statistics. Analyses were conducted in R (version 4.4.2). Result(s):
Three studies (1 RCT, 2 Observational) comprising 3187 patients met
inclusion criteria. SGLT2 inhibitor use was associated with a reduced risk
of the composite outcome (HR: 0.75; 95% CI: 0.65, 0.86; p < 0.01).
Individually, therapy lowered all-cause mortality (HR: 0.72; 95% CI: 0.53,
0.96; p = 0.03) and HF hospitalisations (HR: 0.74; 95% CI: 0.61, 0.90; p <
0.01). Conclusion(s): In patients with severe AS undergoing TAVR,
SGLT2 inhibitors were associated with significant reductions in all-cause
mortality and HF hospitalisations. These findings suggest a promising role
for SGLT2 inhibitors in improving post-TAVR outcomes. However, given the
limited data, larger randomised clinical trials are necessary to
consolidate these findings. Trial Registration:
CRD420251132729. Copyright © 2026 The Author(s). Endocrinology,
Diabetes & Metabolism published by John Wiley & Sons Ltd.

<109>
Accession Number
2043486855
Title
A Single Preoperative Dose of Pregabalin and Chronic Postsurgical Pain
Following Elective Coronary Artery Bypass Graft Surgery: A Secondary
Analysis from a Randomized, Double-Blind, Placebo-Controlled Trial.
Source
Journal of Clinical Medicine. 15(4) (no pagination), 2026. Article Number:
1648. Date of Publication: 01 Feb 2026.
Author
Bouzia A.; Tassoudis K.; Tassoudis V.; Ntalouka M.P.; Michou A.; Bareka
M.; Arnaoutoglou E.
Institution
(Bouzia, Tassoudis, Tassoudis, Ntalouka, Michou, Bareka, Arnaoutoglou)
Department of Anesthesiology, Faculty of Medicine, School of Health
Sciences, University of Thessaly, University Hospital of Larissa, Larisa,
Greece
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Background/Objectives: Chronic persistent postoperative pain after cardiac
surgery, first described as Post CABG Pain Syndrome (PCPS), has been a
well-recognized problem since 1989. This study investigated the effect of
a single preoperatively administrated pregabalin dose on chronic
persistent postoperative pain, in terms of pain intensity, rescue
analgesia, and sleep disturbances, after elective cardiac surgery.
 Method(s): This is a secondary analysis of a prospective double-blind
single center study that took place in a tertiary/referral center
(NCT01701921). Consecutive adult patients who underwent elective cardiac
surgery with median sternotomy and extracorporeal circulation under
general anesthesia were included. Patients were randomly assigned into
three groups {placebo (group 1), oral pregabalin 75 mg (group 2), oral
pregabalin 150 mg (group 3)}. Placebo or either dose of pregabalin were
administered 1 h preoperatively. Postoperatively at 12 and 24 months, the
presence of persistent chronic pain (Numeric Rating Scale, NRS), the need
of daily intake of analgesics, and any potential sleep disturbances were
assessed. Result(s): In total, 93 out of 108 patients completed this
secondary analysis (86,1%). Patients from all three groups reported
persistent postoperative pain at 12 and 24 months, respectively. The mean
NRS scores at 12 months were 1.71 (0.588) group 1, 1.23 (0.560) group 2,
and 1.19 (0.402) group 3. At 24 months, the mean NRS scores were 1.19
(0.543) Group 1, 0.84 (0.454) Group 2, and 0.84 (0.374) Group 3. No
statistically important difference was detected between the two different
pregabalin groups. Regarding the use of analgesics, Pearson Chi-Square
showed p-values p = 0.027 in 12 months and p = 0.01 in 24 months and lower
scores were detected in the high pregabalin dose group. As far as the
sleep disturbances are concerned, there was no significant difference
between groups. The number of patients who reported persistent
postoperative pain at 12 and 24 months was significantly lower in the
pregabalin groups (75 mg and 150 mg) than in the placebo group. Regarding
the NRS score, Kruskal-Wallis showed a value of p = 0.001 and p = 0.005 in
12 and 24 months respectively. Regarding the use of analgesics, Pearson
Chi-Square showed p-values p = 0.027 in 12 months and p = 0.01 in 24
months. Referring to sleep disturbances, there was no significant
difference between groups. Conclusion(s): Based on the results of
this study, it seems that oral administration of a single preoperative
dose of pregabalin may exhibit a significant preventive effect on chronic
persistent postoperative pain after elective cardiac
surgery. Copyright © 2026 by the authors.

<110>
Accession Number
2043551338
Title
Preventing Postpericardiotomy Syndrome: Current Evidence and Future
Directions.
Source
Journal of Cardiovascular Development and Disease. 13(2) (no pagination),
2026. Article Number: 63. Date of Publication: 01 Feb 2026.
Author
Ballas C.E.; Theologou T.; Samara E.; Barkas F.; Bampali T.;
Kintzoglanakis K.; Diamantis C.; Tzimas P.; Katsouras C.S.; Alexiou C.
Institution
(Ballas, Theologou, Alexiou) Department of Cardiac Surgery, University
Hospital of Ioannina, Ioannina, Greece
(Samara, Tzimas) Department of Anesthesiology and Postoperative Intensive
Care, University Hospital of Ioannina, Ioannina, Greece
(Barkas) Faculty of Medicine, School of Health Sciences, University of
Ioannina, Ioannina, Greece
(Bampali) Cardiology Department, Hatzikosta General Hospital, Ioannina,
Greece
(Kintzoglanakis) Local Health-Team Unit of Thebes, Boeotia, Greece
(Diamantis) Department of Primary Care, General Hospital of Livadeia,
Livadeia, Greece
(Katsouras) First Department of Cardiology, University Hospital of
Ioannina, Ioannina, Greece
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Postpericardiotomy syndrome (PPS) is the most frequent inflammatory
after-effect of cardiac surgery and is characterized by high morbidity,
delayed hospitalization, and increased long-term mortality rates. Although
PPS is common, empirical anti-inflammatory therapy has historically been
employed for its prevention, and mechanism-based approaches have not yet
been standardized. In this literature review, which was conducted on the
basis of randomized controlled trials, meta-analyses, cohort studies, and
mechanistic research regarding pharmacologic interventions, surgical
modalities, and biomarker-based preventive strategies, the deficiencies of
a critical synthesis of existing preventive strategies and emerging risk
stratification instruments for PPS are addressed. The review affirms that
the most evidence-based pharmacologic intervention is colchicine, which
demonstrates a consistent reduction in PPS incidence across a range of
randomized trials. Nonsteroidal anti-inflammatory drugs show variable
responses, whereas corticosteroids are no longer recommended for routine
prophylaxis due to relapse. Specific anti-interleukin-1 therapies
represent a promising novel approach for high-risk patients. Surgical
interventions, such as pericardial closure using biomaterials and
posterior pericardiotomy, are important and do not lead to increased
hemodynamic complications, while postoperative effusions, atrial
fibrillation, and tamponade are reduced. Less invasive methods may also be
employed to mitigate inflammatory causes, particularly in valve-sparing
procedures and congenital operations. Emerging biomarker data, including
postoperative neutrophil-to-lymphocyte ratios, C-reactive protein levels,
and pericardial fluid cytokines, enable the identification of high-risk
patients and form the basis for a personalized prevention approach. In
summary, pharmacologic prophylaxis, innovative surgical techniques, and
biomarker-based risk stratification represent a pathway toward reducing
the incidence and burden of PPS in modern cardiac surgery. Copyright
© 2026 by the authors.

<111>
Accession Number
2043500778
Title
Off-Pump Coronary Artery Bypass Grafting: Technical Evolution, Current
Evidence, and Barriers to Universal Adoption.
Source
Journal of Vascular Diseases. 5(1) (no pagination), 2026. Article Number:
7. Date of Publication: 01 Feb 2026.
Author
Raja S.G.
Institution
(Raja) Department of Cardiac Surgery, Harefield Hospital, London, United
Kingdom
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Off-pump coronary artery bypass grafting (OPCAB) represents one of the
most significant technical innovations in contemporary cardiac surgery.
Developed as an alternative to conventional on-pump coronary artery bypass
grafting (ONCAB), OPCAB avoids cardiopulmonary bypass and its associated
systemic inflammatory response, aiming to reduce perioperative morbidity
and improve recovery. Over the past three decades, advances in
stabilization devices, intracoronary shunts, anesthetic management, and
surgical training have refined the procedure, making it safer and more
reproducible. Despite these developments, OPCAB adoption remains
inconsistent worldwide, reflecting ongoing debate about its relative
benefits and limitations. Evidence from randomized controlled trials,
meta-analyses, and large registries suggests that OPCAB achieves
comparable early mortality to ONCAB, with potential advantages in reducing
renal dysfunction, neurocognitive decline, and perioperative bleeding.
These benefits appear most pronounced in high-risk subgroups, including
elderly patients and those with significant comorbidities. However,
concerns persist regarding long-term graft patency, completeness of
revascularization, and variability in outcomes depending on surgeon
experience and institutional expertise. Cost-effectiveness analyses have
suggested potential resource savings, but these are offset by training
requirements and the technical complexity of the procedure. Global
practice variation highlights the influence of surgical culture, guideline
ambiguity, and institutional resources. Barriers to universal adoption
include technical challenges, inconsistent long-term outcomes, and limited
exposure in training programs. In the future, robotic and minimally
invasive OPCAB, as well as hybrid revascularization strategies, may expand
its role. This review synthesizes current evidence, explores barriers to
widespread implementation, and outlines future directions for integrating
OPCAB into balanced, evidence-based clinical practice. Copyright
© 2026 by the author.

<112>
Accession Number
650355717
Title
Right lateral decubitus as a strategy to improve left bronchial blocker
placement in thoracic operations: a randomized clinical trial.
Source
BMC anesthesiology. (no pagination), 2026. Date of Publication: 23 Feb
2026.
Author
Chen S.; Deng Z.; He Y.; Luo J.; Li Y.; Liu Q.; Wu H.; Huang B.; Wang H.;
Luo T.
Institution
(Chen, Deng, Luo, Li, Liu, Wu, Wang, Luo) Department of Anesthesiology,
Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China
(He, Wang, Luo) Key Laboratory of Anesthesia and Organ Protection of
Ministry of Education (In Cultivation), Zunyi Medical University, Zunyi,
Guizhou, China
(He) Department of Radiology, Third Hospital of Zunyi Medical University,
First People's Hospital of Zunyi), Zunyi, Guizhou, China
(Huang) Department of bioengineering, Imperial College London, London,
United Kingdom
Abstract
BACKGROUND: Left-sided bronchial blocker (BB) placement can sometimes be
challenging and time-consuming, often requiring multiple fiberoptic
bronchoscopic examinations. This study evaluated whether right lateral
decubitus positioning improves placement compared to the supine position.
 METHOD(S): In this prospective, single-center randomized controlled
trial, 90 adult patients scheduled for elective thoracic surgery with
right one-lung ventilation were randomized to receive BB placement in
either the right lateral decubitus or supine position. The primary outcome
was ease of placement, defined as first-attempt success or successful
placement under bronchoscopic guidance within 120 s. Secondary outcomes
included placement time, malposition rate, intraoperative hemodynamic and
blood gas changes, and postoperative recovery. Additionally, nine patients
had chest CT scans in both positions to assess tracheobronchial alignment.
 RESULT(S): Right lateral positioning significantly improved placement
compared to supine, with higher ease of placement (87% vs. 27%), greater
first-attempt success (29% vs. 11%), shorter median time to placement (97
s vs. 201 s), and lower malposition rate (11% vs. 29%). In the supine
group, all patients required bronchoscopic verification after lateral
repositioning, and 11.1% needed repositioning; no additional verification
was needed in the lateral group. CT analysis revealed that right lateral
positioning increased the left main bronchus angle (148.3degreevs
142.9degree), aligning the BB more directly with the opening of the left
main bronchus. CONCLUSION(S): Right lateral decubitus enhances left
BB placement by increasing first-attempt success, reducing procedural
time, and decreasing malposition. CT imaging confirms anatomical
realignment facilitating insertion. Copyright © 2026. The
Author(s).

<113>
Accession Number
650353661
Title
The 2025 European Society of Cardiology/European Association of
Cardiothoracic Surgery joint guidelines for the management of valvular
heart disease: Revolution or evolution?.
Source
Kardiologia polska. (no pagination), 2026. Date of Publication: 23 Feb
2026.
Author
Wojakowski W.; Tendera M.; Praz F.
Institution
(Wojakowski, Tendera) Division of Cardiology and Structural Heart
Diseases, Medical University of Silesia, Katowice, Poland
(Praz) Department of Cardiology, Bern University Hospital, Bern,
Switzerland
Abstract
The 2025 European Society of Cardiology (ESC)/European Society of
Cardiothoracic Surgery guidelines for the management of valvular heart
disease (VHD), presented at the ESC Congress in Madrid, update the 2021
document and respond to the rapid growth of evidence from randomized
trials, meta-analyses, and large registries. Developed by a
multidisciplinary Heart Team including patient representatives, the
guidelines emphasize patient-centered "lifetime" management, shared
decision-making, and treatment at high-volume expert Heart Valve Centers,
especially for complex surgical and transcatheter procedures. The scope
has been broadened to address cancer and radiation-associated VHD,
cardiogenic shock and acute heart failure, multiple and mixed VHD, and
sex-specific issues. Key changes in indications for imaging, treatment,
and follow-up of VHD are discussed in the perspective of evidence-based
medicine. Key updates include earlier intervention in severe,
high-gradient, asymptomatic aortic stenosis, refined age thresholds
favoring transfemoral transcatheter aortic valve implantation, and its use
in bicuspid aortic stenosis and aortic regurgitation in high-risk or
inoperable patients. Recommendations for secondary mitral regurgitation
(MR) distinguish atrial from ventricular mechanisms and upgrade mitral
transcatheter edge-to-edge repair to class I in selected cases of
ventricular secondary MR. At the same time, surgery remains first-line for
primary MR, with defined triggers for early repair and emerging roles for
transcatheter edge-to-edge repair and transcatheter mitral valve
implantation in high-risk patients. The document also strengthens guidance
on tricuspid interventions, structured assessment of right ventricular
dysfunction, and simplifies antithrombotic strategies, including
restricted use of dual antiplatelet therapy after transcatheter aortic
valve implantation in patients without another indication for oral
anticoagulation. Implementing these recommendations should streamline care
pathways and reduce the burden of VHD.

<114>
Accession Number
650334730
Title
Efficacy of intranasal insulin in reducing the incidence of postoperative
delirium: A systematic review and meta-analysis of randomised controlled
trials.
Source
Journal of perioperative practice. (pp 17504589261421004), 2026. Date of
Publication: 22 Feb 2026.
Author
Desai A.; Bisht R.; Carrion E.M.M.; Maheshwari V.; Misra S.; Joshi M.;
Bhardwaj A.
Institution
(Desai, Bisht, Maheshwari, Joshi) Department of General Surgery, Armed
Forces Medical College, Pune, India
(Carrion) Department of General Surgery, Universidad San Francisco de
Quito, Quito, Ecuador
(Misra) Department of General Surgery, University of Texas Southwestern
Medical Center, Dallas, TX, United States
(Bhardwaj) Department of Internal Medicine, University of Missouri, Kansas
City, MO, United States
Abstract
BACKGROUND: Postoperative delirium is a common and serious complication in
surgical patients, often leading to prolonged hospitalisation and
increased morbidity. Intranasal insulin has shown promising results in
preventing postoperative delirium and protecting cognitive function.
However, its use has not been standardised and is not part of treatment
protocols. We performed a systematic review and meta-analysis on the
effect of intranasal insulin in reducing postoperative delirium.
 METHOD(S): PubMed, EMBASE, Cochrane Central, and Web of Science
databases were searched from inception to October 2025 for randomised
controlled trials investigating intranasal insulin for postoperative
delirium prevention in patients undergoing surgery. Risk ratios with 95%
confidence intervals were computed using a random-effects model.
Heterogeneity was assessed with I2 statistics. We performed subgroup
analyses of orthopaedics, gastrointestinal, and cardiac surgeries.
 RESULT(S): A total of 1039 patients from nine randomised controlled
trials were included, of whom 574 (55.2%) received treatment with
intranasal insulin. The overall incidence of delirium was significantly
lower in patients treated with intranasal insulin (risk ratio = 0.36; 95%
confidence interval = 0.28-0.46; p < 0.001). Subgroup analyses also
demonstrated significant reductions in delirium following orthopaedic
surgeries (p < 0.001), gastrointestinal surgeries (p < 0.001), and cardiac
surgeries (p = 0.013). CONCLUSION(S): Perioperative intranasal
insulin significantly reduced the incidence of postoperative delirium in
patients undergoing surgery.

<115>
Accession Number
650355039
Title
Frailty and functional recovery after cardiac surgery: a randomized pilot
trial of extended exercise-based rehabilitation.
Source
BMC geriatrics. (no pagination), 2026. Date of Publication: 24 Feb 2026.
Author
Tamuleviciute-Prasciene E.; Balne K.; Kuznecova I.; Beigiene A.;
Stonkuviene V.; Kubilius R.
Institution
(Tamuleviciute-Prasciene, Beigiene, Stonkuviene, Kubilius) Department of
Rehabilitation, Lithuanian University of Health Sciences, Eiveniu Str. 2,
Kaunas, Lithuania
(Balne, Kuznecova) Department of Cardiology, Lithuanian University of
Health Sciences, Eiveniu Str.. 2, Kaunas, Lithuania

<116>
Accession Number
650350487
Title
Neuroprotective Role of Sonolysis in Cardiovascular Interventions. A
Systematic Review and Meta-analysis.
Source
CardioVascular and Interventional Radiology. Conference: British Society
of Interventional Radiology Annual Scientific Meeting, BSIR 2025.
Liverpool United Kingdom. 49(1 Supplement) (pp S74), 2026. Date of
Publication: 01 Jan 2026.
Author
Shehata M.; Hamdy A.; Elfakharany B.; Jibril N.; Elsharkawy M.;
El-Shirbiny H.; Kashbour M.; Amro S.; Mustafa Q.R.
Institution
(Shehata) Faculty of Medicine, Modern University for Technology and
Information, Cairo, Egypt
(Hamdy) Faculty of Medicine, Zagazig University, Sharkia, Egypt
(Elfakharany) Department of Radiation Therapy, Baheya Foundation for Early
Detection and Treatment of Breast Cancer, Giza, Egypt
(Jibril) Faculty of Medicine, Menofia University, Menofia, Egypt
(Elsharkawy) Alexandria Main University Hospitals, Alexandria, Egypt
(El-Shirbiny) Faculty of Medicine, Kafrelsheikh University Hospitals,
Kafrelsheikh, Egypt
(Kashbour) Depa8rtment of Diagnostic Radiology, National Cancer Institute,
Misrata, Libyan Arab Jamahiriya
(Amro) Department of Nuclear Medicine, University Hospitals Sussex Nhs
Foundation Trust, Brighton, United Kingdom
(Shehata, Hamdy, Elfakharany, Jibril, Elsharkawy, El-Shirbiny, Kashbour,
Amro, Mustafa) Medical Research Group of Egypt (MRGE), Negida Academy,
Arlington, United States
Publisher
Springer
Abstract
Purpose Sonolysis is a promising neuroprotective strategy to enhance
thrombolysis and reduce brain ischemic lesions after cardiovascular
interventions such as carotid endarterectomy (CEA), carotid artery
stenting (CAS) and cardiac surgery. This meta-analysis evaluates the
efficacy of adding sonolysis during these interventions for
neuroprotection. Methods A systematic search of PubMed, Scopus, Cochrane
Library and Web of Science was conducted up to April 2025 for studies
evaluating the use of sonolysis during cardiovascular interventions. Our
outcomes included postprocedural MRI-detected brain ischemic lesions,
incidence of transient ischemic attacks (TIAs)/strokes, intracranial
bleeding, mortality and cognitive outcomes. Results Five RCTs with 1607
participants were included. Sonolysis showed to significantly reduce the
risk of new brain ischemic lesions on MRI (RR 0.72, 95% CI: 0.58-0.88;p
=0.002) with a greater effect for lesions >0.5 mL (RR 0.31, 95% CI:
0.19-0.51; p< 0.00001).The TIA /stroke risk was lower (RR 0.27, 95%
CI: 0.14-0.49; p< 0.0001) with no significant increase in intracranial
bleeding (RR1.02, 95% CI: 0.14-7.31; p = 0.99). Subgroup analysis revealed
significant benefits of sonolysis in carotid interventions, particularly
CEA with reduced brain ischemic lesions (RR 0.46; 95% CI: 0.30-0.70; p=
0.0002) and TIA/stroke risk (RR 0.28; 95% CI: 0.15-0.53; p = 0.0001); no
significant effects were observed for cardiac interventions, MCA ischemia,
mortality or cognitive outcomes. Conclusion Sonolysis is effective as a
neuroprotective strategy in reducing brain ischemic risk during carotid
interventions, particularly in carotid endarterectomy. The lack of benefit
in cardiac interventions highlights the need for procedure-specific
evaluation of sonolysis.

<117>
Accession Number
2043091751
Title
Cognitive Outcomes in Randomized Controlled Trials of Coronary Artery
Bypass Graft Surgery From 2005 to 2025: A Systematic Review.
Source
Journal of the American Heart Association. 15(2) (no pagination), 2026.
Article Number: e041946. Date of Publication: 14 Jan 2026.
Author
Srivatsa S.; Sujanthan S.; Paleczny S.; Ripsman D.A.; de Rivera S.N.;
Dimagli A.; Taghdiri F.; Cheng P.-S.; Lou W.; Farkouh M.E.; Fremes S.E.;
Gaudino M.F.; Rabin J.; Razzouk L.; Owen A.M.; Creber R.M.; Swartz R.H.
Institution
(Srivatsa) Department of Medicine, University of North Carolina School of
Medicine, Chapel Hill, NC, United States
(Srivatsa, Rabin, Swartz) Department of Medicine (Neurology), Hurvitz
Brain Sciences Program, Sunnybrook HSC, Institute of Medical Sciences,
University of Toronto, Toronto, ON, Canada
(Paleczny) Department of Neuroscience, Schulich School of Medicine and
Dentistry, Western University, London, ON, Canada
(Ripsman) Department of Medicine (Neurology), University of British
Columbia, Vancouver, BC, Canada
(de Rivera, Creber) Columbia University School of Nursing, Columbia
University Irving Medical Center, New York, NY, United States
(Dimagli) Department of Surgery, Columbia University Irving Medical
Center, New York, NY, United States
(Taghdiri) Division of Neurology, Department of medicine, University of
Toronto, Toronto, ON, Canada
(Cheng) Biostatistics Division, Dalla Lana School of Public Health,
University of Toronto, Toronto, ON, Canada
(Lou) Dalla Lana School of Public Health, University of Toronto, Toronto,
ON, Canada
(Farkouh) Academic Affairs, Cedars-Sinai Health System, Los Angeles, CA,
United States
(Sujanthan, Fremes) Division of Cardiac Surgery, Schulich Heart Centre,
Sunnybrook HSC, Department of Surgery, Institute of Medical Sciences,
Institute of Health Policy Management and Evaluation, University of
Toronto, Toronto, ON, Canada
(Gaudino) Department of Cardio-thoracic Surgery, Cornell Medicine, New
York, NY, United States
(Rabin) Harquail Centre for Neuromodulation, Sunnybrook Research
Institute, Toronto, ON, Canada
(Razzouk) Department of Interventional Cardiology, Leon H. Charney
Division of Cardiology, New York University Grossman School of Medicine,
New York, NY, United States
(Owen) Department of Physiology and Pharmacology and Department of
Psychology, Western University, London, ON, Canada
Publisher
American Heart Association Inc.
Abstract
BACKGROUND: Cognitive decline after coronary artery bypass graft (CABG) is
common and affects morbidity, mortality, and quality of life. We
systematically reviewed randomized CABG trial control arms to characterize
cognitive assessments, testing frequency, attrition, and ability to detect
perioperative change. METHOD(S): We searched MEDLINE, Embase,
Cochrane Library, and PsycINFO for randomized controlled trials of CABG
surgery that included at least one arm of patients solely undergoing CABG
and that reported at least one objective cognitive assessment, from
January 2005 to February 2025. Trials with mixed cardiac surgery or only
subjective measures were excluded. We summarized task frequency, cognitive
domains, and attrition. For tasks assessed preoperatively and
postoperatively in >=3 trials, we reported control group means and SDs.
Risk of bias was assessed using the Cochrane Risk of Bias tool among 6
bias domains. This study was supported by NIH-R01NS123639. RESULT(S):
Of 3494 screened studies, 2284 were CABG trials, and only 71 (3.1%)
reported cognitive evaluation. These involved 15 925 patients (79% men;
mean age, 64.2 years; median follow-up, 90 days) and used 145 unique
cognitive tasks, with the Trail Making Test Part B (40 of 71; 56.3%) and
Part A (38 of 71; 53.5%) being the most frequently administered. Among 7
tasks with sufficient data, none detected preoperative to postoperative
changes. Attrition rates averaged 18.9%, with a broad range of 0 to 62%.
 CONCLUSION(S): Cognitive assessment is uncommon in CABG trials, and
commonly used tests rarely detect change. Heterogeneity precluded
meta-analysis, and high attrition raises concerns about selection and
survivorship bias. To evaluate cognitive impact after CABG, trials need
standardized, sensitive assessment strategies resilient to attrition and
feasible for broad deployment. Copyright © 2026 The Author(s).
Published on behalf of the American Heart Association, Inc., by Wiley.
This is an open access article under the terms of the Creative Commons
Attribution-NonCommercial-NoDerivs License, which permits use and
distribution in any medium, provided the original work is properly cited,
the use is non-commercial and no modifications or adaptations are made.

<118>
Accession Number
2037730479
Title
COMPARISON OF DEXMEDETOMIDINE AND ONDANSETRON FOR PREVENTION OF POST
OPERATIVE NAUSEA AND VOMITING IN LAPAROSCOPIC SURGERIES.
Source
International Journal of Medicine and Public Health. 16(1) (pp 1347-1354),
2026. Date of Publication: 01 Jan 2026.
Author
Choudhary G.; Baloda R.; Kumar S.; Yadav P.; Johar S.
Institution
(Choudhary, Baloda, Yadav, Johar) Department of Anesthesia, PGIMS,
Haryana, Rohtak, India
(Kumar) MH, Haryana, Hisar, India
Publisher
Pink Petals Publications Pvt Ltd
Abstract
Background: Postoperative nausea and vomiting (PONV) remains a common
complication following laparoscopic surgeries, adversely affecting patient
satisfaction, recovery, and healthcare costs. While ondansetron is widely
used for prophylaxis, dexmedetomidine-an alpha2-adrenergic agonist with
sedative, analgesic, and antiemetic properties-has emerged as a potential
alternative. The objective is to compare the efficacy and safety of
dexmedetomidine versus ondansetron in preventing PONV in patients
undergoing elective laparoscopic surgery. Material(s) and Method(s):
In this prospective, randomized, double-blind trial, 90 patients (ASA
I-II) scheduled for laparoscopic procedures under general anesthesia were
divided into two groups. Group I (n=45) received dexmedetomidine 1 mug/kg
diluted in 100 mL normal saline over 10-15 minutes after intubation, while
Group II (n=45) received ondansetron 4 mg intravenously. PONV incidence,
severity, need for rescue antiemetics, hemodynamic parameters, sedation
scores, and adverse events were recorded at 0, 4, and 12 hours
postoperatively. Result(s): At 0 hours, significantly more patients
in the dexmedetomidine group were free from PONV symptoms compared to the
ondansetron group (68.9% vs. 40%, p=0.034), with vomiting occurring in
only 8.9% vs. 26.7%, respectively. Rescue antiemetic use was also lower in
the dexmedetomidine group at 0 hours (15.6% vs. 40%, p=0.010). No
significant differences were observed at 4 and 12 hours. Dexmedetomidine
was associated with a lower heart rate during surgery but without
significant hemodynamic instability. Sedation profiles were comparable,
and adverse events were minimal in both groups. Conclusion(s):
Dexmedetomidine is more effective than ondansetron in preventing early
postoperative nausea and vomiting following laparoscopic surgery and
reduces the immediate need for rescue antiemetics, without causing
excessive sedation or clinically significant hemodynamic compromise. It
may be preferred in settings where early PONV control is crucial, though
vigilant monitoring for bradycardia is advised. Copyright © 2026,
Pink Petals Publications Pvt Ltd. All rights reserved.

<119>
Accession Number
2043411396
Title
Transcatheter versus surgical aortic valve replacement in low-risk
patients with severe aortic stenosis: a systematic review and
meta-analysis.
Source
BMC Cardiovascular Disorders. 26(1) (no pagination), 2026. Article Number:
181. Date of Publication: 01 Dec 2026.
Author
Fadl Z.A.; Darwish M.Y.; Moawad W.M.; Aboelmagd N.O.; Fadl G.A.; El
Husseny M.W.A.; Abdelsattar N.K.; Taha T.A.-E.A.
Institution
(Fadl, Darwish, Moawad, Fadl, Abdelsattar, Taha) Faculty of Medicine,
Fayoum University, Fayoum, Egypt
(Aboelmagd) Faculty of Medicine, Qena University, Qena, Egypt
(El Husseny) Department of Adult Cardiology, Aswan Heart Centre, Aswan,
Egypt
(El Husseny) Department of Cardiology, Faculty of medicine, Fayoum
university, Egypt
Publisher
BioMed Central Ltd
Abstract
Background: The optimal revascularization strategy for low-risk patients
with severe aortic stenosis (AS), transcatheter (TAVI) versus surgical
aortic valve replacement (SAVR), remains a subject of ongoing debate,
particularly regarding long-term outcomes. We aimed to synthesize the
evidence on the comparative safety and efficacy of TAVI and SAVR in this
population. Method(s): We conducted a systematic review and
meta-analysis, searching PubMed, Scopus, Web of Science, and Cochrane
Library until March 2025. We included randomized controlled trials (RCTs)
and comparative observational studies enrolling low-risk patients with
severe AS. Primary outcomes were all-cause mortality and stroke, analyzed
at different time points. Data were pooled using random-effects models,
with subgroup analyses based on study design. Result(s): Thirty
studies, including 48,210 patients, were included. TAVI was associated
with a significantly lower risk of 30-day mortality (Relative Risk [RR]
0.66, 95% CI 0.50-0.76) and 30-day stroke (RR 0.70, 95% CI 0.53-0.92).
However, in the overall analysis, SAVR was favored for one-year mortality
(RR 1.11, 95% CI 1.01-1.21), with equipoise in long-term follow-up. TAVI
significantly reduced the risks of 30-day major bleeding (RR 0.38, 95% CI
0.21-0.70) and atrial fibrillation (RR 0.41, 95% CI 0.22-0.76).
Conversely, TAVI was associated with a persistently higher risk of
permanent pacemaker implantation (RR 2.44 at 30 days, 95% CI 1.76-3.40)
and paravalvular leakage (RR > 5-fold at both 30 days and 1 year).
 Conclusion(s): In low-risk patients with severe AS, TAVI offers clear
early procedural safety advantages, particularly regarding stroke,
bleeding, and atrial fibrillation. While the overall analysis suggested a
30-day mortality benefit for TAVI and a 1-year mortality benefit for SAVR,
these findings were driven principally by observational data and were not
statistically significant in the subgroup of randomized controlled trials.
These procedural benefits are counterbalanced by a persistently higher
risk of permanent pacemaker implantation and paravalvular leakage with
TAVI. The choice of intervention requires a nuanced, individualized
approach through shared decision-making, weighing early recovery benefits
against device-related risks and the divergence between trial and registry
outcomes. Copyright © The Author(s) 2026.

<120>
Accession Number
650355564
Title
Comparison of Ozaki and Ross procedures for paediatric aortic valve
disease: a systematic review and meta-analysis.
Source
Cardiology in the young. (pp 1-6), 2026. Date of Publication: 24 Feb
2026.
Author
Lu Q.; Xu K.; Li P.; Wang P.; Huang P.; Yuan Z.; Liu J.
Institution
(Lu, Xu, Li, Wang, Huang, Yuan, Liu) https://ror.org/05n50qc07Beijing
Anzhen Hospital of Capital Medical University Nanchong Branch- Nanchong,
China
Abstract
OBJECTIVES: To compare the clinical efficacy and prognosis of Ozaki
procedure and Ross procedure in the treatment of paediatric aortic valve
disease. METHOD(S): According to the predetermined inclusion and
exclusion criteria, relevant clinical studies were comprehensively
searched in three databases, and relevant data were extracted for analysis
and comparison. RESULT(S): This meta-analysis included four
retrospective cohort studies with a total of 243 patients (117 undergoing
Ozaki procedure and 126 undergoing Ross procedure). There were no
significant difference in the in-hospital all-cause mortality [odds ratio
= 1.38; 95% confidence interval: 0.38, 5.07, p = 0.63] and all-cause
mortality during the follow-up period [odds ratio = 1.85; 95% confidence
interval: 0.54, 6.32, p = 0.32] between Ozaki procedure and Ross
procedure. The reoperation on the aortic valve [odds ratio = 10.48; 95%
confidence interval: 2.22, 49.40, p = 0.003] was higher in the Ozaki
procedure than in the Ross procedure. There were no patients who underwent
pulmonary valve reoperation after Ozaki procedure [odds ratio = 0.21; 95%
confidence interval: 0.03, 1.23, p = 0.08]. The cumulative reoperation
rate after Ozaki procedure [odds ratio = 2.29; 95% confidence interval:
0.93, 5.66, p = 0.07] was higher than that of Ross procedure, but the
difference was not statistically significant. The cardiopulmonary bypass
time after Ozaki procedure [odds ratio = -32.09; 95% confidence
interval:-45.05, -19.14, p < 0.00001] was shorter than that of Ross
procedure. The incidence of postoperative complications [odds ratio =
0.24; 95% confidence interval: 0.04, 1.62, p = 0.14], aortic
cross-clamping time [odds ratio = -20.39; 95% confidence interval: -43.68,
2.90, p = 0.09], ventilator assistance time [odds ratio = 1.71; 95%
confidence interval: -42.70, 46.13, p = 0.94], and ICU time [odds ratio =
-0.38; 95% confidence interval: -0.93, 0.16, p = 0.17] in Ozaki procedure
was not statistically significant compared to Ross procedure.
 CONCLUSION(S): In the treatment of children with aortic valve
disease, there is no statistically significant difference between the
Ozaki procedure and the Ross procedure in terms of freedom from
reoperation and all-cause mortality.

<121>
Accession Number
650334882
Title
Effect of Age on Restrictive and Liberal Transfusion Outcomes in Patients
with Anemia and Myocardial Infarction.
Source
American heart journal. (pp 107381), 2026. Date of Publication: 19 Feb
2026.
Author
Goldsweig A.M.; Ballantyne C.M.; White H.D.; Abbott J.D.; Fergusson D.A.;
Herbert B.M.; Goodman S.G.; Carson J.L.; Brooks M.M.
Institution
(Goldsweig) Department of Cardiovascular Medicine, Baystate Medical Center
and Division of Cardiovascular Medicine, University of
Massachusetts-Baystate, Springfield, MA, USA; Division of Cardiovascular
Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Electronic address: andrewg@nyu.edu
(Ballantyne, Herbert, Brooks) Department of Epidemiology, University of
Pittsburgh, Pittsburgh, PA, United States
(White) Green Lane Clinical Coordinating Centre, Auckland, New Zealand
(Abbott) Division of Cardiology, Warren Alpert Medical School, Brown
University, Providence, RI, United States
(Fergusson) Ottawa Hospital Research Institute, Ottawa, ON, Canada
(Goodman) St. Michael's Hospital, Unity Health Toronto; Peter Munk Cardiac
Centre, University Health Network; University of Toronto, Toronto,
Ontario, Canada; Canadian VIGOUR Centre, University of Alberta, Edmonton,
Alberta, Canada
(Carson) Division of General Internal Medicine, Rutgers Robert Wood
Johnson Medical School, New Brunswick, NJ, United States
Abstract
For patients with anemia and myocardial infarction, the randomized,
3504-patient MINT trial found that a liberal transfusion threshold (10
g/dL) may be preferable to a restrictive threshold (8 g/dL) in terms of
death or myocardial infarction. The relative effects of liberal versus
restrictive transfusion in younger and older patients are unknown. The
present prespecified MINT sub-study found no significant interaction
between age and transfusion strategy for death or myocardial infarction,
heart failure, revascularization procedures, cardiac death, pulmonary
embolism or deep vein thrombosis, and bacteremia or pneumonia and death at
30 and 180 days. A liberal transfusion approach appears to be safe and may
be the preferred transfusion strategy in anemic patients with myocardial
infarction, regardless of age. MINT Trial, ClinicalTrials.gov Number
NCT02981407, https://www.minttrial.org/. Copyright © 2026
Elsevier Inc. All rights reserved.

<122>
Accession Number
650354110
Title
The efficacy and safety of cerebral embolic protection devices in patients
undergoing transcatheter aortic valve replacement: a systematic review and
meta-analysis with trial sequential analysis of randomized controlled
trials.
Source
Expert review of cardiovascular therapy. (no pagination), 2026. Date of
Publication: 23 Feb 2026.
Author
Elazab A.; Hageen A.W.; Elbataa A.; Labeeb E.E.; Najah Q.; Elbahloul M.A.;
Elnady M.I.; Abdelsatar S.M.; Mansour A.; Elkasaby M.H.; Odat R.M.;
Rhabneh L.; Nassar M.; Turkmani M.; Hakim D.
Institution
(Elazab) Faculty of Medicine, South Valley University, Qena, Egypt
(Hageen) Faculty of Medicine, Tanta University, Egypt
(Elbataa, Mansour, Labeeb, Mansour, Elkasaby) Faculty of Medicine,
Al-Azhar University, Cairo, Egypt
(Najah) Faculty of Medicine, Elmergib University, Libyan Arab Jamahiriya
(Elbahloul, Elnady) Faculty of Medicine, Kafr El Sheik University, Egypt
(Abdelsatar) Faculty of Nursing, Beni-Suef National University, Egypt
(Odat) Faculty of Medicine, Jordan University of Science and Technology,
Irbid, Jordan
(Rhabneh) Department of Internal Medicine, HMH Ocean University Medical
Center, Brick, NJ, United States
(Nassar) Division of Endocrinology and Diabetes, Larner College of
Medicine, University of Vermont, Burlington, VT, United States
(Turkmani) Faculty of Medicine, Michigan State University, East Lansing,
MI, United States
(Turkmani) Department of Pulmonary and Critical Care, University of
Toledo, Toledo, OH , USA
(Hakim) Brigham & Women's Hospital/Harvard Medical School, Boston, MA,
United States
Abstract
INTRODUCTION: Transcatheter aortic valve replacement (TAVR) is an
established treatment for severe aortic stenosis but carries a risk of
stroke and cerebral embolism. Cerebral embolic protection devices (CEPD),
including filter-based and deflection-based systems (Sentinel and
TriGUARD), aim to reduce embolic complications; however, their clinical
benefit remains uncertain. This study evaluated the efficacy and safety of
CEPD during TAVR using trial sequential analysis (TSA) and the Grading of
Recommendations, Assessment, Development, and Evaluation (GRADE)
framework. METHOD(S): Randomized controlled trials (RCTs comparing
TAVR with and without CEPD were identified through four electronic
databases from inception to April 2025. Primary outcomes were all-cause
mortality, major adverse cardiovascular and cerebrovascular events
(MACCE), stroke, and disabling stroke. Pooled risk ratios (RR) with 95%
confidence intervals (CI) were calculated. TSA was conducted with a 5%
type I error and 80% power. RESULT(S): Nine RCTs including 11,876
patients were analyzed. CEPD use showed no significant reduction in
mortality, MACCE, stroke, or disabling stroke. Secondary and subgroup
analyses yielded consistent findings. TSA demonstrated that the accrued
evidence was insufficient to confirm a clinical benefit.
 CONCLUSION(S): Current evidence does not support the routine use of
CEPD during TAVR, given the lack of significant benefit in key clinical
outcomes. REGISTRATION: The protocol of this study was registered at
Prospero CRD420251036308.

<123>
Accession Number
650356607
Title
Surgical management of double outlet right ventricle with outflow
obstruction: a systematic review of biventricular strategies.
Source
Cardiology in the young. (pp 1-7), 2026. Date of Publication: 24 Feb
2026.
Author
Semyashkin A.; Nesteruk J.; Ben Mime L.
Institution
(Semyashkin) Department of Pediatric Cardiac Surgery, Klinikum Stuttgart
Olgahospital Frauenklinikhttps://ror.org/059jfth35, Germany
(Nesteruk) University Heart Center Freiburg Bad Krozingen, Germany
(Ben Mime) Center for Congenital Heart Defects and Pediatric Heart Center,
Pediatric Heart Surgery, University Hospital of the Ruhr University
Bochum, Medical Faculty OWL University Bielefeld, Bad Oeynhausen, Germany
Abstract
BACKGROUND: Double outlet right ventricle is a heterogeneous congenital
defect in which both great arteries arise predominantly from the right
ventricle. Several operative strategies exist, but contemporary paediatric
outcome data have not been systematically synthesised. MATERIAL AND
METHODS: A systematic search of PubMed, Embase, Scopus, the Cochrane
Library, and medRxiv (2000-2025) identified cohort studies and case series
including >=10 children undergoing biventricular repair strategies
reported in double outlet right ventricle cohorts, including
intraventricular rerouting procedures, root-based realignment techniques,
and neonatal pathway operations such as the Yasui procedure. Two reviewers
independently screened studies, extracted anatomical and operative data,
and assessed risk of bias. Early mortality and 10-year survival were
pooled using random-effects models with logit transformation.
 RESULT(S): Thirteen studies (413 children; median follow-up ~7 years)
met inclusion criteria. Early mortality ranged from 0% to 6.8%. Pooled
early mortality was 2.7% for Rastelli, 3.6% for REV, and 5.8% for
Nikaidoh/Bex operations. Ten-year survival exceeded 90% across all major
strategies. Conduit replacement was frequent after Rastelli and
Nikaidoh/Bex repair. REV avoided a conduit but required right ventricular
outflow tract reinterventions in about one-quarter of patients.
Nikaidoh/Bex procedures provided durable left ventricular outflow but
showed 19-35% conduit failure. Yasui repairs achieved excellent neonatal
survival but required frequent conduit replacement. CONCLUSION(S):
Contemporary double outlet right ventricle repair provides excellent
long-term survival with early mortality <6%. Procedure selection should
consider ventricular septal defect position, risk of postoperative left
ventricular outflow tract obstruction, coronary anatomy, and patient size.

<124>
Accession Number
650354523
Title
Transcatheter aortic valve implantation for symptomatic severe aortic
stenosis and its expanding clinical indications.
Source
The Korean journal of internal medicine. (no pagination), 2026. Date of
Publication: 24 Feb 2026.
Author
Kook H.; Lim Y.-H.
Institution
(Kook, Lim) Division of Cardiology, Department of Internal Medicine,
College of Medicine, Hanyang University, Seoul, South Korea
Abstract
Transcatheter aortic valve implantation (TAVI) is a minimally invasive
treatment for symptomatic severe aortic stenosis (AS) that was initially
developed for patients with prohibitive surgical risk. Since the
first-in-human procedure in 2002, TAVI has gained global acceptance owing
to its favorable clinical outcomes and faster recovery than those
associated with surgical aortic valve replacement. Landmark trials have
demonstrated the noninferiority or superiority of TAVI across high-,
intermediate-, and low-surgical risk populations, leading to guideline
endorsement as a recommended option for appropriately selected patients
across all surgical risk groups. Furthermore, long-term follow-up data
support the durability of contemporary TAVI devices. Beyond its current
established indications, TAVI is being explored for broader applications
such as asymptomatic severe AS, moderate AS with heart failure, and pure
aortic regurgitation; however, these uses remain investigational and are
not yet part of formal guidelines. This review summarizes TAVI's
historical evolution, pivotal clinical trial evidence, and procedural
innovations that have enabled its widespread use. We explore
Korea-specific experiences with TAVI implementation, highlighting national
registry data, healthcare policy considerations, and institutional
adoption. Future perspectives include long-term device performance,
lifetime valve management strategies, and the integration of artificial
intelligence into transcatheter valve therapy.

<125>
Accession Number
650349161
Title
Clinical efficacy and safety of robotic-assisted thoracic surgery after
neoadjuvant therapy in non-small cell lung cancer: a systematic review and
meta-analysis.
Source
Updates in surgery. (no pagination), 2026. Date of Publication: 23 Feb
2026.
Author
Liang G.; Peng H.; Li Y.
Institution
(Liang, Peng, Li) Department of Cardiothoracic Surgery, First Affiliated
Hospital of Guangxi Medical University, NO 6 Shuangyong Road, Nanning,
Guangxi, China

<126>
Accession Number
2043456490
Title
Left Atrial Appendage Occlusion Versus NOACs in patients With Atrial
Fibrillation: Rationale and Design of the CATALYST Trial.
Source
American Heart Journal. 296 (no pagination), 2026. Article Number: 107367.
Date of Publication: 01 Jun 2026.
Author
Reddy V.Y.; Hylek E.; Camm A.J.; Halperin J.L.; Diener H.-C.; Thaler D.;
Schmidt B.; Hara H.; Huisman M.V.; Price M.J.; Lakkireddy D.; Gage R.;
Zhao H.; Jensen T.P.; Quintana M.; Windecker S.
Institution
(Reddy, Halperin) Mount Sinai Fuster Heart Hospital, Icahn School of
Medicine at Mount Sinai, New York, NY, United States
(Hylek) Boston University School of Medicine, Boston, MA, United States
(Camm) City St. George's University of London, London, United Kingdom
(Diener) University Duisburg-Essen, Essen, Germany
(Thaler) Tufts Medical Center, Boston, MA, United States
(Schmidt) Cardioangiologisches Centrum Bethanien, Frankfurt, Germany
(Hara) Toho University Ohashi Medical Center, Tokyo, Japan
(Huisman) Leiden University Medical Center, Leiden, Netherlands
(Price) Scripps Clinic, La Jolla, CA, United States
(Lakkireddy) Kansas City Heart Rhythm Institute and Research Foundation,
Overland Park, KS, United States
(Gage, Zhao) Abbott, St. Paul, MN, United States
(Jensen, Quintana) Berry Consultants, Austin, TX, United States
(Windecker) Department of Cardiology, Bern University Hospital, University
of Bern, Bern, Switzerland
Publisher
Elsevier Inc.
Abstract
Introduction Both percutaneous left atrial appendage occlusion (LAAO) and
nonvitamin K antagonist oral anticoagulants (NOACs) are noninferior to
warfarin for stroke prevention in high-risk patients with atrial
fibrillation (AF). However, there is limited data comparing LAAO with
NOACs. The CATALYST trial compares a dual-seal LAAO device (AmplatzerTM
AmuletTM) to NOACs in AF patients indicated for thromboprophylaxis. Method
CATALYST is a prospective, multicenter, randomized controlled, open-label
trial with an adaptive statistical design. Up to 2,650 AF patients with
CHA<inf>2</inf>DS<inf>2</inf>-VASc score >=2 (men) or >=3 (women) will be
randomly assigned to LAAO or NOAC at 123 global sites. Patients randomized
to NOACs take the appropriate labeled dose with compliance monitored at
each visit, while LAAO patients receive dual antiplatelet therapy followed
by aspirin monotherapy for >=12 months postimplant. Patients are followed
through 5 years, with postimplant cardiac imaging at 3- and 12-months.
There are three co-primary endpoints: (1) ischemic stroke, systemic
embolism, or cardiovascular death through 2 years, tested for
noninferiority; (2) major or clinically relevant nonmajor bleeding through
2 years, tested for superiority; and (3) ischemic stroke or systemic
embolism through 3 years, tested for noninferiority. The following
secondary endpoints will be tested if the primary endpoints are met: (1)
all-bleeding, tested for noninferiority; (2) followed by testing for
superiority; (3) disabling or fatal strokes, tested for superiority; all
through 2 years. Conclusions CATALYST is evaluating the safety and
effectiveness of a dual seal LAAO device compared to NOACs in patients
with AF at increased risk of stroke. Clinical Trial Registration URL
https://clinicaltrials.gov ; Unique Identifier NCT04226547. Copyright
© 2026 The Authors.

<127>
Accession Number
2043391639
Title
Study design for an emulated trial of a 2 arm, parallel, stratified,
adaptive, RCT of CABG versus PCI in people requiring myocardial
revascularization at high risk (High-Risk REVASC).
Source
American Heart Journal. 296 (no pagination), 2026. Article Number: 107368.
Date of Publication: 01 Jun 2026.
Author
Liao W.; Rashid M.; Brookes C.L.; Barber S.; Turner R.M.; Gravel G.M.;
Petrie M.C.; Lipsic E.; Doenst T.; Fremes S.; Murphy G.J.; White I.;
Redfors B.; Rouleau J.; Omerovic E.; Cooke A.; Murray S.
Institution
(Liao, Rashid, Murphy, White, Redfors, Rouleau, Omerovic, Cooke, Murray)
Division of Cardiovascular Sciences, School of Medical Sciences,
University of Leicester, Leicester, United Kingdom
(Brookes, Barber, Murphy, White, Redfors, Rouleau, Omerovic, Cooke,
Murray) Leicester Clinical Trials Unit, University of Leicester,
Leicester, United Kingdom
(Turner, White, Redfors, Rouleau, Omerovic, Cooke, Murray) Medical
Research Council Clinical Trials Unit at UCL, United Kingdom
(Gravel, White, Redfors, Rouleau, Omerovic, Cooke, Murray) Montreal Heart
Institute, Universite de Montreal, Montreal, QC, Canada
(Petrie, White, Redfors, Rouleau, Omerovic, Cooke, Murray) School of
Cardiovascular and Metabolic Health, University of Glasgow, Glasgow,
United Kingdom
(Lipsic, White, Redfors, Rouleau, Omerovic, Cooke, Murray) Department of
Cardiology, University of Groningen, University Medical Center Groningen,
Groningen, Netherlands
(Doenst, White, Redfors, Rouleau, Omerovic, Cooke, Murray) Jena University
Hospital, Friedrich-Schiller-University of Jena, Jena, Germany
(Fremes, White, Redfors, Rouleau, Omerovic, Cooke, Murray) Department of
Surgery, University of Toronto for Fremes, Toronto, Canada
Publisher
Elsevier Inc.
Abstract
Aim This study aims to use routinely collected health data and trial
emulation methodology to inform the design of a pragmatic randomized
controlled trial (RCT) in people requiring multivessel coronary
revascularization with severe symptomatic multivessel disease and
high-risk characteristics, typically underrepresented in previous RCTs.
Methods Hospital episode statistics (HES) linked to Office for National
Statistics will be the main data source. The study population is patients
who require multivessel myocardial revascularization with at least one of
the following high-risk characteristics: age >75 years, female, diagnosed
with acute coronary syndrome, heart failure, chronic kidney disease,
peripheral vascular disease, or intermediate frailty risk. The
intervention procedure is coronary artery bypass grafting (CABG) and the
control (reference) is percutaneous coronary intervention (PCI). Outcomes
include all-cause and cardiovascular (CV) death, CV hospitalization, major
adverse cardiovascular events, and major vascular complications or
bleeding within 5 years of the index procedure. This study includes 3
stages of statistical analyses: (1) latent class analysis (LCA) to
identify mutually exclusive patient clusters (latent classes) representing
different clinical phenotypes, (2) instrumental variable analysis (IVA) to
estimate the average treatment effect (ATE) in the whole population and
each patient cluster; and (3) repeating stage 2 in an emulated trial
population obtained by matching the HES population with individual
participant data from an RCT. We will then co-design the protocol for a
definitive clinical trial in partnership with patients, public, and
stakeholders. Discussion This study introduces a novel, stepwise data
science framework that integrates machine learning (unsupervised learning
through LCA), causal inference, and trial emulation methods applied in big
data, to design a future stratified and adaptive RCT of CABG versus PCI in
high-risk patients. Our proposed approach fosters new collaborations among
data scientists, trial methodologists, clinicians, and patient and public
representatives in complex trial designs for diverse, high-risk
populations. This study represents a new framework for co-production in
trials of cardiovascular interventions, which offers a scalable model and
has the potential to transfer to other disease areas. Clinical trial
registration URL : https://www.clinicaltrials.gov/study/NCT05853536 .
Unique identifier : NCT05853536. Copyright © 2026 The Authors.

<128>
Accession Number
2043416638
Title
Hypoalbuminaemia contributes to postoperative pulmonary complications and
mortality: a systematic review and meta-analysis.
Source
BMC Anesthesiology. 26(1) (no pagination), 2026. Article Number: 142. Date
of Publication: 01 Dec 2026.
Author
Wang X.; Tang H.; Zheng M.; Xu F.
Institution
(Wang, Tang, Zheng, Xu) Department of Critical Care Medicine, The First
Affiliated Hospital of Chongqing Medical University, Yuzhong, China
Publisher
BioMed Central Ltd
Abstract
Objective: This review aimed to assess whether hypoalbuminaemia can
predict postoperative pulmonary complications (PPCs) and mortality in
patients receiving general anaesthesia for surgery. Method(s):
PubMed, Web of Science, EMBASE, and the Cochrane Library were searched for
relevant articles published up to 18 July 2024. Three authors
independently reviewed the studies and assessed the quality of related
articles via the Newcastle-Ottawa Scale. The data were recorded, and a
meta-analysis was performed using Review Manager version 5.4.1.
 Result(s): A total of 40 studies with 477,701 patients were included
in the meta-analysis. Adjusted data were pooled to calculate the odds
ratio (OR). A sensitivity test was conducted. A meta-analysis of 18
studies demonstrated that hypoalbuminaemia was a significant predictor of
PPCs and mortality after general anaesthesia (OR: 2.88, 95% CI 2.50 to
3.32, P < 0.01, I2 = 90%). The 40 studies were divided into 4
groups based on surgical site: the orthopaedic surgery group (OR: 4.03,
95% CI 3.49 to 4.64, P < 0.01, I2 = 43%), the thoracic surgery
group (OR: 1.82, 95% CI 1.46 to 2.26, P < 0.01, I2 = 23%), the
abdominal surgery group (OR: 2.48, 95% CI 1.81 to 3.40, P < 0.01,
I2 = 95%) and the other surgery group (OR: 2.34, 95% CI 1.66 to
3.29, P < 0.01, I2 = 87%). In addition, patients with
hypoalbuminaemia had increased mortality (OR: 4.31, 95% CI 4.124.51, P,
I2 = 68%). Conclusion(s): Preoperative hypoalbuminaemia is
significantly associated with postoperative pulmonary complications and
has different correlation coefficients in different types of surgeries.
Trial registration: This systematic review and meta-analysis was
registered at the International Prospective Register of Systematic Reviews
(Number CRD42024540493). Copyright © The Author(s) 2025.

<129>
Accession Number
2043771077
Title
Outcomes of No-Touch Vs Conventionally Harvested Saphenous Veins for
Coronary Artery Bypass Surgery: Individual Patient Data Meta-Analysis
Protocol.
Source
CJC Open. (no pagination), 2026. Date of Publication: 2026.
Author
Gregg A.C.; Tian M.; Gaudino M.; Angelini G.; Fremes S.; Jeppsson A.;
Modrau I.S.; Redfors B.; Sandner S.; Sartipy U.; Thelin S.; Hu S.; James
S.
Institution
(Gregg, Gaudino, Redfors, Sandner) Department of Cardiothoracic Surgery,
Weill Cornell Medicine, New York, NY, United States
(Tian, Hu) Department of Surgery, National Center for Cardiovascular
Disease, China & Fuwai Hospital, Chinese Academy of Medical Sciences &
Peking Union Medical College, Beijing, China
(Angelini) Bristol Heart Institute, University of Bristol, Bristol, United
Kingdom
(Fremes) Division of Cardiac Surgery, Schulich Heart Centre, Department of
Surgery, Sunnybrook Health Sciences Centre, University of Toronto,
Toronto, ON, Canada
(Jeppsson, Redfors) Department of Cardiothoracic Surgery, Sahlgrenska
University Hospital, Gothenburg, Sweden
(Jeppsson, Redfors) Department of Molecular and Clinical Medicine,
Institute of Medicine, Sahlgrenska Academy, University of Gothenburg,
Gothenburg, Sweden
(Modrau) Department of Cardiothoracic and Vascular Surgery, Aarhus
University Hospital, Aarhus, Denmark
(Modrau) Department of Clinical Medicine, Aarhus University, Aarhus,
Denmark
(Redfors) Department of Population Health Sciences, Weill Cornell
Medicine, New York, NY, United States
(Sandner) Department of Cardiac Surgery, Medical University of Vienna,
Vienna, Austria
(Sartipy) Department of Cardiothoracic Surgery, Karolinska University
Hospital, Stockholm, Sweden
(Sartipy) Department of Molecular Medicine and Surgery, Karolinska
Institute, Stockholm, Sweden
(Thelin) Department of Thoracic Surgery, Uppsala University Hospital,
Uppsala, Sweden
(James) Department of Medical Sciences, Cardiology, Uppsala University
Hospital, Uppsala, Sweden
Publisher
Elsevier Inc.
Abstract
The effect of no-touch (NT) vs conventional (CON) saphenous vein graft
(SVG) harvesting on SVG patency and clinical outcomes in coronary artery
bypass remains unclear. Although prior trial-level meta-analyses have
generally reported improved patency with NT SVG, outcomes show variability
across studies, and evidence from 2 recent, larger multicentre randomized
clinical trials is discordant. This individual patient data meta-analysis
(IPDMA) will evaluate the impact of harvesting techniques on graft patency
and clinical outcomes. A systematic literature search was conducted for
randomized clinical trials comparing NT SVG and CON SVG. Studies were
eligible if they included at least 1 year of follow-up evaluation with
graft imaging. The primary efficacy outcome will be graft failure, defined
as graft-level study SVG occlusion. The secondary outcomes will include
leg wound complications, patient-level graft failure, graft malfunction
(composite of graft occlusion or stenosis), and major adverse cardiac
events (MACE) defined as the composite of all-cause death, myocardial
infarction, or any repeat revascularization. A 2-stage IPDMA will be
performed. In the first stage, mixed-effects logistic regression models
will be fitted separately within each trial. In the second stage,
trial-level estimates will be pooled using random-effects models to
generate overall effects. Prespecified subgroup analyses will be conducted
via a 2-stage framework to evaluate potential effect modification by key
patient-level characteristics. This IPDMA will enable more robust
evaluation of the effect of harvesting techniques on SVG patency and
clinical outcomes, leveraging patient-level datasets for in-depth
analyses, particularly among patient subgroups with distinct risk
profiles. Copyright © 2026 The Authors

<130>
Accession Number
650332098
Title
Challenges of conducting trials across multiple clinical specialities.
Source
Trials. Conference: 5th International Clinical Trials Methodology
Conference, ICTMC 2019. Brighton United Kingdom. 20(1 Supplement) (no
pagination), 2019. Date of Publication: 01 Oct 2019.
Author
Rogers C.A.; Baos S.; Culliford L.; Pufulete M.; Gibbison B.
Institution
(Rogers, Baos, Culliford, Pufulete, Gibbison) University of Bristol,
Bristol, United Kingdom
Publisher
BioMed Central Ltd
Abstract
Introduction: Clinical trials are expensive and take several years to
complete. Initiatives to improve efficiency and maximise generalisability
of findings are actively encouraged. We describe the challenges of
conducting an RCT across multiple specialties. Method(s): The
NIHR-funded GAP study (ISRCTN63614165), to evaluate the effectiveness of
gabapentin vs. placebo for pain management after surgery is being
conducted in three surgical specialties (cardiac, thoracic and abdominal)
in two hospitals. Result(s): Surgical specialties are led by
different clinical and research nurse teams based in different
locations/departments within the hospitals. Despite this, regulations
permit only one local PI for each hospital. This has presented logistical
challenges (e.g. number of site files to have?) and has disincentivised
clinicians in some specialties. PI delegation of responsibilities (e.g.
assessing eligibility/safety) to colleagues in other specialties has had
to be much higher than usual. Training of non-GCP-trained clinical staff
has been a major undertaking, facilitated with targeted training materials
covering key aspects of GCP. Designing study materials (e.g. information
leaflets, data collection forms) that include all necessary and
appropriate information for different patient populations and recruitment
pathways (e.g. cardiac surgery vs. cancer surgery) required careful
consideration. Adaptable study coordination and monitoring procedures are
necessary; allowing for different ways of working across specialties (e.g.
greenlighting the site or specialty) and enabling identification of trends
at site and specialty level. The sponsor, whilst viewing each hospital as
a single site, has monitored speciality separately. The system for
capturing local research activity does not allow recruitment to be easily
attributed to different specialties, resulting in discrepancies and
frustration for local teams. Discussion(s): The study design,
involving three surgical specialties was chosen to maximise the value of
the research for the NHS. This study highlights that while the design is
methodologically attractive, the current regulatory structures and NHS
systems make implementation sub-optimal.

<131>
Accession Number
650329218
Title
The Effect of a Virtual Reality Distraction Intervention on Pain in
Patients Following a Percutaneous Coronary Intervention: A Randomized
Clinical Trial.
Source
Pain management nursing : official journal of the American Society of Pain
Management Nurses. (no pagination), 2026. Date of Publication: 19 Feb
2026.
Author
Shutnan A.H.I.; Athbi H.A.; Dokoohaki R.; Torabizadeh C.; Rahimi S.
Institution
(Shutnan) Kerbala Health Department, Al-Imam Al-Hassan Al-Mujtaba Teaching
Hospital, Iraq
(Athbi) Department of Adult Nursing, College of Nursing, University of
Kerbala, Iraq
(Dokoohaki, Rahimi) Community-Based Psychiatric Care Research Center,
School of Nursing and Midwifery, Shiraz University of Medical Sciences,
Shiraz, Iran, Islamic Republic of
(Torabizadeh) Department of Nursing, School of Nursing and Midwifery,
Shiraz University of Medical Sciences, Shiraz, Iran, Islamic Republic of
Abstract
BACKGROUND: Post-procedural pain following percutaneous coronary
intervention (PCI) remains a significant clinical challenge, affecting 5%
of patients and potentially impairing recovery and quality of life. While
pharmacological interventions are commonly used, their side effects
highlight the need for non-invasive alternatives. Recent studies
demonstrate VR's efficacy in acute pain settings, yet its application in
post-PCI pain management remains underexplored. OBJECTIVE(S): This
study evaluated the efficacy of VR on pain management in patients
undergoing PCI. As a secondary objective, we assessed patient
acceptability and satisfaction with the VR intervention using a 5-item
Likert questionnaire (range 1 = very dissatisfied to 5 = very satisfied).
 METHOD(S): A randomized clinical trial was conducted at two
tertiary-care centers in Karbala, Iraq: the Karbala Center for Cardiac
Diseases and Surgery and Al-Imam Al-Hassan Al-Mujtaba Teaching Hospital,
from September 2024 to January 2025. Participants (N = 144) were equally
allocated to control (routine care) and intervention (VR-based distraction
via 3D nature videos with relaxing music) groups. Pain levels were
assessed using the Visual Analogue Scale (VAS). The collected data were
analyzed in SPSS v. 27, and the level of significance was set at p < 0.05.
This study adheres to the CONSORT (Consolidated Standards of Reporting
Trials) guidelines for reporting randomized controlled trials.
 RESULT(S): Most participants were male (56.9% in the intervention
group). Mean ages were 57.38 +/- 6.514 (intervention) and 60.53 +/- 7.530
(control) years. A statistically significant reduction in pain scores (p <
0.01) was observed in the VR group, whereas the control group showed no
significant changes (p > 0.05). CONCLUSION(S): VR-based distraction
significantly reduces post-PCI pain. The intervention demonstrated high
acceptability and safety with no adverse effects. VR is recommended as a
proactive, non-pharmacological strategy for pain management following
PCI. Copyright © 2026. Published by Elsevier Inc.

<132>
Accession Number
2043674988
Title
A Comparative Study Between Intravenous Dexmedetomidine Versus Nebulized
Dexmedetomidine in Attenuating Laryngoscopy and Intubation Induced
Sympathetic Response and Hemodynamic Changes in Coronary Artery Disease
Patients Posted for Elective CABG Procedure.
Source
International Journal of Current Pharmaceutical Review and Research. 18(2)
(pp 231-240), 2026. Date of Publication: 2026.
Author
Elumalai B.; Mohanasundaram J.; Kavitha A.J.
Institution
(Elumalai, Mohanasundaram) Institute of Anaesthesiology, Madras Medical
College, Tamil Nadu, India
(Kavitha) Department of Anaesthesiology, Vels Medical College, Tamil Nadu,
India
Publisher
Dr. Yashwant Research Labs Pvt. Ltd.
Abstract
Background: Laryngoscopy and intubation trigger sympathetic surges that
increase heart rate (HR) and blood pressure (BP), posing significant risks
for patients with coronary artery disease (CAD). Dexmedetomidine, a
sympatholytic alpha-2 agonist, may mitigate these stress responses.
 Aim(s): To compare the effectiveness and safety of intravenous (IV)
versus nebulized dexmedetomidine in attenuating hemodynamic stress
responses during laryngoscopy and intubation in CAD patients undergoing
elective coronary artery bypass grafting (CABG). Material(s) and
Method(s): Seventy-eight elective CABG patients were randomized into two
groups (n=39 each). Group A received nebulized dexmedetomidine (1
microg/kg) over 10 minutes, while Group B received IV dexmedetomidine (1
microg/kg) over 10 minutes. HR, systolic BP, diastolic BP, and mean
arterial pressure (MAP) were monitored at baseline and peri- intubation.
 Result(s): Both routes effectively blunted the pressor response to
laryngoscopy. However, the IV group experienced a more precipitous decline
in MAP and a significantly higher incidence of bradycardia and
hypotension. Nebulized administration maintained superior cardiovascular
stability and was associated with a lower incidence of postoperative sore
throat. Post-operative recovery times were comparable between groups.
 Conclusion(s): While both routes attenuate hemodynamic responses
during laryngoscopy and intubation in CAD patients, nebulized
dexmedetomidine is a clinically advantageous, non- invasive alternative
for high-risk CAD patients. Its superior safety profile-specifically the
reduced risk of cardiovascular instability-makes it a viable and
attractive option for perioperative management. Copyright ©
(2026), (Dr. Yashwant Research Labs Pvt. Ltd.). All rights reserved.

<133>
[Use Link to view the full text]
Accession Number
650327945
Title
Better in, better out: advancing transplant care through prehabilitation
and rehabilitation: towards a multimodal continuum of care before and
after solid organ transplantation.
Source
Current opinion in organ transplantation. (no pagination), 2026. Date of
Publication: 19 Feb 2026.
Author
Van Criekinge H.; Leunis S.; Pol R.A.; Monbaliu D.
Institution
(Van Criekinge, Leunis, Monbaliu) Laboratory of Abdominal Transplantation,
Department of Microbiology, Immunology and Transplantation, KU Leuven,
Leuven, Belgium
(Pol) Division of Transplant Surgery, Department of Surgery, University of
Groningen, Groningen, Netherlands
(Monbaliu) Transplantoux foundation, Leuven, Belgium
Abstract
PURPOSE OF REVIEW: Solid organ transplantation is life-saving but imposes
substantial physical and psychological demands across the pre, peri-, and
posttransplant trajectory. Emerging evidence highlights the potential of
prehabilitation and rehabilitation to enhance resilience before surgery,
support recovery afterward, and reduce surgical and medical complications,
ultimately improving long-term health after transplantation. Despite
growing evidence of their benefits, these strategies remain underutilized
in transplant care. This review aims to introduce multimodal continuum of
care that integrates prehabilitation and rehabilitation into a unified
pathway before and after transplantation to optimize outcomes in solid
organ transplantation. RECENT FINDINGS: Multimodal programs combining
exercise, nutrition, and psychosocial support have demonstrated reductions
in complications, shorter hospital stays, and improved survival and
quality of life in surgical populations, with emerging evidence in
transplantation. Consensus statements advocate individualized, adaptive
interventions across the transplant continuum, delivered by
interdisciplinary teams. Leveraging the same multidisciplinary team before
and after transplantation fosters consistency, efficiency, and patient
engagement-critical for adherence and empowerment. SUMMARY: Although
high-quality transplant-specific evidence remains limited, targeted,
multimodal prehabilitation and rehabilitation represent promising
strategies to enhance functional capacity and long-term health. We
therefore propose "better in, better out" as a guiding principle for
transplant care, calling for its adoption as a new standard supported by
emerging evidence across kidney, liver, lung, and heart
transplantation. Copyright © 2026 Wolters Kluwer Health, Inc. All
rights reserved.

<134>
Accession Number
650332150
Title
The ADAPTT Study: Using routinely-collected data to emulate a randomised
trial.
Source
Trials. Conference: 5th International Clinical Trials Methodology
Conference, ICTMC 2019. Brighton United Kingdom. 20(1 Supplement) (no
pagination), 2019. Date of Publication: 01 Oct 2019.
Author
Harris J.; Sterne J.A.C.; Reeves B.C.; Johnson T.W.; Benedetto U.;
Lasserson D.; Loke Y.; Mumford A.; Rogers C.A.; Pufulete M.
Institution
(Harris, Reeves, Rogers, Pufulete) Clinical Trials and Evaluation Unit,
Bristol Trials Centre, University of Bristol, Bristol, United Kingdom
(Sterne) NIHR Biomedical Research Centre, Department of Population Health
Sciences, University of Bristol, Bristol, United Kingdom
(Johnson) Bristol Heart Institute, Bristol, United Kingdom
(Benedetto, Mumford) Bristol Medical School, University of Bristol,
Bristol, United Kingdom
(Lasserson) Institute of Applied Health Research, University of
Birmingham, Birmingham, United Kingdom
(Loke) Norwich Medical School, University of East Anglia, Norwich, United
Kingdom
Publisher
BioMed Central Ltd
Abstract
Introduction: Target trial emulation means applying the design principles
from randomised controlled trials (RCTs) to the analysis of observational
data. The ADAPTT study (ISRCTN ISRCTN76607611) is using
routinely-collected health data to emulate four pragmatic target RCTs to
quantify associations between different regimens of dual antiplatelet
therapy (DAPT) and bleeding events in four populations: I) acute coronary
syndrome (ACS) undergoing percutaneous coronary intervention (PCI); ii)
stable angina undergoing PCI; iii) coronary artery bypass grafting (CABG);
and iv) ACS treated conservatively (medication only). Method(s): We
defined eligibility criteria, treatment strategies, assignment to
interventions and follow up using clinical input and review of the DAPT
literature. We applied the eligibility criteria and identified our
populations from fully anonymised, linked Hospital Episode Statistics
(HES) and Clinical Practice Research Datalink (CPRD) data. To emulate
random assignment to different DAPT regimens at baseline, we identified
potential confounding factors (systematically, using literature review,
interviews with clinicians and short surveys with additional clinicians)
to allow description of comparability of groups at baseline and adjustment
for these factors. Bleeding events were identified from GP consultations
(CPRD) and inpatient stays (HES) in the year after assignment to DAPT
interventions. Result(s): Preliminary analyses show variation in
bleeding risk consistent with expectation based on the characteristics of
the DAPT regimens. For example, in the ACS PCI population, bleeding
occurred in 10% of patients receiving more potent DAPT versus 8% in
patients receiving less potent DAPT (adjusted hazard ratio 1.38, 95%
confidence interval 1.16 to 1.64). We are unable to control for some
confounding factors that were identified. Discussion(s): Detailed
consideration of eligibility criteria, treatment assignment, start and end
of follow-up period and potential confounding factors, along with an
intention-to-treat analysis strategy, will hopefully avoid the common
pitfalls of observational studies.

<135>
Accession Number
650331409
Title
Using data from routine sources in the development of an objective measure
of early outcome after surgery.
Source
Trials. Conference: 5th International Clinical Trials Methodology
Conference, ICTMC 2019. Brighton United Kingdom. 20(1 Supplement) (no
pagination), 2019. Date of Publication: 01 Oct 2019.
Author
Maishman R.; Gibbison B.; Reeves B.; Rogers C.
Institution
(Maishman, Reeves, Rogers) Clinical Trials and Evaluation Unit, Bristol
Trials Centre, University of Bristol, Bristol, United Kingdom
(Gibbison) Department of Cardiac Anaesthesia and Intensive Care, Bristol
Heart Institute, University Hospitals Bristol NHS FT, Bristol, United
Kingdom
Publisher
BioMed Central Ltd
Abstract
Introduction: In trials in surgery, post-operative length of hospital stay
(LoS) is often used as a proxy for early outcome. However, blinding of
surgeons is typically not possible, which leads to potential for bias, as
the surgeon decides when a patient is ready for discharge. This has led us
to investigate how routinely collected clinical measures during the first
24 hours and complications that occur throughout the post-operative stay
could be used to develop a more objective measure of early outcome.
 Method(s): Measurements routinely collected during the first 24 hours
after surgery have been extracted from hospital electronic records and
combined with trial data for a cohort of patients who have previously
participated in a cardiac surgery RCT. Relationships between six
measurements (summarised over the first 24 hours) and LoS have been
investigated to identify early indicators of poor outcome. The six
measures were chosen in discussion with clinician colleagues. Provisional
results: A total of 808 patients who had participated in one of 7 trials
were included. Initial univariable and multivariable analyses suggest
higher arterial mean blood pressure and higher minimum haemoglobin were
significantly associated with shorter LoS, while higher maximum lactate
and maximum potassium were associated with longer LoS. Heart rate and
temperature were not associated with LoS. Effect estimates were attenuated
for all measurements in the multivariate analysis. We will also describe
the association between these measures and complications and how these are
being combined, alongside patient and clinician ratings of complication
severity, to develop of an objective measure of early outcome. Potential
relevance and impact: Supplementing clinical trial data with routinely
collected measurements provides more detailed information on early outcome
at minimal additional cost. The methodology to develop this measure is
applicable in other clinical areas.

<136>
Accession Number
650332160
Title
Do study participants complete electronic questionnaires?.
Source
Trials. Conference: 5th International Clinical Trials Methodology
Conference, ICTMC 2019. Brighton United Kingdom. 20(1 Supplement) (no
pagination), 2019. Date of Publication: 01 Oct 2019.
Author
Culliford L.A.; Gidman E.; Hopkins E.; Maishman R.; Mazza G.; Walker-Smith
T.; Blazeby J.M.; Rogers C.A.
Institution
(Culliford, Gidman, Hopkins, Maishman, Mazza, Walker-Smith, Rogers) CTEU
Bristol BTC, Translational Health Sciences, Bristol Medical School, United
Kingdom
(Blazeby) Bristol Centre for Surgical Research, Population Health
Sciences, Bristol Medical School, United Kingdom
Publisher
BioMed Central Ltd
Abstract
Introduction: Electronic capture of patient reported outcomes (PROs) is
increasingly utilised in clinical research. Resources are required to
develop and maintain electronic PRO tools, but this is offset with savings
in printing and postage costs and data entry of paper questionnaires.
Personal computers and smart phones have made the internet more
accessible. However, if participants prefer paper questionnaires, or if
data quality is compromised with electronic data capture, resources may
not be optimally used. We present data from two large studies offering
postal and online questionnaires to assess participant preferences and
data completeness. Method(s): The Studies: OMACS - Outcome
Monitoring After Cardiac Surgery (ISRCTN90204321), a cohort study in
cardiac surgery, collecting Quality of Life (QoL) data for 1y and
By-Band-Sleeve (BBS; ISRCTN00786323) - A multicentre RCT of bariatric
surgery collecting QoL data at multiple timepoints over 3y.
 Result(s): OMACS: 642 participants, 12% of whom opted for online
completion of the PRO. Compared to the paper completion group, the online
completion group contained proportionally fewer females (26% vs 23%) and
were on average 3 years younger (median age 69 vs 63y). Completion rates
were lower in the online completion group (3 months 97% vs 93%; 12 months
86% vs 63%) BBS: 1296 participants, 34% of whom opted for online
completion of the PRO. Again, the online completion group contained fewer
females (81% vs 69%) and were younger (median 52 vs 49y). Overall, 280 of
~5700 (~5%) questionnaires were completed online, with the remainder
completed by post or in clinic. Discussion(s): Uptake of the
electronic PRO completion option is low and completion rates were lower
than when paper was used. Many BBS participants who opted for online data
capture have in practice completed questionnaires by post or in clinic.
Reasons for these choices need investigation. Both studies were funded by
the NIHR.

<137>
[Use Link to view the full text]
Accession Number
650316638
Title
Safety and effectiveness of somatostatin and analogues on chest tube
output after coronary artery bypass grafting: A scoping review.
Source
Journal of cardiovascular pharmacology. (no pagination), 2026. Date of
Publication: 19 Feb 2026.
Author
Gibson C.M.; Escano A.K.; Hobe K.D.; Brody E.R.; Montealgre R.; Chery J.
Institution
(Gibson) Virginia Commonwealth University School of Pharmacy 410 N. 12th
St Richmond, VA, United States
(Escano) Virginia Commonwealth University School of Pharmacy, Inova Campus
Inova Fairfax Medical Campus 3300 Gallows Road Falls Church, VA, United
States
(Hobe) Sentara Martha Jefferson Hospital 500 Martha Jefferson Drive
Charlottesville, VA, United States
(Brody) Virginia Commonwealth University Health Sciences Library 509 N.
12th St Richmond, VA, United States
(Montealgre) PharmD Baylor University Medical Center 3500 Gaston Ave
Dallas, TX, United States
(Chery) Virginia Commonwealth University School of Medicine, Department of
Surgery 1201 E Marshall St #4-100 Richmond, VA, United States
Abstract
Somatostatin and analogues may reduce chest tube (CT) output in
chylothorax caused by post-coronary artery bypass grafting (CABG).
However, data is limited to case reports and series. This scoping review
aimed to describe the efficacy and safety of somatostatin/analogue use in
post-CABG chylothorax. We retrieved from PubMed, Embase, and OVID all
studies and case reports describing somatostatin/analogue use in adult
patients post-CABG for resolution of chylothorax. The primary outcome was
time from somatostatin/analogue initiation to daily CT output <100 mL/day.
Chest tube duration, need to repeat invasive intervention, and safety
events associated with somatostatin/analogues were also analyzed.
Somatostatin/analogues were associated with reductions in CT output, but
one-third of patients still required pleurodesis or surgical intervention.
No safety events were identified. Patients with lower daily CT outputs at
the time of somatostatin/analogue initiation were more likely to avoid
repeat intervention than those with higher outputs. In conclusion,
somatostatin/analogues appear safe and possibly effective in management of
post-CABG chylothorax. Future studies should investigate which patients
are most likely to benefit from this therapy. Copyright © 2026
Wolters Kluwer Health, Inc. All rights reserved.

<138>
Accession Number
650320534
Title
Coronary artery bypass grafting versus percutaneous coronary intervention
for patients with multivessel coronary artery disease and advanced heart
failure.
Source
Scientific reports. (no pagination), 2026. Date of Publication: 19 Feb
2026.
Author
Jonik S.; Gumiezna K.; Kochman J.; Huczek Z.; Kusmierczyk M.; Opolski G.;
Grabowski M.; Mazurek T.
Institution
(Jonik, Gumiezna, Kochman, Huczek, Opolski, Grabowski, Mazurek) Department
of Cardiology, Medical University of Warsaw, Banacha 1a Str. 01-267,
Warsaw, Poland
(Kusmierczyk) Department of Heart, Thorax Surgery and Transplantology,
Medical University of Warsaw, Banacha 1a Str. 01-267, Warsaw, Poland
Abstract
Coronary artery disease (CAD) is a leading cause of heart failure (HF),
including HF with severely reduced left ventricular ejection fraction
(LVEF <= 35%). While revascularization may improve outcomes, optimal
treatment strategies remain uncertain, especially in patients with
multivessel disease (MVD). To compare long-term outcomes of percutaneous
coronary intervention (PCI) versus coronary artery bypass grafting (CABG)
in a real-world cohort of patients with MVD and HF with LVEF <= 35%. In
this prospective observational study, 586 patients with LVEF <= 35% were
evaluated by a multidisciplinary Heart Team and assigned to PCI (n = 394)
or CABG (n = 192). Outcomes over a 6-year of follow-up included all-cause
mortality, hospitalization for HF, myocardial infarction (MI), stroke and
need for repeat revascularization (RR). The primary endpoint (all-cause
mortality or hospitalization for HF) at 6 years was comparable between
both cohorts (56.8% vs. 64.7% for PCI, p = 0.06). We found no significant
differences in overall rates of death between CABG and PCI (40.1% vs.
47.4% for PCI, p = 0.09) or hospitalization for HF (27.1% vs. 32.7% for
PCI, p = 0.16), however these rates were lower in CABG-cohort. Individuals
who underwent PCI had higher incidences of MI and RR (18.8% vs. 9.9% for
CABG, p = 0.003 and 25.9% vs. 12.5% for CABG, p = 0.0002, respectively),
while higher rates of strokes (9.4% vs. 4.8% for PCI, p = 0.03) penalized
CABG. Furthermore, patients who underwent surgery experienced also longer
postprocedural hospital stay (9.3 (3.1) vs. 2.8 (1.4) days, p < 0.001).
In-hospital mortality was nonsignificantly higher in CABG-cohort (5.2% vs.
2.3% for PCI, p = 0.06). Over a 6-year of follow-up, for real-life
all-comer patients with MVD and severe LV dysfunction, we found no
significant differences between surgery or percutaneous approach -
all-cause mortality and hospitalization for HF were similar, rates of MI
and RR favour CABG, while patients who underwent PCI were burdened with
lower incidence of stroke. Nevertheless, an increased perioperative risks
in this cohort highlight the need for individualized, Heart Team-driven
decisions. Further randomized-controlled trials to optimize management in
this high-risk population are strongly desirable. Copyright ©
2026. The Author(s).

<139>
Accession Number
650319061
Title
Conduction disturbances after transcatheter aortic valve implantation.
Source
European heart journal. (no pagination), 2026. Date of Publication: 19
Feb 2026.
Author
Maznyczka A.; Pilgrim T.; Philippon F.; Rodes-Cabau J.; De Backer O.
Institution
(Maznyczka) Heart Centre, Rigshospitalet, Inge Lehmanns Vej 7, Copenhagen,
Denmark
(Pilgrim) Department of Cardiology, Inselspital, Bern University Hospital,
University of Bern, Bern, Switzerland
(Philippon, Rodes-Cabau) Institut Universitaire de Cardiologie et de
Pneumologie de Quebec, Laval University, Quebec City, QC, Canada
(Rodes-Cabau) Cardiology Department, Institut Clinic Cardiovascular,
Barcelona, Spain
(De Backer) Heart Centre, Rigshospitalet, Denmark and Department of
Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
Abstract
Conduction disturbances and permanent pacemaker implantation remain the
most common complications after transcatheter aortic valve implantation.
The strongest predictors of conduction abnormalities and subsequent
permanent pacemaker implantation after transcatheter aortic valve
implantation include pre-existing right bundle branch block, a short
membranous interventricular septum, deep transcatheter heart valve
implantation, and valve type. Importantly, both new permanent pacemaker
implantation and new left bundle branch block after transcatheter aortic
valve implantation are associated with increased mortality and heart
failure hospitalizations. As transcatheter aortic valve indications expand
to lower risk and younger populations, with longer life expectancy,
strategies to minimize the risk of conduction disturbances and optimize
their detection and management become increasingly crucial. Refined
transcatheter heart valve implantation techniques may be associated with a
reduction in rhythm disturbances after transcatheter aortic valve
implantation and anti-inflammatory treatments are under investigation.
Ongoing trials are investigating the impact of beta-blocker withdrawal to
prevent conduction abnormalities, electrophysiology studies for risk
stratification, and conduction system pacing to prevent adverse cardiac
remodelling. This review aims to provide an overview of the incidence,
pathophysiology, and consequences of conduction disturbances after
transcatheter aortic valve implantation, discuss preventive strategies,
highlight the relevant ongoing studies, and provide an evidence-based
framework for the management of this important clinical
issue. Copyright © The Author(s) 2026. Published by Oxford
University Press on behalf of the European Society of Cardiology. All
rights reserved. For commercial re-use, please contact reprints@oup.com
for reprints and translation rights for reprints. All other permissions
can be obtained through our RightsLink service via the Permissions link on
the article page on our site-for further information please contact

<140>
Accession Number
650318492
Title
Effect of respiratory muscle training on functional capacity related to
the quality of life of patients undergoing coronary artery bypass grafting
with cardiopulmonary bypass: randomized clinical trial.
Source
Einstein (Sao Paulo, Brazil). 24 (pp eAO1720), 2026. Date of Publication:
2026.
Author
Ribeiro M.S.D.C.N.; Via F.D.; Falcao A.L.E.; Oliveira Neto A.F.; Kosour C.
Institution
(Ribeiro, Via, Kosour) Universidade Federal de Alfenas, MG, Alfenas,
Brazil
(Falcao, Oliveira Neto) Universidade Estadual de Campinas, Campinas,
Brazil
Abstract
OBJECTIVE: To evaluate the effects of inspiratory muscle training using
POWERbreathe in patients undergoing myocardial revascularization with
extracorporeal circulation, focusing on respiratory and peripheral muscle
strength, exercise capacity, functional independence, and quality of life,
from hospitalization to a 30 and 90 day followup. METHOD(S): This
randomized controlled clinical trial included 70 patients aged 44-78 years
who were randomized into two groups. The Control Group underwent
conventional physical therapy (Control Group, n=34), whereas the
Intervention Group underwent conventional physical therapy combined with
inspiratory muscle training using POWERbreathe (Intervention Group, n=36).
Respiratory and peripheral muscle strength, capacity, functional
independence, and quality of life were evaluated preoperatively and 5, 30,
and 90 days after surgery. RESULT(S): A statistically significant
increase in exercise capacity in the Intervention Group was observed 90
days after surgery (p=0.0192), as well as in the functional capacity
domain of quality of life at 30 and 90 days after surgery (p=0.0079). The
maximal inspiratory pressure and handgrip strength showed a negative
correlation, ranging from weak to moderate intensity, in both groups over
time. CONCLUSION(S): Inspiratory muscle training with the
POWERBreathe combined with physical therapy improves exercise capacity and
quality of life in patients undergoing myocardial
revascularization.Prospero database registration: RBR-2p4mz5.

<141>
Accession Number
2043396505
Title
Rhomboid intercostal block versus erector spinae plane block for
perioperative analgesia in patients undergoing reduction mammoplasty: a
prospective randomized study.
Source
BMC Anesthesiology. 26(1) (no pagination), 2026. Article Number: 138. Date
of Publication: 01 Dec 2026.
Author
Abd Ellatif S.E.; Wahdan R.A.; Ibrahim E.S.; Galal Eldin A.M.
Institution
(Abd Ellatif, Wahdan, Wahdan, Galal Eldin) Department of Anesthesia,
Intensive Care, and Pain Management, Faculty of Medicine, Zagazig
University, Al- qwmiah, Zagazig, Egypt
(Ibrahim) Department of Plastic and Reconstructive Surgery, Faculty of
Medicine, Zagazig University, Zagazig, Egypt
Publisher
BioMed Central Ltd
Abstract
Background: Erector spinae plane block (ESP) is inevitably effective in
posterior thoracic surgeries, but its efficacy and safety in anterior
thoracic surgeries-particularly bilateral surgeries-remain in dispute.
This study aimed to evaluate the analgesic efficacy of rhomboid
intercostal block (RIB) and ESP after reduction mammoplasty.
 Method(s): This prospective randomized controlled study was conducted
on 72 patients scheduled for reduction mammoplasty. Patients were randomly
assigned to three groups. Group C received general anesthesia, and groups
ESP and RIB received ESP and RIB blocks, and general anesthesia. The
primary outcome was the first rescue analgesic time. Postoperative pain
score, 24 h nalbuphine consumption, and dermatomal level were the
secondary outcomes. Result(s): Compared with those in the ESP and
control groups, the first rescue analgesic time and 24 h nalbuphine
consumption were significantly longer and lower, respectively, in the RIB
group. Furthermore, the RIB group had the lowest significant pain scores
within the first 6 h postoperatively. Significant sensory blocking of the
anterior hemithorax from T2-T9 was accomplished by the RIB, while more
dermatomal blockade of the posterior hemithorax from T2-T9 was provided by
the ESP. Conclusion(s): RIB is more effective than ESP in managing
pain after reduction mammoplasty. It prolongs the duration of analgesia,
reduces postoperative nalbuphine consumption and is associated with a
lower incidence of complications; hence, RIB can be utilized as a
promising alternative in anterior thoracic wall surgeries such as
reduction mammoplasty. Trial registration: This clinical trial was
approved by Zagazig University's Institutional Review Board (IRB) (ZU-IRB#
11408/January15, 2024) and ClinicalTrials.gov (NCT06225895, registration
date January 26, 2024), with the first research participant enrolled on
February 1, 2024. Copyright © The Author(s) 2026.

<142>
Accession Number
650318246
Title
Figure-of-8 Suture With a 3-Way Tap Versus Manual Compression After Atrial
Fibrillation Ablation: The HARNESS Randomized Controlled Trial.
Source
JACC. Clinical electrophysiology. (no pagination), 2026. Date of
Publication: 12 Feb 2026.
Author
Mills M.T.; Calvert P.; Tidbury L.; Wilson K.; Evans T.; de Francesco L.;
Najm A.; Tripathi R.; Farinha J.M.; Xydis P.; Thu K.; Snowdon R.; Borbas
Z.; Waktare J.; Mahida S.N.; Denham N.; Ashrafi R.; Todd D.; Modi S.;
Luther V.; Gupta D.
Institution
(Mills, Calvert, Luther, Gupta) Department of Cardiology, Liverpool Heart
& Chest Hospital, Liverpool, United Kingdom; Liverpool Centre for
Cardiovascular Science at University of Liverpool, Liverpool John Moores
University and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom
(Tidbury) Liverpool Centre for Cardiovascular Science at University of
Liverpool, Liverpool John Moores University and Liverpool Heart & Chest
Hospital, Liverpool, United Kingdom; Research Department, Liverpool Heart
& Chest Hospital, Liverpool, United Kingdom
(Wilson) Research Department, Liverpool Heart & Chest Hospital, Liverpool,
United Kingdom
(Evans, de Francesco, Najm, Tripathi, Farinha, Xydis, Thu, Snowdon,
Borbas, Waktare, Mahida, Denham, Ashrafi, Todd, Modi) Department of
Cardiology, Liverpool Heart & Chest Hospital, Liverpool, United Kingdom
Abstract
BACKGROUND: Reliable hemostasis is essential to minimize femoral venous
access site complications after transcatheter cardiovascular procedures,
particularly atrial fibrillation (AF) ablation, which require large-bore
sheath insertion and systemic heparinization. A figure-of-8 suture secured
with a 3-way tap (Fo8TAP) offers a simple and low-cost alternative to
manual compression (MC). OBJECTIVE(S): The HARNESS (Haemostasis After
Venous Access in Atrial Fibrillation Catheter Ablation) randomized
controlled trial evaluated the efficacy of Fo8TAP and its impact on
post-procedural bed rest duration. METHOD(S): Patients undergoing AF
ablation via unilateral femoral venous access were randomized 1:1:1 to: 1)
MC with 4-hour bed rest (MC-4), 2) Fo8TAP with 4-hour bed rest (TAP-4),
and 3) Fo8TAP with 2-hour bed rest (TAP-2). The primary endpoint of any
access site complication before hospital discharge was assessed for
superiority (TAP-4 vs MC-4) and noninferiority (TAP-2 vs TAP-4). Bleeding
was graded from 1 (minor) to 4 (life-threatening). Secondary endpoints
included times to hemostasis, catheter laboratory exit, and mobilization.
 RESULT(S): Three hundred thirty-six patients (median age 64 years,
34.2% female, median body mass index 28.9 kg/m2) were enrolled and
randomized to MC-4 (n = 110), TAP-4 (n = 110), and TAP-2 (n = 116). The
primary endpoint occurred in 16 patients (14.5%) in the TAP-4 group and 36
patients (32.7%) in the MC-4 group (P = 0.002 for superiority). In the
TAP-2 group, the primary endpoint occurred in 36 (31.0%) patients (P =
0.156; which did not meet the prespecified noninferiority margin vs
TAP-4). No major vascular complications occurred. Most events were grade 1
bleeding (85/92, 92.4%), with the remainder minor hematomas (7/92, 7.6%).
Median time to hemostasis was significantly shorter with Fo8TAP (MC-4: 12
min; TAP-4 and TAP-2: 1 min; P < 0.001). Median time to catheter
laboratory exit was shortest with Fo8TAP (MC-4: 16 min; TAP-4: 9 min;
TAP-2: 8 min; P < 0.001). Median time to mobilization was shortest with
TAP-2 (MC-4: 242 min; TAP-4: 241 min; TAP-2: 122 min; P < 0.001).
 CONCLUSION(S): After AF catheter ablation, Fo8TAP was superior to MC
in lowering the incidence of access site complications and was associated
with health care efficiencies. However, a 2-hour bed rest strategy failed
to meet noninferiority criteria versus 4 hours. (Haemostasis After Venous
Access in Atrial Fibrillation Catheter Ablation [HARNESS];
NCT06470555). Copyright © 2026 The Authors. Published by Elsevier
Inc. All rights reserved.

<143>
Accession Number
2043658328
Title
SGLT2 inhibitors in cardiac procedures: associations with reduced atrial
fibrillation and acute kidney injury.
Source
American Journal of the Medical Sciences. Conference: American Journal of
the Medical Sciences. New Orleans United States. 371(Supplement 1) (pp
S4-S5), 2026. Date of Publication: 01 Feb 2026.
Author
Javaid S.; Maniya M.; Imtiaz N.; Khan L.A.; Hamid A.; Mentz R.; Butler J.;
Hall M.E.
Institution
(Javaid, Khan, Butler, Hall) University of Mississippi Medical Center,
Ridgeland, MS, United States
(Maniya, Imtiaz) Ziauddin University, Karachi, Pakistan
(Hamid) Baylor College of Medicine, Houston, TX, United States
(Mentz) Duke University Medical Center, Durham, NC, United States
(Butler) Baylor Scott and White Research Institute, Dallas, TX, United
States
Publisher
Elsevier B.V.
Abstract
Purpose: SGLT2 inhibitors improve cardiovascular and renal outcomes in
non-surgical settings, but their utility in the context of cardiac surgery
and interventional procedures remains uncertain. Method(s): PubMed,
Embase, and trial registries were searched through September 2025.
Eligible studies compared SGLT2 inhibitors with placebo or other
hypoglycemics in adults undergoing cardiac procedures. Pooled results were
reported as odds ratios (ORs) with 95% confidence intervals (Cls).
 Result(s): A total of 16 studies comprising 5,129 individuals were
analyzed. SGLT2 inhibitors significantly reduced the risk of postoperative
atrial fibrillation (POAF) when administered intraoperatively (OR: 0.36;
95% CI: 0.16-0.81). They were also associated with a significant reduction
in acute kidney injury (AKI) risk (OR: 0.53; 95% CI: 0.31-0.91). Nominal
reductions were observed in all-cause mortality (OR: 0.75; 95% CI:
0.54-1.04) and heart failure (HF) hospitalization (OR: 0.61; 95% CI:
0.36-1.03), though neither reached statistical significance. No
significant effects were noted for cardiovascular mortality or urinary
tract infection risk, while a trend toward increased risk of diabetic
ketoacidosis (DKA) was observed (p=0.06). Conclusion(s): SGLT2
inhibitors reduced POAF with intraoperative use and lowered the risk of
AKI. Nonsignificant reductions were seen in mortality and HF
hospitalization, whereas a notable but nonsignificant increase in DKA risk
was observed. Further research is needed to define their optimal timing
and benefits in cardiac procedures. Copyright © 2025

<144>
Accession Number
2043799455
Title
Does tranexamic acid fix all bleeding in surgery?.
Source
Journal of the National Medical Association. (no pagination), 2026. Date
of Publication: 2026.
Author
Lonjin T.; Prasanna P.; Zhang D.
Institution
(Lonjin, Prasanna) Department of Anesthesiology, Virginia Commonwealth
University, Richmond, VA, United States
(Zhang) Virginia Commonwealth University School of Medicine, Richmond, VA,
United States
Publisher
National Medical Association
Abstract
Excessive hemorrhage is a major contributor to morbidity and mortality in
perioperative settings. Tranexamic acid (TXA), a synthetic
antifibrinolytic agent, effectively reduces blood loss by preventing
fibrin degradation. This review summarizes the clinical applications,
efficacy, and safety considerations of TXA across various surgical
specialties. A comprehensive review of studies across various surgical
specialties confirms TXA's efficacy in minimizing the risk of hemorrhage
and transfusion needs. While TXA is a valuable tool in hemostasis, proper
patient selection and dosing are crucial to avoid risks, especially in
those with thromboembolic conditions or renal impairment. Further research
is needed to refine dosing protocols and expand its safe use across
patient populations. Copyright © Published by Elsevier Inc. on
behalf of National Medical Association.

<145>
Accession Number
2043386475
Title
Technological advancements for improving preoperative assessment and
precision in cardiovascular surgery.
Source
Expert Review of Cardiovascular Therapy. (no pagination), 2026. Date of
Publication: 2026.
Author
Galyfos G.; Chamzin A.; Theodorou A.; Sigala F.; Filis K.; Theodorou D.
Institution
(Galyfos, Chamzin, Theodorou, Sigala, Filis, Theodorou) Vascular Surgery
Unit, First Department of Propedeutic Surgery, National and Kapodistrian
University of Athens, Hippocration Hospital, Athens, Greece
Publisher
Taylor and Francis Ltd.
Abstract
Introduction: Cardiovascular surgery, including cardiac surgery and
complex endovascular procedure, needs careful preoperative planning as
well as intraoperative precision to improve outcomes and ameliorate
complications. During the last decades, several technological advancements
have been made that could improve preoperative assessment, design of the
surgical procedure, risk prediction as well as surgical precision. Areas
covered: Several areas of technological advancements referring to
cardiovascular surgery are discussed in this review. Data have been
collected using the Pubmed, Scopus, and Google Scholar databases. We
report advancements regarding the utilization of artificial intelligence
in preoperative assessment and risk prediction. We also report on
advancements made in intraoperative imaging including holographic and
fusion imaging techniques. Furthermore, operating techniques such as the
use of novel endovascular tools or robotic surgery are also discussed.
Finally, other novel technologies, such as three-dimentional (3D)
printing, is also presented. Expert opinion: In the next 5 years,
technological advancements in cardiovascular surgery will be definitely
improved and more broadly used. Although these advancements are associated
with a very high cost and a longer learning curve, the associated
healthcare cost benefit is evident. Due to bioethical reasons, this
progress will need to be contained and controlled by humans. Copyright
© 2026 Informa UK Limited, trading as Taylor & Francis Group.

<146>
Accession Number
650308349
Title
Influence of exercise on functional status after tavi intervention: A
literature review.
Source
European Geriatric Medicine. Conference: 20th Congress of the European
Geriatric Medicine Society. Valencia Spain. 15(1 Supplement) (pp S363),
2024. Date of Publication: 01 Dec 2024.
Author
Molero-De-Avila R.; Lorente-Escudero M.; Martinez-Velilla N.;
Garaioa-Aramburu K.J.; Dicastillo-Ripa A.
Institution
(Molero-De-Avila, Lorente-Escudero, Martinez-Velilla, Garaioa-Aramburu,
Dicastillo-Ripa) Hospital Universitario de Navarra, Spain
Publisher
Springer Science and Business Media Deutschland GmbH
Abstract
Introduction: Aortic stenosis is a significant concern in the older adults
due to its connection with age-related valvular degeneration.
Approximately 12.5% of individuals older than 75 experience aortic
stenosis, with 3.4% of cases being severe. When symptomatic, aortic
stenosis can negatively impact quality of life and survival. Recently,
transcatheter aortic valve implantation (TAVI) has emerged as the
preferred treatment option for older patients. Studies suggest that
mortality rates for this intervention in this population are around 20%
per year. However, the impact of frailty and pre-intervention status on
risk prediction, as well as the potential influence of perihabilitation on
these results, remain open questions. Method(s): We conducted a
literature search using the following terms: ("exercise"[MeSH Terms] OR
"exercise"[Title/Abstract] OR ("functional status"[Title/Abstract] OR
"functional outcome"[Title/ Abstract]) AND ("transcatheter aortic valve
implantation"[MeSH Terms] OR "TAVI"[Title/Abstract] OR "transcatheter
aortic valve replacement"[Title/Abstract]), limiting our review to
articles published in the past decade. Result(s): Our analysis
identified 17 articles, of which 6 focused on exercise or rehabilitation
for TAVI patients. Only one article reported results for SPPB, while the
remaining five examined 6MWT, quality of life, or strength measures. The
results generally favored the exercise group. Notably, the PERFORM-TAVR
study protocol will also assess SPPB as one of its variables.
 Conclusion(s): Rehabilitation ought to be considered a fundamental
cornerstone in the treatment of TAVI, while simultaneously exploring the
impact of both intervention and post-rehabilitation measures on the
functional capacity of older adult.

<147>
Accession Number
2043768409
Title
Treatment of rheumatoid arthritis-associated interstitial lung disease:
what is new since the 2022 SER-SEPAR recommendations?.
Source
Reumatologia Clinica. (no pagination), 2026. Article Number: 502104. Date
of Publication: 2026.
Author
Narvaez J.; Diaz del Campo Fontecha P.; Nieto M.A.; Villaverde Garcia V.;
Candelas Rodriguez G.; Balsa A.
Institution
(Narvaez) Servicio de Reumatologia, Hospital Universitario de Bellvitge,
Barcelona, Hospitalet de Llobregat, Spain
(Diaz del Campo Fontecha) Unidad de Investigacion, Sociedad Espanola de
Reumatologia, Madrid, Spain
(Nieto) Servicio de Neumologia, Hospital Clinico San Carlos, Madrid, Spain
(Villaverde Garcia) Servicio de Reumatologia, Hospital Universitario de
Mostoles, Madrid, Mostoles, Spain
(Candelas Rodriguez) Servicio de Reumatologia, Hospital Universitario
Clinico San Carlos, Madrid, Spain
(Balsa) Servicio de Reumatologia, Hospital Universitario La Paz, Madrid,
Spain
Publisher
Ediciones Doyma, S.L.
Abstract
Objective: In 2020, the Spanish Society of Rheumatology (SER) and the
Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) published
joint recommendations on the management of rheumatoid arthritis-associated
interstitial lung disease (RA-ILD). Since then, new evidence has emerged
supporting an update focused on treatment. Method(s): A systematic
literature review was conducted covering the period from October 2020 to
October 2025. Result(s): IL-6 and JAK inhibitors (JAKi) show efficacy
comparable to rituximab (RTX) and abatacept (ABA) in controlling joint
disease, preserving pulmonary function, limiting radiological progression,
and reducing RA-ILD-related mortality, without a significant increase in
serious respiratory events. ABA has not demonstrated a lower risk of
severe or opportunistic infections; therefore, these four options (ABA,
RTX, anti-IL6, and JAKi) may be used interchangeably in RA-ILD patients
requiring treatment intensification. In those with a progressive fibrosing
phenotype and intolerance to nintedanib, pirfenidone may be considered.
 Conclusion(s): Recent evidence has expanded the therapeutic options
available for RA-ILD. Copyright © 2026 Sociedad Espanola de
Reumatologia (SER), Colegio Mexicano de Reumatologia (CMR) y Elsevier
Espana, S.L.U.

EPICORE Embase Updates

Saturday, March 7, 2026

EMBASE Cardiac Update AutoAlert: EPICORE Cardiac Surgery Blogger2

Followers

Blog Archive

About Me